---
document_datetime: 2023-09-21 20:57:51
document_pages: 120
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/apexxnar-epar-public-assessment-report_en.pdf
document_name: apexxnar-epar-public-assessment-report_en.pdf
version: success
processing_time: 198.7045892
conversion_datetime: 2025-12-30 02:18:06.086608
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 December 2021 EMA/12384/20222 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Apexxnar

Common name: pneumococcal polysaccharide conjugate vaccine (20valent, adsorbed)

Procedure No. EMEA/H/C/005451/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                             | ..........................................7                                                            |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ................................................................................        | 7                                                                                                      |
| 1.2. Legal basis, dossier content..............................................................................        | 7                                                                                                      |
| 1.3. Information on Paediatric requirements                                                                            | ............................................................. 7                                        |
| 1.4. Information relating to orphan market exclusivity                                                                 | ............................................... 7                                                      |
| 1.4.1. Similarity                                                                                                      | .................................................................................................... 7 |
| 1.4.2. Derogation(s) from market exclusivity                                                                           | ............................................................ 7                                         |
| 1.5. Applicant's request(s) for consideration .............................................................            | 8                                                                                                      |
| 1.5.1. Accelerated assessment................................................................................          | 8                                                                                                      |
| 1.5.2. New active substance status..........................................................................           | 8                                                                                                      |
| 1.6. Scientific advice..............................................................................................   | 8                                                                                                      |
| 1.7. Steps taken for the assessment of the product                                                                     | ................................................... 9                                                  |
| 2. Scientific                                                                                                          | ..........................................................................10                           |
| discussion                                                                                                             |                                                                                                        |
| 2.1. Problem statement.........................................................................................10      |                                                                                                        |
| 2.1.1. Disease or condition                                                                                            | ....................................................................................10                 |
| 2.1.2. Epidemiology and risk factors                                                                                   | .......................................................................10                              |
| 2.1.3. Biologic features                                                                                               | .........................................................................................11            |
| 2.1.4. Clinical presentation, diagnosis                                                                                | .....................................................................11                                |
| 2.1.5. Management                                                                                                      | ..............................................................................................11       |
| 2.2. About the product                                                                                                 | ..........................................................................................12           |
| 2.3. Type of application and aspects on development................................................13                  |                                                                                                        |
| 2.4. Quality aspects..............................................................................................13   |                                                                                                        |
| 2.4.1. Introduction                                                                                                    | ...............................................................................................13      |
| 2.4.2. Active Substance (AS)                                                                                           | .................................................................................13                    |
| 2.4.3. Finished Medicinal Product............................................................................18        |                                                                                                        |
| 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects                                   | ..20                                                                                                   |
| 2.5. Non-clinical aspects........................................................................................20    |                                                                                                        |
| 2.5.1. Introduction                                                                                                    | ...............................................................................................20      |
| 2.5.2. Pharmacology.............................................................................................21     |                                                                                                        |
| 2.5.3. Pharmacokinetics                                                                                                | ........................................................................................22             |
| 2.5.4. Toxicology..................................................................................................22  |                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment.....................................................24                |                                                                                                        |
| 2.5.6. Discussion on the non-clinical aspects............................................................24            |                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects                                                                          | ...........................................................25                                          |
| 2.6. Clinical aspects..............................................................................................25  |                                                                                                        |
| 2.6.1. Introduction                                                                                                    | ...............................................................................................25      |
| 2.6.2. Clinical pharmacology..................................................................................28       |                                                                                                        |
| 2.6.3. Discussion on clinical pharmacology                                                                             | ..............................................................28                                       |
| 2.6.4. Conclusions on clinical pharmacology.............................................................29             |                                                                                                        |
| 2.6.5. Clinical efficacy (immunogenicity)                                                                              | .................................................................29                                    |
| 2.6.6. Discussion on clinical efficacy........................................................................71       |                                                                                                        |
| 2.6.7. Conclusions on the clinical efficacy                                                                            | ................................................................79                                     |
| 2.6.8. Clinical safety .............................................................................................79 |                                                                                                        |
| 2.6.9. Discussion on clinical safety........................................................................102        |                                                                                                        |

<div style=\"page-break-after: always\"></div>

| 2.6.10. Conclusions on the clinical safety...............................................................107         |                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| 2.7. Risk Management Plan..................................................................................107       |                                                                                                    |
| 2.7.1. Safety concerns                                                                                               | ........................................................................................107        |
| 2.7.2. Pharmacovigilance plan..............................................................................107       |                                                                                                    |
| 2.7.3. Risk minimisation measures                                                                                    | .......................................................................108                         |
| 2.7.4. Conclusion................................................................................................109 |                                                                                                    |
| 2.8. Pharmacovigilance                                                                                               | .......................................................................................109         |
| 2.8.1. Pharmacovigilance system..........................................................................109         |                                                                                                    |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                        | ...............................109                                                                 |
| 2.9. Product information......................................................................................109    |                                                                                                    |
| 2.9.1. User consultation                                                                                             | ......................................................................................109          |
| 2.9.2. Labelling exemptions.................................................................................109      |                                                                                                    |
| 2.9.3. Additional monitoring.................................................................................109     |                                                                                                    |
| 3. Benefit-Risk Balance                                                                                              | .......................................................................110                         |
| 3.1. Therapeutic Context.....................................................................................110     |                                                                                                    |
| 3.1.1. Disease or condition                                                                                          | ..................................................................................110              |
| 3.1.2. Available therapies and unmet medical need                                                                    | ................................................110                                                |
| 3.1.3. Main clinical studies...................................................................................111   |                                                                                                    |
| 3.2. Favourable effects........................................................................................111   |                                                                                                    |
| 3.3. Uncertainties and limitations about favourable effects                                                          | ......................................112                                                          |
| 3.4. Unfavourable effects.....................................................................................113    |                                                                                                    |
| 3.5. Uncertainties and limitations about unfavourable effects                                                        | ...................................115                                                             |
| 3.6. Effects Table                                                                                                   | ...............................................................................................115 |
| 3.7. Benefit-risk assessment and discussion...........................................................116            |                                                                                                    |
| 3.7.1. Importance of favourable and unfavourable effects                                                             | .......................................116                                                         |
| 3.7.2. Balance of benefits and risks ......................................................................118       |                                                                                                    |
| 3.8. Conclusions.................................................................................................118 |                                                                                                    |
| 4. Recommendations...........................................................................118                     |                                                                                                    |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

20vPnC

20-valent pneumococcal polysaccharide conjugate vaccine

13vPnC

13-valent pneumococcal polysaccharide conjugate vaccine

7vPnC

7-valent pneumococcal conjugate vaccine

PPSV23

23-valent pneumococcal polysaccharide vaccine

## Quality:

AlPO4

aluminium phosphate

APQR

Annual Product Quality Review

CPP's

critical process parameters

CPV

Continued Process Verification

CQAs

critical quality attributes

CRM197 (CY process)

diphtheria cross reactive material manufactured with casamino acid-yeast extract based medium

CRM197 (DM process)  diphtheria cross reactive material manufactured with defined medium

DMSO

dimethyl sulfoxide

DOC

sodium deoxycholate

DOE

design of experiments

FP

finished product

AS

active substance

ASI

active substance intermediate

FC's

flexible containers

GMP

Good Manufacturing Practice

HA

hydroxyapatite

HB

hexadecyltrimethylammonium bromide

IPT-Cs

in-process tests for control

IPT-Ms

in-process tests for monitoring

LOQ

limit of quantitation

MBC

monovalent bulk conjugates

MCB

master cell bank

NaBH3CN

sodium cyanoborohydride

NaCl

sodium chloride

NaI

sodium iodide

NaIO4

sodium meta periodate

NCS

N-chlorosuccinimide

NMR

nuclear magnetic resonance

NOR

normal operating range

OD

optical density

OSV

Original Source Vials

PARs

proven acceptable ranges

PE

polyethylene

PFS

pre-filled syringe

PS80

polysorbate 80

PPQ

process performance qualification

PV

Process validation

RM

reference material

SME

subject matter expert

SS

stainless steel

TSE

Transmissible Spongiform Encephalopathy

UFDF

ultrafiltration diafiltration

US FDA

United States Food and Drug Administration

WCB

working cell bank

WFI

water for injection

<div style=\"page-break-after: always\"></div>

## Non-clinical/ clinical:

4KQ

4-keto-N-quinovosamine

ACVP

American College of Veterinary Pathologists

ADR

Adverse Drug Reaction

AE

Adverse Event

c7vPnC

Complementary 7-Valent Pneumococcal Conjugate Vaccine

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence Interval

CRF

Case Report Form

CSR

Clinical Study Report

dLIA

Direct Luminex Immunoassay

ECDC

European Centre for Disease Prevention and Control

e-diary

Electronic Diary

ELISA

Enzyme-Linked Immunosorbent Assay

EMA

European Medicines Agency

FIH

First in Human

GLP

Good Laboratory Practice

GMC

Geometric Mean Concentration

GMFR

Geometric Mean Fold Rise

GMR

Geometric Mean Ratio

GMT

Geometric Mean Titre

HIV

Human Immunodeficiency Virus

HSCT

Hematopoietic Stem-Cell Transplantation

IgG

Immunoglobulin G

IPD

Invasive Pneumococcal Disease

IRT

Interactive Response Technology

ISS

Integrated Summary of Safety

ITT

Intention to Treat

LLOQ

Lower Limit of Quantitation

LOD

Limit of Detection

MAA

Marketing Authorisation Application

NOAEL

no observed adverse effect level

NZW

New Zealand White

MedDRA

Medical Dictionary for Regulatory Activities

NDCMC

Newly diagnosed chronic medical condition

NI

Non-inferiority margin

NITAGS

National Immunisation Technical Advisory Groups

OC

Other Concern

OPA

Opsonophagocytic Activity

PI

Principal Investigator

PIP

Paediatric Investigation Plan

PRAC

Pharmacovigilance Risk Assessment Committee

PT

Preferred Term

PWG

pathology working group

SA

Scientific Advice

SAE

Serious Adverse Event

SAP

Statistical Analysis Plan

SmPC

Summary of Product Characteristics

SOC

System Organ Class

Tdap

Tetanus, Diphtheria, and acellular Pertussis Vaccine

VE

Vaccine Effectiveness

WHO

World Health Organization

yoa

years of age

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Pfizer Europe MA EEIG submitted on 5 February 2021 an application for marketing authorisation to the European Medicines Agency (EMA) for Apexxnar, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 19 September 2019.

The applicant applied for the following indication:

'Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults 18 years of age and older.

See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.

The use of TRADENAME should be determined on the basis of official recommendations taking into consideration the risk of invasive disease and pneumonia in different age groups, underlying comorbidities, as well as the variability of serotype epidemiology in different geographical areas.'

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0159/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0159/2020 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.4.2. Derogation(s) from market exclusivity

Not applicable

<div style=\"page-break-after: always\"></div>

## 1.5. Applicant's request(s) for consideration

## 1.5.1. Accelerated assessment

The applicant requested accelerated assessment in accordance to Article 14 (9) of Regulation (EC) No 726/2004.

## 1.5.2. New active substance status

The applicant requested the active substance 'pneumococcal polysaccharide serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F conjugated to CRM197 carrier protein' contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union which was initially agreed.

However, based on the recent positive CHMP opinion (14.10.2021) for pneumococcal vaccine [Vaxneuvance (15-valent, adsorbed)], which contains serotypes 22F and 33F conjugated to CRM197, the applicant was requested to revise the NAS claim, which was done accordingly.

The CHMP now considers that pneumococcal polysaccharide serotypes 8, 10A, 11A, 12F and 15B conjugated to CRM197 carrier protein can be qualified as new active substances.

## 1.6. Scientific advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date             | Reference                             | SAWP co-ordinators               |
|------------------|---------------------------------------|----------------------------------|
| 13 December 2018 | EMEA/H/SA/3940/1/2018/III CORRIGENDUM | Dr Peter Mol, Dr Filip Josephson |

The Scientific advice pertained to the following quality, non-clinical, and clinical aspects:

- Manufacturing comparability
- Strategy regarding lots used for shelf life establishment and Process Performance Qualification
- Plan to eliminate rabbit pyrogenicity testing for drug product
- Preclinical programme to support Phase 3 in adults and children
- Concurrence with the phase 3 programme to support indications for IPD and pneumonia for the 20 serotypes contained in the vaccine in adults 18 yoa and older
- Success criteria for the phase 3 non inferiority studies
- Safety and immunogenicity databased to support licensure in different age groups and pneumococcal vaccine status groups
- SmPC claims on high risk adult population and cross-protection for serotype 15C from 15B

<div style=\"page-break-after: always\"></div>

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Daniela Philadelphy

Co-Rapporteur:  Jean-Michel Race

| The application was received by the EMA on                                                                                                                                               | 5 February 2021   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                                 | 25 March 2021     |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                             | 14 June 2021      |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                          | 14 June 2021      |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                             | 25 June 2021      |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                  | 22 July 2021      |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                      | 08 September 2021 |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                          | 19 October 2021   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 28 October 2021   |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                                                                                | 11 November 2021  |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 17 November 2021  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 01 December 2021  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Apexxnar on | 16 December 2021  |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                             | 16 December 2021  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) is a protein conjugated polysaccharide vaccine intended for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age.

Invasive pneumococcal disease (IPD) can occur when S. pneumoniae gains access to the blood or otherwise normally sterile sites. Depending on the site where invasion occurs, this can lead to different disease manifestations (e.g. meningitis, bacteraemia, sepsis, bacteraemic pneumonia, and septic arthritis).

S. pneumoniae is the leading bacterial pathogen that causes community-acquired pneumonia (CAP). CAP is amongst the most common causes of acute infection that require hospital administration.

## 2.1.2. Epidemiology and risk factors

Streptococcus pneumoniae continues to be a major cause of vaccine-preventable disease worldwide, resulting in considerable morbidity and mortality. Older adults (≥65 years of age), adults ≥18 years of age with certain comorbid conditions (e.g. chronic lung disease, chronic liver disease, chronic heart disease, diabetes mellitus, asthma), and immunocompromised adults (e.g. human immunodeficiency virus (HIV), haematopoietic stem-cell transplantation (HSCT) patients) are particularly susceptible to pneumococcal disease.

Studies from Europe have reported a high proportion of community-acquired pneumonia (CAP) due to S. pneumoniae in hospitalised adults. In a recent population-based cohort study from the UK, 36.6% of CAP cases in adults ≥16 years of age were caused by S. pneumoniae . Similar proportions were also found in the Netherlands, Germany, Spain, and Sweden and by a metaanalysis of 35 pneumonia studies in adults predominantly conducted in developed countries. Nonbacteraemic pneumococcal pneumonia is much more common than bacteraemic pneumococcal pneumonia. For example, 89.7% and 82.3% of adult cases of pneumococcal CAP large pneumonia surveillance studies in the UK (2013-2018) and Spain (2011-2014) were non-invasive.

Invasive pneumococcal disease (IPD) incidence rates in adults for surveillance years between 2013 and 2019 have been reported for several European countries. The annual incidence per 100,000 population in adults ≥65 years of age was between 22.2 and 51.0 with 30 -day case fatality rates for IPD varying between 11% and 30% based on several publications in European countries. According to the ECDC a total of 24,663 IPD cases were reported in the EU/EEA in 2018 (6.4 cases/ 100,000 population). IPD rates were highest at the extremes of age (infants ≤1 yoa: 14.4 cases/ 100,000 popula tion; adults ≥65 yoa: 18.7/ 100,000 population).  The case -fatality rate of IPD has not decreased over the past two decades.

## Burden of the seven additional non-13vPnC serotypes covered by 20vPnC

According to the ECDC the 10 most common serotypes (≥70% of i solates) causing IPD in Europe in 2018 were in order of decreasing frequency: 8, 3, 19A, 22F, 12F, 9N, 15A, 10A, 23B and 6C. In adults ≥65 yoa 73% of cases were caused by serotypes targeted by PPSV23 and 29% by serotypes

<div style=\"page-break-after: always\"></div>

targeted by 13vPnC (source: Invasive pneumococcal disease - Annual Epidemiological Report for 2018; 8 Sep 2020). Notably, despite being targeted by 13vPnC and PPSV23, serotypes 3 and 19A remain amongst the most frequent IPD causing serotypes in Europe in adults ≥ 65 yoa (14.7% and 7.6%, respectively).  The seven additional serotypes covered by 20vPnC but not by 13vPnC (8, 10A, 11A, 12F, 15B, 22F, and 33F) are responsible for a substantial proportion of the remaining IPD disease burden In the EU, serotype 8 is of particular concern, causing 14% of all IPD cases in older adults in 2018, followed by 22F (7.4%), 12F (4.0%), 11A (2.8%), 33F (2.5%) and 10A (2.3%). Overall, the serotypes included in 20vPnC represent seven of the 10 most prevalent serotypes that caused IPD in adults ≥65 year s of age.

In addition, these serotypes have characteristics that make them medically important, including antibiotic resistance (11A, 15B), association with outbreaks (8, 12F), and a tendency to cause more severe disease (e.g. association with meningitis and/or increased mortality rate) (10A, 11A, 22F).

## 2.1.3. Biologic features

The Gram-positive bacterium Streptococcus pneumoniae commonly asymptomatically colonises the human nasopharynx. Carriage rates decline with age (approx. 1/3rd to 2/3rds of children and ≤10% of adults are colonised). Transmission occurs mainly via nasal shedding (mucus droplets). Pneumococcal spread to more distal sites (e.g. middle ear, the lung, bloodstream or brain) can cause a range of disease manifestations (see clinical presentation below). This process depends on complex host-pathogen interactions, involving a multitude of bacterial virulence factors and inflammatory host cascades. The capsule consists of layers of polysaccharides, is the major surface antigen and exists in approx. 100 different chemical compositions called serotypes. It is a prerequisite for virulence (non-encapsulated strains exist but show reduced virulence or are avirulent), prevents mucus entrapment of S. pneumoniae and counteracts opsonophagocytosis. Generation of anti-capsular antibodies which enhance opsonophagocytosis forms the basis of currently approved pneumococcal vaccines. Conferred protection is serotype-specific, no serotypeindependent pneumococcal vaccines are available.

## 2.1.4. Clinical presentation, diagnosis

Pneumococcal disease mainly presents as non-invasive disease, such as non-bacteraemic pneumonia, sinusitis or acute otitis media (the latter most commonly in young children). The comparably less frequent albeit generally more severe invasive pneumococcal disease (IPD) occurs when S. pneumoniae gains access to more distal, normally sterile anatomical sites. IPD presents as meningitis, bacteraemic pneumonia, bacteraemia without focus and septic arthritis.

Regardless of the presence of bacteraemia, pneumococcal pneumonia is associated with complications and long-term sequelae in all age groups, including respiratory failure requiring hospitalisation, empyema, and necrotizing pneumonia, exacerbations of chronic medical conditions, declines in quality of life, and with a significant increased risk of death within 30 days (acute) and 1 year (long-term) after the event.

## 2.1.5. Management

## Disease Treatment

<div style=\"page-break-after: always\"></div>

S. pneumoniae infections are treated based on clinical presentation and susceptibility data to antimicrobials. Broad-spectrum antibiotics are the most commonly used antimicrobials against S. pneumoniae . Although S. pneumoniae is considered as a 'classical' multi-resistant pathogen, increasing resistance rates have been reported which may lead to treatment failures.

## Disease Prevention

At time of Marketing Authorisation Application, three pneumococcal vaccines were licensed in the EU:

- -The unconjugated polysaccharide vaccine PPSV23 (Pneumovax23) was initially authorised via national procedures in EU member states in the 1980s. PPSV23 contains capsular polysaccharides for 23 different serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). It is indicated for use in persons 2 years of age and older for whom there is an increased risk of morbidity and mortality from pneumococcal disease due to aging and/or underlying medical conditions.
- -The initial pneumococcal conjugate vaccine , 7vPnC (Prevenar), was licensed in 2000 for use in children, but is no longer authorised in the EU. 13vPnC (Prevenar 13) was subsequently developed to expand disease coverage in children (first licensed in 2010) and to better address disease in adults (first licensed in 2011). It targets serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

Efficacy against IPD and pneumonia was demonstrated in a randomised clinical trial in adults ≥65 years of age. Since its introduction, 13vPnC has demonstrated real -world effectiveness against pneumococcal disease in adults

-Synflorix was licensed in the EU in 2009 and is indicated for infants and children from 6 weeks up to 5 years of age.

During this procedure, Vaxneuvance received a positive CHMP opinion (14 10 2021), with Commission Decision (authorisation) adopted on 13.12.2021. This pertains to a 15-valent pneumococcal vaccine containing the 13 serotypes included in Prevenar 13 and additionally serotypes 22F and 33F. All 15 serotypes are also contained in 20vPnC (Apexxnar).

## 2.2. About the product

20vPnC is a pneumococcal conjugate vaccine, modelled after 13vPnC. 20vPnC contains the same 13 serotype-specific capsular polysaccharide antigens included in the authorised 13vPnC (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), plus 7 additional serotype-specific capsular polysaccharides (8, 10A, 11A, 12F, 15B, 22F, and 33F).

Each antigen is covalently linked (i.e. conjugated) to CRM197. This carrier protein modifies the immune response to the polysaccharide from a T cell independent response to a T cell dependent response. The T cell dependent response leads to both an enhanced antibody response and generation of memory B cells, allowing for an anamnestic (booster) response on re-exposure to the bacteria. 20vPnC was developed to further expand protection against the global burden of vaccinepreventable pneumococcal disease.

In adults, the levels of circulating antibodies that correlate with protection against pneumococcal disease have not been clearly defined.

<div style=\"page-break-after: always\"></div>

20vPnC is to be administered as a single dose to adults 18 years of age and older. Based on the clinical experience with 13vPnC, if the use of PPSV23 is considered appropriate, 20vPnC should be given first.

The targeted indication for 20vPnC is: Active immunisation for the prevention of invasive disease and pneumonia caused by S pneumoniae in adults ≥18 years of age.

## 2.3. Type of application and aspects on development

The CHMP did not agree to the applicant's request for an accelerated assessment as the product was not considered to be of major public health interest. This was based on the vaccine technology employed from the viewpoint of therapeutic innovation not being considered of major interest as it is an extension of an existing formulation (13vPnC/ Prevenar 13). Moreover, despite the known limitations of an unconjugated polysaccharide vaccine such as PPSV23 and the general advantages of a conjugate vaccine, there is a licensed vaccine available largely covering the same serotypes as 20vPnC.

## 2.4. Quality aspects

## 2.4.1. Introduction

This 20-valent pneumococcal polysaccharide conjugate vaccine consists of capsular polysaccharide antigens of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F with each saccharide individually conjugated to diphtheria CRM197 protein. The conjugates induce serotype-specific responses to the capsular polysaccharides contained in the vaccine (and within-serogroup for certain serotypes, e.g. serotype 15C) intended to protect against disease due to the vaccine serotypes.

Other ingredients are succinate buffer containing sodium chloride (NaCl), succinic acid and polysorbate 80 in water for injections, at pH 5.8, with aluminium phosphate as an adjuvant.

The vaccine is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes, administered by intramuscular injection.

The target indication for 20-valent pneumococcal conjugate vaccine (20vPnC) is active immunisation for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

## 2.4.2. Active Substance (AS)

## 2.4.2.1. General information

Information on the nomenclature of pneumococcal polysaccharide serotypes is provided in the dossier and previous quality assessment reports for the EU-authorised product, Prevenar 13.

The active substances are the following:

- Pneumococcal polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F conjugated to diphtheria cross reactive material (CRM197). These are the same serotypes as already included in the 13-valent Pneumococcal conjugate vaccine Prevenar

<div style=\"page-break-after: always\"></div>

13 from the same manufacturer. These serotypes are named 13vPnC serotypes in the following text.

- Pneumococcal polysaccharides of serotype 8, 10A, 11A, 12F, 15B, 22F and 33F conjugated to CRM197. These serotypes are named novel serotypes in the following text.

Information on the nomenclature related to CRM197, is provided in the table below.

Table 1: Nomenclature for CRM197

| Name                                                | Description                                 |
|-----------------------------------------------------|---------------------------------------------|
| Recommended International Nonproprietary Name (INN) | Diphtheria cross reactive material: CRM197  |
| Compendial Name, if relevant                        | Not applicable                              |
| Chemical Name(s)                                    | Diphtheria cross reactive material (CRM197) |

Information  on  the  nomenclature  of  pneumococcal  saccharide-CRM197  conjugate  serotypes  is provided in the following table.

| Name            | Description                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------------------|
| Compendial name | Monovalent Bulk Conjugate Serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F |

## 2.4.2.1. Manufacture, characterisation and process controls

## Description of manufacturing process and process controls

The applicant has provided the stability data for all 20 MBC and also for the CRM197. An annual stability programme is foreseen as well.

## Overall manufacture

With respect to the manufacturing process, all the individual steps as well as the applicable controls were properly described. The polysaccharide production scheme is a four-stage fermentation process followed by cellular inactivation plus a harvest step. The four stages of the fermentation process are: seed bottles, seed fermentor, intermediate fermentor and production fermentor. After fermentation, the polysaccharides are purified. Purified serotypes are shipped with a validated shipping process. Upon activation, polysaccharides are conjugated to the CRM. Conjugation occurs in aqueous or DMSO conditions.

With respect to the novel serotypes, all individual steps of the fermentation, purification activation and conjugation have also been provided in sufficient detail in the eCTD. Whenever serotype specific steps are involved, these were also described and explained. All in-process controls and inprocess monitoring tests were mentioned.

Conjugation of the novel serotypes is mostly also performed under either DMSO or aqueous conditions. Serotype 33F conjugation is performed under specific conditions that are different from the other serotypes, but this is also described in sufficient detail in the dossier.

<div style=\"page-break-after: always\"></div>

The production scheme of CRM197 is a four-stage fermentation process plus a harvest step followed by ultrafitration, UF concentration and impurity precipitation/ depth filtration in preparation for purification. The four stages of the fermentation process are: primary flasks, secondary/aspirator flasks, seed fermentor and production fermentor.

Purification is a four-stage process. The four stages of the purification process are: batch pooling and concentration/diafiltration column chromatography purification, concentration/diafiltration, and filtration and dispensing. The CRM197 is then frozen and stored -75 ± 5°C.

In preparation for conjugation of CRM with serotypes 6A, 6B, 7F, 8, 10A, 11A, 12F, 15B, 19F, 22F and 23F activated saccharides are lyophilised in a three-stage process. The 1 L Type 1 glass bottles containing lyophilised active substance intermediate are stored at -20 ± 5°C from the date of lyophilisation completion. The description of the manufacture of the CRM197 is acceptable.

## Control of materials

Each manufacturing site has a vendor management programme and appropriate quality systems to ensure control of raw materials used for Good Manufacturing Practice (GMP) manufacturing. Raw materials are purchased from approved suppliers and tested and released. Non-compendial raw materials may be replaced with compendial materials following appropriate qualification of the new sources of the raw materials. Water for injection (WFI) manufactured at the facility is used throughout the process and meets USP/Ph. Eur. requirements.

The control of materials has been provided for the 13vPnC serotypes, the novel serotypes and the CRM carrier. All information on raw materials has been provided, also for materials of biological origin. The applicant has given complete and detailed description on the source, history and generation of the cell banks (MCB and WCB) for all the 20 polysaccharides and the CRM carrier.

## Control of critical steps and intermediates

Controls of critical process steps are employed during manufacture of pneumococcal polysaccharide serotypes to ensure product quality is maintained. The process controls include release and stability tests and in-process tests with their respective acceptance criteria. If the results of these parameters/controls are outside of the acceptable ranges, an evaluation of the deviation is performed, and the decision about material disposition for further manufacture is based on the investigation conclusion.

In-process tests and acceptance criteria for pneumococcal polysaccharide serotypes are provided. All analytical methods for in process testing of pneumococcal polysaccharides were properly described in the eCTD. Validation of the methods has been done according to ICH Q2(R1).

The release and stability specifications for pneumococcal polysaccharide serotypes are provided and justified.13vPnC serotypes are dispensed and stored in 50 L stainless steel (SS) vessels. Pneumococcal polysaccharide for the novel serotypes is stored in 5 L polyethylene (PE) flexible containers fitted with ports and tubing to facilitate dispensing into the FCs and subsequent dispensing of ASI during active substance manufacturing.

The data presented provide rationale and justification for the pneumococcal polysaccharides commercial shelf life when stored at the recommended temperature of -15 to -25°C. Activated saccharides are filled into 1 L Type 1 glass bottles, lyophilised and closed with a grey butyl stopper. The stopper is secured with a non-product contact cap. The materials of construction for all product-contact components have been demonstrated to be compatible with the activated saccharides through stability studies for each serotype.

<div style=\"page-break-after: always\"></div>

## Process Validation and/or Evaluation

- 13vPnC serotypes

As part of the 20-valent pneumococcal conjugate vaccine (20vPnC) preparation for licensure, Pfizer did not repeat process validation for the 13 serotypes included in the 13-valent pneumococcal conjugate vaccine (13vPnC) as the processes have been validated before and product quality is monitored by the routine Annual Product Quality Review (APQR) and the Continued Process Verification (CPV) programme which verify that the quality attributes are being appropriately controlled following process validation.

The purpose of process validation was to demonstrate that the pneumococcal polysaccharide conjugate manufacturing process is under control and produces pneumococcal polysaccharide, activated saccharide and monovalent bulk conjugate (MBC) active substance of acceptable quality by meeting all the pre-determined acceptance criteria.

- Novel serotypes

Validation of the novel pneumococcal polysaccharide-CRM197 conjugate serotypes manufacturing processes has been successfully completed starting from each of 3 independent, consecutive thaws of the WCB used in production of pneumococcal polysaccharide active substance intermediate. The validation was designed to demonstrate that the manufacturing process, when operating within defined process controls, can consistently produce polysaccharide and polysaccharide-CRM197 conjugate meeting pre-determined acceptance criteria and demonstrate expected, reproducible, and consistent process performance.

- CRM197

Validation of the manufacturing process for CRM197 has been successfully completed from each of three independent, consecutive thaws of the WCB. The validation was designed to demonstrate that the manufacturing process, when operating within defined process controls, would consistently produce CRM197 meeting pre-determined acceptance criteria and demonstrate expected, reproducible and consistent process performance.

## Manufacturing process development

For the 13vPnC serotypes the pneumococcal polysaccharide processes used commercially in the 13vPnC vaccine are the result of process development work and learning from commercial experience and the activation and conjugation process used commercially is the result of process development work and learning from commercial experience.

As can be seen in the description of the manufacturing process, the fermentation, activation and conjugation for the novel serotypes are similar to what is used for the 13vPnC serotypes while the purification process is different.

The CRM197 processes for all conjugate serotypes are the result of process development work and learning from commercial experience

A comprehensive understanding of the manufacturing processes has been developed through commercial-scale runs and process characterisation studies that include design of experiments (DOE) and using scale-down models of individual unit operations. No design space is claimed.

In alignment with ICH Q10, effective quality systems are in place to support continued quality/process verification and post-approval change management.

<div style=\"page-break-after: always\"></div>

A recurring risk review, including a review of the classification of process parameters, takes place periodically throughout the lifecycle of the product. Knowledge management supports interpretation of all relevant data gathered in support of continuous improvement.

## Characterisation

The applicant has given detailed information on the characterisation of the pneumococcal polysaccharides, the activated pneumococcal polysaccharides and the conjugated polysaccharides.

## 2.4.2.2. Specification

The specifications of the conjugated serotypes contain the same attributes for the 13vPnC and novel serotypes.

The proposed release and stability tests for the pneumococcal monovalent bulk conjugates are in compliance with Ph. Eur. 2150.

## Analytical procedures and reference standards

A summary of the analytical procedures used for pneumococcal saccharide-CRM197 conjugates is provided in the eCTD. Validation or verification of analytical procedures was performed to ensure the quality, identity, purity, and safety of monovalent bulk conjugates (MBC). Analytical procedures were confirmed suitable for their intended use by assessing all relevant validation elements described in ICH Q2(R1), Validation of Analytical Procedures: Text and Methodology. Compendial procedures were verified according to USP &lt;1226&gt; Verification of Compendial Procedures, as well as the relevant Ph. Eur. and JP general chapters.

Non-compendial quantitative analytical procedures were validated for precision, accuracy, specificity, linearity and range. Quantitative procedures used to determine the content of minor constituents were further validated for limit of quantitation. Compendial procedures were confirmed fit for use through method verification.

## Batch analysis and justification of specification

All batches fulfil the acceptance criteria and show, within each serotype, reproducible results well within the limits.

## Container closure

The monovalent bulk conjugate (MBC) is dispensed and stored in engineered film, 2 L (FCs).

## 2.4.2.3. Stability

The data presented provide rationale and justification for the novel pneumococcal saccharideCRM197 conjugate serotypes , 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F commercial shelf lives when stored at the recommended temperature of 2-8 °C.

The data presented provide rationale and justification for the liquid CRM197 commercial shelf life when stored at the recommended temperature of -75±5 °C.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

The 20-valent pneumococcal conjugate (20vPnC) vaccine is a sterile liquid suspension for intramuscular administration of capsular polysaccharide antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F with each saccharide individually conjugated to diphtheria cross reactive material (CRM197).

The vaccine is supplied in a 1 mL glass syringe with a Luer lock closure. Each 1 mL syringe contains a 0.5 mL dose of vaccine, supplied as a single-dose injection for parenteral administration, with no preservative. A 25G x 5/8\" (0.5 x 16 mm) needle or 25G x 1″ (0.5 x 25 mm) needle can be included in the packaging.

## Pharmaceutical Development

The 20vPnC vaccine contains 20 active substances (monovalent bulk conjugate (MBC) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F), each supplied at a target conjugate concentration of 0.5 g/L saccharide.

No novel excipients are used and no excipients of human or animal origin and no novel excipients are used.

Each prefilled syringe of 20vPnC vaccine is designed to deliver 2.2 μg of each conjugate serotype (except serotype 6B) and 4.4 μg of conjugate serotype 6B in 0.5 mL dose of vaccine. The vaccine is formulated in succinate buffer containing sodium chloride (NaCl) and polysorbate 80 (PS80), at pH 5.8, and containing aluminium phosphate (AlPO4) aluminium as an adjuvant. Each 1 mL syringe contains a 0.5 mL dose of vaccine, supplied as a single-dose injection for parenteral administration, with no preservative.

## 2.4.3.2. Manufacture of the product and process controls

Pfizer Manufacturing Belgium N.V. Rijksweg 12, Puurs, Belgium is the manufacturer responsible for the batch release.

## Manufacturing process controls

The 20vPnC vaccine formulation contains 20 monovalent bulk conjugates (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in succinate/ sodium chloride (NaCl) buffer, pH 5.8, and aluminium phosphate (AlPO4) at 0.25 mg/mL aluminium as adjuvant with polysorbate 80.

These IPCs are identified at the level of the formulation step and during the filling process. No reprocessing steps have been identified in the finished product manufacturing process.

## Process validation / verification

Validation of the 20vPnC vaccine finished product manufacturing process has been successfully completed. The validation was designed to demonstrate that the manufacturing process, when operating within defined process controls, can consistently produce 20vPnC finished product meeting pre-determined acceptance criteria and demonstrate expected, reproducible, and consistent process performance.

<div style=\"page-break-after: always\"></div>

## 2.4.3.3. Product specification

All excipients used for 20vPnC vaccine finished product are compendial except for aluminium phosphate suspension (AlPO4).

The release and stability specification for the compendial and non-compendial excipients have been provided. This is deemed acceptable.

The specifications for the final product have been provided and these have been set in compliance with the Ph. Eur. monograph for Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) (2150).

## Analytical procedures and reference standards

Analytical  procedures  were  provided  and  adequately  described.  The  results  generated  for  the verification/validation of the analytical procedures were found satisfactory and demonstrate that the analytical procedures are suitable for use in release and stability testing (assays for content/potency, total and bound antigenicity).

## Batch analysis and justification of specification

Sufficient  batch  data  have  been  included  for  the  different  batches  used  in  the  manufacturing development of the vaccine. Batches have always been tested against the specifications in force at time of testing.

## Container closure

The 20vPnC in a prefilled syringe (PFS) is defined as an integral drug-device combination that is governed as a medicinal product under Directive 2001/83/EC, as amended, as the device component forms an integral product intended exclusively for use in combination with the drug product syringe. The PFS is designed and developed in conformance with ISO 13485:2016.

## 2.4.3.4. Stability of the product

The shelf life claim of 20vPnC finished product is 24 months when stored at the recommended temperature of 2-8°C. The shelf life claim is based on 24 months of real time stability data from 4 primary stability lots of 20vPnC finished product stored at the intended condition of 5±3°C

## 2.4.3.5. Adventitious agents

Multiple mechanisms and procedures are used to minimize the entry of adventitious agents into the process stream. The adventitious agent control programme includes the engineering systems of the facility and vessels, the control of the materials used in the process, various filtration steps to control microbial load in media, buffers and the process stream, and in-process and environmental testing to monitor the level of adventitious agents in and around the process stream.

20vPnC is composed of components derived from microbial fermentation and is not a viral product. Several ingredients of animal origin are used in the preparation of the vaccine component, and the main theoretical risk associated with these ingredients is contamination of the product by transmissible spongiform encephalopathy (TSE) agents. To minimize this risk, the applicant has been vigilant in assuring proper use and control of animal derived materials by:

- Working with suppliers to collect the most up-to-date information on animal derived materials used in this process;

<div style=\"page-break-after: always\"></div>

- Working with the United States Food and Drug Administration (US FDA) for updates on regulations and practices to control TSE in the US;
- Working with other agencies worldwide, including the Committee for Medicinal Products for Human Use (CHMP), when needed, to keep current on any changes in compliance expectations.

Details of the starting material/reagent containing material of animal origin including its source and preparation were discussed and considered satisfactory with regard to TSE. These materials are commercially available and are not specifically produced for the applicant. Other materials of animal origin are used in the production of polymer for the stoppers, filters, manifolds, containers and/or filters components. These components may contain traces of animal tallow derivatives. The tallow is considered compliant with the TSE note for guidance (EMA/410/01, Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products).

Moreover, equipment and materials are cleaned, sterilised and/or chemically decontaminated according to validated procedures, thereby further reducing process risk.

## 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects

The CMC part, Module3 of the dossier was extensive and of high quality.

The applicant has provided detailed descriptions of the intermediates (20 pneumococcal polysaccharides and carrier protein CRM197) and the 20 active substances (Monovalent bulk conjugates). The starting and raw materials have been appropriately described and all process steps have been described and have been validated during the process validation and development. Specifications have been set for intermediates and individual active substances. Analytical methods were described, and validation summaries provided. All acceptance criteria for specifications are properly justified for intermediates and active substances.

Container closure data are provided, and stability programmes are running. The batches used for shelf life claim are deemed representative for commercial batches and as such, acceptable for setting the shelf life. Depending on the serotype-conjugate, a shelf life from 12 months up to 36 months for individual AS is accepted.

Finished product manufacturing process, the control of materials, the process controls and the process development were adequately described. FP specifications and justifications were provided as well as information on the analytical methods, which were properly validated or qualified. Container closure systems for FP were described and are deemed suitable.

Stability data were provided for clinical and PPQ FP lots. The applicant claims a shelf life of 24 months when stored at 2-8°C, which can be granted based on the available data.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

The non-clinical toxicity assessment for 20vPnC consisted of 9 Good Laboratory Practice (GLP)compliant studies, which were conducted in accordance with Good Laboratory Practice for Nonclinical Laboratory Studies, in an OECD member state.

<div style=\"page-break-after: always\"></div>

GLP inspection:  No request for a GLP inspection (routine or triggered) has been made.

The scope of the non-clinical programme is in line with applicable guidelines for the development of a vaccine and is considered adequate. In principle, the vaccine lots used in non-clinical studies should be adequately representative of the formulation intended for clinical investigation. Minor differences are present in the analytical data for nonclinical toxicity study and clinical study drug product lots. However, they are not considered to impact the results of the respective studies.

## 2.5.2. Pharmacology

Non-clinical studies were performed in mice, rats and rabbits to demonstrate immunogenicity of 20vPnC and the monovalent conjugates of the seven new serotypes contained in 20vPnC (serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F). The responses to each of the seven new antigens contained in 20vPnC were evaluated separately as well as in combination. However, according to the European Centre for Disease Prevention and Control (ECDC) the 10 most common serotypes accounting for 70% of typed isolates circulating in Europe are: 8, 3, 19A, 22F, 12F, 9N, 15A, 10A, 23B and 6C (in order of decreasing frequency). Clinical relevance of any cross-functional immune responses for the serotypes not included in 20vPnC may be determined in a post-marketing setting.

The pharmacology studies were adequately designed to assess relevant immune parameters, including functional immune response leading to protection (i.e. IgG induction and opsonophagocytic activity).

In mice, dose-dependent immune responses to the polysaccharide conjugates for the 7 additional serotypes were determined by increases in OPA titres following two SC administrations three weeks apart.

Immunogenicity of each new serotype conjugate was assessed after 2 or 3 SC injections. Even if presented results support immunogenicity of the newly added conjugate serotype, there are limits in the study because of the route of injection used (SC versus IM), and the number of injections (2 or 3 versus 1 in clinics).

In rats, the 7 additional conjugates in 20vPnC were administered as a combined 7-valent vaccine once every three weeks for a total of three doses. Humoral and functional immune responses were observed as measured by dLIA and OPA. Study VR-VTR-10666 has been conducted in female rats only, by the SC route, and with three repeated injections, which does not mimic the foreseen clinical schema (1 unique IM injection in adults in the clinic.

In general, it was demonstrated that the polysaccharide conjugates for the 7 additional serotypes included in 20vPnC are immunogenic in mice and rats. 20vPnC was also found to be immunogenic in rabbits.

In rabbits, increases in serotype-specific IgG and OPA responses were observed following two IM administrations of 20vPnC three weeks apart. Serum IgG levels increased by at least 2 logs compared to baseline. OPA titres increased by at least 27-fold compared to baseline after immunisation.

The serotype 12F capsular polysaccharide structure was found to contain a partial substitution of N-acetyl-galactosamine by 4KQ using newer methodology as compared to the current published structure. Presence or absence of this substitution in the 12F polysaccharide was not found to impact immunogenicity against clinical 12F isolates.

<div style=\"page-break-after: always\"></div>

Standalone safety pharmacology studies were not performed for this submission. This approach is acceptable for vaccines and in line with recent guidance. Furthermore, clinical cage-side observations in combination with microscopic examination of the nervous system and respiratory tract were conducted in the pivotal repeat-dose toxicity study (12GR385) and led to the conclusion that there were no clinical signs indicative of respiratory or neurologic system effects.

The absence of cardiovascular functional endpoints in the pivotal toxicity study is somewhat problematic, since histopathological findings of cardiotoxicity were observed in two animals treated with 20vPnC in that study. These findings are discussed in the toxicology section of this report.

## 2.5.3. Pharmacokinetics

Pharmacokinetic studies have not been conducted for 20vPnC as according to the relevant EMA and WHO Guidelines they are not required for vaccines

## 2.5.4. Toxicology

The initial toxicity assessment for 20vPnC consisted of three GLP-compliant studies in NZW rabbits, including an initial pivotal repeat-dose toxicity study, a fertility and developmental toxicity study and a local tolerance study. Following signs of cardiotoxicity in the pivotal toxicity study, a series of investigative studies was conducted

## 2.5.4.1. Repeat dose toxicity

The toxicity of 20vPnC was evaluated in a pivotal 59-day toxicity study in rabbits when administered by IM injection once every 2 weeks for a total of 5 doses followed by a 4-week dosefree recovery phase. Injection site findings consisting of minimal to moderate chronic-active inflammation and degeneration/necrosis of myofibers as well as injection site reactogenicity were observed. The severity of these reactions in the 20vPnC-dosed animals was comparable to the vehicle group but greater than in rabbits administered saline and was decreased at the end of the recovery phase. All injection site findings and reactogenicity were considered non-adverse in this study.

Microscopic findings of mild to moderate multifocal inflammation with degeneration/necrosis of cardiomyocytes and minimal increased interstitial fibrosis in the papillary muscle of the left ventricle of the heart were observed in one 20vPnC low dose (once the human dose) animal and in one 20vPnC high dose (twice the human dose) animal at the end of the dosing phase. At the end of the recovery phase, marked multifocal interstitial fibrosis was observed in the interventricular septum of one 20vPnC low dose animal. Heart findings were initially attributed to test article administration; however, following multiple investigative activities, the heart findings were considered not related to the vaccine or its components but likely due to stress associated with handling and procedures (see below).

Based on the non-adverse injection site findings and the follow-up investigations on the microscopic heart findings, 2x the clinical dose of 20vPnC (2x 0.5 mL) was considered the NOAEL in this study. However, the heart findings require further explanation, as discussed below.

## Investigative repeat-dose toxicity studies

Additional investigative studies were conducted to understand the potential causative factors in the development of the heart findings observed in the pivotal toxicity study.

<div style=\"page-break-after: always\"></div>

The weight of evidence from these investigative activities indicates that the heart findings were not related to the vaccine conjugates or other vaccine components. This conclusion is based on evidence that comparable heart findings can occur independent of test article in rabbits, heart findings were not due to direct or immune-mediated cardiotoxicity, and comparable findings may be induced in rabbits with increased handling and study procedures, suggesting the potential contribution of factors extrinsic to test article, such as stress, in the development of heart findings.

These conclusions were supported by an external pathology working group comprised of 3 independent, ACVP board-certified veterinary pathologists who performed a blinded review and evaluation of all heart slides from animals diagnosed with inflammation with degeneration/necrosis of cardiac myocytes along with slides without this finding from the initial repeat-dose toxicity study and the 6 follow-on investigative studies. In addition, slides from 3 animals with mild and moderate myocardial inflammation from the historical database were also included in the review.

It is acknowledged that extensive efforts were made to further examine the unexpected heart findings. The additional studies were well designed and the evaluation by an independent pathology working group is appreciated.

During the evaluation procedure, the applicant provided additional data in support of the notion that the cardiac lesions were rabbit-specific, incidental or caused by stress.

## 2.5.4.2. Genotoxicity/ carcinogenicity

No genotoxicity or carcinogenicity studies have been conducted with 20vPnC. In line with the relevant EMA and WHO Guidelines, non-clinical studies evaluating genotoxicity or carcinogenicity are not required for vaccines.

## 2.5.4.3. Reproductive and developmental toxicity

The combined fertility and developmental study (including teratogenicity and postnatal investigations) in rabbits is considered appropriate to detect the effects of 20vPnC on fertility and pre- and postnatal development in pregnant and lactating female F0 animals and on in utero and postnatal development of the offspring. 20vPnC was administered by IM injection at the intended human dose on 4 treatment days (17 and 4 days before mating and on GD 10 and GD 24). Suitability of the animal model was demonstrated by immune response to the vaccine as determined by serum antibody measurements in F0 females, foetuses and pups.

Based on the results of this study, IM administration of 20vPnC before and during gestation to female rabbits did not cause maternal systemic toxicity. Further, there were no 20vPnC-related effects on mating performance or fertility in female rabbits or on embryo-foetal or postnatal survival, growth, or development in the F1 offspring.

## 2.5.4.4. Local tolerance

Local tolerance was examined in female NZW rabbits after administration of a single 0.5 mL subcutaneous injection of 20vPnC. Non-adverse erythema, oedema, and mass at the injection site were observed in that study. This tissue response at the injection site is considered an expected response to vaccines with aluminium-based adjuvants. In order to better elucidate the effect of the adjuvant, however, it would have been preferable to run a vehicle control group in parallel.

<div style=\"page-break-after: always\"></div>

## 2.5.4.5. Other toxicity studies

No antigenicity, immunotoxicity and dependence studies, and no studies on metabolites and impurities were submitted. According to relevant guidance on non-clinical vaccine development, this is acceptable. Immunogenicity was assessed in the pharmacology studies and in several of the toxicity studies.

## 2.5.5. Ecotoxicity/environmental risk assessment

An environmental risk assessment has not been submitted. The absence of an ERA for vaccines is in accordance with CHMP guidance EMEA/CHMP/SWP/4447/00 and therefore acceptable. Discussion on non-clinical aspects

## 2.5.6. Discussion on the non-clinical aspects

In general, the scope of the non-clinical programme is in line with applicable guidelines for the development of a vaccine and is considered adequate.

The vaccine lots used in non-clinical studies should be adequately representative of the formulation intended for clinical investigation and, ideally, should be the same lots as used in clinical studies. According to the Quality part of the dossier, minor differences are present in the analytical data for nonclinical toxicity study and clinical study drug product lots. However, they are not considered to impact the results of the respective studies.

Pharmacology studies conducted with mice, rats and rabbits demonstrated humoral and functional immunogenicity of 20vPnC and the monovalent conjugates of the seven new serotypes contained in it, respectively. In addition, rabbits receiving the full human dose of 20vPnC by two occasions elicited a robust humoral response that was both specific for PnPS and associated with functional killing of the bacterium.

The initial toxicity assessment for 20vPnC consisted of three GLP-compliant studies in rabbits, including a pivotal repeat-dose toxicity study, a fertility and developmental toxicity study and a local tolerance study. Following signs of cardiotoxicity in the pivotal toxicity study, a series of investigative studies was conducted to understand the potential causative factors of the heart findings observed in the pivotal toxicity study. The weight of evidence from these investigative activities indicates that the heart findings were not related to the vaccine conjugates or other vaccine components. This conclusion is based on several observations from the series of investigative studies and was supported by an external pathologist working group.

In the pivotal toxicity study in rabbits, injection site findings consisting of minimal to moderate chronic-active inflammation and degeneration/necrosis of myofibers as well as injection site reactogenicity were observed. The severity of these reactions in the 20vPnC-dosed animals was comparable to the vehicle group and all injection site findings and reactogenicity were considered non-adverse in this study. Microscopic findings of inflammation with degeneration/necrosis of cardiomyocytes and interstitial fibrosis in the heart were observed in three animals treated with 20vPnC.

The submission also contains a combined fertility and developmental study (including teratogenicity and postnatal investigations) in rabbits. Based on the results of this study, IM administration of 20vPnC before and during gestation to female rabbits did not cause maternal systemic toxicity. Further, there were no 20vPnC-related effects on mating performance or fertility in female rabbits or on embryo-foetal or postnatal survival, growth, or development in the F1 offspring.

<div style=\"page-break-after: always\"></div>

In a local subcutaneous tolerance study in female rabbits, non-adverse erythema, oedema, and mass at the injection site were observed. This tissue response at the injection site is considered an expected response to vaccines with aluminium-based adjuvants

## 2.5.7. Conclusion on the non-clinical aspects

Overall, the non-clinical pharmacology studies provided evidence that 20vPnC induces functional antibody activity, which is expected to protect against pneumococcal infection.

The toxicity studies revealed local effects that can be expected for an aluminium-adjuvanted vaccine. Histopathologic findings in the hearts of rabbits were observed in the repeat-dose toxicity studies and were further examined in a serious of investigative studies. It is overall concluded that the findings were incidental, or stress induced and do not raise specific safety concerns.

From a non-clinical point of view, there are no objections against the market approval of 20vPnC.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

Table 2:  20vPnC Clinical Trials Included in the Submission

| Trial (Countries)                                                                                                   | Subject Age/Pneumococcal                        | Groups: Number Subjects                                                                                                                                    | of Primary and Secondary Immunogenicity Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Exploratory Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B7471007 (USA, Sweden): Phase 3, multicentre, randomised, double- blind study with an age- based 3-cohort design    | ≥18 years of age / pneumococcal vaccine naïve   | Cohort 1 (≥60 years) 20vPnC/saline: 1514 13vPnC/PPSV23: 1495 Cohort 2 (50-59 years) 20vPnC: 334 13vPnC: 111 Cohort 3 (18-49 years) 20vPnC: 336 13vPnC: 112 | Primary Objectives: - To describe the safety profile of 20vPnC in adults 18 years of age (yoa) and older (all cohorts). - To demonstrate that the immune responses to the 13 matched serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23 F) induced by 20vPnC in adults ≥60 yoa are non - inferior to the immune response induced by 13vPnC - To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) induced by 20vPnC in adults ≥60 yoa are non -inferior to the immune response induced by PPSV23 Secondary Objectives: - To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 50 through 59 yoa are non-inferior to the immune responses induced by 20vPnC in adults 60 through 64 yoa. - To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 18 through 49 yoa are non-inferior to the immune responses induced by 20vPnC in adults 60 through 64 yoa - To describe the immune responses to 20vPnC in adults ≥60 yoa and older, 50 through 59 years of age, and 18 through 49 yoa | To further describe the immune responses to 20vPnC, including cross- reactivity to serotype 15C, in adults ≥60 years of age, 50 through 59 years of age, and 18 through 49 years of age To describe the immune responses to the 20 serotypes induced by 20vPnC in adults ≥18 years of age with underlying medical conditions or other factors that put them at increased risk for serious pneumococcal infection (eg, asthma, diabetes mellitus, chronic lung disease, cigarette smoking) |
| B7471008 (USA): Phase 3, multicentre, randomised, double- blind, lot consistency study with a 4-arm parallel design | 18-49 years of age / pneumococcal vaccine naïve | 20vPnC Lot 1: 465 20vPnC Lot 2: 475 20vPnC Lot 3: 460 13vPnC: 235                                                                                          | Primary Objective: To describe the safety profile of 20vPnC. Secondary Objectives: To demonstrate that the immune responses to the 20 serotypes induced by 20vPnC are equivalent across 3 lots To describe the immune response to 20vPnC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | To further describe the immune response induced by 20vPnC                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| B7471006 (USA, Sweden): Phase 3, multicentre, randomised, open- label study with a 3- cohort design based on prior pneumococcal vaccination status   | ≥65 years of age / Cohort A: vaccinated with PPSV23 ≥1 year and ≤5 years prior to vaccination in the study, and no prior 13vPnC vaccination Cohort B: vaccinated wi th 13vPnC ≥6 months prior to vaccination in the study, and no prior PPSV23 vaccination Cohort C: vaccinated with 13vPnC followed by PPSV23 (PPSV23 vaccination ≥1 year prior to vaccination in the study)   | Cohort A 20vPnC: 253 13vPnC: 122 Cohort B 20vPnC: 248 13vPnC: 127 Cohort C 20vPnC: 125   | Primary Objectives: To describe the safety profile of 20vPnC. To describe the immune responses to 20vPnC in adults previously vaccinated with PPSV23, previously vaccinated with 13vPnC, or previously vaccinated with both 13vPnC and PPSV23 Secondary Objective: To further describe the immune responses to 20vPnC in adults previously vaccinated with PPSV23, previously vaccinated with 13vPnC, or previously vaccinated with both 13vPnC and PPSV23   | To further describe the immune responses induced by 20vPnC                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| B7471002 (USA): Phase 2, multicentre, randomised, active- controlled, double- blind study with a 2- arm parallel design                              | 60-64 years of age / pneumococcal vaccine naïve                                                                                                                                                                                                                                                                                                                                 | 20vPnC/saline: 222 13vPnC/PPSV23: 222                                                    | Primary Objective: To describe the safety profile of 20vPnC in the study population. Secondary Objective: To describe the immunogenicity of 20vPnC in the study population                                                                                                                                                                                                                                                                                   | To further describe the immune responses induced by 20vPnC in the study population              |
| B7471005 (USA): Phase 1b, randomised, controlled, double- blind study with a 3- arm parallel design, in adults of Japanese descent                   | 18-49 years of age / pneumococcal vaccine naïve                                                                                                                                                                                                                                                                                                                                 | 20vPnC: 35 c7vPnC a : 34 13vPnC: 35                                                      | Primary Objective: To describe the safety profile of 20vPnC and c7vPnC in the study population. Secondary Objective: To describe the immunogenicity of 20vPnC and c7vPnC a in the study population                                                                                                                                                                                                                                                           | To further describe the immune responses induced by 20vPnC and c7vPnC a in the study population |
| B7471001 (USA): Phase 1, first-in-human, randomised, controlled, observer- blinded study with a 2-arm parallel design                                | 18-49 years of age / pneumococcal vaccine naïve                                                                                                                                                                                                                                                                                                                                 | 20vPnC: 33 Tdap: 33                                                                      | Primary Objective: To describe the safety profile of 20vPnC in adults. Secondary Objective: To describe the immune responses induced by 20vPnC in adults.                                                                                                                                                                                                                                                                                                    | To further describe the immune responses induced by 20vPnC in adults                            |

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

No clinical pharmacokinetic (PK) studies with 20vPnC were conducted as these studies are not routinely conducted as part of the evaluation of vaccines, as described in the CHMP 'Guidance on Clinical Evaluation of New Vaccines' (EMEA/CHMP/VWP/164653/2005).

## 2.6.2.2. Pharmacodynamics

Immunogenicity represents the PD effect of the vaccine. Results are described and assessed below in section 2.6.5.

## Mechanism of action

20vPnC contains 20 pneumococcal capsular polysaccharides all conjugated to a CRM197 carrier protein, which modifies the immune response to the polysaccharide from a T-cell independent response to a T-cell dependent response. The T-cell dependent response leads to both an enhanced antibody response and generation of memory B cells, allowing for an anamnestic (booster) response on reexposure to the bacteria.

Vaccination with 20vPnC induces serum antibody production and immunologic memory against the serotypes contained within the vaccine.

In adults, the levels of circulating antibodies that correlate with protection against pneumococcal disease have not been clearly defined.

## Assays

In the clinical programme, vaccine-induced, serotype-specific immune responses in the form of opsonophagocytic activity (OPA) and IgG for all 20 serotypes included in 20vPnC were measured using microcolony OPA assay and direct-binding Luminex immunoassays (dLIA), respectively. Evaluation of serotype-specific OPA responses was the primary objective of the Phase 3 studies supporting licensure; evaluation of serotype-specific total IgG responses was only performed in the Phase 1 and 2 studies.

## 2.6.3. Discussion on clinical pharmacology

Vaccination with 20vPnC induces serum antibody production against 20 pneumococcal serotypes contained in the vaccine. Protection against pneumococcal disease is thought to be mediated by opsonophagocytic mechanisms.

No PK studies were conducted which is acceptable and in accordance with the respective EMA documents.

This MAA is based on an immune-bridging approach between 20vPnC and the previously licensed vaccines with known efficacy (13vPnC and PPSV23). The strategy relies on a comparative evaluation of induction of binding antibodies (Phase 1 &amp; 2 studies) and functional opsonophagocytic antibodies (all clinical studies). As no correlate of protection against pneumococcal disease exists in adults, OPA GMTs are commonly used as surrogate thereof, which is endorsed. Immunogenicity represents the PD effect of the vaccine and is considered main evidence for this MAA since no efficacy studies were conducted (see Clinical Efficacy).

<div style=\"page-break-after: always\"></div>

## 2.6.4. Conclusions on clinical pharmacology

Pivotal evidence for this Marketing Authorisation Application is based on induction of opsonophagocytic antibodies by 20vPnC compared to vaccination with authorised vaccines (13PnC and PPSV23), which is acceptable.

Microcolony OPA assays and direct-binding Luminex immunoassays (dLIA) were used to measure opsonophagocytic activity and IgG, respectively. The microcolony opsonophagocytic assay to detect functional antibodies is considered validated and fit for purpose.

## 2.6.5. Clinical efficacy (immunogenicity)

## 2.6.5.1. Dose response studies

No dose-finding studies were performed. 20vPnC contains the same number of pneumococcal polysaccharides per serotype as 13vPnC: 2.2 μg pneumococcal polysaccharide per serotype (4.4 μg f or serotype 6B) per single dose of 0.5 mL IM.

## Study B7471001 (Phase 1)

Study B7471001 was a phase 1 FIH, randomised, controlled (2-arm parallel design), observer-blinded trial, conducted at one site in the US to compare the safety and immunogenicity of 20vPnC to a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine (Adacel) in 66 healthy adults aged 18 to 49 years (randomised 1:1).

Baseline OPA GMTs of all 20 serotypes were generally similar in the 20vPnC and Tdap groups. There was an increase in OPA GMTs from Day 0 to 1 month after vaccination for all 20 serotypes only in the 20vPnC group. The OPA GMTs measured 1 month after vaccination were higher in the group receiving 20vPnC compared to Tdap with no overlap in 95% CIs. The results were confirmed with OPA GMFRs and the proportion of subjects with an OPA titre ≥ LLOQ. Similar results were observed with IgG GMCs and GMFRs, respectively.

## 2.6.5.2. Main studies

The immunogenicity data obtained in studies B7471007 and B7471006 are considered as the main evidence for this MAA. Combined, both studies represent the target population for pneumococcal vaccination.

Study B7471007, is the pivotal Phase 3, randomised, active-controlled, double-blind non-inferiority trial in pneumococcal vaccine naïve adults ≥18 years of age (with the majority ≥ 60 years of age). The study also includes non-immunocompromised participants with risk factors for pneumococcal disease. This study provides the main evidence for the immunological bridge via different steps represented by the primary and secondary objectives. Participants (target n= 3880) were enrolled in three cohorts and randomised to receive 20vPnC or control (13vPnC groups in Cohorts 2 and 3 were controls for safety only):

<div style=\"page-break-after: always\"></div>

Cohort1:≥60yearsofage（randomized1:1,targetN=3000)

<!-- image -->

Figure 1: Design of study B7471007

Study B7471006 was a phase 3, randomised, multicentre, controlled, open-label trial to evaluate the safety and immunogenicity of 20vPnC in adults ≥65 years of age with prior pneumococcal vaccination.

A pproximately 875 adults ≥65 years of age were targeted to be enrolled into three different cohorts (A, B, C) based on their prior pneumococcal vaccination history.

- Cohort A: Approximately 375 participants who had received PPSV23 ≥1 to ≤5 years previously but had not been vaccinated with 13vPnC were to be randomised (2:1) to receive either 20vPnC or 13vPnC (control for safety only).
- Cohort B: Approximately 375 participants who had received 13vPnC ≥6 months previously, but had not been vaccinated with PPSV23, were to be randomised (2:1) to receive either 20vPnC or PPSV23 (control for safety only).
- Cohort C: Approximately 125 participants who had previously received 13vPnC followed by PPSV23 (PPSV23 vaccination must have been given ≥1 year prior to vaccination in this study) were to receive 20vPnC.

Study B7471007: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal VaccineNaïve Adults 18 Years of Age and Older

Study B7471006: A Phase 3, Randomized, Open-Label Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Adults ≥ 65 Years of Age With Prior Pneumococcal Vaccination

## Methods

- Study Participants

The inclusion and exclusion criteria were designed to include the following populations:

B7471007: Pneumococcal VaccineNaïve Adults ≥18 Years of Age

<div style=\"page-break-after: always\"></div>

B7471006: Adults with prior pneumococcal vaccination (13vPnC and/or PPSV23) ≥65 Years of Age

- Treatments

Investigational Product: 20vPnC (Apexxnar)

## Control Products

13vPnC (Prevenar13): Prevenar 13 contains the same serotypes (in the same amount) and excipients as 20vPnC. It is approved in the EU for the adult population since 2011.

PPSV23 (PNEUMOVAX23): PPSV23 is an unconjugated polysaccharide vaccine. It is nationally approved in the EU since the 1980's. The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F. Further excipients are phenol and sodium chloride. All seven serotypes additionally included in 20vPnC compared to 13vPnC are included in PPSV23.

Table 3: Treatments used in main clinical studies (all given as 0.5 mL single dose, IM)

| Study Code         | Key subject elements                                                                                                                                                                           | Treatments, Planned Sample Size, Randomisation, Timing of Treatment                                                                                                                                                  |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B7471007 (pivotal) | Pneumococcal vaccine- naïve adults ≥18 yoa Cohort 1: ≥ 60 yoa Cohort 2: 50-59 yoa Cohort 3: 18-49 yoa                                                                                          | Cohort 1: n= 3000 (1:1, 20vPnC/saline vs 13vPnC/PPSV23); saline or PPSV23 given 1 month after 20vPnC or 13vPnC, respectively Cohort 2: n= 440 (3:1, 20vPnC vs 13vPnC a ) Cohort 3: n= 440 (3:1, 20vPnC vs 13vPnC a ) |
| B7471006           | Adults ≥ 65 yoa with prior pneumococcal vaccination Cohort A: PPSV23 1-5 years previously Cohort B: 13vPnC ≥6 months previously Cohort C: 13vPnC followed by PPSV23; PPSV23 ≥1 year previously | Cohort A: n= 375 (2:1, 20vPnC vs 13vPnC a ) Cohort B: n= 375 (2:1, 20vPnC vs PPSV23 a ) Cohort C: n= 125 (20vPnC only) All treatments were given at visit 1.                                                         |

a  control for safety only

## · Objectives

## B7471007 Pneumococcal vaccinenaïve adults ≥18 yoa (pivotal);

Primary Immunogenicity Objectives (Cohort 1, ≥60 yoa):

- To demonstrate that the immune responses to the 13 serotypes in 13vPnC (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) induced by 20vPnC in adults 60 years of age and older are non-inferior (lower bound of 2-sided 95% CI for OPA GMR &gt;0.5 [2-fold NI margin]) to the immune response induced by 13vPnC.
- To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) induced by 20vPnC in adults 60 years of age and older are non-inferior (lower bound of 2-sided 95% CI for OPA GMR &gt;0.5 [2-fold NI margin]) to the immune response induced by PPSV23.

<div style=\"page-break-after: always\"></div>

## Secondary Immunogenicity Objective (Cohort 2, 50-59 yoa):

- To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 50 through 59 years of age are non-inferior (lower bound of 2-sided 95% CI for OPA GMR &gt;0.5 [2-fold NI margin]) to the immune responses induced by 20vPnC in adults 60 through 64 years of age.

## Secondary Immunogenicity Objective (Cohort 3, 18-49 yoa):

- To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 18 through 49 years of age are non-inferior (lower bound of 2-sided 95% CI for OPA GMR &gt;0.5 [2-fold NI margin]) to the immune responses induced by 20vPnC in adults 60 through 64 years of age.

## Secondary Immunogenicity Objective (all Cohorts):

- To describe the immune responses to 20vPnC in adults 60 years of age and older, 50 through 59 years of age, and 18 through 49 years of age.

## Exploratory Immunogenicity Objectives (all Cohorts):

- To further describe the immune responses to 20vPnC in adults 60 years of age and older, 50 through 59 years of age, and 18 through 49 years of age.
- To describe the immune responses to the 20 serotypes induced by 20vPnC in adults 18 years of age and older with underlying medical conditions or other factors that put them at increased risk for serious pneumococcal infection (e.g., asthma, diabetes mellitus, chronic lung disease, cigarette smoking).

## B7471006 Adults ≥ 65 yoa with prior pneumococcal vaccination; open label

## Primary Immunogenicity Objective:

- To describe the immune responses to 20vPnC in adults previously vaccinated with PPSV23, previously vaccinated with 13vPnC or previously vaccinated with both (13vPnC and PPSV23).

## Secondary Immunogenicity Objective:

- To further describe the immune responses to 20vPnC in adults previously vaccinated with PPSV23, previously vaccinated with 13vPnC or previously vaccinated with both (13vPnC and PPSV23).

## Exploratory Immunogenicity Objective:

- To further describe the immune responses induced by 20vPnC.

## · Outcomes/endpoints

## B7471007 Pneumococcal vaccinenaïve adults ≥18 yoa (pivotal); (Cohort 1: ≥60 yoa, Cohort 2: 50-59 yoa, Cohort 3: 1849 yoa); double -blind

Primary Immunogenicity Endpoint (Cohort 1, ≥60 yoa):

- Serotype-specific OPA titres 1 month after vaccination.

## Secondary Immunogenicity Endpoints (Cohort 2, 50-59 yoa; Cohort 3, 1849 yoa):

- Serotype-specific OPA titres 1 month after vaccination.

<div style=\"page-break-after: always\"></div>

Secondary I mmunogenicity Endpoints (all Cohorts):

- Fold rise in serotype-specific OPA titres from before to 1 month after vaccination.
- ≥4 -Fold rise in serotype-specific OPA titres from before to 1 month after vaccination.
- Serotypespecific OPA titres ≥ LLOQ 1 month af ter vaccination.

Exploratory Immunogenicity Endpoints (all Cohorts):

- ≥4 -Fold rise in pneumococcal serotype 15C OPA titre from before to 1 month after vaccination.
- Pneumococcal serotype 15C OPA titre ≥ LLOQ 1 month after vaccination.
- Pneumococcal serotype 15C OPA titre 1 month after vaccination.
- Fold rise in pneumococcal serotype 15C OPA titre from before to 1 month after vaccination.
- Serotype-specific OPA titres 1 month after vaccination (for participants with an increased risk for serious pneumococcal infection).

## B7471006 Adults ≥ 65 yoa with prior pneumococcal vaccination; open label

Primary Immunogenicity Endpoint:

- Pneumococcal serotype-specific OPA titres 1 month after vaccination.

Secondary Immunogenicity Endpoints:

- Fold rise in serotype-specific OPA titres from before to 1 month after vaccination.
- ≥4 -Fold rise in serotype-specific OPA titres from before to 1 month after vaccination.
- Serotypespecific OPA titres ≥ LLOQ 1 month after vaccination.

## Exploratory Immunogenicity Endpoints:

- ≥4 -Fold rise in pneumococcal serotype 15C OPA titres from before to 1 month after vaccination.
- Pneumococcal serotype 15C OPA titre ≥ LLOQ 1 month after vaccination.
- Pneumococcal serotype 15C OPA titre 1 month after vaccination.
- Fold rise in pneumococcal serotype 15C OPA titre from before to 1 month after vaccination.

## · Randomisation and Blinding (masking)

## Randomisation:

B7471007 (pivotal study): Allocation of subjects to vaccine groups used a centre-based interactive response technology (IRT) system (interactive web-based response [IWR]) within the age cohorts.

B7471006 : A centre-based interactive response technology system (interactive Web-based response) was used to randomize participants to either 20vPnC or control vaccine group in Cohort A and Cohort B. Every participant received 20vPnC in Cohort C.

## Blinding:

Study B7471006 was an open-label study.

<div style=\"page-break-after: always\"></div>

B7471007 (pivotal study): The study was sponsor, participant, and investigator blinded. Vaccination 1 was to be administered in a double-blind fashion, as the appearance and prefilled syringes of 20vPnC and 13vPnC were identical. At Vaccination 2 (Cohort 1 only), the PI was supposed to assign the responsibility of administering saline and PPSV23 to third-party unblinded site staff who was not to participate in the evaluation of any study subject.

## · Statistical methods

## B7471007: Analysis sets

## Immunogenicity Populations

Three evaluable immunogenicity populations were defined for the analyses of the immunogenicity data: the evaluable 13-matched immunogenicity population (Cohort 1), the evaluable 7-additional immunogenicity population (Cohort 1), and the evaluable-20 immunogenicity population. In addition, the all-available immunogenicity population was defined as well.

Subjects were to be included in the vaccine group as randomised.

## All-Available Immunogenicity Population

This population included all participants who received at least 1 dose of 20vPnC, 13vPnC, PPSV23, or saline and had at least 1 valid and determinate OPA titre after any vaccination. For cohort-specific analysis, the need for all-available tables was assessed separately within each cohort. Only the evaluable population was used for the immunogenicity analyses if there was less than a 5% difference in sample size between the all-available and evaluable populations, (ie, if the evaluable sample size was ≥95% of the all -available sample size).

For the cross-cohort analysis where Cohort 2 or Cohort 3 was being compared to the participants 60 through 64 years of age in Cohort 1, if either cohort in the comparison had less than a 5% difference in sample size between the all-available and evaluable populations (ie, if the evaluable sample size was ≥95% of the all -available sample size), analyses would be based on the evaluable populations only.

## Evaluable 13-Matched Immunogenicity Population, Evaluable 7-Additional Immunogenicity Population and Evaluable-20 Immunogenicity Population

The applicant defined specific primary analysis populations for immunogenicity results of the serotypes included in the respective analysis. The populations are defined similarly based on valid respective OPA titres, appropriate randomisation and vaccination(s) etc. (for detailed definitions of the analysis sets please refer to the clinical AR).

## Safety population

The safety population will include any subject who:

1. receives 1 dose of any of the following: 20vPnC, 13vPnC, PPSV23, or saline; and
2. has safety follow-up after any vaccination.

Subjects will be included in the vaccine group corresponding to the vaccine actually received. The safety population will be the analysis population for safety and reactogenicity endpoints.

<div style=\"page-break-after: always\"></div>

## Primary Immunogenicity objective

Hypothesis testing was planned to be performed to assess noninferiority comparing the 20vPnC/saline vaccine group against the 13vPnC/PPSV23 vaccine group in Cohort 1 for each of the 20 serotypespecific OPA titres. The null hypothesis for each serotype specific OPA titre was:

where

- ln(0.5) corresponds to a 2-fold margin for noninferiority.
- ln(µA) is the natural log of the geometric mean OPA titre 1 month after 20vPnC administration for the 20vPnC/saline group.
- ln(µB) is the natural log of the geometric mean OPA titre 1 month after 13vPnC administration for the 13vPnC/PPSV23 group when the endpoint is the geometric mean OPA titre from 1 of the shared 13 serotypes in 13vPnC, or,
- ln(µB) is the natural log of the geometric mean OPA titre 1 month after PPSV23 administration for the 13vPnC/PPSV23 group when the endpoint is the geometric mean OPA titre from 1 of the 7 additional serotypes.

The primary analysis approach was to be based on a linear regression model. For the comparison of OPA results in Cohort 1, the following terms will be included in the regression model: corresponding baseline OPA titre, age, sex (male or female), smoking status (current smoker, ex-smoker, never smoked), and vaccine group. The difference between these least squares (LS) means on the natural log scale and associated CI estimated from the linear regression model was to be transformed back to the original scale to obtain the GMR and CI. 2-sided 95% CIs were to be used for the noninferiority comparisons of the 20vPnC/saline group to the 13vPnC/PPSV23 group.

As a sensitivity/robustness analysis, the unadjusted serotype-specific OPA GMR and 95%-CI was also planned to be calculated for each of the serotypes by calculating differences in means and 95% CIs on the natural log scale based on the t-distribution, then exponentiating the results.

After the noninferiority between the 20vPnC/saline and 13vPnC/PPSV23 vaccine groups in Cohort 1 for each of the 7 additional serotypes was established, superiority of serotype-specific OPA titres comparing 20vPnC/saline to 13vPnC/PPSV23 was planned to be evaluated for the 7 additional serotypes. The 7 superiority hypotheses were planned to be tested at a 0.025 level (1-sided) with Hochberg's step-up procedure to control the type I error rate. Since the superiority hypotheses for the 7 additional serotypes were planned to be tested only after the noninferiority was achieved for the 7 serotypes, the familywise type I error rate for all hypothesis assessments in Cohort 1 was considered well controlled.

For Cohort 1, subgroup analyses by age group (60 through 64, 65 through 69, 70 through 79, and ≥80 years of age), sex (male and female), and race (white, African American, and others [the rest combined]) for the following immunogenicity endpoints were planned to be performed:

- -Serotype-specific OPA GMTs and the associated 95% CIs at baseline and 1 month after vaccination.
- -GMFRs and the associated 95% CIs in serotype specific OPA titres from before to 1 month after vaccination.
- -Proportion and the associated 95% CIs of subjects with a ≥4 -fold rise in serotype-specific OPA titres from before to 1 month after vaccination.
- -Proportion and the associated 95% CIs of subjects with serotype specific OPA titres ≥ LLOQ before and 1 month after vaccination.

<div style=\"page-break-after: always\"></div>

Additionally, serotype specific OPA GMTs and the associated 95% CIs at baseline and 1 month after vaccination were planned to be summarised by country for subjects ≥65 years of age from Cohort 1.

## Secondary Immunogenicity objective

Hypothesis testing was also planned to be performed to assess noninferiority comparing the 20 serotype-specific OPA titres 1 month after vaccination in each of the 20vPnC groups in the younger cohorts (subjects 50 through 59 years of age in Cohort 2 and subjects 18 through 49 years of age in Cohort 3) against subjects 60 through 64 years of age from Cohort 1 one month after vaccination in the 20vPnC/saline group. Again, a 2-fold margin was planned to be used for each of the noninferiority hypothesis tests. The null hypothesis for each serotype specific OPA titre was:

where

- ln(0.5) corresponds to a 2-fold margin for noninferiority.
- ln(µC) is the natural log of the geometric mean OPA titre 1 month after 20vPnC administration for the younger group, subjects 50 through 59 years of age (Cohort 2) or subjects 18 through 49 years of age (Cohort 3).
- ln(µA) is the natural log of the geometric mean OPA titre 1 month after 20vPnC administration for subjects 60 through 64 years of age from Cohort 1.

The analysis approach was planned to be based on a linear regression model. The following terms were to be included in the regression model: corresponding baseline OPA titre, sex (male or female), smoking status (current smoker, ex-smoker, never smoked), and cohort. Two separate regression models were to be fitted, one for comparing Cohort 2 results to Cohort 1 (subjects 60 through 64 years of age) results, and the other for comparing Cohort 3 results to Cohort 1 (subjects 60 through 64 years of age) results. Only the OPA data from the 20vPnC/saline group in Cohort 1 (subjects 60 through 64 years of age) and the OPA data from the 20vPnC group in Cohort 2/Cohort 3 were to be included in the regression models.

The difference between these least squares (LS) means on the natural log scale and associated CI estimated from the linear regression model were to be transformed back to the original scale to obtain the GMR and CI. 2-sided 95% CIs were to be used for the noninferiority comparison of the 20vPnC group from Cohort 2/Cohort 3 to the 20vPnC/saline group from subjects 60 through 64 years of age in Cohort 1.

Like in the primary analysis setting, as a sensitivity/robustness analysis, the unadjusted serotypespecific OPA GMR and 95%-CI was also planned to be calculated for each of the serotypes by calculating differences in means and 95% CIs on the natural log scale based on the t-distribution, then exponentiating the results.

In the SAP it was noted that these secondary noninferiority assessments comparing the younger age groups (Cohort 3 [subjects 18 through 49 years of age] or Cohort 2 [subjects 50 through 59 years of age]) to the subjects 60 through 64 years of age in Cohort 1 were considered meaningful only after the establishment of overall comparability between 20vPnC and the corresponding controls in Cohort 1. Therefore, there no increase in the type I error rate was formally seen at the planning stage, and no type I error adjustments were seen needed in the immunogenicity assessments for the 2 younger age cohorts (Cohort 2 or Cohort 3).

For Cohort 2 and Cohort 3, subgroup analyses by sex (male and female) and race (white, African American, and others [the rest combined]) for serotype-specific GMTs and the associated 95% CIs were planned to be provided for the 20vPnC group only at both baseline and 1 month after vaccination.

<div style=\"page-break-after: always\"></div>

## Further secondary and exploratory immunogenicity endpoints and interim analysis B7471006: Analysis sets

## Safety population

The safety population was to include any subject who received 1 dose of 20vPnC, PPSV23, or 13vPnC and had safety follow-up after vaccination. Subjects were to be included in the vaccine group corresponding to the vaccine actually received. The safety population was planned to be used as the analysis population for safety and reactogenicity endpoints.

## Evaluable Immunogenicity Populations

The evaluable immunogenicity population was planned to include any subject who

- receives 20vPnC as randomised,
- is enrolled in the appropriate cohort based on prior pneumococcal vaccination history,
- has the Visit 2 blood collection within 27 to 49 days after vaccination,
- has at least 1 valid and determinate OPA titre for any serotype for Visit 2, and
- does not have any other major protocol deviations as determined by the clinician.

The evaluable immunogenicity population was planned to be the primary analysis population for immunogenicity results.

## All-available Immunogenicity Populations

The all-available immunogenicity population was planned to include all subjects who receive 20vPnC, and had at least 1 valid and determinate OPA titre 1 month after vaccination. The all-available immunogenicity population was planned to be the secondary analysis population for immunogenicity analysis. Only the evaluable population was to be used for the summary of immunogenicity results if there was less than a 10% difference in sample size between the all-available and evaluable populations.

## Statistical analysis methods

Safety/reactogenicity results were summarised by standard statistical analysis methods as described in detail in the SAP, separately for each cohort.

Immunogenicity results of serotype specific OPA titres were to be determined only for subjects who received 20vPnC in each cohort as subjects who received 13vPnC or PPSV23 were included in the study served as the control for safety. Immunogenicity results from the 20vPnC groups were to be summarised side by side from all 3 cohorts. For immunogenicity results of serotype-specific OPA titres, geometric mean titres (GMTs) as well as geometric mean-fold rises (GMFR) were to be computed along with associated 95% CIs.

Standard descriptive statistical methodology was pre-planned to summarise: Subject disposition, demographic characteristics, prior vaccination status, and medical history.

<div style=\"page-break-after: always\"></div>

## Results

## · Participant flow

## Table 4: Study B7471007 Disposition of All Subjects - Cohort 1 - All Randomised

|                                                         | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   |              |
|---------------------------------------------------------|---------------------------------|---------------------------------|--------------|
|                                                         | 20vPnC/Saline (%) g!I           | 13vPnC/PPSV23 (%) !             | Total na (%) |
| Randomizedb                                             | 1514 (100.0)                    | 1495 (100.0)                    | 3009 (100.0) |
| Not vaccinated                                          | 7 (0.5)                         | 5 (0.3)                         | 12 (0.4)     |
| Vaccinated                                              |                                 |                                 |              |
| Vaccination 1                                           | 1507 (99.5)                     | 1490 (99.7)                     | 2997 (99.6)  |
| Vaccination 2c                                          | 1461 (96.5)                     | 1446 (96.7)                     | 2907 (96.6)  |
| Completed 1-month follow-up after Vaccination 2/Visit 3 | 1441 (95.2)                     | 1428 (95.5)                     | 2869 (95.3)  |
| Completed study                                         | 1418 (93.7)                     | 1417 (94.8)                     | 2835 (94.2)  |
| Withdrawn from study                                    | 96 (6.3)                        | 78 (5.2)                        | 174 (5.8)    |
| Reason for withdrawal                                   |                                 |                                 |              |
| Adverse event                                           | 11 (0.7)                        | 8 (0.5)                         | 19 (0.6)     |
| Death                                                   | 1 (0.0)                         | 0                               | 1 (0.0)      |
| Lost to follow-up                                       | 41 (2.7)                        | 28 (1.9)                        | 69 (2.3)     |
| No longer meets eligibility criteria                    | 3 (0.2)                         | 9 (0.6)                         | 12 (0.4)     |
| Protocol deviation                                      | 21 (1.4)                        | 13 (0.9)                        | 34 (1.1)     |
| Withdrawal by subject                                   | 19 (1.3)                        | 20 (1.3)                        | 39 (1.3)     |

Table 5: Study B7471007 Disposition of All Subjects - Cohort 2 - All Randomised

|                                                      | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   |              |
|------------------------------------------------------|---------------------------------|---------------------------------|--------------|
|                                                      | 20vPnC na (%)                   | 13vPnC (%) vI                   | Total na (%) |
| Randomizedb                                          | 334 (100.0)                     | 111 (100.0)                     | 445 (100.0)  |
| Not vaccinated                                       | 0                               | 0                               | 0            |
| Vaccinated                                           | 334 (100.0)                     | 111 (100.0)                     | 445 (100.0)  |
| Completed 1-monthfollow up after vaccination/Visit 2 | 330 (98.8)                      | 110 (99.1)                      | 440 (98.9)   |
| Completed study                                      | 323 (96.7)                      | 109 (98.2)                      | 432 (97.1)   |
| Withdrawn from study                                 | 11 (3.3)                        | 2 (1.8)                         | 13 (2.9)     |
| Reason for withdrawal                                |                                 |                                 |              |
| Lost to follow-up                                    | 9 (2.7)                         | 2 (1.8)                         | 11 (2.5)     |
| Protocol deviation                                   | 1 (0.3)                         | 0                               | 1 (0.2)      |
| Withdrawal by subject                                | 1 (0.3)                         | 0                               | 1 (0.2)      |

<div style=\"page-break-after: always\"></div>

Table 6: Study B7471007 Disposition of All Subjects - Cohort 3 - All Randomised

|                                                       | Vaccine Group (asRandomized)   | Vaccine Group (asRandomized)   |              |
|-------------------------------------------------------|--------------------------------|--------------------------------|--------------|
|                                                       | 20vPnC (%) vlI                 | 13vPnC (%) gII                 | Total (%) 1I |
| Randomizedb                                           | 336 (100.0)                    | 112 (100.0)                    | 448 (100.0)  |
| Not vaccinated                                        | 1 (0.3)                        | 0                              | 1 (0.2)      |
| Vaccinated                                            | 335 (99.7)                     | 112 (100.0)                    | 447 (99.8)   |
| Completed 1-month follow up after vaccination/Visit 2 | 325 (96.7)                     | 109 (97.3)                     | 434 (96.9)   |
| Completed study                                       | 319 (94.9)                     | 104 (92.9)                     | 423 (94.4)   |
| Withdrawn from study                                  | 17 (5.1)                       | 8 (7.1)                        | 25 (5.6)     |
| Reason for withdrawal                                 |                                |                                |              |
| Lost to follow-up                                     | 14 (4.2)                       | 8 (7.1)                        | 22 (4.9)     |
| No longer meets eligibility criteria                  | 1 (0.3)                        | 0                              | 1 (0.2)      |
| Protocol deviation                                    | 1 (0.3)                        | 0                              | 1 (0.2)      |
| Withdrawal by subject                                 | 1 (0.3)                        | 0                              | 1 (0.2)      |

a. n =Number of subjects with the specified characteristic b. These values are the denominators for the percentage calculations.

Table 7: Study B7471006 Disposition of All Subjects - All Randomised

|                                               | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)             | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   |
|-----------------------------------------------|---------------------------------|---------------------------------|-------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                               | 20vPnC (%) g!I                  | Cohort A 13vPnC (%) e!I         | Total na (%)                              | 20vPnC (%) v!I                  | Cohort B PPSV23 (%) g!I         | Total (%) eI                    | Cohort C 20vPnC n² (%)          |
| Randomizedb                                   | 253 (100.0)                     | 122 (100.0)                     | 375 (100.0)                               | 248 (100.0)                     | 127 (100.0)                     |                                 | 375 (100.0)125 (100.0)          |
| Not vaccinated                                | 0                               | 0                               | 0                                         | 2 (0.8)                         | 0                               | 2 (0.5)                         | 0                               |
| Vaccinated                                    | 253 (100.0)                     | 122 (100.0)                     | 375 (100.0) 246 (99.2)                    |                                 | 127 (100.0)                     | 373 (99.5)                      | 125 (100.0)                     |
| Completed 1-month follow-up after vaccination |                                 |                                 | 251 (99.2) 120 (98.4)371 (98.9)245 (98.8) |                                 | 127 (100.0)                     |                                 | 372 (99.2)125 (100.0)           |
| Completed study                               |                                 |                                 |                                           |                                 |                                 |                                 | ）125 (100.0)                    |
| Withdrawn from study                          | 3 (1.2)                         | 3 (2.5)                         | 6 (1.6)                                   | 3 (1.2)                         | 1 (0.8)                         | 4 (1.1)                         | 0                               |
| Reason for withdrawal                         |                                 |                                 |                                           |                                 |                                 |                                 |                                 |
| Lost to follow-up                             | 1 (0.4)                         | 1 (0.8)                         | 2 (0.5)                                   | 0                               | 0                               | 0                               | 0                               |
| No longer meets eligibility criteria          | 0                               | 1 (0.8)                         | 1 (0.3)                                   | 0                               | 0                               | 0                               | 0                               |
| Protocol deviation                            | 1 (0.4)                         | 1 (0.8)                         | 2 (0.5)                                   | 2 (0.8)                         | 0                               | 2 (0.5)                         | 0                               |
| Withdrawal by subject                         | 1 (0.4)                         | 0                               | 1 (0.3)                                   | 1 (0.4)                         | 1 (0.8)                         | 2 (0.5)                         | 0                               |

b. These values are the denominators for the percentage calculations.

<div style=\"page-break-after: always\"></div>

## · Baseline data

## Table  8:  Study  B7471007  Demographic  Characteristics  and  Smoking  History  -  Cohort  1  Safety Population

|                                                       | Vaccine Group (as Administered)   | Vaccine Group (as Administered)   |                        |
|-------------------------------------------------------|-----------------------------------|-----------------------------------|------------------------|
|                                                       | 20vPnC/Saline (N*=1507) (%) q1I   | 13vPnC/PPSV23 (N*=1490) (%) qI    | Total (N*=2997) (%) qI |
| Sex                                                   |                                   |                                   |                        |
| Male                                                  | 610 (40.5)                        | 611 (41.0)                        | 1221 (40.7)            |
| Female                                                | 897 (59.5)                        | 879 (59.0)                        | 1776 (59.3)            |
| Race                                                  |                                   |                                   |                        |
| White                                                 | 1295 (85.9)                       | 1237 (83.0)                       | 2532 (84.5)            |
| Black orAffricanAmerican                              | 177 (11.7)                        | 212 (14.2)                        | 389 (13.0)             |
| Asian                                                 | 19 (1.3)                          | 15 (1.0)                          | 34 (1.1)               |
| AmericanIndianorAlaskaNative                          | 6 (0.4)                           | 9 (0.6)                           | 15 (0.5)               |
| NativeHawaiianorotherPacificIslander                  | 1 (0.0)                           | 1 (0.0)                           | 2 (0.0)                |
| Multiracial                                           | 7 (0.5)                           | 9 (0.6)                           | 16 (0.5)               |
| Not reported                                          | 2 (0.1)                           | 7 (0.5)                           | 9 (0.3)                |
| Ethnicity                                             |                                   |                                   |                        |
| Hispanic/Latino                                       | 167 (11.1)                        | 169 (11.3)                        | 336 (11.2)             |
| Non-Hispanic/non-Latino                               | 1324 (87.9)                       | 1308 (87.8)                       | 2632 (87.8)            |
| Not reported                                          | 16 (1.1)                          | 13 (0.9)                          | 29 (1.0)               |
| Age group                                             |                                   |                                   |                        |
| 60 to 64 Years                                        | 993 (65.9)                        | 992 (66.6)                        | 1985 (66.2)            |
| 65 to 69 Years                                        | 319 (21.2)                        | 305 (20.5)                        | 624 (20.8)             |
| 70 to 79 Years                                        | 160 (10.6)                        | 159 (10.7)                        | 319 (10.6)             |
| ≥80 Years                                             | 35 (2.3)                          | 34 (2.3)                          | 69 (2.3)               |
| Age at Vaccination 1 (years)                          |                                   |                                   |                        |
| Mean (SD)                                             | 64.6 (4.82)                       | 64.6 (4.81)                       | 64.6 (4.82)            |
| Median                                                | 63.0                              | 63.0                              | 63.0                   |
| Min, max                                              | (60, 91)                          | (60, 89)                          | (60, 91)               |
| Smoking History                                       |                                   |                                   |                        |
| Current smoker                                        | 170 (11.3)                        | 192 (12.9)                        | 362 (12.1)             |
| Time since the current smoker started smoking (years) |                                   |                                   |                        |
| Mean (SD)                                             | 38.4 (15.36)                      | 37.4 (14.44)                      | 37.9 (14.86)           |
| Median                                                | 43.7                              | 42.3                              | 42.8                   |
| Min, max                                              | (0.2, 62.8)                       | (0.4, 67.7)                       | (0.2, 67.7)            |
| Ex-smoker                                             | 446 (29.6)                        | 472 (31.7)                        | 918 (30.6)             |
| Time since the ex-smoker stopped smoking (years)      |                                   |                                   |                        |
| Mean (SD)                                             | 23.5 (14.62)                      | 24.7 (14.84)                      | 24.1 (14.74)           |
| Median                                                | 22.8                              | 25.6                              | 23.8                   |
| Min, max                                              | (0.1, 59.6)                       | (0.0, 56.4)                       | (0.0, 59.6)            |
| Never smoked                                          | 891 (59.1)                        | 826 (55.4)                        | 1717 (57.3)            |

a. N=number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.

b. n=Number of subjects with the specified characteristic.

<div style=\"page-break-after: always\"></div>

Table 9: Study B7471007 Demographic Characteristics and Smoking History - Cohort 2 Safety Population

|                                                  | Vaccine Group (as Administered)   | Vaccine Group (as Administered)   | Vaccine Group (as Administered)   |
|--------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                                  | 20vPnC (N=334) (%) q              | 13vPnC (N=111) (%) q              | Total (N*=445) (%) ql             |
| Sex                                              |                                   |                                   |                                   |
| Male                                             | 139 (41.6)                        | 42 (37.8)                         | 181 (40.7)                        |
| Female                                           | 195 (58.4)                        | 69 (62.2)                         | 264 (59.3)                        |
| Race                                             |                                   |                                   |                                   |
| White                                            | 278 (83.2)                        | 90 (81.1)                         | 368 (82.7)                        |
| Black or African American                        | 35 (10.5)                         | 15 (13.5)                         | 50 (11.2)                         |
| Asian                                            | 10 (3.0)                          | 2 (1.8)                           | 12 (2.7)                          |
| American Indian or Alaska Native                 | 0                                 | 3 (2.7)                           | 3 (0.7)                           |
| Multiracial                                      | 6 (1.8)                           | 1 (0.9)                           | 7 (1.6)                           |
| Not reported                                     | 5 (1.5)                           | 0                                 | 5 (1.1)                           |
| Ethnicity                                        |                                   |                                   |                                   |
| Hispanic/Latino                                  | 12 (3.6)                          | 8 (7.2)                           | 20 (4.5)                          |
| Non-Hispanic/non-Latino                          | 319 (95.5)                        | 101 (91.0)                        | 420 (94.4)                        |
| Not reported                                     | 3 (0.9)                           | 2 (1.8)                           | 5 (1.1)                           |
| Age at vaccination (years)                       |                                   |                                   |                                   |
| Mean (SD)                                        | 54.9 (2.77)                       | 55.0 (3.11)                       | 54.9 (2.85)                       |
| Median                                           | 55.0                              | 56.0                              | 55.0                              |
| Min, max                                         | (50, 59)                          | (48, 59)                          | (48, 59)                          |
| Smoking History                                  |                                   |                                   |                                   |
| Current smoker                                   | 52 (15.6)                         | 17 (15.3)                         | 69 (15.5)                         |
| Mean (SD)                                        | 31.6 (11.42)                      | 28.7 (13.54)                      | 30.9 (11.94)                      |
| Median                                           | 35.6                              | 30.7                              | 34.7                              |
| Min, max                                         | (1.7, 48.7)                       | (0.6, 50.6)                       | (0.6, 50.6)                       |
| Ex-smoker                                        | 67 (20.1)                         | 22 (19.8)                         | 89 (20.0)                         |
| Time since the ex-smoker stopped smoking (years) |                                   |                                   |                                   |
| Mean (SD)                                        | 18.5 (11.57)                      | 18.8 (13.30)                      | 18.5 (11.94)                      |
| Median                                           | 19.7                              | 19.6                              | 19.7                              |
| Min, max                                         | (0.5, 41.6)                       | (0.1, 40.6)                       | (0.1, 41.6)                       |
| Never smoked                                     | 215 (64.4)                        | 72 (64.9)                         | 287 (64.5)                        |

Note: One Subject was incorrectly enrolled in Cohort 2 (50-59 years of age), rather than in Cohort 3 (18-49 years of age),and is included in the cohort 2 data analysis.

a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.

b. n=Number of subjects with the specified characteristic.

<div style=\"page-break-after: always\"></div>

Table 10: Study B7471007 Demographic Characteristics and Smoking History - Cohort 3 Safety Population

| Sex                                                   |             |             |             |
|-------------------------------------------------------|-------------|-------------|-------------|
| Male                                                  | 121 (36.1)  | 35 (31.3)   | 156 (34.9)  |
| Female                                                | 214 (63.9)  | 77 (68.8)   | 291 (65.1)  |
| Race                                                  |             |             |             |
| White                                                 | 274 (81.8)  | 101 (90.2)  | 375 (83.9)  |
| Black or African American                             | 34 (10.1)   | 7 (6.3)     | 41 (9.2)    |
| Asian                                                 | 11 (3.3)    | 1 (0.9)     | 12 (2.7)    |
| AmericanIndian orAlaskaNative                         | 1 (0.3)     | 1 (0.9)     | 2 (0.4)     |
| NativeHawaiian or other PacificIslander               | 3 (0.9)     | 1 (0.9)     | 4 (0.9)     |
| Multiracial                                           | 8 (2.4)     | 1 (0.9)     | 9 (2.0)     |
| Not reported                                          | 4 (1.2)     | 0           | 4 (0.9)     |
| Ethnicity                                             |             |             |             |
| Hispanic/Latino                                       | 24 (7.2)    | 7 (6.3)     | 31 (6.9)    |
| Non-Hispanic/non-Latino                               | 300 (89.6)  | 102 (91.1)  | 402 (89.9)  |
| Not reported                                          | 11 (3.3)    | 3 (2.7)     | 14 (3.1)    |
| Age at vaccination (years)                            |             |             |             |
| Mean (SD)                                             | 34.0 (8.77) | 33.9 (8.03) | 34.0 (8.58) |
| Median                                                | 34.0        | 32.0        | 33.0        |
| Min, max                                              | (18, 60)    | (19, 49)    | (18, 60)    |
| Smoking History                                       |             |             |             |
| Current smoker                                        | 49 (14.6)   | 22 (19.6)   | 71 (15.9)   |
| Time since the current smoker started smoking (years) |             |             |             |
| Mean (SD)                                             | 14.8 (8.88) | 13.5 (8.99) | 14.4 (8.87) |
| Median                                                | 13.6        | 15.1        | 13.6        |
| Min, max                                              | (0.2, 34.5) | (0.1, 33.6) | (0.1, 34.5) |
| Ex-smoker                                             | 47 (14.0)   | 22 (19.6)   | 69 (15.4)   |
| Time since the ex-smoker stopped smoking (years)      |             |             |             |
| Mean (SD)                                             | 8.1 (6.92)  | 6.8 (5.85)  | 7.7 (6.58)  |
| Median                                                | 6.6         | 5.6         | 6.6         |
| Min, max                                              | (0.3, 25.5) | (0.5, 20.6) | (0.3, 25.5) |
| Never smoked                                          | 239 (71.3)  | 68 (60.7)   | 307 (68.7)  |

Note: One Subject was incorrectly enrolled in Cohort 3 (18-49 years of age), rather than in Cohort 1 ( ≥60 years of age ), and is included in he Cohort 3 data analysis.

a. N=number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.

b. n=Number of subjects with the specified characteristic.

In study B7471007 the following frequencies of subjects with one or more risk factor(s) other than smoking (evaluable 13-Matched Immunogenicity Population for Cohort 1 and evaluable 20-Matched Immunogenicity Population for Cohorts 2 and 3) were reported: Cohort 1: 20vPnC/Saline (354/1435; 24.7%) vs 13vPnC/PPSV23 (404/1420; 28.5%). Cohort 2: 20vPnC (65/321; 20.2%) vs 13vPnC (21/108; 19.4%). Cohort 3: 20vPnC (39/317; 12.3%) vs 13vPnC (13/106; 12.3%). The three most common medical conditions or disease with multiple medical conditions reported (with total frequencies in brackets for cohorts 1, 2 and 3, respectively) were Type 2 diabetes mellitus (14.3%, 11.5%, 2.8%), asthma (6.1%, 5.6%, 7.6%) and chronic cardiovascular disease (4.9%, 3.7%, 0.9%).

<div style=\"page-break-after: always\"></div>

Table 11: Study B7471006 Demographic Characteristics and Smoking History- Safety Population

|                                                       | Vaccine Group (asAdministered)   | Vaccine Group (asAdministered)                                | Vaccine Group (asAdministered)              | Vaccine Group (asAdministered)   | Vaccine Group (asAdministered)   | Vaccine Group (asAdministered)                                 | Vaccine Group (asAdministered)   |
|-------------------------------------------------------|----------------------------------|---------------------------------------------------------------|---------------------------------------------|----------------------------------|----------------------------------|----------------------------------------------------------------|----------------------------------|
|                                                       | 20vPnC (N=253)                   | Cohort A 13vPnC (N=122)                                       | Total (N=375)                               | 20vPnC (Na=246)                  | Cohort B PPSV23 (N=127)          | Total (N=373)                                                  | Cohort C 20vPnC (N=125)          |
|                                                       |                                  | nb (%)                                                        |                                             |                                  |                                  |                                                                |                                  |
|                                                       | nb (%)                           |                                                               | (%) qlI                                     | (%) qlI                          | (%) qlI                          | nb (%)                                                         | nb (%)                           |
| Sex                                                   |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| Male                                                  |                                  | 113 (44.7) 58 (47.5)                                          |                                             | 171 (45.6)108 (43.9) 59 (46.5)   |                                  | 167 (44.8)                                                     | 60 (48.0)                        |
| Female                                                |                                  |                                                               |                                             |                                  |                                  | 206 (55.2)                                                     | 65 (52.0)                        |
| Race                                                  |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| White                                                 |                                  | 236 (93.3) 110 (90.2)                                         | 346 (92.3)                                  |                                  | 226 (91.9) 118 (92.9)            | 344 (92.2)                                                     | 117 (93.6)                       |
| Black or African American                             | 15 (5.9)                         | 8 (6.6)                                                       | 23 (6.1)                                    | 14 (5.7)                         | 6 (4.7)                          | 20 (5.4)                                                       | 4 (3.2)                          |
| Asian                                                 | 1 (0.4)                          | 2 (1.6)                                                       | 3 (0.8)                                     | 0                                | 2 (1.6)                          | 2 (0.5)                                                        | 0                                |
| American Indian or Alaskan                            | 1 (0.4)                          | 0                                                             | 1 (0.3)                                     | 1 (0.4)                          | 0                                | 1 (0.3)                                                        | 0                                |
| Native Native Hawaiian or other                       | 0                                | 1 (0.8)                                                       | 1 (0.3)                                     | 1 (0.4)                          | 1 (0.8)                          | 2 (0.5)                                                        | 0                                |
| Pacific Islander Multiracial                          | 0                                | 0                                                             | 0                                           | 1 (0.4)                          | 0                                | 1 (0.3)                                                        | 3 (2.4)                          |
| Not reported                                          | 0                                | 1 (0.8)                                                       | 1 (0.3)                                     | 3 (1.2)                          | 0                                | 3 (0.8)                                                        | 1 (0.8)                          |
| Ethnicity                                             |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| Hispanic/Latino                                       | 4 (1.6)                          | 3 (2.5)                                                       | 7 (1.9)                                     | 6 (2.4)                          | 1 (0.8)                          | 7 (1.9)                                                        | 2 (1.6)                          |
| Non-Hispanic/non-Latino                               | 247 (97.6) 117 (95.9)            |                                                               | 364 (97.1)                                  | 231 (93.9) 122 (96.1)            |                                  | 353 (94.6)                                                     | 113 (90.4)                       |
| Not reported                                          | 2 (0.8)                          | 2 (1.6)                                                       | 4 (1.1)                                     | 9 (3.7)                          | 4 (3.1)                          | 13 (3.5)                                                       | 10 (8.0)                         |
| Country                                               |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| USA                                                   |                                  |                                                               | 163 (64.4)79 (64.8)242 (64.5)               | 246 (100.0)                      | 127 (100.0)                      | 373 (100.0)125 (100.0)                                         |                                  |
| Sweden                                                |                                  |                                                               | 90 (35.6)43 (35.2)133 (35.5)                | 0                                | 0                                | 0                                                              | 0                                |
| Age group                                             |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| 65 to 69 years                                        | 143 (56.5) 63 (51.6)             |                                                               | 206 (54.9)136 (55.3) 72 (56.7)              |                                  |                                  | 208 (55.8)                                                     | 70 (56.0)                        |
| 70 to 79 years                                        | 105 (41.5) 57 (46.7)             |                                                               | 162 (43.2)                                  | 86 (35.0)                        | 43 (33.9)                        | 129 (34.6)                                                     | 47 (37.6)                        |
| ≥80 years                                             | 5 (2.0)                          | 2 (1.6)                                                       | 7 (1.9)                                     | 24 (9.8)                         | 12 (9.4)                         | 36 (9.7)                                                       | 8 (6.4)                          |
| Age at vaccination (years)                            |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| Mean (SD)                                             | 69.6                             | 70.2                                                          | 69.8 (3.96)                                 | 70.7                             | 70.6                             | 70.7 (5.71)                                                    | 70.8 (4.26)                      |
|                                                       | (3.88)                           | (4.09)                                                        |                                             | (5.71)                           | (5.73)                           |                                                                |                                  |
| Median                                                | 69.0                             | 69.0                                                          | 69.0                                        | 68.0                             | 68.0                             | 68.0                                                           | 69.0                             |
| Min, Max                                              | (65, 84)                         | (65, 80)                                                      | (65, 84)                                    | (65, 92)                         | (65, 90)                         | (65, 92)                                                       | (65, 81)                         |
| Smoking History                                       |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| Current smoker                                        | 24 (9.5)                         | 7 (5.7)                                                       | 31 (8.3)                                    | 13 (5.3)                         | 6 (4.7)                          | 19 (5.1)                                                       | 5 (4.0)                          |
| Time since the current smoker started smoking (years) |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| Mean (SD)                                             | 46.2 (13.68)                     | 39.6 (18.13)                                                  | 44.7 (14.74)                                | 37.5 (16.86)                     | 47.5 (6.23)                      | 40.6 (14.94)50.9 (7.02)                                        |                                  |
| Median                                                | 49.1                             | 47.1                                                          | 49.0                                        | 43.7                             | 47.8                             | 45.7                                                           | 51.7                             |
| Min, max                                              |                                  |                                                               | (2.0, 63.0) (1.9,56.1) (1.9,63.0)(2.7,52.8) |                                  | (39.6, 57.2)                     | (2.7, 57.2)                                                    | (43.7, 58.7)                     |
| Ex-smoker                                             |                                  |                                                               |                                             |                                  |                                  |                                                                | 43 (34.4)                        |
| Time since the ex-smoker stopped smoking (years)      |                                  |                                                               |                                             |                                  |                                  |                                                                |                                  |
| Mean (SD)                                             | 24.7                             | 26.0 (14.93)                                                  | 25.1 (14.46)                                | 27.8 (15.58)                     | 30.8 (14.70)                     |                                                                | 28.6 (15.35) 33.4 (15.44)        |
| Median                                                | (14.31) 25.1                     | 24.9                                                          | 24.9                                        | 25.7                             | 30.7                             | 27.7                                                           | 33.8                             |
| Min, max                                              |                                  |                                                               |                                             |                                  |                                  | (0.1,52.0) (0.3,52.0)(0.1,52.0)(0.1,62.6) (4.9,55.6)(0.1,62.6) | (3.8, 58.7)                      |
| Never smoked                                          |                                  | 135 (53.4) 72 (59.0)207 (55.2) 138 (56.1) 85 (66.9)223 (59.8) |                                             |                                  |                                  |                                                                | 77 (61.6)                        |

a. calculations.

b. n=Number of subjects with the specified characteristic.

<div style=\"page-break-after: always\"></div>

## · Outcomes and estimation

## Study B7471007

In total 3902 participants were enrolled in the following cohorts based on age:

- Cohort  1:  subjects  ≥  60  yoa  (n=3009;  random ised  1:1  to  receive  either  20vPnC/saline  or 13vPnC/PPSV23)
- Cohort 2: 50-59 yoa (n=445; randomised 3:1 to receive 20vPnC or 13vPnC)
- Cohort 3: 18-49 yoa (n=448; randomised 3:1 to receive 20vPnC or 13vPnC)

## Primary objectives: Noninferiority of 20vPnC to comparator in adults ≥60 years of age (Cohort 1)

## 13 shared serotypes:

20vPnC met the primary immunogenicity objective for the 13 matched vaccine serotypes. One month after 20vPnC or 13vPnC, the immune responses to all 13 matched serotypes induced by 20vPnC were non-inferior to those induced by 13vPnC, as demonstrated by the lower bounds of the 2-sided 95% CIs for the primary analysis of model-based OPA GMRs (20vPnC relative to 13vPnC group) &gt;0.5 (2-fold NI margin).

Figure 2: Model-Based OPA GMRs of 20vPnC to 13vPnC for the 13 Matched Serotypes 1 Month After Vaccination B7471007 Cohort 1 (≥60 Years of Age)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 12: Pneumococcal OPA GMTs and GMRs for the 13vPnC Serotypes 1 Month After Vaccination - Linear Regression Model - Cohort 1

| Sero type   | Vaccination 1 20vPnC/Saline   | Vaccination 1 20vPnC/Saline   | Vaccination 1 20vPnC/Saline   | Vaccination 1 13vPnC/PPSV23   | Vaccination 1 13vPnC/PPSV23   | Vaccination 1 13vPnC/PPSV23   | Vaccine Comparison   | Vaccine Comparison   |
|-------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|----------------------|----------------------|
| Sero type   | n                             | GMT                           | (95% CI)                      | n                             | GMT                           | (95% CI)                      | GMR                  | (95% CI)             |
| 1           | 1430                          | 123.4                         | (112.3, 135.5)                | 1419                          | 153.8                         | (140.2, 168.8)                | 0.80                 | (0.71, 0.90)         |
| 3           | 1415                          | 40.7                          | (38.0, 43.6)                  | 1411                          | 47.8                          | (44.7, 51.2)                  | 0.85                 | (0.78, 0.93)         |
| 4           | 1415                          | 508.7                         | (456.5, 566.9)                | 1409                          | 626.9                         | (563.5, 697.4)                | 0.81                 | (0.71, 0.93)         |
| 5           | 1418                          | 91.6                          | (83.4, 100.5)                 | 1395                          | 109.7                         | (100.1, 120.3)                | 0.83                 | (0.74, 0.94)         |
| 6A          | 1403                          | 889.0                         | (795.0, 994.1)                | 1390                          | 1165.1                        | (1043.3, 1301.0)              | 0.76                 | (0.66, 0.88)         |
| 6B          | 1413                          | 1115.2                        | (1003.1, 1239.8)              | 1401                          | 1341.3                        | (1208.5, 1488.8)              | 0.83                 | (0.73, 0.95)         |
| 7F          | 1409                          | 968.8                         | (887.0, 1058.3)               | 1391                          | 1129.2                        | (1034.7, 1232.4)              | 0.86                 | (0.77, 0.96)         |
| 9V          | 1399                          | 1455.5                        | (1317.5, 1608.0)              | 1391                          | 1567.8                        | (1420.5, 1730.5)              | 0.93                 | (0.82, 1.05)         |
| 14          | 1418                          | 746.7                         | (679.0, 821.2)                | 1408                          | 746.7                         | (679.8, 820.1)                | 1.00                 | (0.89, 1.13)         |
| 18C         | 1420                          | 1252.6                        | (1123.1, 1397.0)              | 1403                          | 1482.3                        | (1330.5, 1651.5)              | 0.85                 | (0.74, 0.97)         |
| 19A         | 1420                          | 517.9                         | (472.2, 568.0)                | 1398                          | 645.3                         | (588.9, 707.1)                | 0.80                 | (0.71, 0.90)         |
| 19F         | 1421                          | 265.8                         | (240.2, 294.1)                | 1403                          | 333.3                         | (301.5, 368.3)                | 0.80                 | (0.70, 0.91)         |
| 23F         | 1424                          | 276.5                         | (242.5, 315.2)                | 1409                          | 335.1                         | (294.4, 381.4)                | 0.83                 | (0.70, 0.97)         |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. n = Number of subjects with valid and determinate OPA titres for the specified serotype.

Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with vaccine group, sex, smoking status, age at vaccination in years (continuous), and baseline log transformed OPA titres.

GMRs (ratio of GMTs 20vPnC/saline to 13vPnC/PPSV23) and 2-sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

## Seven additional serotypes:

20vPnC met the primary immunogenicity objective for 6 of the 7 additional serotypes. One month after 20vPnC or PPSV23, the immune responses to 6 of the 7 additional vaccine serotypes induced by 20vPnC were non-inferior to those induced by PPSV23, as demonstrated by the lower bounds of the 2sided 95% CIs for the primary analysis of model based OPA GMRs (20vPnC/saline relative to 13vPnC/PPSV23 group) &gt;0.5.

Although superiority of 20vPnC to PPSV23 couldn't be formally evaluated due to a missed NI for 1 serotype (serotype 8) as per the statistical analysis plan, the lower bounds of the 2-sided 95% CIs for the GMRs were &gt;1, with nominal p values for superiority &lt;0.001 for the 6 serotypes.

Figure 3: Model-Based OPA GMRs of 20vPnC to PPSV23 for the 7 Additional Serotypes 1 Month After Vaccination B7471007 Cohort 1 (≥60 Years of Age)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 13: Pneumococcal OPA GMTs and GMRs for the 7 Additional Serotypes 1 Month After Vaccination - Linear Regression Model - Cohort 1

| Sero type   | Vaccination 1 20vPnC/Saline   | Vaccination 1 20vPnC/Saline   | Vaccination 1 20vPnC/Saline   | Vaccination 2 13vPnC/PPSV23   | Vaccination 2 13vPnC/PPSV23   | Vaccination 2 13vPnC/PPSV23   | Vaccine Comparison   | Vaccine Comparison   | Vaccine Comparison   |
|-------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|----------------------|----------------------|----------------------|
|             | n                             | GMT                           | (95% CI)                      | n                             | GMT                           | (95% CI)                      | GMR                  | (95% CI)             | p-Value              |
| 8           | 1374                          | 465.6                         | (422.5, 513.1)                | 1319                          | 848.1                         | (769.1, 935.2)                | 0.55                 | (0.49, 0.62)         | >0.999               |
| 10A         | 1310                          | 2007.6                        | (1808.0, 2229.1)              | 1263                          | 1079.9                        | (972.1, 1199.7)               | 1.86                 | (1.63, 2.12)         | <0.001               |
| 11A         | 1198                          | 4426.8                        | (3965.5, 4941.8)              | 1209                          | 2534.9                        | (2276.8, 2822.3)              | 1.75                 | (1.52, 2.01)         | <0.001               |
| 12F         | 1294                          | 2538.7                        | (2255.3, 2857.7)              | 1222                          | 1716.6                        | (1521.8, 1936.3)              | 1.48                 | (1.27, 1.72)         | <0.001               |
| 15B         | 1283                          | 2398.2                        | (2090.6, 2751.2)              | 1249                          | 768.5                         | (669.7, 881.9)                | 3.12                 | (2.62, 3.71)         | <0.001               |
| 22F         | 1274                          | 3666.2                        | (3244.4, 4143.0)              | 1227                          | 1846.2                        | (1636.6, 2082.6)              | 1.99                 | (1.70, 2.32)         | <0.001               |
| 33F         | 1157                          | 5125.9                        | (4611.3, 5698.0)              | 1201                          | 3720.6                        | (3356.2, 4124.6)              | 1.38                 | (1.21, 1.57)         | <0.001               |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. n = Number of subjects with valid and determinate OPA titres for the specified serotype.

Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with vaccine group, sex, smoking status, age at vaccination in years (continuous), and baseline log transformed OPA titres. GMRs (ratio of GMTs 20vPnC/saline to 13vPnC/PPSV23) and 2-sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

Table 14 : Proportion of Subjects Achieving a ≥4 -Fold Rise in Serotype-Specific OPA Titres From Before Vaccination to 1 Month After Vaccination - 7 additional serotypes - Cohort 1

| Serotype   | 20vPnC/Saline   | 20vPnC/Saline   | 20vPnC/Saline   | 20vPnC/Saline   | 13vPnC/PPSV23   | 13vPnC/PPSV23   | 13vPnC/PPSV23   | 13vPnC/PPSV23   |
|------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Serotype   | N               | n               | %               | (95% CI)        | N               | n               | %               | (95% CI)        |
| 8          | 1353            | 1053            | 77.8            | (75.5, 80.0)    | 1293            | 1122            | 86.8            | (84.8, 88.6)    |
| 10A        | 1208            | 912             | 75.5            | (73.0, 77.9)    | 1164            | 764             | 65.6            | (62.8, 68.4)    |
| 11A        | 973             | 576             | 59.2            | (56.0, 62.3)    | 993             | 515             | 51.9            | (48.7, 55.0)    |
| 12F        | 1226            | 1072            | 87.4            | (85.5, 89.2)    | 1147            | 924             | 80.6            | (78.1, 82.8)    |
| 15B        | 1228            | 955             | 77.8            | (75.3, 80.1)    | 1178            | 752             | 63.8            | (61.0, 66.6)    |
| 22F        | 1178            | 974             | 82.7            | (80.4, 84.8)    | 1156            | 888             | 76.8            | (74.3, 79.2)    |
| 33F        | 1020            | 613             | 60.1            | (57.0, 63.1)    | 1080            | 599             | 55.5            | (52.4, 58.5)    |

Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. N = number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections. These values are the denominators for the percentage calculations. n = Number of su bjects with a ≥4 -fold rise in titres from before Vaccination 1 to 1 month after vaccination for the specified serotype.

Note: For the 20vPnC/saline group, fold rise is calculated using assay results from before Vaccination 1 to 1 month after Vaccination 1; for subjects in the 13vPnC/PPSV23 group, fold rise is calculated using assay results from before Vaccination 1 to 1 month after Vaccination 2.; 95% CI: Exact 2-sided CI based on the Clopper and Pearson method.

## Additional results for serotype 8:

For serotype 8, the model-based GMR (2-sided 95% CI) was 0.55 (0.49, 0.62), narrowly missing the statistical non-inferiority criterion. Based on additional analyses that further characterize the immune responses to serotype 8, the immune response is expected to provide protection similar to the other 19 vaccine serotypes in 20vPnC that met non-inferiority:

- A GMFR of 22.1 was observed for serotype 8 from before to 1 month after 20vPnC, which is within the range of the observed GMFRs (5.8 for serotype 3 to 42.6 for serotype 6A) for the 13 matched serotypes from before to 1 month after 13vPnC.
- After 20vPnC, 77.8% of subjects achieved a ≥4 -fold rise in OPA titres from before to 1 month after vaccination for serotype 8, which is within the range of proportions observed (54.0% for serotype 14 to 84.0% for serotype 6A) for the 13 matched serotypes after 13vPnC.

Secondary objectives: Non-inferiority of 20vPnC in younger age groups (Cohort 2 and 3) compared with adults 60 through 64 years of age (subset of Cohort 1)

20vPnC met the secondary immunogenicity objective for all 20 vaccine serotypes based on

<div style=\"page-break-after: always\"></div>

- comparison of the immune responses in subjects 50 through 59 years of age (Cohort 2) to those in subjects 60 through 64 years of age in Cohort 1 (Figure 4, Table 15 ),
- and comparison of the immune responses in subjects 18 through 49 years of age (Cohort 3) to those in subjects 60 through 64 years of age in Cohort 1 (Figure 5, Table 16 ).

One month after 20vPnC, the immune responses to all 20 vaccine serotypes in Cohort 2 and Cohort 3 were non-inferior to those in Cohort 1 subjects 60 through 64 years of age. The lower bounds of the 2sided 95% CIs for the primary analysis of model-based OPA GMRs (younger cohort relative to Cohort 1 subjects 60 through 64 years of age) were &gt;0.5 (2-fold NI margin). The finding of higher responses in younger adults compared with older adults is consistent with the experience with 13vPnC.

Figure 4: Model-Based OPA GMRs of Cohort 2 (50 Through 59 Years of Age) to Cohort 1 Subjects 60 Through 64 Years of Age for the 20vPnC Serotypes 1 Month After Vaccination

<!-- image -->

Table 15: Comparisons of Pneumococcal OPA GMTs 1 Month After 20vPnC Vaccination in Cohort 2 and Cohort 1 Subjects 60 Through 64 Years of Age - Linear Regression

|          | 20vPnC Group in Cohort 2   | 20vPnC Group in Cohort 2   | 20vPnC Group in Cohort 2   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   |
|----------|----------------------------|----------------------------|----------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Serotype | n                          | GMT                        | (95% CI)                   | n                                                                   | GMT (95% CI)                                                        | GMR                                                                 | (95% CI)                                                            |
| 13vPnC   |                            |                            |                            |                                                                     |                                                                     |                                                                     |                                                                     |
| 1        | 320                        | 135.9                      | (113.1, 163.4)             | 941                                                                 | 131.8 (117.2, 148.3)                                                | 1.03                                                                | (0.84, 1.26)                                                        |
| 3        | 318                        | 43.3                       | (38.0, 49.4)               | 935                                                                 | 40.9 (37.6, 44.5)                                                   | 1.06                                                                | (0.92, 1.22)                                                        |
| 4        | 318                        | 633.3                      | (513.9, 780.4)             | 931                                                                 | 577.9 (505.5, 660.6)                                                | 1.10                                                                | (0.87, 1.38)                                                        |
| 5        | 313                        | 84.6                       | (70.3, 101.8)              | 935                                                                 | 96.5 (85.8, 108.6)                                                  | 0.88                                                                | (0.72, 1.07)                                                        |
| 6A       | 318                        | 1203.9                     | (968.1, 1497.1)            | 921                                                                 | 997.1 (866.5, 1147.5)                                               | 1.21                                                                | (0.95, 1.53)                                                        |
| 6B       | 318                        | 1502.7                     | (1228.2, 1838.5)           | 933                                                                 | 1199.0 (1054.3, 1363.4)                                             | 1.25                                                                | (1.00, 1.56)                                                        |
| 7F       | 313                        | 1047.0                     | (884.0, 1240.2)            | 924                                                                 | 1173.0 (1052.9, 1306.9)                                             | 0.89                                                                | (0.74, 1.07)                                                        |
| 9V       | 312                        | 1725.7                     | (1424.4, 2090.6)           | 922                                                                 | 1687.9 (1493.7, 1907.3)                                             | 1.02                                                                | (0.83, 1.26)                                                        |
| 14       | 313                        | 926.2                      | (761.8, 1126.0)            | 933                                                                 | 742.3 (655.8, 840.2)                                                | 1.25                                                                | (1.01, 1.54)                                                        |
| 18C      | 315                        | 1805.0                     | (1459.6, 2232.2)           | 937                                                                 | 1355.2 (1184.3, 1550.7)                                             | 1.33                                                                | (1.06, 1.68)                                                        |
| 19A      | 318                        | 618.4                      | (519.9, 735.5)             | 932                                                                 | 600.3 (537.5, 670.6)                                                | 1.03                                                                | (0.85, 1.25)                                                        |

<div style=\"page-break-after: always\"></div>

| 19F        | 320   | 286.7   | (236.0, 348.2)   | 937   | 290.4   | (256.4, 329.0)   | 0.99   | (0.80, 1.22)   |
|------------|-------|---------|------------------|-------|---------|------------------|--------|----------------|
| 23F        | 319   | 549.1   | (425.4, 708.9)   | 937   | 327.5   | (278.2, 385.6)   | 1.68   | (1.27, 2.22)   |
| Additional |       |         |                  |       |         |                  |        |                |
| 8          | 314   | 486.9   | (400.6, 591.9)   | 901   | 502.3   | (442.8, 569.8)   | 0.97   | (0.78, 1.20)   |
| 10A        | 296   | 2520.4  | (2076.0, 3060.0) | 857   | 2437.0  | (2149.8, 2762.5) | 1.03   | (0.84, 1.28)   |
| 11A        | 271   | 6416.9  | (5131.9, 8023.6) | 796   | 5248.9  | (4564.5, 6035.9) | 1.22   | (0.96, 1.56)   |
| 12F        | 292   | 3445.1  | (2807.8, 4227.1) | 855   | 3105.2  | (2722.7, 3541.4) | 1.11   | (0.88, 1.39)   |
| 15B        | 284   | 3355.9  | (2582.0, 4361.8) | 830   | 2873.7  | (2438.1, 3387.1) | 1.17   | (0.88, 1.56)   |
| 22F        | 284   | 3808.1  | (2998.2, 4836.8) | 835   | 4228.4  | (3629.6, 4926.0) | 0.90   | (0.69, 1.17)   |
| 33F        | 266   | 5571.3  | (4495.7, 6904.2) | 765   | 5445.2  | (4749.2, 6243.2) | 1.02   | (0.81, 1.30)   |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. n = Number of subjects with a determinate OPA titre to the given serotype.

Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with cohort, sex, smoking status, and baseline log transformed OPA titres.

Figure 5: Model-Based OPA GMRs of Cohort 3 (18 Through 49 Years of Age) to Cohort 1 Subjects 60 Through 64 Years of Age for the 20vPnC Serotypes 1 Month After Vaccination

<!-- image -->

Table 16: Comparisons of Pneumococcal OPA GMTs 1 Month After 20vPnC Vaccination in Cohort 3 and Cohort 1 Subjects 60 Through 64 Years of Age - Linear Regression Model

| Serotype   | 20vPnC Group in Cohort 3   | 20vPnC Group in Cohort 3   | 20vPnC Group in Cohort 3   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   | 20vPnC/Saline Group in Cohort 1 (60 - 64 Years of Age) Comparison   |
|------------|----------------------------|----------------------------|----------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
|            | n                          | GMT                        | (95% CI)                   | n                                                                   | GMT (95% CI)                                                        | GMR                                                                 | (95% CI)                                                            |
| 13vPnC     |                            |                            |                            |                                                                     |                                                                     |                                                                     |                                                                     |
| 1          | 316                        | 162.6                      | (135.1, 195.6)             | 941                                                                 | 132.0 (117.7, 148.1)                                                | 1.23                                                                | (1.01, 1.50)                                                        |
| 3          | 316                        | 42.1                       | (36.9, 48.1)               | 935                                                                 | 42.0 (38.7, 45.7)                                                   | 1.00                                                                | (0.87, 1.16)                                                        |
| 4          | 315                        | 1966.7                     | (1599.5, 2418.3)           | 931                                                                 | 594.5 (522.9, 675.9)                                                | 3.31                                                                | (2.65, 4.13)                                                        |
| 5          | 317                        | 107.9                      | (89.4, 130.1)              | 935                                                                 | 96.9 (86.2, 109.0)                                                  | 1.11                                                                | (0.91, 1.36)                                                        |
| 6A         | 315                        | 3930.5                     | (3176.0, 4864.4)           | 921                                                                 | 1022.8 (896.1, 1167.4)                                              | 3.84                                                                | (3.06, 4.83)                                                        |
| 6B         | 314                        | 4260.0                     | (3461.3, 5243.1)           | 933                                                                 | 1250.4 (1102.3, 1418.4)                                             | 3.41                                                                | (2.73, 4.26)                                                        |
| 7F         | 311                        | 1872.8                     | (1564.2, 2242.4)           | 924                                                                 | 1187.2 (1064.4, 1324.2)                                             | 1.58                                                                | (1.30, 1.91)                                                        |
| 9V         | 315                        | 6041.4                     | (4962.5, 7354.9)           | 922                                                                 | 1726.7 (1529.2, 1949.7)                                             | 3.50                                                                | (2.83, 4.33)                                                        |
| 14         | 316                        | 1848.4                     | (1514.7, 2255.7)           | 933                                                                 | 772.8 (684.7, 872.3)                                                | 2.39                                                                | (1.93, 2.96)                                                        |
| 18C        | 312                        | 4460.5                     | (3584.6, 5550.4)           | 937                                                                 | 1395.3 (1220.9, 1594.5)                                             | 3.20                                                                | (2.53, 4.04)                                                        |

<div style=\"page-break-after: always\"></div>

| 19A        | 312   | 1415.0   | (1181.8, 1694.2)   | 932   | 611.3   | (547.8, 682.3)   | 2.31   | (1.91, 2.81)   |
|------------|-------|----------|--------------------|-------|---------|------------------|--------|----------------|
| 19F        | 315   | 654.8    | (538.2, 796.8)     | 937   | 301.2   | (266.7, 340.1)   | 2.17   | (1.76, 2.68)   |
| 23F        | 315   | 1559.2   | (1208.1, 2012.2)   | 937   | 324.5   | (277.1, 380.1)   | 4.80   | (3.65, 6.32)   |
| Additional |       |          |                    |       |         |                  |        |                |
| 8          | 306   | 867.0    | (709.7, 1059.2)    | 901   | 508.1   | (448.8, 575.3)   | 1.71   | (1.38, 2.12)   |
| 10A        | 292   | 4157.3   | (3410.9, 5067.0)   | 857   | 2569.7  | (2274.0, 2903.7) | 1.62   | (1.31, 2.00)   |
| 11A        | 263   | 7169.3   | (5735.7, 8961.1)   | 796   | 5419.7  | (4737.7, 6199.7) | 1.32   | (1.04, 1.68)   |
| 12F        | 273   | 5875.4   | (4719.8, 7314.1)   | 855   | 3074.5  | (2697.9, 3503.7) | 1.91   | (1.51, 2.41)   |
| 15B        | 279   | 4601.0   | (3487.9, 6069.4)   | 830   | 3019.0  | (2562.8, 3556.4) | 1.52   | (1.13, 2.05)   |
| 22F        | 273   | 7568.2   | (5927.4, 9663.2)   | 835   | 4482.5  | (3862.7, 5201.8) | 1.69   | (1.30, 2.20)   |
| 33F        | 251   | 7976.9   | (6341.7, 10033.7)  | 765   | 5693.2  | (4970.1, 6521.5) | 1.40   | (1.10, 1.79)   |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. n = Number of subjects with a determinate OPA titre to the given serotype.

Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titers using a regression model with cohort, sex, smoking status, and baseline log transformed OPA titres.

GMRs (ratio of 20vPnC group in Cohort 3 to 20vPnC/saline group in Cohort 1 [60 through 64 years of age]) and 2- sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

## Additional data to illustrate the immune response of 20vPnC compared to 13vPnC (ad hoc analysis by the Rapporteur)

For cohort 2 and 3 no comparison between both vaccines was intended in the study, nevertheless GMT data for both cohorts for 13vPnC were available and are shown below.

Immune response elicited by 20vPnC is consistently numerically lower in all cohorts compared to 13vPnC for the 13vPnC serotypes. In Cohort 2, including 50-59-year-old subjects, the difference seems even more pronounced, although the conclusions are somewhat hampered by the smaller sample size for 13vPnC. The observations of reduced response are further confirmed with the proportion of subjects with a  ≥4 -fold  rise.  Similar  reductions  have  also  been  observed  in  the  lot  consistency  study  B7471008 (13vPnC was included mainly as control arm for the safety assessment, see section 2.6.5.5 for further details  of  this  study)  and  a  paediatric  study,  submitted  by  the  applicant  (B7471003),  although  this population is not part of the current indication (study not further described in this report).

Table 17: Pneumococcal OPA GMFRs From Before Vaccination to 1 Month After Vaccination Cohort 2 - Evaluable-20 Immunogenicity Population

|          |                               |     | Sampling Time Point   | Sampling Time Point   | Sampling Time Point       | Sampling Time Point       |                                               |                                               |
|----------|-------------------------------|-----|-----------------------|-----------------------|---------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|
|          |                               |     | Before Vaccination    | Before Vaccination    | 1 Month After Vaccination | 1 Month After Vaccination | 1 Month After Vaccination/ Before Vaccination | 1 Month After Vaccination/ Before Vaccination |
| Serotype | Vaccine Group (as Randomised) | n a | GMT b                 | (95% CI b )           | GMT b                     | (95% CI b )               | GMFR b                                        | (95% CI b )                                   |
| 13vPnC   |                               |     |                       |                       |                           |                           |                                               |                                               |
| 1        | 20vPnC                        | 319 | 11.6                  | (10.7, 12.6)          | 167.0                     | (140.1, 199.0)            | 14.4                                          | (12.0, 17.3)                                  |
|          | 13vPnC                        | 107 | 10.8                  | (9.8, 12.0)           | 191.4                     | (138.3, 265.1)            | 17.7                                          | (12.8, 24.3)                                  |
| 3        | 20vPnC                        | 317 | 9.5                   | (8.6, 10.6)           | 48.5                      | (42.6, 55.3)              | 5.1                                           | (4.4, 5.9)                                    |
|          | 13vPnC                        | 108 | 8.3                   | (7.3, 9.4)            | 44.7                      | (34.7, 57.7)              | 5.4                                           | (4.2, 7.0)                                    |
| 4        | 20vPnC                        | 304 | 16.6                  | (14.4, 19.1)          | 719.7                     | (590.6, 877.2)            | 43.4                                          | (34.4, 54.9)                                  |
|          | 13vPnC                        | 106 | 16.7                  | (13.1, 21.2)          | 1141.9                    | (809.8, 1610.2)           | 68.5                                          | (46.0, 102.1)                                 |
| 5        | 20vPnC                        | 312 | 16.3                  | (15.4, 17.2)          | 96.4                      | (81.0, 114.8)             | 5.9                                           | (5.0, 7.0)                                    |
|          | 13vPnC                        | 108 | 15.5                  | (14.2, 16.9)          | 175.3                     | (130.8, 235.0)            | 11.3                                          | (8.4, 15.2)                                   |
| 6A       | 20vPnC                        | 312 | 27.5                  | (24.2, 31.2)          | 1383.8                    | (1130.1, 1694.4)          | 50.3                                          | (40.2, 63.0)                                  |
|          | 13vPnC                        | 104 | 28.2                  | (23.2, 34.3)          | 1603.3                    | (1170.5, 2196.2)          | 56.8                                          | (39.8, 81.2)                                  |
| 6B       | 20vPnC                        | 299 | 56.2                  | (46.9, 67.2)          | 1782.2                    | (1491.1, 2130.1)          | 31.7                                          | (25.3, 39.7)                                  |
|          | 13vPnC                        | 103 | 58.8                  | (44.3, 78.0)          | 2216.4                    | (1667.8, 2945.4)          | 37.7                                          | (25.9, 54.8)                                  |
| 7F       | 20vPnC                        | 300 | 85.6                  | (76.2, 96.2)          | 1097.2                    | (941.0, 1279.2)           | 12.8                                          | (10.7, 15.4)                                  |
|          | 13vPnC                        | 106 | 72.9                  | (61.9, 85.9)          | 1835.4                    | (1407.3, 2393.8)          | 25.2                                          | (18.5, 34.2)                                  |
| 9V       | 20vPnC                        | 288 | 160.3                 | (137.3, 187.1)        | 1933.8                    | (1609.6, 2323.4)          | 12.1                                          | (9.9, 14.7)                                   |
|          | 13vPnC                        | 97  | 170.7                 | (127.1, 229.2)        | 3489.9                    | (2436.4, 4998.9)          | 20.4                                          | (13.5, 30.9)                                  |
| 14       | 20vPnC                        | 300 | 101.5                 | (83.6, 123.2)         | 1058.5                    | (880.5, 1272.5)           | 10.4                                          | (8.3, 13.0)                                   |
|          | 13vPnC                        | 103 | 139.5                 | (98.8, 197.1)         | 1361.1                    | (1014.2, 1826.5)          | 9.8                                           | (6.7, 14.3)                                   |
| 18C      | 20vPnC                        | 308 | 42.2                  | (35.0, 50.9)          | 2040.0                    | (1701.0, 2446.5)          | 48.3                                          | (37.9, 61.5)                                  |

<div style=\"page-break-after: always\"></div>

|            | 13vPnC   | 106   | 38.1   | (28.1, 51.5)    | 2617.3   | (1889.5, 3625.4)   | 68.8   | (43.6, 108.5)   |
|------------|----------|-------|--------|-----------------|----------|--------------------|--------|-----------------|
| 19A        | 20vPnC   | 310   | 28.7   | (24.4, 33.8)    | 679.4    | (584.6, 789.6)     | 23.6   | (19.2, 29.1)    |
|            | 13vPnC   | 105   | 29.5   | (22.1, 39.4)    | 1154.5   | (903.4, 1475.4)    | 39.1   | (27.7, 55.3)    |
| 19F        | 20vPnC   | 316   | 34.2   | (30.9, 37.8)    | 315.5    | (260.9, 381.5)     | 9.2    | (7.6, 11.3)     |
|            | 13vPnC   | 106   | 30.6   | (26.9, 34.9)    | 568.8    | (401.3, 806.2)     | 18.6   | (13.0, 26.5)    |
| 23F        | 20vPnC   | 313   | 11.8   | (10.1, 13.7)    | 563.1    | (445.4, 711.9)     | 47.8   | (37.2, 61.3)    |
|            | 13vPnC   | 106   | 11.4   | (8.9, 14.6)     | 881.6    | (592.8, 1311.3)    | 77.4   | (51.3, 116.7)   |
| Additional |          |       |        |                 |          |                    |        |                 |
| 8          | 20vPnC   | 310   | 22.7   | (20.3, 25.5)    | 542.7    | (450.8, 653.3)     | 23.9   | (19.3, 29.6)    |
|            | 13vPnC   | 106   | 21.9   | (18.2, 26.5)    | 23.6     | (18.9, 29.4)       | 1.1    | (0.9, 1.4)      |
| 10A        | 20vPnC   | 273   | 162.9  | (131.5, 201.9)  | 2923.9   | (2433.7, 3512.9)   | 17.9   | (14.2, 22.6)    |
|            | 13vPnC   | 96    | 168.3  | (115.2, 245.9)  | 151.5    | (102.3, 224.3)     | 0.9    | (0.7, 1.2)      |
| 11A        | 20vPnC   | 213   | 643.9  | (497.1, 834.1)  | 6714.7   | (5281.8, 8536.4)   | 10.4   | (7.7, 14.2)     |
|            | 13vPnC   | 73    | 979.9  | (602.6, 1593.3) | 1121.1   | (694.1, 1810.6)    | 1.1    | (0.8, 1.6)      |
| 12F        | 20vPnC   | 279   | 37.0   | (32.3, 42.3)    | 3964.7   | (3323.4, 4729.7)   | 107.3  | (85.8, 134.1)   |
|            | 13vPnC   | 101   | 38.0   | (29.7, 48.5)    | 44.8     | (33.3, 60.2)       | 1.2    | (1.0, 1.4)      |
| 15B        | 20vPnC   | 263   | 50.9   | (39.5, 65.5)    | 3668.0   | (2876.7, 4676.9)   | 72.1   | (51.9, 100.1)   |
|            | 13vPnC   | 85    | 39.7   | (26.3, 59.9)    | 51.9     | (33.9, 79.4)       | 1.3    | (1.0, 1.7)      |
| 22F        | 20vPnC   | 256   | 71.9   | (54.5, 94.8)    | 4568.1   | (3594.1, 5806.1)   | 63.5   | (44.8, 90.1)    |
|            | 13vPnC   | 90    | 84.3   | (52.7, 134.8)   | 69.3     | (42.2, 113.7)      | 0.8    | (0.6, 1.1)      |
| 33F        | 20vPnC   | 233   | 678.2  | (560.0, 821.5)  | 6202.9   | (5008.8, 7681.6)   | 9.1    | (7.1, 11.7)     |
|            | 13vPnC   | 86    | 778.7  | (575.1, 1054.3) | 719.0    | (524.2, 986.1)     | 0.9    | (0.7, 1.2)      |

Abbreviations:  GMFR  =  geometric  mean  fold  rise;  GMT  =  geometric  mean  titre;  LLOQ  =  lower  limit  of  quantitation;  OPA  = opsonophagocytic activity.

Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

a. n = Number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections.

b. GMTs, GMFRs, and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titres or fold rises and the corresponding CIs (based on the Student t distribution).

Table 18: Pneumococcal OPA GMFRs From Before Vaccination to 1 Month After Vaccination Cohort 3 - Evaluable-20 Immunogenicity Population

|            |                               |     | Sampling Time Point   | Sampling Time Point   | Sampling Time Point       | Sampling Time Point       |                                               |                                               |
|------------|-------------------------------|-----|-----------------------|-----------------------|---------------------------|---------------------------|-----------------------------------------------|-----------------------------------------------|
|            |                               |     | Before Vaccination    | Before Vaccination    | 1 Month After Vaccination | 1 Month After Vaccination | 1 Month After Vaccination/ Before Vaccination | 1 Month After Vaccination/ Before Vaccination |
| Serotype   | Vaccine Group (as Randomised) | n a | GMT b                 | (95% CI b )           | GMT b                     | (95% CI b )               | GMFR b                                        | (95% CI b )                                   |
| 13vPnC     |                               |     |                       |                       |                           |                           |                                               |                                               |
| 1          | 20vPnC                        | 315 | 10.5                  | (9.9, 11.1)           | 195.2                     | (166.8, 228.5)            | 18.6                                          | (16.0, 21.8)                                  |
|            | 13vPnC                        | 105 | 10.6                  | (9.5, 11.8)           | 288.9                     | (216.2, 386.2)            | 27.3                                          | (20.5, 36.3)                                  |
| 3          | 20vPnC                        | 312 | 9.7                   | (8.8, 10.7)           | 46.8                      | (41.4, 52.9)              | 4.8                                           | (4.2, 5.5)                                    |
|            | 13vPnC                        | 105 | 10.4                  | (8.5, 12.6)           | 53.0                      | (42.4, 66.3)              | 5.1                                           | (4.0, 6.5)                                    |
| 4          | 20vPnC                        | 302 | 17.0                  | (14.5, 19.9)          | 2235.5                    | (1908.8, 2618.1)          | 131.8                                         | (106.4, 163.4)                                |
|            | 13vPnC                        | 103 | 20.1                  | (14.6, 27.8)          | 3144.1                    | (2322.1, 4256.9)          | 156.4                                         | (104.3, 234.5)                                |
| 5          | 20vPnC                        | 315 | 15.6                  | (14.9, 16.4)          | 123.8                     | (104.8, 146.2)            | 7.9                                           | (6.7, 9.4)                                    |
|            | 13vPnC                        | 106 | 14.7                  | (14.4, 15.1)          | 161.7                     | (120.0, 217.9)            | 11.0                                          | (8.2, 14.7)                                   |
| 6A         | 20vPnC                        | 305 | 31.9                  | (27.6, 36.9)          | 4676.8                    | (4060.3, 5386.9)          | 146.5                                         | (120.6, 178.0)                                |
|            | 13vPnC                        | 103 | 30.2                  | (23.9, 38.3)          | 4971.2                    | (3627.5, 6812.6)          | 164.4                                         | (114.3, 236.5)                                |
| 6B         | 20vPnC                        | 286 | 76.2                  | (61.4, 94.6)          | 5355.2                    | (4575.5, 6267.7)          | 70.3                                          | (55.7, 88.7)                                  |
|            | 13vPnC                        | 97  | 92.6                  | (62.4, 137.3)         | 6654.3                    | (5041.2, 8783.5)          | 71.9                                          | (46.5, 111.1)                                 |
| 7F         | 20vPnC                        | 284 | 102.1                 | (88.6, 117.5)         | 2015.4                    | (1719.2, 2362.5)          | 19.7                                          | (16.1, 24.3)                                  |
|            | 13vPnC                        | 97  | 109.8                 | (82.7, 146.0)         | 3301.8                    | (2634.0, 4138.9)          | 30.1                                          | (21.4, 42.2)                                  |
| 9V         | 20vPnC                        | 281 | 201.2                 | (169.6, 238.6)        | 7065.4                    | (5999.3, 8321.0)          | 35.1                                          | (27.9, 44.2)                                  |
|            | 13vPnC                        | 99  | 209.8                 | (154.5, 284.9)        | 8475.1                    | (6280.3, 11437)           | 40.4                                          | (26.7, 61.2)                                  |
| 14         | 20vPnC                        | 291 | 147.6                 | (117.3, 185.9)        | 2158.3                    | (1854.9, 2511.4)          | 14.6                                          | (11.3, 18.9)                                  |
|            | 13vPnC                        | 100 | 180.5                 | (118.7, 274.6)        | 2823.9                    | (2210.5, 3607.6)          | 15.6                                          | (9.7, 25.4)                                   |
| 18C        | 20vPnC                        | 299 | 44.6                  | (35.9, 55.2)          | 4980.5                    | (4202.1, 5903.2)          | 111.8                                         | (86.8, 143.8)                                 |
|            | 13vPnC                        | 96  | 55.5                  | (36.6, 84.0)          | 5656.6                    | (4166.5, 7679.6)          | 102.0                                         | (62.7, 165.9)                                 |
| 19A        | 20vPnC                        | 299 | 42.4                  | (34.3, 52.4)          | 1658.7                    | (1441.5, 1908.6)          | 39.1                                          | (30.9, 49.6)                                  |
|            | 13vPnC                        | 105 | 40.8                  | (29.0, 57.5)          | 1962.4                    | (1529.3, 2518.1)          | 48.1                                          | (32.5, 71.0)                                  |
| 19F        | 20vPnC                        | 310 | 41.5                  | (36.8, 46.7)          | 738.9                     | (626.5, 871.3)            | 17.8                                          | (14.7, 21.6)                                  |
|            | 13vPnC                        | 105 | 45.7                  | (35.8, 58.5)          | 837.7                     | (623.0, 1126.3)           | 18.3                                          | (13.1, 25.5)                                  |
| 23F        | 20vPnC                        | 309 | 15.0                  | (12.3, 18.3)          | 1774.2                    | (1461.3, 2154.1)          | 118.2                                         | (92.7, 150.7)                                 |
|            | 13vPnC                        | 104 | 12.1                  | (8.9, 16.4)           | 2556.7                    | (1888.9, 3460.7)          | 212.0                                         | (144.4, 311.2)                                |
| 8          | 20vPnC                        | 300 | 28.7                  | (24.9, 33.1)          | 991.3                     | (833.5, 1178.9)           | 34.6                                          | (27.8, 43.0)                                  |
| Additional |                               |     |                       |                       |                           |                           |                                               |                                               |

<div style=\"page-break-after: always\"></div>

|     | 13vPnC   |   103 |   28.8 | (22.2, 37.4)           | 30.7   | (23.3, 40.6)     |   1.1 | (0.8, 1.4)     |
|-----|----------|-------|--------|------------------------|--------|------------------|-------|----------------|
| 10A | 20vPnC   |   260 |  219.3 | (174.8, 275.0)         | 4985.9 | (4277.7, 5811.3) |  22.7 | (17.8, 29.0)   |
|     | 13vPnC   |    86 |  177.4 | (119.1, 264.2)         | 272.1  | (176.5, 419.6)   |   1.5 | (1.1, 2.1)     |
| 11A | 20vPnC   |   220 | 1632.3 | (1296.8, 2054.6)8521.7 |        | (7045.7, 10307)  |   5.2 | (3.9, 6.9)     |
|     | 13vPnC   |    64 | 2152.6 | (1415.4, 3273.8)2254.7 |        | (1509.0, 3368.9) |   1   | (0.7, 1.5)     |
| 12F | 20vPnC   |   252 |   42.4 | (35.9, 50.2)           | 7263.1 | (6105.7, 8639.9) | 171.1 | (135.1, 216.8) |
|     | 13vPnC   |    88 |   52.4 | (37.6, 73.1)           | 60.0   | (41.8, 86.0)     |   1.1 | (0.9, 1.4)     |
| 15B | 20vPnC   |   248 |   76.8 | (57.3, 102.8)          | 4989.4 | (3929.9, 6334.7) |  65   | (44.8, 94.4)   |
|     | 13vPnC   |    90 |   56.3 | (35.1, 90.2)           | 75.0   | (44.9, 125.0)    |   1.3 | (0.9, 1.9)     |
| 22F | 20vPnC   |   241 |  140.4 | (103.9, 189.7)         | 9730.9 | (7878.4, 12019)  |  69.3 | (48.4, 99.4)   |
|     | 13vPnC   |    83 |  129.7 | (75.0, 224.1)          | 173.7  | (98.8, 305.3)    |   1.3 | (0.9, 2.0)     |
| 33F | 20vPnC   |   213 | 1393.3 | (1151.9, 1685.2)10425  |        | (8494.4, 12795)  |   7.5 | (5.8, 9.7)     |
|     | 13vPnC   |    78 | 1882.4 | (1351.5, 2621.9)1675.0 |        | (1232.0, 2277.3) |   0.9 | (0.7, 1.2)     |

Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

a. n = Number of subjects with valid and determinate assay results for both before and 1 month after vaccination blood sample collections.

b. GMTs, GMFRs, and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers or fold rises and the corresponding CIs (based on the Student t distribution).

Table 19: Proportion of Subjects Achieving a ≥ 4-Fold Rise in Serotype-Specific OPA Titres From Before Vaccination to 1 Month After Vaccination -Cohort 2 -Evaluable-20 Immunogenicity Population

|            | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   |
|------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|            | 20vPnC                          | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          |
| Serotype   | N a                             | n b                             | %                               | (95% CI c )                     | N a                             | n b                             | %                               | (95% CI c )                     |
| 13vPnC     |                                 |                                 |                                 |                                 |                                 |                                 |                                 |                                 |
| 1          | 319                             | 239                             | 74.9                            | (69.8, 79.6)                    | 107                             | 84                              | 78.5                            | (69.5, 85.9)                    |
| 3          | 317                             | 187                             | 59.0                            | (53.4, 64.5)                    | 108                             | 65                              | 60.2                            | (50.3, 69.5)                    |
| 4          | 304                             | 256                             | 84.2                            | (79.6, 88.1)                    | 106                             | 90                              | 84.9                            | (76.6, 91.1)                    |
| 5          | 312                             | 171                             | 54.8                            | (49.1, 60.4)                    | 108                             | 78                              | 72.2                            | (62.8, 80.4)                    |
| 6A         | 312                             | 268                             | 85.9                            | (81.5, 89.6)                    | 104                             | 92                              | 88.5                            | (80.7, 93.9)                    |
| 6B         | 299                             | 236                             | 78.9                            | (73.9, 83.4)                    | 103                             | 85                              | 82.5                            | (73.8, 89.3)                    |
| 7F         | 300                             | 219                             | 73.0                            | (67.6, 77.9)                    | 106                             | 91                              | 85.8                            | (77.7, 91.9)                    |
| 9V         | 288                             | 212                             | 73.6                            | (68.1, 78.6)                    | 97                              | 74                              | 76.3                            | (66.6, 84.3)                    |
| 14         | 300                             | 187                             | 62.3                            | (56.6, 67.8)                    | 103                             | 62                              | 60.2                            | (50.1, 69.7)                    |
| 18C        | 308                             | 254                             | 82.5                            | (77.8, 86.5)                    | 106                             | 88                              | 83.0                            | (74.5, 89.6)                    |
| 19A        | 310                             | 248                             | 80.0                            | (75.1, 84.3)                    | 105                             | 91                              | 86.7                            | (78.6, 92.5)                    |
| 19F        | 316                             | 203                             | 64.2                            | (58.7, 69.5)                    | 106                             | 83                              | 78.3                            | (69.2, 85.7)                    |
| 23F        | 313                             | 254                             | 81.2                            | (76.4, 85.3)                    | 106                             | 93                              | 87.7                            | (79.9, 93.3)                    |
| Additional |                                 |                                 |                                 |                                 |                                 |                                 |                                 |                                 |
| 8          | 310                             | 246                             | 79.4                            | (74.4, 83.7)                    | 106                             | 8                               | 7.5                             | (3.3, 14.3)                     |
| 10A        | 273                             | 215                             | 78.8                            | (73.4, 83.5)                    | 96                              | 6                               | 6.3                             | (2.3, 13.1)                     |
| 11A        | 213                             | 130                             | 61.0                            | (54.1, 67.6)                    | 73                              | 9                               | 12.3                            | (5.8, 22.1)                     |
| 12F        | 279                             | 260                             | 93.2                            | (89.6, 95.9)                    | 101                             | 6                               | 5.9                             | (2.2, 12.5)                     |
| 15B        | 263                             | 217                             | 82.5                            | (77.4, 86.9)                    | 85                              | 9                               | 10.6                            | (5.0, 19.2)                     |
| 22F        | 256                             | 206                             | 80.5                            | (75.1, 85.1)                    | 90                              | 5                               | 5.6                             | (1.8, 12.5)                     |
| 33F        | 233                             | 149                             | 63.9                            | (57.4, 70.1)                    | 86                              | 8                               | 9.3                             | (4.1, 17.5)                     |

Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

a. N = number of subjects with valid and determinate assay results to the specified serotype from both before and  1  month  after  vaccination  blood  sample  collections.  These  values  are  the  denominators  for  the  percentage calculations.

b. n = Number of subjects with a ≥ 4-fold rise in titres from before vaccination to 1 month after vaccination for the specified serotype.

c. Exact 2-sided CI based on the Clopper and Pearson method.

<div style=\"page-break-after: always\"></div>

Table 20: Proportion of Subjects Achieving a ≥ 4-Fold Rise in Serotype-Specific OPA Titres From Before Vaccination to 1 Month After Vaccination -Cohort 3 -Evaluable-20 Immunogenicity Population

|            | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   |
|------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|            | 20vPnC                          | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          |
| Serotype   | N a                             | n b                             | %                               | (95% CI c )                     | N a                             | n b                             | %                               | (95% CI c )                     |
| 13vPnC     |                                 |                                 |                                 |                                 |                                 |                                 |                                 |                                 |
| 1          | 315                             | 271                             | 86.0                            | (81.7, 89.7)                    | 105                             | 92                              | 87.6                            | (79.8, 93.2)                    |
| 3          | 312                             | 177                             | 56.7                            | (51.0, 62.3)                    | 105                             | 66                              | 62.9                            | (52.9, 72.1)                    |
| 4          | 302                             | 276                             | 91.4                            | (87.6, 94.3)                    | 103                             | 94                              | 91.3                            | (84.1, 95.9)                    |
| 5          | 315                             | 204                             | 64.8                            | (59.2, 70.0)                    | 106                             | 79                              | 74.5                            | (65.1, 82.5)                    |
| 6A         | 305                             | 295                             | 96.7                            | (94.1, 98.4)                    | 103                             | 98                              | 95.1                            | (89.0, 98.4)                    |
| 6B         | 286                             | 255                             | 89.2                            | (85.0, 92.5)                    | 97                              | 84                              | 86.6                            | (78.2, 92.7)                    |
| 7F         | 284                             | 216                             | 76.1                            | (70.7, 80.9)                    | 97                              | 82                              | 84.5                            | (75.8, 91.1)                    |
| 9V         | 281                             | 236                             | 84.0                            | (79.2, 88.1)                    | 99                              | 80                              | 80.8                            | (71.7, 88.0)                    |
| 14         | 291                             | 181                             | 62.2                            | (56.4, 67.8)                    | 100                             | 62                              | 62.0                            | (51.7, 71.5)                    |
| 18C        | 299                             | 261                             | 87.3                            | (83.0, 90.8)                    | 96                              | 83                              | 86.5                            | (78.0, 92.6)                    |
| 19A        | 299                             | 247                             | 82.6                            | (77.8, 86.7)                    | 105                             | 85                              | 81.0                            | (72.1, 88.0)                    |
| 19F        | 310                             | 243                             | 78.4                            | (73.4, 82.8)                    | 105                             | 81                              | 77.1                            | (67.9, 84.8)                    |
| 23F        | 309                             | 271                             | 87.7                            | (83.5, 91.1)                    | 104                             | 95                              | 91.3                            | (84.2, 96.0)                    |
| Additional |                                 |                                 |                                 |                                 |                                 |                                 |                                 |                                 |
| 8          | 300                             | 249                             | 83.0                            | (78.3, 87.1)                    | 103                             | 11                              | 10.7                            | (5.5, 18.3)                     |
| 10A        | 260                             | 205                             | 78.8                            | (73.4, 83.6)                    | 86                              | 15                              | 17.4                            | (10.1, 27.1)                    |
| 11A        | 220                             | 104                             | 47.3                            | (40.5, 54.1)                    | 64                              | 3                               | 4.7                             | (1.0, 13.1)                     |
| 12F        | 252                             | 236                             | 93.7                            | (89.9, 96.3)                    | 88                              | 5                               | 5.7                             | (1.9, 12.8)                     |
| 15B        | 248                             | 182                             | 73.4                            | (67.4, 78.8)                    | 90                              | 10                              | 11.1                            | (5.5, 19.5)                     |
| 22F        | 241                             | 202                             | 83.8                            | (78.5, 88.2)                    | 83                              | 11                              | 13.3                            | (6.8, 22.5)                     |
| 33F        | 213                             | 129                             | 60.6                            | (53.7, 67.2)                    | 78                              | 8                               | 10.3                            | (4.5, 19.2)                     |

Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

a. N = number of subjects with valid and determinate assay results to the specified serotype from both before and  1  month  after  vaccination  blood  sample  collections.  These  values  are  the  denominators  for  the  percentage calculations.

b. n = Number of subjects with a ≥ 4-fold rise in titres from before vaccination to 1 month after vaccination for the specified serotype.

- c. Exact 2-sided CI based on the Clopper and Pearson method.

## Selected exploratory endpoint: Immune response by risk status

Approximately one-third of the total evaluable subjects across all 3 cohorts combined had risk factors for serious pneumococcal disease (648 subjects), including diabetes mellitus (13.9%), smoking (12.8%), chronic pulmonary disease including asthma (8.5%), medical conditions related to chronic cardiovascular disease (5.3%), and liver disease (0.4%).

The initial analysis was criticised by the Rapporteurs and the applicant has performed an additional unplanned ad hoc analysis for the participants with and without risk factors by each age cohort in the B7471007 study (≥60 years [Cohort 1], 50 -59 years [Cohort 2], and 18-49 years of age [Cohort 3]). The study was not designed or powered for any formal between-group comparisons in this ad hoc analysis.  The 13vPnC arms in Cohorts 2 and 3 were included for safety only, however the immunogenicity in all cohorts was measured to maintain blinding during the assay work.  Additionally, because the number of participants 18 through 49 years of age in B7471007 is somewhat small when split into those subpopulations, an analysis was performed among participants in this age range from B7471007 pooled with the participants from B7471008 (all 18-49 years of age) to increase the precision. Note that the 13vPnC control group in Study B7471008 was included for safety only, however the immunogenicity in all groups was measured to maintain blinding during the assay work. There was no other study that overlapped with the adults 50 through 59 years of age. Post hoc supplemental data on the proportion of subjects with ≥4 -fold rises in OPA titres from before to 1 month after vaccination are summarised in the tables below.

<div style=\"page-break-after: always\"></div>

Substantial increases in OPA GMTs from before to 1 month after 20vPnC were observed in subjects with and without risk factors in all cohorts. 20vPnC elicited OPA GMTs in the participants with risk factors that were observed to be slightly lower for several serotypes than in participants without risk factors. This trend was consistent in both the 20vPnC group and the corresponding control group 13vPnC for the 13 serotypes and PPSV23 for the 7 additional serotypes. In participants ≥60 years of age with risk factors, approximately 50% to 80% of participants responded to 20vPnC with a ≥4 -fold increase in OPA titre to the vaccine serotypes, as did approximately 40% to 90% of those 50 through 59 and 18 through 49 years of age. The sample size becomes relatively small in the subsets of the younger populations (for example, as low as 30 participants in 50 through 59 years of age) so that results in a few subjects may have a disproportionate effect and increased overall variabilities in the summary.

Table 21: Pneumococcal OPA GMTs and GMRs for the 13vPnC Serotypes 1 Month After Vaccination by Risk Status - Linear Regression Model - Cohort 1

| Sero   |                              | Vaccine Group (as   | Vaccine Group (as   | Vaccine Group (as                            | Randomised)   | Randomised)   | Randomised)      | Vaccine Comparison   | Vaccine Comparison        |
|--------|------------------------------|---------------------|---------------------|----------------------------------------------|---------------|---------------|------------------|----------------------|---------------------------|
|        |                              | 20vPnC              | 20vPnC              | 20vPnC                                       | 13vPnC        | 13vPnC        | 13vPnC           | 20vPnC/13vPnC        | 20vPnC/13vPnC             |
| type   | Risk Status a                | n b                 | GMT c               | (95% CI c )                                  | n b           | GMT c         | (95% CI c )      | GMR d                | (95% CI d )               |
| 1      | Overall                      | 1430                | 149.2               | (137.0, 162.4)                               | 1419          | 183.4         | (168.4, 199.7)   | 0.81                 | (0.72, 0.92)              |
|        | With Risk Factors            | 464                 | 113.4               | (97.1, 132.4)                                | 516           | 143.1         | (123.5, 165.8)   | 0.79                 | (0.64, 0.98)              |
|        | Without Risk Factors         | 966                 | 172.1               | (155.6, 190.3)                               | 903           | 214.6         | (193.4, 238.2)   | 0.80                 | (0.70, 0.92)              |
| 3      | Overall                      | 1415                | 42.6                | (40.1, 45.4)                                 | 1411          | 49.9          | (46.9, 53.1)     | 0.85                 | (0.78, 0.93)              |
|        | With Risk Factors            | 457                 | 40.4                | (36.0, 45.3)                                 | 512           | 49.8          | (44.7, 55.4)     | 0.81                 | (0.69, 0.95)              |
|        | Without Risk Factors         | 958                 | 43.7                | (40.6, 47.1)                                 | 899           | 50.2          | (46.5, 54.1)     | 0.87                 | (0.79, 0.97)              |
| 4      | Overall                      | 1415                | 601.1               | (545.3, 662.7)                               | 1409          | 731.0         | (663.1, 805.8)   | 0.82                 | (0.72, 0.94)              |
|        | With Risk Factors            | 459                 | 488.7               | (409.7, 583.0)                               | 512           | 648.8         | (549.5, 765.9)   | 0.75                 | (0.59, 0.96)              |
|        | Without Risk Factors         | 956                 | 661.6               | (588.9, 743.3)                               | 897           | 785.8         | (696.7, 886.2)   | 0.84                 | (0.71, 0.99)              |
| 5      | Overall                      | 1418                | 101.0               | (92.9, 109.8)                                | 1395          | 119.8         | (110.1, 130.3)   | 0.84                 | (0.75, 0.95)              |
|        | With Risk Factors            | 458                 | 94.0                | (81.7, 108.2)                                | 506           | 113.6         | (99.4, 129.8)    | 0.83                 | (0.68, 1.00)              |
|        | Without Risk Factors         | 960                 | 104.6               | (94.2, 116.1)                                | 889           | 124.2         | (111.4, 138.4)   | 0.84                 | (0.73, 0.98)              |
| 6A     | Overall                      | 1403                | 990.3               | (896.0, 1094.6)                              | 1390          | 1283.2        | (1160.4, 1418.9) | 0.77                 | (0.67, 0.89)              |
|        | With Risk Factors            | 456                 | 981.5               | (821.4, 1172.8)                              | 508           | 1229.4        | (1039.6, 1453.8) | 0.80                 | (0.63, 1.02)              |
|        | Without Risk Factors         | 947                 | 998.5               | (884.5, 1127.2)                              | 882           | 1330.2        | (1172.5, 1509.1) | 0.75                 | (0.63, 0.89)              |
| 6B     | Overall                      | 1413                | 1227.7              | (1116.8, 1349.7)                             | 1401          | 1460.5        | (1328.4, 1605.8) | 0.84                 | (0.74, 0.96)              |
|        | With Risk Factors            | 455                 | 1231.0              | (1040.7, 1456.2)                             | 507           | 1428.0        | (1219.0, 1672.8) | 0.86                 | (0.68, 1.09)              |
|        | Without Risk Factors         | 958                 | 1226.4              | (1093.2, 1375.7)                             | 894           | 1494.8        | (1327.2, 1683.6) | 0.82                 | (0.70, 0.97)              |
| 7F     | Overall                      | 1409                | 1025.2              | (947.4, 1109.5)                              | 1391          | 1193.2        | (1102.3, 1291.7) | 0.86                 | (0.77, 0.96)              |
|        | With Risk Factors            | 459                 | 895.0               | (780.8, 1025.9)                              | 504           | 1080.4        | (948.9, 1230.2)  | 0.83                 | (0.69, 1.00)              |
|        | Without Risk Factors         | 950                 | 1091.2              | (990.4, 1202.2)                              | 887           | 1261.7        | (1141.3, 1394.7) | 0.86                 | (0.75, 0.99)              |
| 9V     | Overall                      | 1399                | 1550.1              | (1418.1, 1694.3)                             | 1391          | 1663.1        | (1520.3, 1819.3) | 0.93                 | (0.82, 1.06)              |
|        | With Risk Factors            | 450                 | 1348.8              | (1146.5, 1586.8)                             | 504           | 1565.9        | (1341.5, 1827.9) | 0.86                 | (0.69, 1.08)              |
|        | Without Risk Factors         | 949                 | 1659.7              | (1492.6, 1845.4)                             | 887           | 1732.2        | (1551.3, 1934.2) | 0.96                 | (0.82, 1.11)              |
| 14     | Overall                      | 1418                | 761.8               | (699.6, 829.5)                               | 1408          | 761.5         | (699.2, 829.3)   | 1.00                 | (0.89, 1.13)              |
|        | With Risk Factors            | 461                 | 837.4               | (725.6, 966.3)                               | 512           | 717.6         | (625.8, 822.9)   | 1.17                 | (0.96, 1.42)              |
|        | Without Risk Factors         | 957                 | 727.9               | (654.6, 809.4)                               | 896           | 794.5         | (712.4, 886.1)   | 0.92                 | (0.79, 1.06)              |
| 18C    | Overall                      | 1420                | 1358.0              | (1231.8, 1497.2)                             | 1403          | 1601.5        | (1451.9, 1766.4) | 0.85                 | (0.74, 0.97)              |
|        | With Risk Factors            | 460                 | 1136.9              | (959.0, 1347.8)                              | 512           | 1508.9        | (1284.5, 1772.6) | 0.75                 | (0.60, 0.95)              |
|        | Without Risk Factors         | 960                 | 1482.2              | (1315.5, 1669.9)                             | 891           | 1671.5        | (1477.0, 1891.6) | 0.89                 | (0.75, 1.05)              |
| 19A    | Overall                      | 1420                | 579.1               | (533.0, 629.3)                               | 1398          | 715.6         | (658.2, 778.1)   | 0.81                 | (0.72, 0.91)              |
|        | With Risk Factors            | 460                 | 502.0               | (434.4, 580.1)                               | 507           | 627.2         | (546.4, 720.0)   | 0.80                 | (0.66, 0.98)              |
|        | With Risk Factors            | 960 1421 459        | 622.6 295.1         | (562.6, 689.0) (269.5, 323.1) (224.1, 309.1) | 1403 510      | 779.4 367.0   | (701.5, 866.0)   | 0.80                 | (0.69, 0.92) (0.71, 0.91) |
| 19F    | Without Risk Factors Overall |                     |                     |                                              | 891           |               | (335.1, 402.0)   | 0.80                 |                           |
|        | Without Risk Factors         | 962 1424            | 263.2 312.9         | (280.2, 349.3)                               | 893           | 356.6         | (306.3, 415.2)   | 0.74 0.83            | (0.59, 0.92) (0.71, 0.97) |
| 23F    | Overall                      | 461                 | 299.8               | (266.6, 337.1)                               | 1409          | 377.3 361.6   | (336.6, 423.0)   | 0.83 0.88            | (0.70,                    |
|        |                              |                     |                     |                                              |               |               | (321.4, 406.7)   |                      | 0.98)                     |
|        | With Risk Factors            |                     | 295.1               | (240.0, 363.0)                               | 511           | 334.1         | (274.5, 406.6)   | 0.79                 | (0.66, 1.17)              |
|        | Without Risk Factors         | 963                 | 299.3               | (259.5, 345.4)                               | 898           | 377.5         | (325.7, 437.6)   |                      | (0.65, 0.97)              |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

a. Group with risk factors includes subjects with one or more medical history conditions or other factors (smoker) that puts them with an increased risk for serious pneumococcal disease; group with no risk factors includes subjects without an identified medical condition or other factors that would put them with an increased risk for serious pneumococcal disease.

b. n = Number of subjects with valid and determinate OPA titters for the specified serotype.

c. GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with vaccine group, sex, age at vaccination in years (continuous), and baseline log transformed OPA titres.

d. GMRs (ratio of GMTs 20vPnC to 13vPnC) and 2-sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

<div style=\"page-break-after: always\"></div>

Table 22: Pneumococcal OPA GMTs and GMRs for the 7 Additional Serotypes 1 Month After Vaccination by Risk Status - Linear Regression Model - Cohort 1

|      |                      | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Comparison   | Vaccine Comparison   |
|------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------|----------------------|
| Sero |                      | 20vPnC                          | 20vPnC                          | 20vPnC                          | PPSV23                          | PPSV23                          | PPSV23                          | 20vPnC/PPSV23        | 20vPnC/PPSV23        |
| type | Risk Status a        | n b                             | GMT c                           | (95% CI c )                     | n b                             | GMT c                           | (95% CI c )                     | GMR d                | (95% CI d )          |
| 8    | Overall              | 1374                            | 523.8                           | (479.9, 571.6)                  | 1319                            | 948.6                           | (867.5, 1037.3)                 | 0.55                 | (0.49, 0.63)         |
|      | With Risk Factors    | 446                             | 421.0                           | (358.1, 494.8)                  | 484                             | 816.2                           | (698.4, 953.8)                  | 0.52                 | (0.41, 0.65)         |
|      | Without Risk Factors | 928                             | 582.9                           | (525.9, 646.0)                  | 835                             | 1046.7                          | (939.1, 1166.7)                 | 0.56                 | (0.48, 0.65)         |
| 10A  | Overall              | 1310                            | 2114.1                          | (1926.0, 2320.7)                | 1263                            | 1133.1                          | (1030.4, 1245.9)                | 1.87                 | (1.64, 2.13)         |
|      | With Risk Factors    | 423                             | 1891.2                          | (1604.7, 2229.0)                | 461                             | 1044.8                          | (892.3, 1223.4)                 | 1.81                 | (1.44, 2.27)         |
|      | Without Risk Factors | 887                             | 2219.0                          | (1980.9, 2485.7)                | 802                             | 1179.2                          | (1046.4, 1328.9)                | 1.88                 | (1.60, 2.21)         |
| 11A  | Overall              | 1198                            | 4689.2                          | (4248.4, 5175.7)                | 1209                            | 2675.7                          | (2426.4, 2950.6)                | 1.75                 | (1.53, 2.01)         |
|      | With Risk Factors    | 379                             | 3593.5                          | (3007.9, 4293.2)                | 439                             | 2535.7                          | (2146.9, 2994.9)                | 1.42                 | (1.11, 1.81)         |
|      | Without Risk Factors | 819                             | 5349.6                          | (4751.6, 6022.9)                | 770                             | 2768.9                          | (2453.4, 3125.0)                | 1.93                 | (1.63, 2.28)         |
| 12F  | Overall              | 1294                            | 3077.7                          | (2765.9, 3424.7)                | 1222                            | 2064.9                          | (1849.1, 2306.0)                | 1.49                 | (1.28, 1.74)         |
|      | With Risk Factors    | 427                             | 2244.4                          | (1848.5, 2725.1)                | 451                             | 1630.6                          | (1347.6, 1972.9)                | 1.38                 | (1.05, 1.81)         |
|      | Without Risk Factors | 867                             | 3636.2                          | (3204.8, 4125.7)                | 771                             | 2414.9                          | (2111.4, 2762.1)                | 1.51                 | (1.26, 1.81)         |
| 15B  | Overall              | 1283                            | 2623.6                          | (2320.5, 2966.2)                | 1249                            | 837.9                           | (739.2, 949.8)                  | 3.13                 | (2.63, 3.73)         |
|      | With Risk Factors    | 426                             | 2155.0                          | (1744.2, 2662.6)                | 452                             | 888.3                           | (722.7, 1091.8)                 | 2.43                 | (1.81, 3.26)         |
|      | Without Risk Factors | 857                             | 2899.0                          | (2492.6, 3371.7)                | 797                             | 819.6                           | (699.6, 960.2)                  | 3.54                 | (2.85, 4.39)         |
| 22F  | Overall              | 1274                            | 4270.4                          | (3827.0, 4765.2)                | 1227                            | 2114.2                          | (1893.4, 2360.7)                | 2.02                 | (1.73, 2.36)         |
|      | With Risk Factors    | 410                             | 3643.3                          | (2985.9, 4445.4)                | 450                             | 1705.2                          | (1410.1, 2061.9)                | 2.14                 | (1.62, 2.81)         |
|      | Without Risk Factors | 864                             | 4680.0                          | (4106.3, 5333.8)                | 777                             | 2435.7                          | (2127.3, 2788.6)                | 1.92                 | (1.60, 2.31)         |
| 33F  | Overall              | 1157                            | 5640.5                          | (5126.5, 6206.0)                | 1201                            | 4081.2                          | (3717.6, 4480.4)                | 1.38                 | (1.21, 1.58)         |
|      | With Risk Factors    | 380                             | 4535.6                          | (3850.6, 5342.6)                | 428                             | 3496.9                          | (2999.5, 4076.8)                | 1.30                 | (1.04, 1.62)         |
|      | Without Risk Factors | 777                             | 6299.7                          | (5601.8, 7084.7)                | 773                             | 4444.7                          | (3952.3, 4998.5)                | 1.42                 | (1.20, 1.67)         |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

a. Group with risk factors includes subjects with one or more medical history conditions or other factors (smoker) that puts them with an increased risk for serious pneumococcal disease; group with no risk factors includes subjects without an identified medical condition or other factors that would put them with an increased risk for serious pneumococcal disease.

- b. n = Number of subjects with valid and determinate OPA titres for the specified serotype.
- c. GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with vaccine group, sex, age at vaccination in years (continuous), and baseline log transformed OPA titres.
- d. GMRs (ratio of GMTs 20vPnC to PPSV23) and 2-sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

Table 23: Pneumococcal OPA GMTs and GMRs for the 13vPnC Serotypes 1 Month After Vaccination by Risk Status - Linear Regression Model - Cohort 2

| Sero   |                      | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Comparison   | Vaccine Comparison   |
|--------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------|----------------------|
|        |                      | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          | 20vPnC/13vPnC        | 20vPnC/13vPnC        |
| type   | Risk Status a        | n b                             | GMT c                           | (95% CI c )                     | n b                             | GMT c                           | (95% CI c )                     | GMR d                | (95% CI d )          |
| 1      | Overall              | 320                             | 163.2                           | (136.5, 195.1)                  | 107                             | 192.3                           | (141.4, 261.6)                  | 0.85                 | (0.60, 1.21)         |
|        | With Risk Factors    | 104                             | 117.2                           | (85.4, 161.0)                   | 32                              | 84.6                            | (47.7, 149.9)                   | 1.39                 | (0.72, 2.67)         |
|        | Without Risk Factors | 216                             | 198.4                           | (160.5, 245.3)                  | 75                              | 277.1                           | (193.9, 395.8)                  | 0.72                 | (0.48, 1.08)         |
| 3      | Overall              | 318                             | 48.1                            | (42.2, 54.9)                    | 108                             | 47.0                            | (37.5, 58.9)                    | 1.03                 | (0.79, 1.33)         |
|        | With Risk Factors    | 102                             | 44.6                            | (35.5, 56.2)                    | 32                              | 52.5                            | (34.7, 79.4)                    | 0.85                 | (0.53, 1.37)         |
|        | Without Risk Factors | 216                             | 49.9                            | (42.3, 58.8)                    | 76                              | 45.2                            | (34.4, 59.5)                    | 1.10                 | (0.81, 1.51)         |
| 4      | Overall              | 318                             | 693.5                           | (569.3, 844.9)                  | 108                             | 1102.5                          | (790.0, 1538.7)                 | 0.63                 | (0.43, 0.92)         |
|        | With Risk Factors    | 103                             | 589.3                           | (426.3, 814.6)                  | 32                              | 632.6                           | (352.4, 1135.4)                 | 0.93                 | (0.48, 1.82)         |
|        | Without Risk Factors | 215                             | 760.2                           | (592.0, 976.2)                  | 76                              | 1381.1                          | (916.2, 2081.8)                 | 0.55                 | (0.34, 0.88)         |
| 5      | Overall              | 313                             | 93.6                            | (78.7, 111.3)                   | 108                             | 171.4                           | (127.7, 229.9)                  | 0.55                 | (0.39, 0.77)         |
|        | With Risk Factors    | 100                             | 63.9                            | (48.5, 84.3)                    | 32                              | 111.4                           | (68.2, 181.9)                   | 0.57                 | (0.33, 1.01)         |
|        | Without Risk Factors | 213                             | 113.7                           | (91.4, 141.3)                   | 76                              | 217.2                           | (151.6, 311.2)                  | 0.52                 | (0.35, 0.79)         |
| 6A     | Overall              | 318                             | 1410.9                          | (1156.4, 1721.3)                | 107                             | 1644.9                          | (1167.5, 2317.6)                | 0.86                 | (0.58, 1.27)         |
|        | With Risk Factors    | 103                             | 1305.7                          | (924.1, 1845.0)                 | 32                              | 2113.8                          | (1123.6, 3976.7)                | 0.62                 | (0.30, 1.27)         |
|        | Without Risk Factors | 215                             | 1480.2                          | (1155.9, 1895.5)                | 75                              | 1530.3                          | (1012.6, 2312.6)                | 0.97                 | (0.60, 1.55)         |
| 6B     | Overall              | 318                             | 1780.2                          | (1495.9, 2118.7)                | 105                             | 2227.4                          | (1658.0, 2992.4)                | 0.80                 | (0.57, 1.12)         |
|        | With Risk Factors    | 104                             | 1601.7                          | (1182.8, 2168.8)                | 30                              | 2071.5                          | (1190.5, 3604.3)                | 0.77                 | (0.41, 1.45)         |
|        | Without Risk Factors | 214                             | 1882.7                          | (1515.6, 2338.8)                | 75                              | 2330.9                          | (1635.5, 3322.1)                | 0.81                 | (0.54, 1.22)         |
| 7F     | Overall              | 313                             | 1086.8                          | (932.1, 1267.2)                 | 108                             | 1888.9                          | (1458.4, 2446.5)                | 0.58                 | (0.43, 0.78)         |
|        | With Risk Factors    | 101                             | 1028.8                          | (779.3, 1358.2)                 | 32                              | 1989.7                          | (1228.9, 3221.7)                | 0.52                 | (0.30, 0.90)         |
|        | Without Risk Factors | 212                             | 1136.9                          | (942.9, 1370.8)                 | 76                              | 1906.9                          | (1399.1, 2599.1)                | 0.60                 | (0.42, 0.85)         |
| 9V     | Overall              | 312                             | 1906.0                          | (1586.5, 2289.7)                | 105                             | 3369.0                          | (2458.4, 4616.8)                | 0.57                 | (0.39, 0.81)         |
|        | With Risk Factors    | 100                             | 1531.9                          | (1120.1, 2095.1)                | 30                              | 2254.7                          | (1265.4, 4017.5)                | 0.68                 | (0.35, 1.31)         |
|        | Without Risk Factors | 212                             | 2146.2                          | (1709.7, 2694.2)                | 75                              | 4109.8                          | (2815.3, 5999.6)                | 0.52                 | (0.34, 0.81)         |
| 14     | Overall              | 313                             | 1090.5                          | (915.8, 1298.6)                 | 108                             | 1306.9                          | (970.1, 1760.7)                 | 0.83                 | (0.59, 1.18)         |
|        | With Risk Factors    | 103                             | 948.2                           | (706.5, 1272.7)                 | 32                              | 1296.6                          | (763.3, 2202.5)                 | 0.73                 | (0.40, 1.34)         |
|        | Without Risk Factors | 210                             | 1185.6                          | (952.7, 1475.5)                 | 76                              | 1362.4                          | (946.9, 1960.2)                 | 0.87                 | (0.57, 1.32)         |
| 18C    | Overall              | 315                             | 2008.6                          | (1667.8, 2419.1)                | 107                             | 2616.4                          | (1909.2, 3585.6)                | 0.77                 | (0.53, 1.10)         |
|        | With                 |                                 | 1822.2                          |                                 |                                 |                                 |                                 |                      |                      |
|        | Risk Factors         | 102                             |                                 | (1296.2, 2561.6)                | 32                              | 1501.6                          | (814.2, 2769.2)                 | 1.21                 | (0.60, 2.45)         |
|        | Without Risk Factors | 213                             | 2151.8                          | (1720.3, 2691.6)                | 75                              | 3391.0                          | (2346.5, 4900.3)                | 0.63                 | (0.42, 0.97)         |
| 19A    | Overall              | 318                             | 682.9                           | (588.7, 792.3)                  | 108                             | 1165.1                          | (903.5, 1502.2)                 |                      | (0.44, 0.78)         |
|        |                      |                                 |                                 |                                 |                                 |                                 |                                 | 0.59                 |                      |

<div style=\"page-break-after: always\"></div>

|     | With Risk Factors    |   104 |   600.2 | (463.5, 777.2)   |   32 |   997.3 | (629.4, 1580.2)   |   0.60 | (0.35, 1.02)   |
|-----|----------------------|-------|---------|------------------|------|---------|-------------------|--------|----------------|
|     | Without Risk Factors |   214 |   741.2 | (616.6, 890.9)   |   76 |  1286.2 | (945.0, 1750.6)   |   0.58 | (0.41, 0.82)   |
| 19F | Overall              |   320 |   311.4 | (256.7, 377.7)   |  107 |   584.1 | (418.9, 814.3)    |   0.53 | (0.36, 0.78)   |
|     | With Risk Factors    |   104 |   251.5 | (178.8, 353.7)   |   32 |   537.8 | (289.5, 999.0)    |   0.47 | (0.23, 0.95)   |
|     | Without Risk Factors |   216 |   352.1 | (277.4, 447.0)   |   75 |   614.5 | (411.1, 918.4)    |   0.57 | (0.36, 0.91)   |
| 23F | Overall              |   319 |   563.3 | (447.6, 708.9)   |  107 |   901.1 | (607.7, 1336.0)   |   0.63 | (0.40, 0.98)   |
|     | With Risk Factors    |   104 |   557.3 | (376.2, 825.5)   |   32 |   721.4 | (359.5, 1447.3)   |   0.77 | (0.35, 1.72)   |
|     | Without Risk Factors |   215 |   586.3 | (439.9, 781.4)   |   75 |  1018.7 | (627.7, 1653.4)   |   0.58 | (0.33, 1.00)   |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

a. Group with risk factors includes subjects with one or more medical history conditions or other factors (smoker) that puts them with an increased risk for serious pneumococcal disease; group with no risk factors includes subjects without an identified medical condition or other factors that would put them with an increased risk for serious pneumococcal disease.

- b. n = Number of subjects with valid and determinate OPA titres for the specified serotype.
- c. GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with vaccine group, sex, age at vaccination in years (continuous), and baseline log transformed OPA titres.
- d. GMRs (ratio of GMTs 20vPnC to 13vPnC) and 2-sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

Table 24: Pneumococcal OPA GMTs and GMRs for the 13vPnC Serotypes 1 Month After Vaccination by Risk Status - Linear Regression Model - B7471008 and 18-49 Years of Age in B7471007

| Sero   |                      | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Comparison 20vPnC/13vPnC   | Vaccine Comparison 20vPnC/13vPnC   |
|--------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------------------------|------------------------------------|
|        |                      | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          |                                    |                                    |
| type   | Risk Status a        | n b                             | GMT c                           | (95% CI c )                     | n b                             | GMT c                           | (95% CI c )                     | GMR d                              | (95% CI d )                        |
| 1      | Overall              | 1702                            | 201.4                           | (184.6, 219.6)                  | 337                             | 286.7                           | (245.0, 335.5)                  | 0.70                               | (0.59, 0.83)                       |
|        | With Risk Factors    | 474                             | 146.7                           | (123.0, 175.1)                  | 90                              | 214.6                           | (155.8, 295.6)                  | 0.68                               | (0.48, 0.97)                       |
|        | Without Risk Factors | 1228                            | 228.1                           | (206.9, 251.6)                  | 247                             | 317.1                           | (265.8, 378.3)                  | 0.72                               | (0.60, 0.87)                       |
| 3      | Overall              | 1694                            | 47.1                            | (44.2, 50.1)                    | 337                             | 52.8                            | (47.1, 59.2)                    | 0.89                               | (0.79, 1.01)                       |
|        | With Risk Factors    | 472                             | 44.0                            | (38.9, 49.8)                    | 91                              | 56.9                            | (45.5, 71.0)                    | 0.77                               | (0.61, 0.99)                       |
|        | Without Risk Factors | 1222                            | 48.4                            | (45.0, 52.1)                    | 246                             | 51.2                            | (44.8, 58.5)                    | 0.95                               | (0.82, 1.09)                       |
| 4      | Overall              | 1689                            | 1893.0                          | (1728.7, 2072.9)                | 333                             | 2397.2                          | (2033.3, 2826.3)                | 0.79                               | (0.66, 0.94)                       |
|        | With Risk Factors    | 465                             | 1791.1                          | (1498.3, 2141.2)                | 88                              | 2498.3                          | (1802.6, 3462.6)                | 0.72                               | (0.50, 1.02)                       |
|        | Without Risk Factors | 1224                            | 1923.5                          | (1731.0, 2137.4)                | 245                             | 2340.2                          | (1934.9, 2830.5)                | 0.82                               | (0.67, 1.01)                       |
| 5      | Overall              | 1690                            | 129.8                           | (118.7, 142.0)                  | 337                             | 183.9                           | (156.4, 216.3)                  | 0.71                               | (0.59, 0.84)                       |
|        | With Risk Factors    | 471                             | 115.0                           | (97.1, 136.2)                   | 90                              | 162.3                           | (119.5, 220.4)                  | 0.71                               | (0.51, 0.99)                       |
|        | Without Risk Factors | 1219                            | 136.5                           | (122.8, 151.6)                  | 247                             | 191.3                           | (158.1, 231.3)                  | 0.71                               | (0.58, 0.88)                       |
| 6A     | Overall              | 1683                            | 4277.2                          | (3922.1, 4664.4)                | 338                             | 4675.5                          | (4000.1, 5465.0)                | 0.91                               | (0.77, 1.08)                       |
|        | With Risk Factors    | 468                             | 3913.6                          | (3269.6, 4684.3)                | 91                              | 3884.3                          | (2796.2, 5395.9)                | 1.01                               | (0.70, 1.44)                       |
|        | Without Risk Factors | 1215                            | 4444.8                          | (4029.1, 4903.5)                | 247                             | 4953.1                          | (4156.7, 5902.1)                | 0.90                               | (0.74, 1.08)                       |
| 6B     | Overall              | 1694                            | 4812.7                          | (4420.4, 5239.7)                | 331                             | 5502.8                          | (4721.5, 6413.3)                | 0.87                               | (0.74, 1.03)                       |
|        | With Risk Factors    | 472                             | 4651.4                          | (3923.1, 5514.8)                | 89                              | 5522.8                          | (4060.9, 7510.8)                | 0.84                               | (0.60, 1.18)                       |
|        | Without Risk Factors | 1222                            | 4875.9                          | (4422.0, 5376.3)                | 242                             | 5443.7                          | (4568.4, 6486.7)                | 0.90                               | (0.74, 1.08)                       |
| 7F     | Overall              | 1668                            | 2040.1                          | (1876.4, 2218.1)                | 329                             | 2709.3                          | (2329.3, 3151.1)                | 0.75                               | (0.64, 0.89)                       |
|        | With Risk Factors    | 464                             | 1669.2                          | (1416.2, 1967.4)                | 89                              | 3044.3                          | (2271.1, 4080.5)                | 0.55                               | (0.40, 0.76)                       |
|        | Without Risk Factors | 1204                            | 2197.1                          | (1994.5, 2420.3)                | 240                             | 2592.1                          | (2175.7, 3088.1)                | 0.85                               | (0.70, 1.02)                       |
| 9V     | Overall              | 1682                            | 6005.0                          | (5520.3, 6532.3)                | 335                             | 6679.3                          | (5748.7, 7760.5)                | 0.90                               | (0.76, 1.06)                       |
|        | With Risk Factors    | 468                             | 5775.8                          | (4949.2, 6740.5)                | 89                              | 7874.4                          | (5974.5, 10378.4)               | 0.73                               | (0.54, 0.99)                       |
|        | Without Risk Factors | 1214                            | 6077.7                          | (5497.2, 6719.6)                | 246                             | 6259.9                          | (5238.3, 7480.6)                | 0.97                               | (0.80, 1.18)                       |
| 14     | Overall              | 1688                            | 2161.9                          | (1996.6, 2340.9)                | 334                             | 2314.0                          | (2005.9, 2669.5)                | 0.93                               | (0.80, 1.09)                       |
|        | With Risk Factors    | 468                             | 2034.0                          | (1738.8, 2379.5)                | 91                              | 2292.7                          | (1729.0, 3040.1)                | 0.89                               | (0.65, 1.21)                       |
|        | Without Risk Factors | 1220                            | 2221.1                          | (2025.2, 2436.0)                | 243                             | 2312.6                          | (1960.2, 2728.5)                | 0.96                               | (0.80, 1.15)                       |
| 18C    | Overall              | 1681                            | 4781.5                          | (4352.0, 5253.5)                | 329                             | 5398.0                          | (4551.0, 6402.6)                | 0.89                               | (0.74, 1.06)                       |
|        | With Risk Factors    | 467                             | 4499.8                          | (3776.5, 5361.6)                | 88                              | 5550.4                          | (4034.6, 7635.8)                | 0.81                               | (0.57, 1.15)                       |
|        | Without Risk Factors | 1214                            | 4915.3                          | (4394.4, 5497.9)                | 241                             | 5330.7                          | (4355.3, 6524.5)                | 0.92                               | (0.74, 1.14)                       |
| 19A    | Overall              | 1678                            | 1577.2                          | (1462.8, 1700.6)                | 334                             | 1831.1                          | (1599.4, 2096.3)                | 0.86                               | (0.74, 1.00)                       |
|        | With Risk Factors    | 464                             | 1624.9                          | (1409.4, 1873.3)                | 90                              | 1582.5                          | (1230.7, 2034.9)                | 1.03                               | (0.78, 1.35)                       |
|        | Without Risk Factors | 1214                            | 1557.2                          |                                 | 244                             |                                 |                                 | 0.81                               | (0.68, 0.96)                       |
| 19F    | Overall              | 1688                            | 620.8                           | (1424.3, 1702.5)                | 336                             | 1930.8                          | (1644.4, 2267.1)                | 0.73                               | (0.61, 0.88)                       |
|        |                      |                                 | 560.6                           | (566.3, 680.5) (469.7, 669.1)   |                                 | 847.7                           | (718.5, 1000.3) (536.0, 1014.0) | 0.76                               | (0.54, 1.08)                       |
|        | With Risk Factors    | 468                             |                                 |                                 | 91                              | 737.2                           |                                 | 0.72                               |                                    |
| 23F    | Overall              | 1220                            | 642.4                           | (576.9, 715.4)                  | 337                             | 1917.7                          | (731.5, 1076.7)                 |                                    | (0.70, 1.06)                       |
|        | Without Risk Factors | 1699                            | 1652.7                          | (1483.3, 1841.4)                | 245                             | 887.5                           | (1577.5, 2331.3)                | 0.86                               | (0.59, 0.89)                       |
|        | With Risk Factors    | 474                             | 1312.5                          | (1060.3, 1624.7)                | 90                              | 1465.0                          | (995.6, 2155.6)                 | 0.90                               | (0.59, 1.36)                       |
|        | Without Risk         | 1225                            | 1801.9                          | (1591.8, 2039.8)                | 247                             | 2106.1                          | (1684.6, 2632.9)                | 0.86                               | (0.67, 1.09)                       |
|        | Factors              |                                 |                                 |                                 |                                 |                                 |                                 |                                    |                                    |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titre; LLOQ = lower limit of quantitation; LS = least squares; OPA = opsonophagocytic activity. Notes: Assay results below the LLOQ were set to 0.5 ✕ LLOQ in the analysis.

Evaluable Immunogenicity Population: Evaluable 13-Matched Immunogenicity Population for Cohort 1, Evaluable-20 Immunogenicity Population for Cohort 2 and 3 for B7471007 and Evaluable Immunogenicity Population for B7471008.

a. Group with risk factors includes subjects with one or more medical history conditions or other factors (smoker) that puts them with an increased risk for serious pneumococcal disease; group with no risk factors includes subjects without an identified medical condition or other factors that would put them with an increased risk for serious pneumococcal disease.

b. n = Number of subjects with valid and determinate OPA titres for the specified serotype.

c. GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titres using a regression model with study, vaccine group, sex, age at vaccination in years (continuous), and baseline log transformed OPA titres.

d. GMRs (ratio of GMTs 20vPnC to 13vPnC) and 2-sided CIs were calculated by exponentiating the difference of LS means and the corresponding CIs based on the same regression model as above.

<div style=\"page-break-after: always\"></div>

Table 25: Proportion of Subjects Achieving a ≥4 -Fold Rise in OPA Titres From Before Vaccination to 1 Month After Vaccination for the 13vPnC Serotypes by Risk Status - Cohort 1

| Sero   | Risk Status a        | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   |
|--------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| type   |                      | 20vPnC                          | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          |
|        |                      | N b                             | n c                             | %                               | (95% CI d )                     | N b                             | n c                             | %                               | (95% CI d )                     |
| 1      | Overall              | 1425                            | 1027                            | 72.1                            | (69.7, 74.4)                    | 1418                            | 1060                            | 74.8                            | (72.4, 77.0)                    |
|        | With Risk Factors    | 463                             | 293                             | 63.3                            | (58.7, 67.7)                    | 516                             | 344                             | 66.7                            | (62.4, 70.7)                    |
|        | Without Risk Factors | 962                             | 734                             | 76.3                            | (73.5, 79.0)                    | 902                             | 716                             | 79.4                            | (76.6, 82.0)                    |
| 3      | Overall              | 1404                            | 787                             | 56.1                            | (53.4, 58.7)                    | 1401                            | 864                             | 61.7                            | (59.1, 64.2)                    |
|        | With Risk Factors    | 453                             | 237                             | 52.3                            | (47.6, 57.0)                    | 510                             | 301                             | 59.0                            | (54.6, 63.3)                    |
|        | Without Risk Factors | 951                             | 550                             | 57.8                            | (54.6, 61.0)                    | 891                             | 563                             | 63.2                            | (59.9, 66.4)                    |
| 4      | Overall              | 1370                            | 1035                            | 75.5                            | (73.2, 77.8)                    | 1374                            | 1094                            | 79.6                            | (77.4, 81.7)                    |
|        | With Risk Factors    | 443                             | 304                             | 68.6                            | (64.1, 72.9)                    | 500                             | 376                             | 75.2                            | (71.2, 78.9)                    |
|        | Without Risk Factors | 927                             | 731                             | 78.9                            | (76.1, 81.4)                    | 874                             | 718                             | 82.2                            | (79.4, 84.6)                    |
| 5      | Overall              | 1411                            | 784                             | 55.6                            | (52.9, 58.2)                    | 1394                            | 845                             | 60.6                            | (58.0, 63.2)                    |
|        | With Risk Factors    | 456                             | 231                             | 50.7                            | (46.0, 55.3)                    | 506                             | 302                             | 59.7                            | (55.3, 64.0)                    |
|        | Without Risk Factors | 955                             | 553                             | 57.9                            | (54.7, 61.1)                    | 888                             | 543                             | 61.1                            | (57.9, 64.4)                    |
| 6A     | Overall              | 1382                            | 1112                            | 80.5                            | (78.3, 82.5)                    | 1371                            | 1152                            | 84.0                            | (82.0, 85.9)                    |
|        | With Risk Factors    | 448                             | 351                             | 78.3                            | (74.2, 82.1)                    | 505                             | 408                             | 80.8                            | (77.1, 84.1)                    |
|        | Without Risk Factors | 934                             | 761                             | 81.5                            | (78.8, 83.9)                    | 866                             | 744                             | 85.9                            | (83.4, 88.2)                    |
| 6B     | Overall              | 1360                            | 1029                            | 75.7                            | (73.3, 77.9)                    | 1360                            | 1055                            | 77.6                            | (75.3, 79.8)                    |
|        | With Risk Factors    | 439                             | 308                             | 70.2                            | (65.6, 74.4)                    | 494                             | 372                             | 75.3                            | (71.3, 79.0)                    |
|        | Without Risk Factors | 921                             | 721                             | 78.3                            | (75.5, 80.9)                    | 866                             | 683                             | 78.9                            | (76.0, 81.5)                    |
| 7F     | Overall              | 1367                            | 981                             | 71.8                            | (69.3, 74.1)                    | 1355                            | 979                             | 72.3                            | (69.8, 74.6)                    |
|        | With Risk Factors    | 445                             | 294                             | 66.1                            | (61.5, 70.5)                    | 491                             | 323                             | 65.8                            | (61.4, 70.0)                    |
|        | Without Risk Factors | 922                             | 687                             | 74.5                            | (71.6, 77.3)                    | 864                             | 656                             | 75.9                            | (72.9, 78.7)                    |
| 9V     | Overall              | 1317                            | 892                             | 67.7                            | (65.1, 70.3)                    | 1294                            | 897                             | 69.3                            | (66.7, 71.8)                    |
|        | With Risk Factors    | 430                             | 260                             | 60.5                            | (55.7, 65.1)                    | 475                             | 309                             | 65.1                            | (60.6, 69.3)                    |
|        | Without Risk Factors | 887                             | 632                             | 71.3                            | (68.1, 74.2)                    | 819                             | 588                             | 71.8                            | (68.6, 74.9)                    |
| 14     | Overall              | 1370                            | 797                             | 58.2                            | (55.5, 60.8)                    | 1366                            | 737                             | 54.0                            | (51.3, 56.6)                    |
|        | With Risk Factors    | 453                             | 252                             | 55.6                            | (50.9, 60.3)                    | 495                             | 240                             | 48.5                            | (44.0, 53.0)                    |
|        | Without Risk Factors | 917                             | 545                             | 59.4                            | (56.2, 62.6)                    | 871                             | 497                             | 57.1                            | (53.7, 60.4)                    |
| 18C    | Overall              | 1407                            | 1093                            | 77.7                            | (75.4, 79.8)                    | 1396                            | 1111                            | 79.6                            | (77.4, 81.7)                    |
|        | With Risk Factors    | 455                             | 322                             | 70.8                            | (66.4, 74.9)                    | 508                             | 387                             | 76.2                            | (72.2, 79.8)                    |
|        | Without Risk Factors | 952                             | 771                             | 81.0                            | (78.3, 83.4)                    | 888                             | 724                             | 81.5                            | (78.8, 84.0)                    |
| 19A    | Overall              | 1400                            | 1031                            | 73.6                            | (71.3, 75.9)                    | 1379                            | 1069                            | 77.5                            | (75.2, 79.7)                    |
|        | With Risk Factors    | 456                             | 312                             | 68.4                            | (63.9, 72.7)                    | 501                             | 364                             | 72.7                            | (68.5, 76.5)                    |
|        | Without Risk Factors | 944                             | 719                             | 76.2                            | (73.3, 78.9)                    | 878                             | 705                             | 80.3                            | (77.5, 82.9)                    |
| 19F    | Overall              | 1405                            | 894                             | 63.6                            | (61.1, 66.2)                    | 1397                            | 935                             | 66.9                            | (64.4, 69.4)                    |
|        | With Risk Factors    | 454                             | 259                             | 57.0                            | (52.4, 61.7)                    | 507                             | 321                             | 63.3                            | (59.0, 67.5)                    |
|        | Without Risk Factors | 951                             | 635                             | 66.8                            | (63.7, 69.8)                    | 890                             | 614                             | 69.0                            | (65.8, 72.0)                    |
| 23F    | Overall              | 1409                            | 995                             | 70.6                            | (68.2, 73.0)                    | 1402                            | 1043                            | 74.4                            | (72.0, 76.7)                    |
|        | With Risk Factors    | 458                             | 314                             | 68.6                            | (64.1, 72.8)                    | 508                             | 361                             | 71.1                            | (66.9, 75.0)                    |
|        | Without Risk         | 951                             | 681                             | 71.6                            | (68.6, 74.5)                    | 894                             | 682                             | 76.3                            | (73.4,                          |
|        | Factors              |                                 |                                 |                                 |                                 |                                 |                                 |                                 | 79.0)                           |

Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

a. Group with risk factors includes subjects with one or more medical history conditions or other factors (smoker) that puts them with an increased risk for serious pneumococcal disease; group with no risk factors includes subjects without an identified medical condition or other factors that would put them with an increased risk for serious pneumococcal disease.

b. N = number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections. These values are the denominators for the percentage calculations.

c. n = Number of subjects with a ≥4 -fold rise in titers from before vaccination to 1 month after vaccination for the specified serotype. d. Exact 2-sided CI based on the Clopper and Pearson method.

Table 26: Proportion of Subjects Achieving a ≥ 4-Fold Rise in OPA Titres From Before Vaccination to 1 Month After Vaccination for the 13vPnC Serotypes by Risk Status -Cohort 2

| Sero type   | Risk Status a        | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   |
|-------------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|             |                      | 20vPnC                          | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          |
|             |                      | N b                             | n c                             | %                               | (95% CI d )                     | N b                             | n c                             | %                               | (95% CI d )                     |
| 1           | Overall              | 319                             | 239                             | 74.9                            | (69.8, 79.6)                    | 107                             | 84                              | 78.5                            | (69.5, 85.9)                    |
|             | With Risk Factors    | 104                             | 69                              | 66.3                            | (56.4, 75.3)                    | 32                              | 21                              | 65.6                            | (46.8, 81.4)                    |
|             | Without Risk Factors | 215                             | 170                             | 79.1                            | (73.0, 84.3)                    | 75                              | 63                              | 84.0                            | (73.7, 91.4)                    |
| 3           | Overall              | 317                             | 187                             | 59.0                            | (53.4, 64.5)                    | 108                             | 65                              | 60.2                            | (50.3, 69.5)                    |
|             | With Risk Factors    | 102                             | 55                              | 53.9                            | (43.8, 63.8)                    | 32                              | 20                              | 62.5                            | (43.7, 78.9)                    |
|             | Without Risk Factors | 215                             | 132                             | 61.4                            | (54.5, 67.9)                    | 76                              | 45                              | 59.2                            | (47.3, 70.4)                    |
| 4           | Overall              | 304                             | 256                             | 84.2                            | (79.6, 88.1)                    | 106                             | 90                              | 84.9                            | (76.6, 91.1)                    |
|             | With Risk Factors    | 100                             | 82                              | 82.0                            | (73.1, 89.0)                    | 31                              | 23                              | 74.2                            | (55.4, 88.1)                    |
|             | Without Risk Factors | 204                             | 174                             | 85.3                            | (79.7, 89.9)                    | 75                              | 67                              | 89.3                            | (80.1, 95.3)                    |
| 5           | Overall              | 312                             | 171                             | 54.8                            | (49.1, 60.4)                    | 108                             | 78                              | 72.2                            | (62.8, 80.4)                    |
|             | With Risk Factors    | 100                             | 43                              | 43.0                            | (33.1, 53.3)                    | 32                              | 20                              | 62.5                            | (43.7, 78.9)                    |
|             | Without Risk Factors | 212                             | 128                             | 60.4                            | (53.5, 67.0)                    | 76                              | 58                              | 76.3                            | (65.2, 85.3)                    |

<div style=\"page-break-after: always\"></div>

| 6A   | Overall              |   312 |   268 |   85.9 | (81.5, 89.6)   |   104 |   92 |   88.5 | (80.7, 93.9)   |
|------|----------------------|-------|-------|--------|----------------|-------|------|--------|----------------|
|      | With Risk Factors    |   103 |    84 |   81.6 | (72.7, 88.5)   |    31 |   27 |   87.1 | (70.2, 96.4)   |
|      | Without Risk Factors |   209 |   184 |   88   | (82.9, 92.1)   |    73 |   65 |   89   | (79.5, 95.1)   |
| 6B   | Overall              |   299 |   236 |   78.9 | (73.9, 83.4)   |   103 |   85 |   82.5 | (73.8, 89.3)   |
|      | With Risk Factors    |   100 |    75 |   75   | (65.3, 83.1)   |    30 |   25 |   83.3 | (65.3, 94.4)   |
|      | Without Risk Factors |   199 |   161 |   80.9 | (74.7, 86.1)   |    73 |   60 |   82.2 | (71.5, 90.2)   |
| 7F   | Overall              |   300 |   219 |   73   | (67.6, 77.9)   |   106 |   91 |   85.8 | (77.7, 91.9)   |
|      | With Risk Factors    |    96 |    67 |   69.8 | (59.6, 78.7)   |    32 |   27 |   84.4 | (67.2, 94.7)   |
|      | Without Risk Factors |   204 |   152 |   74.5 | (68.0, 80.3)   |    74 |   64 |   86.5 | (76.5, 93.3)   |
| 9V   | Overall              |   288 |   212 |   73.6 | (68.1, 78.6)   |    97 |   74 |   76.3 | (66.6, 84.3)   |
|      | With Risk Factors    |    95 |    66 |   69.5 | (59.2, 78.5)   |    28 |   22 |   78.6 | (59.0, 91.7)   |
|      | Without Risk Factors |   193 |   146 |   75.6 | (69.0, 81.5)   |    69 |   52 |   75.4 | (63.5, 84.9)   |
| 14   | Overall              |   300 |   187 |   62.3 | (56.6, 67.8)   |   103 |   62 |   60.2 | (50.1, 69.7)   |
|      | With Risk Factors    |    96 |    57 |   59.4 | (48.9, 69.3)   |    30 |   18 |   60   | (40.6, 77.3)   |
|      | Without Risk Factors |   204 |   130 |   63.7 | (56.7, 70.3)   |    73 |   44 |   60.3 | (48.1, 71.5)   |
| 18C  | Overall              |   308 |   254 |   82.5 | (77.8, 86.5)   |   106 |   88 |   83   | (74.5, 89.6)   |
|      | With Risk Factors    |   100 |    79 |   79   | (69.7, 86.5)   |    31 |   25 |   80.6 | (62.5, 92.5)   |
|      | Without Risk Factors |   208 |   175 |   84.1 | (78.4, 88.8)   |    75 |   63 |   84   | (73.7, 91.4)   |
| 19A  | Overall              |   310 |   248 |   80   | (75.1, 84.3)   |   105 |   91 |   86.7 | (78.6, 92.5)   |
|      | With Risk Factors    |   101 |    78 |   77.2 | (67.8, 85.0)   |    32 |   25 |   78.1 | (60.0, 90.7)   |
|      | Without Risk Factors |   209 |   170 |   81.3 | (75.4, 86.4)   |    73 |   66 |   90.4 | (81.2, 96.1)   |
| 19F  | Overall              |   316 |   203 |   64.2 | (58.7, 69.5)   |   106 |   83 |   78.3 | (69.2, 85.7)   |
|      | With Risk Factors    |   104 |    62 |   59.6 | (49.5, 69.1)   |    32 |   23 |   71.9 | (53.3, 86.3)   |
|      | Without Risk Factors |   212 |   141 |   66.5 | (59.7, 72.8)   |    74 |   60 |   81.1 | (70.3, 89.3)   |
| 23F  | Overall              |   313 |   254 |   81.2 | (76.4, 85.3)   |   106 |   93 |   87.7 | (79.9, 93.3)   |
|      | With Risk Factors    |   100 |    82 |   82   | (73.1, 89.0)   |    32 |   28 |   87.5 | (71.0, 96.5)   |
|      | Without Risk Factors |   213 |   172 |   80.8 | (74.8, 85.8)   |    74 |   65 |   87.8 | (78.2, 94.3)   |

Abbreviations: LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

a. Group with risk factors includes subjects with one or more medical history conditions or other factors (smoker) that puts them with an increased risk for serious pneumococcal disease; group with no risk factors includes subjects without an identified medical condition or other factors that would put them with an increased risk for serious pneumococcal disease.

b. N = number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections. These values are the denominators for the percentage calculations.

c. n = Number of subjects with a ≥4 -fold rise in titres from before vaccination to 1 month after vaccination for the specified serotype.

d. Exact 2-sided CI based on the Clopper and Pearson method.

Table 27: Proportion of Subjects Achieving a ≥ 4-Fold Rise in OPA Titres From Before Vaccination to 1 Month After Vaccination for the 13vPnC Serotypes by Risk Status -B7471008 and 18-49 years of age in B7471007

| Sero type   | Risk Status a        | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   | Vaccine Group (as Randomised)   |
|-------------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|             |                      | 20vPnC                          | 20vPnC                          | 20vPnC                          | 20vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          | 13vPnC                          |
|             |                      | N b                             | n c                             | %                               | (95% CI d )                     | N b                             | n c                             | %                               | (95% CI d )                     |
| 1           | Overall              | 315                             | 271                             | 86.0                            | (81.7, 89.7)                    | 105                             | 92                              | 87.6                            | (79.8, 93.2)                    |
|             | With Risk Factors    | 79                              | 61                              | 77.2                            | (66.4, 85.9)                    | 30                              | 26                              | 86.7                            | (69.3, 96.2)                    |
|             | Without Risk Factors | 236                             | 210                             | 89.0                            | (84.3, 92.7)                    | 75                              | 66                              | 88.0                            | (78.4, 94.4)                    |
| 3           | Overall              | 312                             | 177                             | 56.7                            | (51.0, 62.3)                    | 105                             | 66                              | 62.9                            | (52.9, 72.1)                    |
|             | With Risk Factors    | 79                              | 44                              | 55.7                            | (44.1, 66.9)                    | 30                              | 20                              | 66.7                            | (47.2, 82.7)                    |
|             | Without Risk Factors | 233                             | 133                             | 57.1                            | (50.5, 63.5)                    | 75                              | 46                              | 61.3                            | (49.4, 72.4)                    |
| 4           | Overall              | 302                             | 276                             | 91.4                            | (87.6, 94.3)                    | 103                             | 94                              | 91.3                            | (84.1, 95.9)                    |
|             | With Risk Factors    | 77                              | 73                              | 94.8                            | (87.2, 98.6)                    | 30                              | 26                              | 86.7                            | (69.3, 96.2)                    |
|             | Without Risk Factors | 225                             | 203                             | 90.2                            | (85.6, 93.8)                    | 73                              | 68                              | 93.2                            | (84.7, 97.7)                    |
| 5           | Overall              | 315                             | 204                             | 64.8                            | (59.2, 70.0)                    | 106                             | 79                              | 74.5                            | (65.1, 82.5)                    |
|             | With Risk Factors    | 79                              | 48                              | 60.8                            | (49.1, 71.6)                    | 31                              | 23                              | 74.2                            | (55.4, 88.1)                    |
|             | Without Risk Factors | 236                             | 156                             | 66.1                            | (59.7, 72.1)                    | 75                              | 56                              | 74.7                            | (63.3, 84.0)                    |
| 6A          | Overall              | 305                             | 295                             | 96.7                            | (94.1, 98.4)                    | 103                             | 98                              | 95.1                            | (89.0, 98.4)                    |
|             | With Risk Factors    | 77                              | 75                              | 97.4                            | (90.9, 99.7)                    | 30                              | 27                              | 90.0                            | (73.5, 97.9)                    |
|             | Without Risk Factors | 228                             | 220                             | 96.5                            | (93.2, 98.5)                    | 73                              | 71                              | 97.3                            | (90.5, 99.7)                    |
| 6B          | Overall              | 286                             | 255                             | 89.2                            | (85.0, 92.5)                    | 97                              | 84                              | 86.6                            | (78.2, 92.7)                    |
|             | With Risk Factors    | 71                              | 62                              | 87.3                            | (77.3, 94.0)                    | 30                              | 28                              | 93.3                            | (77.9, 99.2)                    |
|             | Without Risk Factors | 215                             | 193                             | 89.8                            | (84.9, 93.5)                    | 67                              | 56                              | 83.6                            | (72.5, 91.5)                    |
| 7F          | Overall              | 284                             | 216                             | 76.1                            | (70.7, 80.9)                    | 97                              | 82                              | 84.5                            | (75.8, 91.1)                    |
|             | With Risk Factors    | 70                              | 49                              | 70.0                            | (57.9, 80.4)                    | 29                              | 24                              | 82.8                            | (64.2, 94.2)                    |
|             | Without Risk Factors | 214                             | 167                             | 78.0                            | (71.9, 83.4)                    | 68                              | 58                              | 85.3                            | (74.6, 92.7)                    |
| 9V          | Overall              | 281                             | 236                             | 84.0                            | (79.2, 88.1)                    | 99                              | 80                              | 80.8                            | (71.7, 88.0)                    |
|             | With Risk Factors    | 74                              | 62                              | 83.8                            | (73.4, 91.3)                    | 30                              | 22                              | 73.3                            | (54.1, 87.7)                    |
|             | Without Risk Factors | 207                             | 174                             | 84.1                            | (78.3, 88.8)                    | 69                              | 58                              | 84.1                            | (73.3, 91.8)                    |
| 14          | Overall              | 291                             | 181                             | 62.2                            | (56.4, 67.8)                    | 100                             | 62                              | 62.0                            | (51.7, 71.5)                    |
|             | With Risk Factors    | 74                              | 42                              | 56.8                            | (44.7, 68.2)                    | 29                              | 17                              | 58.6                            | (38.9, 76.5)                    |
|             | Without Risk Factors | 217                             | 139                             | 64.1                            | (57.3, 70.4)                    | 71                              | 45                              | 63.4                            | (51.1, 74.5)                    |
| 18C         | Overall              | 299                             | 261                             | 87.3                            | (83.0, 90.8)                    | 96                              | 83                              | 86.5                            | (78.0, 92.6)                    |
|             | With Risk Factors    | 76                              | 64                              | 84.2                            | (74.0, 91.6)                    | 29                              | 24                              | 82.8                            | (64.2, 94.2)                    |
|             | Without Risk Factors | 223                             | 197                             | 88.3                            | (83.4, 92.2)                    | 67                              | 59                              | 88.1                            | (77.8, 94.7)                    |
| 19A         | Overall              | 299                             | 247                             |                                 |                                 |                                 | 85                              | 81.0                            | (72.1, 88.0)                    |
|             |                      |                                 |                                 | 82.6                            | (77.8, 86.7)                    | 105                             |                                 |                                 |                                 |
|             | With Risk Factors    | 74                              | 64                              | 86.5                            | (76.5, 93.3)                    | 31                              | 23                              | 74.2                            | (55.4, 88.1)                    |

<div style=\"page-break-after: always\"></div>

|     | Without Risk Factors   |   225 |   183 |   81.3 | (75.6, 86.2)   |   74 |   62 |   83.8 | (73.4, 91.3)   |
|-----|------------------------|-------|-------|--------|----------------|------|------|--------|----------------|
| 19F | Overall                |   310 |   243 |   78.4 | (73.4, 82.8)   |  105 |   81 |   77.1 | (67.9, 84.8)   |
|     | With Risk Factors      |    77 |    63 |   81.8 | (71.4, 89.7)   |   30 |   23 |   76.7 | (57.7, 90.1)   |
|     | Without Risk Factors   |   233 |   180 |   77.3 | (71.3, 82.5)   |   75 |   58 |   77.3 | (66.2, 86.2)   |
| 23F | Overall                |   309 |   271 |   87.7 | (83.5, 91.1)   |  104 |   95 |   91.3 | (84.2, 96.0)   |
|     | With Risk Factors      |    79 |    65 |   82.3 | (72.1, 90.0)   |   31 |   26 |   83.9 | (66.3, 94.5)   |
|     | Without Risk Factors   |   230 |   206 |   89.6 | (84.9, 93.2)   |   73 |   69 |   94.5 | (86.6, 98.5)   |

## Study B7471006

Participants were enrolled into different cohorts based on pneumococcal vaccination history:

- Cohort A: Approximately 375 participants who had received PPSV23 ≥1 to ≤5 years previously but had not been vaccinated with 13vPnC were to be randomised (2:1) to receive either 20vPnC or 13vPnC (control for safety only).
- Cohort B: Approximately 375 participants who had received 13vPnC ≥6 months previously, but had not been vaccinated with PPSV23, were to be randomised (2:1) to receive either 20vPnC or PPSV23 (control for safety only).
- Cohort C: Approximately 125 participants who had previously received 13vPnC followed by PPSV23 (PPSV23 vaccination must have been given ≥1 year prior to vaccination in this study) were to receive 20vPnC.

## Primary Immunogenicity Endpoint

## Pneumococcal serotype specific OPA GMTs:

- At 1 month after 20vPnC, OPA GMTs for most of the 20 vaccine serotypes tended to be numerically highest in participants with prior 13vPnC only, ranging from 54.3 (serotype 3) to 4156.5 (serotype 22F) and lowest in participants with prior PPSV23 only, ranging from 31.1 (serotype 3) to 2026.2 (serotype 33F). OPA GMTs in participants with prior 13vPnC and PPSV23 generally fell in between, ranging from 39.3 (serotype 3) to 2717.8 (serotype 22F).

Table 28: Pneumococcal OPA GMTs - Evaluable Immunogenicity Population

| Sero type   | Sampling Time Point       | Cohort A 20vPnC   | Cohort A 20vPnC   | Cohort A 20vPnC   | Cohort B 20vPnC   | Cohort B 20vPnC   | Cohort B 20vPnC   | Cohort C 20vPnC   | Cohort C 20vPnC   | Cohort C 20vPnC   |
|-------------|---------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Sero type   | Sampling Time Point       | n                 | GMT               | (95% CI)          | n                 | GMT               | (95% CI)          | n                 | GMT               | (95% CI)          |
| 13vPnC      | 13vPnC                    | 13vPnC            | 13vPnC            | 13vPnC            | 13vPnC            | 13vPnC            | 13vPnC            | 13vPnC            | 13vPnC            | 13vPnC            |
| 1           | Before vaccination        | 246               | 23.7              | (19.9, 28.2)      | 243               | 33.5              | (27.6, 40.7)      | 121               | 42.2              | (31.9, 55.8)      |
|             | 1 Month after vaccination | 246               | 50.8              | (41.6, 62.0)      | 243               | 115.3             | (96.3, 137.9)     | 120               | 82.1              | (61.2, 110.1)     |
| 3           | Before vaccination        | 247               | 12.8              | (11.2, 14.6)      | 241               | 15.4              | (13.4, 17.7)      | 121               | 20.5              | (16.8, 25.0)      |
|             | 1 Month after vaccination | 243               | 31.1              | (26.7, 36.1)      | 242               | 54.3              | (46.9, 62.8)      | 119               | 39.3              | (32.0, 48.2)      |
| 4           | Before vaccination        | 242               | 28.5              | (23.3, 34.9)      | 235               | 66.6              | (52.5, 84.3)      | 120               | 73.1              | (53.1, 100.7)     |
|             | 1 Month after vaccination | 236               | 149.9             | (118.2, 190.1)    | 241               | 334.9             | (273.8, 409.5)    | 116               | 193.7             | (143.2, 262.0)    |
| 5           | Before vaccination        | 244               | 27.3              | (23.8, 31.3)      | 243               | 37.8              | (32.2, 44.4)      | 121               | 46.6              | (36.9, 58.9)      |
|             | 1 Month after vaccination | 244               | 62.8              | (52.7, 74.9)      | 243               | 87.3              | (73.2, 104.2)     | 120               | 83.5              | (64.8, 107.6)     |
| 6A          | Before vaccination        | 244               | 56.6              | (45.8, 69.9)      | 236               | 125.1             | (98.8, 158.3)     | 118               | 161.0             | (115.7, 224.1)    |
|             | 1 Month after vaccination | 242               | 748.7             | (576.7, 972.0)    | 241               | 1080.9            | (880.2, 1327.4)   | 121               | 1085.3            | (796.9, 1478.1)   |
| 6B          | Before vaccination        | 242               | 107.0             | (86.3, 132.6)     | 240               | 173.9             | (137.9, 219.4)    | 119               | 258.9             | (190.7, 351.6)    |
|             | 1 Month after vaccination | 243               | 727.3             | (573.6, 922.1)    | 241               | 1159.4            | (950.7, 1413.8)   | 121               | 1033.3            | (754.6, 1414.8)   |
| 7F          | Before vaccination        | 240               | 155.7             | (132.1, 183.7)    | 241               | 209.9             | (175.3, 251.2)    | 120               | 205.8             | (163.9, 258.5)    |
|             | 1 Month after vaccination | 240               | 378.1             | (316.4, 451.9)    | 243               | 555.4             | (466.8, 660.9)    | 120               | 345.8             | (277.0, 431.7)    |
| 9V          | Before vaccination        | 231               | 203.0             | (171.0, 241.0)    | 234               | 339.2             | (281.8, 408.2)    | 118               | 352.4             | (270.2, 459.4)    |
|             | 1 Month after vaccination | 241               | 550.3             | (454.0, 666.9)    | 237               | 1085.0            | (893.5, 1317.5)   | 117               | 723.4             | (558.1, 937.6)    |
| 14          | Before vaccination        | 242               | 212.1             | (166.4, 270.3)    | 238               | 282.2             | (223.7, 355.9)    | 121               | 335.5             | (237.9, 473.1)    |
|             | 1 Month after vaccination | 240               | 391.2             | (314.6, 486.3)    | 242               | 664.9             | (554.1, 797.9)    | 119               | 580.5             | (433.7, 777.0)    |
| 18C         | Before vaccination        | 247               | 172.8             | (137.3, 217.5)    | 242               | 219.3             | (176.8, 272.0)    | 120               | 277.8             | (209.1, 369.2)    |
|             | 1 Month after vaccination | 245               | 551.9             | (445.1, 684.4)    | 240               | 845.9             | (692.5, 1033.1)   | 120               | 621.2             | (469.9, 821.3)    |
| 19A         | Before vaccination        | 244               | 81.6              | (66.4, 100.3)     | 240               | 123.6             | (100.0, 152.8)    | 118               | 182.1             | (140.9, 235.4)    |
|             | 1 Month after vaccination | 242               | 238.6             | (197.5, 288.4)    | 242               | 365.1             | (303.0, 440.0)    | 120               | 340.6             | (264.1, 439.2)    |

<div style=\"page-break-after: always\"></div>

| 19F                  | Before vaccination        | 246                  | 60.9                 | (51.9, 71.3)         | 242                  | 88.9                 | (74.0, 106.8)        | 121                  | 120.2                | (93.7, 154.2) (168.1, 281.8)   |
|----------------------|---------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|--------------------------------|
|                      | 1 Month after vaccination | 244                  | 159.0                | (131.4, 192.3)       | 242                  | 242.3                | (199.4, 294.3)       | 118                  | 217.7                |                                |
| 23F                  | Before vaccination        | 244                  | 22.8                 | (18.3, 28.3)         | 242                  | 47.9                 | (37.2, 61.8)         | 120                  | 65.9                 | (46.1, 94.1)                   |
|                      | 1 Month after vaccination | 245                  | 151.6                | (115.3, 199.3)       | 243                  | 450.2                | (357.8, 566.4)       | 120                  | 292.6                | (203.6, 420.5)                 |
| Additional serotypes | Additional serotypes      | Additional serotypes | Additional serotypes | Additional serotypes | Additional serotypes | Additional serotypes | Additional serotypes | Additional serotypes | Additional serotypes | Additional serotypes           |
| 8                    | Before vaccination        | 239                  | 55.4                 | (45.4, 67.5)         | 236                  | 27.9                 | (23.6, 33.0)         | 113                  | 138.8                | (98.6, 195.4)                  |
|                      | 1 Month after vaccination | 230                  | 211.9                | (172.0, 261.0)       | 226                  | 602.9                | (482.9, 752.8)       | 109                  | 293.8                | (220.0, 392.4)                 |
| 10A                  | Before vaccination        | 221                  | 211.6                | (166.2, 269.5)       | 231                  | 141.2                | (112.9, 176.6)       | 119                  | 399.6                | (280.8, 568.5)                 |
|                      | 1 Month after vaccination | 219                  | 1012.1               | (806.7, 1269.8)      | 210                  | 2005.4               | (1586.0, 2535.7)     | 110                  | 1580.3               | (1175.9, 2123.8)               |
| 11A                  | Before vaccination        | 208                  | 510.0                | (396.2, 656.4)       | 210                  | 269.0                | (211.0, 343.0)       | 106                  | 550.4                | (385.7, 785.3)                 |
|                      | 1 Month after vaccination | 216                  | 1473.2               | (1192.4, 1820.2)     | 206                  | 1908.2               | (1541.5, 2362.2)     | 102                  | 1566.6               | (1140.7, 2151.4)               |
| 12F                  | Before vaccination        | 230                  | 147.0                | (112.1, 192.9)       | 227                  | 53.2                 | (43.3, 65.4)         | 113                  | 367.8                | (236.3, 572.5)                 |
|                      | 1 Month after vaccination | 224                  | 1054.5               | (822.0, 1352.7)      | 214                  | 1763.4               | (1371.8, 2266.7)     | 110                  | 1401.2               | (1001.8, 1959.7)               |
| 15B                  | Before vaccination        | 231                  | 140.2                | (104.3, 188.6)       | 215                  | 74.1                 | (55.9, 98.3)         | 110                  | 190.0                | (124.0, 291.0)                 |
|                      | 1 Month after vaccination | 225                  | 647.1                | (490.8, 853.1)       | 201                  | 1479.5               | (1093.0, 2002.8)     | 110                  | 1066.9               | (721.3, 1578.1)                |
| 22F                  | Before vaccination        | 236                  | 167.5                | (122.0, 229.9)       | 223                  | 60.4                 | (44.6, 81.7)         | 116                  | 286.4                | (179.7, 456.4)                 |
|                      | 1 Month after vaccination | 218                  | 1772.8               | (1354.7, 2319.8)     | 206                  | 4156.5               | (3243.8, 5326.2)     | 108                  | 2717.8               | (1978.4, 3733.4)               |
| 33F                  | Before vaccination        | 231                  | 1128.8               | (935.8, 1361.7)      | 226                  | 605.8                | (507.3, 723.4)       | 115                  | 1352.8               | (1036.9, 1764.9)               |
|                      | 1 Month after vaccination | 216                  | 2026.2               | (1684.3, 2437.4)     | 208                  | 3174.9               | (2579.1, 3908.3)     | 103                  | 2182.9               | (1638.6, 2907.8)               |

Abbreviations: GMT = geometric mean titre; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. n = Number of subjects with valid and determinate assay results for the given serotype at the specified time point.

Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titres and the corresponding CIs (based on the Student t distribution).

## Secondary Immunogenicity Endpoints

Serotype-specific pneumococcal OPA GMFRs From Before to 1 Month After Vaccination:

Increases in OPA titres for all 20 vaccine serotypes were observed based on OPA GMFRs from before to 1 month after 20vPnC in all 3 cohorts, regardless of prior pneumococcal vaccination. Immune responses to the 7 additional serotypes 1 month after 20vPnC from participants with prior 13vPnC only (Cohort B) were substantially higher than before vaccination with 20vPnC.

For the 13vPnC serotypes, the GMFRs appeared to be generally highest in Cohort B (prior 13vPnC only), ranging from 2.3 (serotypes 5 and 14) to 9.3 (serotype 23F), followed by Cohort A (prior PPSV23 only), ranging from 1.8 (serotype 14) to 12.6 (serotype 6A) and lowest in Cohort C (prior 13vPnC and PPSV23), ranging from 1.6 (serotype 7F) to 6.5 (serotype 6A); however, differences were small, and as noted above, baseline titres to these serotypes were also higher in participants with prior 13vPnC and PPSV23 relative to participants with prior PPSV23 only. As PPSV23 does not contain the polysaccharide for serotype 6A, participants previously vaccinated with PPSV23 only were naïve to vaccination for that serotype.

For the 7 additional serotypes, GMFRs were higher in participants with prior 13vPnC only, who were naïve to these vaccine serotypes prior to receiving 20vPnC, ranging from 5.4 (serotype 33F) to 66.9 (serotype 22F), than in participants with prior PPSV23 only, ranging from 1.8 (serotype 33F) to 11.1 (serotype 22F), and in participants with prior 13vPnC and PPSV23, ranging from 1.8 (serotype 33F) to 9.8 (serotype 22F).

Table 29: Pneumococcal OPA GMFRs From Before Vaccination to 1 Month After Vaccination Evaluable Immunogenicity Population

| Serotype   | Vaccine Group   | n   | Before Vaccination   | Before Vaccination   | 1 Month After Vaccination   | 1 Month After Vaccination   | 1 Month After Vaccination/ Before Vaccination   | 1 Month After Vaccination/ Before Vaccination   |
|------------|-----------------|-----|----------------------|----------------------|-----------------------------|-----------------------------|-------------------------------------------------|-------------------------------------------------|
| Serotype   | Vaccine Group   | n   | GMT                  | (95% CI)             | GMT                         | (95% CI)                    | GMFR                                            | (95% CI)                                        |
| 13vPnC     |                 |     |                      |                      |                             |                             |                                                 |                                                 |
| 1          | Cohort A 20vPnC | 245 | 23.8                 | (20.0, 28.3)         | 51.2                        | (41.9, 62.5)                | 2.2                                             | (1.9, 2.5)                                      |
|            | Cohort B 20vPnC | 243 | 33.5                 | (27.6, 40.7)         | 115.3                       | (96.3, 137.9)               | 3.4                                             | (2.9, 4.1)                                      |
|            | Cohort C 20vPnC | 120 | 40.9                 | (31.0, 53.8)         | 82.1                        | (61.2, 110.1)               | 2.0                                             | (1.7, 2.4)                                      |
| 3          | Cohort A 20vPnC | 243 | 12.7                 | (11.1, 14.6)         | 31.1                        | (26.7, 36.1)                | 2.4                                             | (2.1, 2.8)                                      |
|            | Cohort B 20vPnC | 240 | 15.3                 | (13.4, 17.6)         | 54.3                        | (46.9, 63.0)                | 3.5                                             | (3.1, 4.1)                                      |
|            | Cohort C 20vPnC | 119 | 20.3                 | (16.6, 24.8)         | 39.3                        | (32.0, 48.2)                | 1.9                                             | (1.6, 2.3)                                      |
| 4          | Cohort A 20vPnC | 231 | 29.9                 | (24.2, 36.9)         | 145.8                       | (114.6, 185.5)              | 4.9                                             | (3.9, 6.1)                                      |
|            | Cohort C 20vPnC | 115 | 78.2                 | (56.4, 108.3)        | 191.4                       | (141.2, 259.2)              | 2.4                                             | (1.9, 3.1)                                      |
| 5          | Cohort A 20vPnC | 241 | 27.4                 | (23.8, 31.4)         | 62.2                        | (52.2, 74.1)                | 2.3                                             | (2.0, 2.6)                                      |
|            | Cohort B 20vPnC | 243 | 37.8                 | (32.2, 44.4)         | 87.3                        | (73.2, 104.2)               | 2.3                                             | (2.0, 2.6)                                      |
|            | Cohort C 20vPnC | 120 | 47.1                 | (37.3, 59.5)         | 83.5                        | (64.8, 107.6)               | 1.8                                             | (1.5, 2.0)                                      |
| 6A         | Cohort A 20vPnC | 239 | 57.9                 | (46.7, 71.8)         | 731.3                       | (562.9, 950.0)              | 12.6                                            | (9.5, 16.7)                                     |
|            | Cohort B 20vPnC | 234 | 127.2                | (100.4, 161.1)       | 1051.2                      | (852.2, 1296.8)             | 8.3                                             | (6.6, 10.4)                                     |

<div style=\"page-break-after: always\"></div>

|            | Cohort C 20vPnC   | 118        | 161.0      | (115.7, 224.1)   | 1048.1   | (765.8, 1434.5)       | 6.5   | (4.7, 9.1)   |
|------------|-------------------|------------|------------|------------------|----------|-----------------------|-------|--------------|
| 6B         | Cohort A 20vPnC   | 238        | 108.9      | (87.6, 135.2)    | 720.3    | (565.6, 917.3)        | 6.6   | (5.2, 8.4)   |
|            | Cohort B 20vPnC   | 238        | 175.5      | (138.9, 221.6)   | 1178.8   | (967.0, 1436.9)       | 6.7   | (5.4, 8.3)   |
|            | Cohort C 20vPnC   | 119        | 258.9      | (190.7, 351.6)   | 1030.3   | (753.0, 1409.6)       | 4.0   | (3.0, 5.2)   |
| 7F         | Cohort A 20vPnC   | 233        | 160.6      | (135.7, 190.0)   | 366.5    | (306.2, 438.7)        | 2.3   | (1.9, 2.7)   |
|            | Cohort B 20vPnC   | 241        | 209.9      | (175.3, 251.2)   | 545.0    | (458.8, 647.5)        | 2.6   | (2.2, 3.0)   |
|            | Cohort C 20vPnC   | 119        | 204.5      | (162.6, 257.3)   | 337.1    | (271.1, 419.2)        | 1.6   | (1.4, 2.0)   |
| 9V         | Cohort A 20vPnC   | 226        | 206.1      | (173.1, 245.4)   | 503.3    | (413.4, 612.7)        | 2.4   | (2.1, 2.9)   |
|            | Cohort B 20vPnC   | 228        | 346.6      | (287.8, 417.5)   | 1058.3   | (867.7, 1290.9)       | 3.1   | (2.6, 3.6)   |
|            | Cohort C 20vPnC   | 114        | 345.4      | (263.9, 452.1)   | 720.5    | (552.2, 940.0)        | 2.1   | (1.7, 2.6)   |
| 14         | Cohort A 20vPnC   | 236        | 213.3      | (167.3, 272.0)   | 386.3    | (309.8, 481.8)        | 1.8   | (1.5, 2.1)   |
|            | Cohort B 20vPnC   | 237        | 285.5      | (226.4, 360.0)   | 659.7    | (548.1, 794.1)        | 2.3   | (1.9, 2.8)   |
|            | Cohort C 20vPnC   | 119        | 341.6      | (241.8, 482.8)   | 580.5    | (433.7, 777.0)        | 1.7   | (1.4, 2.1)   |
| 18C        | Cohort A 20vPnC   | 245        | 175.1      | (139.0, 220.7)   | 551.9    | (445.1, 684.4)        | 3.2   | (2.5, 3.9)   |
|            | Cohort B 20vPnC   | 240        | 217.2      | (174.9, 269.8)   | 845.9    | (692.5, 1033.1)       | 3.9   | (3.2, 4.8)   |
|            | Cohort C 20vPnC   | 119        | 272.5      | (205.1, 362.0)   | 611.3    | (462.2, 808.5)        | 2.2   | (1.8, 2.7)   |
| 19A        | Cohort A 20vPnC   | 239        | 83.8       | (68.1, 103.2)    | 240.6    | (198.8, 291.2)        | 2.9   | (2.4, 3.4)   |
|            | Cohort B 20vPnC   | 239        | 124.4      | (100.6, 153.9)   | 356.0    | (295.7, 428.7)        | 2.9   | (2.4, 3.4)   |
|            | Cohort C 20vPnC   | 117        | 183.5      | (141.7, 237.6)   | 344.9    | (266.3, 446.8)        | 1.9   | (1.6, 2.2)   |
| 19F        | Cohort A 20vPnC   | 243        | 61.0       | (52.0, 71.5)     | 160.2    | (132.4, 193.8)        | 2.6   | (2.2, 3.1)   |
|            | Cohort B 20vPnC   | 241        | 89.4       | (74.4, 107.4)    | 242.2    | (199.2, 294.5)        | 2.7   | (2.3, 3.2)   |
|            | Cohort C 20vPnC   | 118        | 117.5      | (91.1, 151.5)    | 217.7    | (168.1, 281.8)        | 1.9   | (1.5, 2.3)   |
| 23F        | Cohort A 20vPnC   | 242        | 23.0       | (18.5, 28.6)     | 151.3    | (114.8, 199.5)        | 6.6   | (5.1, 8.5)   |
|            | Cohort B 20vPnC   | 242        | 47.9       | (37.2, 61.8)     | 446.6    | (354.8, 562.1)        | 9.3   | (7.4, 11.8)  |
|            | Cohort C 20vPnC   | 119        | 64.3       | (45.0, 91.8)     | 287.7    | (199.9, 414.1)        | 4.5   | (3.4, 6.0)   |
| Additional | Additional        | Additional | Additional | Additional       |          |                       |       |              |
| 8          | Cohort A 20vPnC   | 223        | 57.6       | (46.8, 71.0)     | 207.3    | (168.6, 254.9)        | 3.6   | (2.9, 4.4)   |
|            | Cohort B 20vPnC   | 219        | 27.1       | (22.8, 32.2)     | 608.7    | (485.2, 763.6)        | 22.5  | (17.2, 29.4) |
|            | Cohort C 20vPnC   | 101        | 137.1      | (95.2, 197.4)    | 291.7    | (214.4, 396.9)        | 2.1   | (1.6, 2.8)   |
| 10A        | Cohort A 20vPnC   | 198        | 212.4      | (164.5, 274.3)   | 956.2    | (752.5, 1215.0)       | 4.5   | (3.5, 5.7)   |
|            | Cohort B 20vPnC   | 199        | 133.5      | (105.3, 169.3)   | 1923.2   | (1513.8, 2443.4)      | 14.4  | (10.9, 19.0) |
|            | Cohort C 20vPnC   | 109        | 359.6      | (250.7, 515.8)   | 1595.1   | (1184.4, 2148.3)      | 4.4   | (3.3, 6.0)   |
| 11A        | Cohort A 20vPnC   | 184        | 532.0      | (406.6, 696.0)   | 1348.1   | (1076.8, 1687.9)      | 2.5   | (2.0, 3.2)   |
|            | Cohort B 20vPnC   | 183        | 270.3      | (209.5, 348.8)   | 1806.6   | (1435.1, 2274.2)      | 6.7   | (5.0, 9.0)   |
|            | Cohort C 20vPnC   | 91         | 491.1      | (332.6, 725.2)   | 1514.1   | (1074.7, 2133.2)      | 3.1   | (2.2, 4.4)   |
| 12F        | Cohort A 20vPnC   | 208        | 139.2      | (104.5, 185.3)   | 1000.2   | (772.2, 1295.4) 7.2   |       | (5.5, 9.5)   |
|            | Cohort B 20vPnC   | 200        | 53.2       | (42.6, 66.3)     | 1684.2   | (1290.3, 2198.3)      | 31.7  | (23.1, 43.4) |
|            | Cohort C 20vPnC   | 103        | 358.0      | (225.3, 568.9)   | 1367.0   | (964.3, 1937.8) 3.8   |       | (2.7, 5.5)   |
| 15B        | Cohort A 20vPnC   | 211        | 145.3      | (106.5, 198.2)   | 625.0    | (470.7, 830.0)        | 4.3   | (3.3, 5.7)   |
|            | Cohort B 20vPnC   | 184        | 74.3       | (54.9, 100.5)    | 1401.7   | (1016.7, 1932.4) 18.9 |       | (13.0, 27.4) |
|            | Cohort C 20vPnC   | 99         | 198.6      | (126.8, 311.0)   | 955.9    | (637.1, 1434.3) 4.8   |       | (3.1, 7.5)   |
| 22F        | Cohort A 20vPnC   | 207        | 160.6      | (114.2, 225.8)   | 1779.1   | (1347.2, 2349.5) 11.1 |       | (8.0, 15.3)  |
|            | Cohort B 20vPnC   | 191        | 61.2       | (44.4, 84.4)     | 4099.3   | (3156.5, 5323.6)      | 66.9  | (46.5, 96.4) |
|            | Cohort C 20vPnC   | 104        | 266.0      | (163.5, 432.8)   | 2616.0   | (1900.2, 3601.5) 9.8  |       | (6.2, 15.6)  |
| 33F        | Cohort A 20vPnC   | 203        | 1136.7     | (932.3, 1386.0)  | 2058.6   | (1703.0, 2488.4) 1.8  |       | (1.5, 2.2)   |
|            | Cohort B 20vPnC   | 196        | 564.3      | (470.3, 677.2)   | 3041.1   | (2453.8, 3768.8) 5.4  |       | (4.2, 6.8)   |
|            | Cohort C 20vPnC   | 99         | 1268.8     | (949.7, 1695.1)  | 2233.7   | (1665.8, 2995.2) 1.8  |       | (1.4, 2.2)   |

GMFR = geometric mean fold rise; GMT = geometric mean titre; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. n = Number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections.

Note:  Assay  results  below  the  LLOQ  were  set  to  0.5  ×  LLOQ  in  the  analysis.  GMTs,  GMFRs,  and  the  corresponding  2-sided  CIs  were  calculated  by exponentiating the mean logarithm of the titres or fold rises and the corresponding CIs based on the Student t distribution

Proportion of Participants Achieving a ≥4 -Fold Rise in serotype-specific Pneumococcal OPA Titres From Before to 1 Month After Vaccination:

For most of the 13vPnC serotypes, the proportions of participants who achieved a ≥4 -fold rise in OPA titres from before to 1 month after 20vPnC were generally numerically highest in Cohort B (prior 13vPnC only), ranging from 24.9% (serotype 14) to 58.7% (serotype 23F), followed by Cohort A (prior PPSV23 only), ranging from 15.7% (serotype 14) to 61.5% (serotype 6A). The proportions of participants who achieved a ≥4 -fold rise in OPA titres from before to 1 month after 20vPnC were lowest in Cohort C (prior 13vPnC and PPSV23), ranging from 14.3% (serotype 7F) to 44.9% (serotype 6A).

For the 7 additional serotypes, the proportions of participants with a ≥4 -fold rise in OPA titres from before to 1 month after 20vPnC were higher in participants with prior 13vPnC only, who were naïve to these vaccine serotypes prior to receiving 20vPnC, ranging from 53.6% (serotype 33F) to 83.2% (serotype 22F), than in participants with prior PPSV23 only, ranging from 18.7% (serotype 33F) to 57.0% (serotype 22F) and participants with prior 13vPnC and PPSV23, ranging from 19.2% (serotype 33F) to 54.8% (serotype 22F).

<div style=\"page-break-after: always\"></div>

Table 30: Proportion of Subjects Achiev ing a ≥4 -Fold Rise in Pneumococcal OPA Titres From Before Vaccination to 1 Month After Vaccination - Evaluable Immunogenicity Population

| Serotype   | Cohort   | Cohort   | Cohort   | Cohort       | Cohort B 20vPnC   | Cohort B 20vPnC   | Cohort B 20vPnC   | Cohort B 20vPnC   | Cohort C 20vPnC   | Cohort C 20vPnC   | Cohort C 20vPnC   | Cohort C 20vPnC   |
|------------|----------|----------|----------|--------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Serotype   | N        | n        | %        | (95% CI)     | N                 | n                 | %                 | (95% CI)          | N                 | n                 | %                 | (95% CI)          |
| 13vPnC     |          |          |          |              |                   |                   |                   |                   |                   |                   |                   |                   |
| 1          | 245      | 56       | 22.9     | (17.8, 28.6) | 243               | 98                | 40.3              | (34.1, 46.8)      | 120               | 25                | 20.8              | (14.0, 29.2)      |
| 3          | 243      | 72       | 29.6     | (24.0, 35.8) | 240               | 99                | 41.3              | (35.0, 47.8)      | 119               | 22                | 18.5              | (12.0, 26.6)      |
| 4          | 231      | 95       | 41.1     | (34.7, 47.8) | 235               | 97                | 41.3              | (34.9, 47.9)      | 115               | 29                | 25.2              | (17.6, 34.2)      |
| 5          | 241      | 62       | 25.7     | (20.3, 31.7) | 243               | 66                | 27.2              | (21.7, 33.2)      | 120               | 19                | 15.8              | (9.8, 23.6)       |
| 6A         | 239      | 147      | 61.5     | (55.0, 67.7) | 234               | 132               | 56.4              | (49.8, 62.9)      | 118               | 53                | 44.9              | (35.7, 54.3)      |
| 6B         | 238      | 127      | 53.4     | (46.8, 59.8) | 238               | 131               | 55.0              | (48.5, 61.5)      | 119               | 42                | 35.3              | (26.8, 44.6)      |
| 7F         | 233      | 61       | 26.2     | (20.7, 32.3) | 241               | 73                | 30.3              | (24.6, 36.5)      | 119               | 17                | 14.3              | (8.5, 21.9)       |
| 9V         | 226      | 64       | 28.3     | (22.5, 34.7) | 228               | 82                | 36.0              | (29.7, 42.6)      | 114               | 23                | 20.2              | (13.2, 28.7)      |
| 14         | 236      | 37       | 15.7     | (11.3, 21.0) | 237               | 59                | 24.9              | (19.5, 30.9)      | 119               | 19                | 16.0              | (9.9, 23.8)       |
| 18C        | 245      | 72       | 29.4     | (23.8, 35.5) | 240               | 92                | 38.3              | (32.2, 44.8)      | 119               | 21                | 17.6              | (11.3, 25.7)      |
| 19A        | 239      | 71       | 29.7     | (24.0, 35.9) | 239               | 70                | 29.3              | (23.6, 35.5)      | 117               | 18                | 15.4              | (9.4, 23.2)       |
| 19F        | 243      | 71       | 29.2     | (23.6, 35.4) | 241               | 79                | 32.8              | (26.9, 39.1)      | 118               | 20                | 16.9              | (10.7, 25.0)      |
| 23F        | 242      | 120      | 49.6     | (43.1, 56.1) | 242               | 142               | 58.7              | (52.2, 64.9)      | 119               | 51                | 42.9              | (33.8, 52.3)      |
| Additional |          |          |          |              |                   |                   |                   |                   |                   |                   |                   |                   |
| 8          | 223      | 89       | 39.9     | (33.4, 46.7) | 219               | 159               | 72.6              | (66.2, 78.4)      | 101               | 31                | 30.7              | (21.9, 40.7)      |
| 10A        | 198      | 90       | 45.5     | (38.4, 52.7) | 199               | 141               | 70.9              | (64.0, 77.1)      | 109               | 48                | 44.0              | (34.5, 53.9)      |
| 11A        | 184      | 56       | 30.4     | (23.9, 37.6) | 183               | 100               | 54.6              | (47.1, 62.0)      | 91                | 32                | 35.2              | (25.4, 45.9)      |
| 12F        | 208      | 107      | 51.4     | (44.4, 58.4) | 200               | 153               | 76.5              | (70.0, 82.2)      | 103               | 42                | 40.8              | (31.2, 50.9)      |
| 15B        | 211      | 79       | 37.4     | (30.9, 44.3) | 184               | 122               | 66.3              | (59.0, 73.1)      | 99                | 38                | 38.4              | (28.8, 48.7)      |
| 22F        | 207      | 118      | 57.0     | (50.0, 63.8) | 191               | 159               | 83.2              | (77.2, 88.2)      | 104               | 57                | 54.8              | (44.7, 64.6)      |
| 33F        | 203      | 38       | 18.7     | (13.6, 24.8) | 196               | 105               | 53.6              | (46.3, 60.7)      | 99                | 19                | 19.2              | (12.0, 28.3)      |

LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity. N = number of subjects with valid and determinate assay results to the specified serotype from both before and 1 month after vaccination blood sample collections. These values are the denominators for the percentage calculations. n = Number of subjects with a ≥4 -fold rise in titres from before vaccination to 1 month after vaccination for the specified serotype.

Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. 95% CI: Exact 2-sided CI based on the Clopper and Pearson method.

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 31: Summary of Efficacy for Trial B7471007 (for detailed results please refer to the tables above)

## Title: B7471007

A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults 18 Years of Age and Older

| Study identifier   | Protocol Number: B7471007 EudraCT Number: 2018-004279-11 ClinicalTrials.gov Identifier: NCT03760146   | Protocol Number: B7471007 EudraCT Number: 2018-004279-11 ClinicalTrials.gov Identifier: NCT03760146                 |
|--------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Design             | Parallel, randomised, double blind, multi-centre three cohorts based on age                           | Parallel, randomised, double blind, multi-centre three cohorts based on age                                         |
|                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                        | First Subject First Visit: 12 December 2018 Last Subject Last Visit: 16 December 2019 Not applicable Not applicable |

<div style=\"page-break-after: always\"></div>

| Hypothesis                                      | Cohort 1: Non-inferiority of OPA GMTs between 20vPnC and vaccines Cohort 2: Non-inferiority of OPA GMTs to subgroup of Cohort Cohort 3: Non-inferiority of OPA GMTs to subgroup of Cohort Non-inferior immune response is assumed if the lower bound CI for the ratio of OPA GMTs between the respective comparator fold NI margin].   | Cohort 1: Non-inferiority of OPA GMTs between 20vPnC and vaccines Cohort 2: Non-inferiority of OPA GMTs to subgroup of Cohort Cohort 3: Non-inferiority of OPA GMTs to subgroup of Cohort Non-inferior immune response is assumed if the lower bound CI for the ratio of OPA GMTs between the respective comparator fold NI margin].   | two comparator                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                               | Cohort 1: adults ≥ 60 yoa                                                                                                                                                                                                                                                                                                              | Cohort 1: adults ≥ 60 yoa                                                                                                                                                                                                                                                                                                              | 20vPnC/saline, n= 1514 13vPnC/PPSV23, n= 1495 Vaccinations were administered as single dose one month apart                                                                                                                                                                                                                                                                                    |
| Treatments groups                               | Cohort 2: adults 50-59 yoa                                                                                                                                                                                                                                                                                                             | Cohort 2: adults 50-59 yoa                                                                                                                                                                                                                                                                                                             | 20vPnC, n= 334 13vPnC, n= 111                                                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                               | Cohort 3: adults 18-49 yoa                                                                                                                                                                                                                                                                                                             | Cohort 3: adults 18-49 yoa                                                                                                                                                                                                                                                                                                             | 20vPnC, n= 336 13vPnC, n= 112                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions (only immunogenicity) | Co- Primary endpoint                                                                                                                                                                                                                                                                                                                   | NI Cohort 1 13vPnC                                                                                                                                                                                                                                                                                                                     | To demonstrate non-inferiority of the immune responses to 20vPnC compared with 13vPnC for each of the 13 matched serotypes. For all cohorts: Main parameter: OPA GMTs Additional parameter: GMFR, proportion of subjects achieving a ≥4 -fold rise in OPA titres from before to one month after vaccination and proportion of subjects achieving OPA titres ≥ LLOQ one month after vaccination |
| Endpoints and definitions (only immunogenicity) | Co- Primary endpoint                                                                                                                                                                                                                                                                                                                   | NI Cohort 1 PPSV23                                                                                                                                                                                                                                                                                                                     | To demonstrate non-inferiority of the immune responses to 20vPnC compared with PPSV23 for each of the 7 additional serotypes.                                                                                                                                                                                                                                                                  |
| Endpoints and definitions (only immunogenicity) | Secondary endpoint                                                                                                                                                                                                                                                                                                                     | NI Cohort 2                                                                                                                                                                                                                                                                                                                            | To demonstrate non-inferiority of the immune response in subjects receiving 20vPnC in Cohort 2 compared to subjects 60 through 64 years of age (subset of Cohort 1).                                                                                                                                                                                                                           |
| Endpoints and definitions (only immunogenicity) | Secondary endpoint                                                                                                                                                                                                                                                                                                                     | NI Cohort 3                                                                                                                                                                                                                                                                                                                            | To demonstrate non-inferiority of the immune response in subjects receiving 20vPnC in Cohort 3 compared to subjects 60 through 64 years of age (subset of Cohort 1).                                                                                                                                                                                                                           |
| Endpoints and definitions (only immunogenicity) | Exploratory endpoint                                                                                                                                                                                                                                                                                                                   | Risk factors                                                                                                                                                                                                                                                                                                                           | Descriptive; Immune responses in persons at increased risk for pneumococcal disease compared with persons without risk factors                                                                                                                                                                                                                                                                 |
| Database lock                                   | 20 Feb 2020: initial database release. 10 Apr 2020: database was re-released.                                                                                                                                                                                                                                                          | 20 Feb 2020: initial database release. 10 Apr 2020: database was re-released.                                                                                                                                                                                                                                                          | 20 Feb 2020: initial database release. 10 Apr 2020: database was re-released.                                                                                                                                                                                                                                                                                                                  |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis description                            | Primary Analysis - Cohort 1 - 13vPnC                                                                                                                                                                                                                                                                                                   | Primary Analysis - Cohort 1 - 13vPnC                                                                                                                                                                                                                                                                                                   | Primary Analysis - Cohort 1 - 13vPnC                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Evaluable 13-Matched Immunogenicity Population This population generally included any participant who: 1. received the assigned Vaccination 1 (20vPnC or 13vPnC) as randomised, 2. was enrolled in the appropriate cohort based on age on the day of first vaccination (ie, 60 years of age or older in Cohort 1), 3. had the Visit 2 blood collection within 27 to 49 days after Vaccination 1, 4. had at least 1 valid OPA titre for any of the 13 matched serotypes at Visit 2, 5. had no other major PDs as determined by the clinician. Time point: OPA GMTs one month after vaccination with 20vPnC or 13vPnC                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Results                                          | The immune responses to the 13-matched vaccine serotypes induced by 20vPnC were non-inferior to those induced by 13vPnC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Note                                             | OPA GMT ratios [20vPnC/13vPnC] were consistently around 0.8. The clinical relevance of this reduction in most serotypes is unknown as well as the clinical relevance of the applied NI margin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis description                             | Primary Analysis - Cohort 1 - PPSV23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Analysis population and time point description   | Evaluable 7-Additional Immunogenicity Population This population generally included any participant who: 1. received Vaccination 1 (20vPnC) if randomised to the 20vPnC/saline group or received both vaccinations as randomised if randomised to the 13vPnC/PPSV23 group, 2. was enrolled in the appropriate cohort based on age on the day Evaluable-20 Immunogenicity Population of first vaccination (ie, 60 years of age and older in Cohort 1), 3. had either Visit 2 blood collection within 27 to 49 days after Vaccination 1 for the 20vPnC/saline group or Visit 3 blood collection within 27 to 49 days after Vaccination 2 (PPSV23) for the 13vPnC/PPSV23 group, 4. had at least 1 valid and determinate OPA titre for any of the 7 additional serotypes at either Visit 2 for the 20vPnC/saline group or Visit 3 for the 13vPnC/PPSV23 group, 5. had no other major PDs as determined by the clinician. |
| Results                                          | The immune responses to 6 of the 7 additional vaccine serotypes induced by 20vPnC were non-inferior to those induced by PPSV23.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Note                                             | Reduced response to serotype 8 was observed compared to PPSV23. Serotype 8 is still one of the most prevalent serotypes causing IPD and pneumonia in the EU. Based on additional analyses that further characterize the immune responses to serotype 8, the immune response is expected to provide protection similar to the other 19 vaccine serotypes in 20vPnC that met non-inferiority.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Analysis description                             | Secondary Analysis - Cohort 2 vs 60-64-year-old subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Analysis population and time point description   | Evaluable-20 Immunogenicity Population This population generally included any participant who: 1. received the assigned vaccination at Visit 1 as randomised, 2. was enrolled in the appropriate cohort based on age on the day of first vaccination (i.e., adults 60 through 64 years of age for Cohort 1, 50 through 59 years of age for Cohort 2, and 18 through 49 years of age for Cohort 3), 3. had the Visit 2 blood collection within 27 to 49 days after vaccination, 4. had at least 1 valid and determinate OPA titre for any of the 20 serotypes for Visit 2, 5. had no other major PDs as determined by the clinician. Time point: OPA GMTs one month after vaccination with 20vPnC                                                                                                                                                                                                                     |
| Results                                          | The immune responses to the 20 vaccine serotypes induced by 20vPnC in adults 50 - 59 years of age were non-inferior to those in adults 60 - 64 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Note                                           | It is known also from 13vPnC that immune response declines with age. A comparison to 13vPnC was not intended but the post-hoc analysis performed by the applicant showed numerically lower immune response to 20vPnC compared to 13vPnC overall similar to cohort 1. OPA titres for this cohort are above the titres induced by 13vPnC in cohort 1, which is assumed to provide a protective effect.   |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                           | Secondary Analysis - Cohort 3 vs 60-64-year-old subjects                                                                                                                                                                                                                                                                                                                                               |
| Analysis population and time point description | Evaluable-20 Immunogenicity Population See analysis population definition for cohort 2 Time point: OPA GMTs one month after vaccination with 20vPnC                                                                                                                                                                                                                                                    |
| Results                                        | The immune responses to the 20 vaccine serotypes induced by 20vPnC in adults 18 - 49 years of age were non-inferior to those in adults 60 - 64 years of age.                                                                                                                                                                                                                                           |
| Note                                           | See Note to cohort 2. The same aspects also apply to cohort 3.                                                                                                                                                                                                                                                                                                                                         |
| Analysis description                           | Exploratory Analysis - Risk Factors                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis population and time point description | Evaluable-20 Immunogenicity Population See analysis population definition for cohort 2 Time point: OPA GMTs one month after vaccination with 20vPnC                                                                                                                                                                                                                                                    |
| Results                                        | Immune responses to all 20 vaccine serotypes 1 month after 20vPnC were observed in adults ≥18 years of age with and without increased risk for serious pneumococcal disease based on OPA GMTs, GMFRs, proportions of participants achieving a ≥4 -fold rise in OPA titres, and proportions of participants with OPA titres ≥ LLOQ.                                                                     |
| Note                                           | OPA GMTs for patients with risk factors were approx. 20% lower compared to subjects without risk factors. An analysis combining subjects from all cohorts was performed, as well as a post-hoc comparative analysis by age cohorts. It is not known whether induced titres for patients with risk factors are representative for protection.                                                           |

## Table 32: Summary of Efficacy for Trial B7471006 (for detailed results please refer to the tables above)

| Title: B7471006 A phase 3, randomized, multicentre (33 sites in the US and 8 sites in Sweden), controlled, open-label trial to evaluate the safety and immunogenicity of 20vPnC in adults ≥65 yoa with prior pneumococcal vaccination.   | Title: B7471006 A phase 3, randomized, multicentre (33 sites in the US and 8 sites in Sweden), controlled, open-label trial to evaluate the safety and immunogenicity of 20vPnC in adults ≥65 yoa with prior pneumococcal vaccination.   | Title: B7471006 A phase 3, randomized, multicentre (33 sites in the US and 8 sites in Sweden), controlled, open-label trial to evaluate the safety and immunogenicity of 20vPnC in adults ≥65 yoa with prior pneumococcal vaccination.   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                         | Protocol Number: B7471006 EudraCT: 2018-004278-91 ClinicalTrials.gov Identifier: NCT03835975                                                                                                                                             | Protocol Number: B7471006 EudraCT: 2018-004278-91 ClinicalTrials.gov Identifier: NCT03835975                                                                                                                                             |
| Design                                                                                                                                                                                                                                   | randomised, multicentre, controlled, open-label trial to evaluate the safety and immunogenicity of 20vPnC in adults ≥65 yoa with prior pneumococcal vaccination                                                                          | randomised, multicentre, controlled, open-label trial to evaluate the safety and immunogenicity of 20vPnC in adults ≥65 yoa with prior pneumococcal vaccination                                                                          |
|                                                                                                                                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase                                                                                                                                                            | First Subject First Visit: 12 February 2019 Last Subject Last Visit: 12 February 2020 12 Months not applicable not applicable                                                                                                            |
| Hypothesis                                                                                                                                                                                                                               | not applicable                                                                                                                                                                                                                           | not applicable                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Treatments groups                              | Cohort A (had PPSV23 1-5 previously)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | received years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Single dose 20vPnC or 13vPnC IM at visit 1 (Day 1) n= 375 (2:1, 20vPnC vs 13vPnC)                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                              | Cohort B (had received 13vPnC ≥6 months previously)                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Cohort B (had received 13vPnC ≥6 months previously)                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Single dose 20vPnC or PPSV23 13vPnC IM at visit 1 (Day 1) n= 375 (2:1, 20vPnC vs PPSV23)                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                              | Cohort C (had received 13vPnC followed by PPSV23; PPSV23 ≥1 year previously)                                                                                                                                                                                                                                                                                                                                                                                                                             | Cohort C (had received 13vPnC followed by PPSV23; PPSV23 ≥1 year previously)                                                                                                                                                                                                                                                                                                                                                                                                                             | Single dose 20vPnC IM at visit 1 (Day 1) n= 125 (20vPnC only)                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                      | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | In all three cohort: Pneumococcal serotype specific OPA titres 1 month after vaccination                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                      | Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | In all three cohorts. - Fold rise in serotype-specific OPA titres from before to 1 month after vaccination. - Proportion of subjects who reached ≥4 -Fold rise in serotype-specific OPA titres from before to 1 month after vaccination. - Proportion of subjects who reached serotype- specific OPA titres ≥ LLOQ 1 month after vaccination                                                                                                                                                             |
| Database lock                                  | 13 May 2020: excluding OPA immunogenicity data                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13 May 2020: excluding OPA immunogenicity data                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13 May 2020: excluding OPA immunogenicity data                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Results and Analysis                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis description                           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Analysis population and time point description | Evaluable Immunogenicity Population includes any participant who: • received 20vPnC, • was enrolled in the appropriate cohort based on prior pneumococcal vaccination history, • had Visit 2 blood collection within 27 to 49 days after vaccination, • had at least 1 valid and determinate OPA titre for any serotype for Visit 2, and • did not have any other major protocol deviations as determined by the clinician Participants were included in the vaccine group as randomised in the analyses | Evaluable Immunogenicity Population includes any participant who: • received 20vPnC, • was enrolled in the appropriate cohort based on prior pneumococcal vaccination history, • had Visit 2 blood collection within 27 to 49 days after vaccination, • had at least 1 valid and determinate OPA titre for any serotype for Visit 2, and • did not have any other major protocol deviations as determined by the clinician Participants were included in the vaccine group as randomised in the analyses | Evaluable Immunogenicity Population includes any participant who: • received 20vPnC, • was enrolled in the appropriate cohort based on prior pneumococcal vaccination history, • had Visit 2 blood collection within 27 to 49 days after vaccination, • had at least 1 valid and determinate OPA titre for any serotype for Visit 2, and • did not have any other major protocol deviations as determined by the clinician Participants were included in the vaccine group as randomised in the analyses |
| Results                                        | At 1 month after 20vPnC, OPA GMTs for most of the 20 vaccine serotypes tended to be numerically highest in participants with prior 13vPnC only, ranging from 54.3 (serotype 3) to 4156.5 (serotype 22F) and lowest in participants with prior PPSV23 only, ranging from 31.1 (serotype 3) to 2026.2 (33F). OPA GMTs in participants with prior 13vPnC and PPSV23 generally fell in between                                                                                                               | At 1 month after 20vPnC, OPA GMTs for most of the 20 vaccine serotypes tended to be numerically highest in participants with prior 13vPnC only, ranging from 54.3 (serotype 3) to 4156.5 (serotype 22F) and lowest in participants with prior PPSV23 only, ranging from 31.1 (serotype 3) to 2026.2 (33F). OPA GMTs in participants with prior 13vPnC and PPSV23 generally fell in between                                                                                                               | At 1 month after 20vPnC, OPA GMTs for most of the 20 vaccine serotypes tended to be numerically highest in participants with prior 13vPnC only, ranging from 54.3 (serotype 3) to 4156.5 (serotype 22F) and lowest in participants with prior PPSV23 only, ranging from 31.1 (serotype 3) to 2026.2 (33F). OPA GMTs in participants with prior 13vPnC and PPSV23 generally fell in between                                                                                                               |
| Analysis description                           | Secondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Secondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Secondary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis population and time point description | All-Available Immunogenicity Population includes all participants who: • received 20vPnC and • had at least 1 valid and determinate OPA titre 1 month after vaccination                                                                                                                                                                                                                                                                                                                                  | All-Available Immunogenicity Population includes all participants who: • received 20vPnC and • had at least 1 valid and determinate OPA titre 1 month after vaccination                                                                                                                                                                                                                                                                                                                                  | All-Available Immunogenicity Population includes all participants who: • received 20vPnC and • had at least 1 valid and determinate OPA titre 1 month after vaccination                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Results   | For the 13vPnC serotypes, higher OPA GMFRs and higher proportions of participants with ≥4 -fold rise in OPA titres were noted in cohort B compared to cohort A and C. For the additional 7 serotypes, GMFRs were larger and proportions of participants with a ≥4 -fold rise in OPA titres were higher in cohort B compared to cohort A and C.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Notes     | Immune responses differed considerably between cohorts. No comparison to 13vPnC or PPSV23 is possible.                                                                                                                                                                                                                                           |

## 2.6.5.3. Clinical studies in special populations

Children: No data has been submitted for children &lt; 18 yoa, as the target population for this MAA are adults ≥18 yoa. Studies in children with 20vPnC are currently ongoing. A PIP was discussed with the PDCO and a deferral was agreed.

Elderly: This population is generally considered as one of the most vulnerable for pneumococcal disease and is included in the studied population. Compared to younger populations studied (18-49 yoa and 50-59 yoa), a generally lower humoral immune response (based on OPA GMTs) was induced by 20vPnC (and 13vPnC). This is not unexpected and in line with other (pneumococcal) vaccines.

Table 33: Number of Participants in the 20vPnC and Control Groups (Combined) From the Two Phase 3 Trials That Included Enrollment of Adults ≥65 Years of Age, by Age Group -Safety Population

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 1547/4763                                         | 317/4762                                          | 21/4762                                         |
| Non Controlled Trials | N/A                                               | N/A                                               | N/A                                             |

for Cohorts A and B, but not for Cohort C. This trial was controlled for safety assessments but not for the immunogenicity analyses.

Renal and hepatic impairment : No explicit studies in patients with renal or hepatic impairment were performed. However, subjects with general risk factors for pneumococcal disease were enrolled in the main studies, potentially including respective patients. Respectively, the number of subjects with renal or hepatic impairment who received 20vPnC was very low.

<div style=\"page-break-after: always\"></div>

## 2.6.5.4. Analysis performed across trials (pooled analyses and meta-analysis

None

## 2.6.5.5. Supportive studies

## Study B7471008 (Phase 3), lot-to-lot consistency

This was a Phase 3, multicentre, randomised, double-blind study with a 4-arm parallel design conducted in the US in approximately 1610 adults 18- 49 years of age with no history of pneumococcal vaccination. Participants were randomised into 1 of 4 groups in a 2:2:2:1 ratio (20vPnC Lot 1; 20vPnC Lot 2; 20vPnC Lot 3; 13vPnC) by site-based randomisation.

The primary safety objective was to describe the safety profile of 20vPnC in the study population.  The 13vPnC arm was included as a control for safety assessments.

The pre-specified equivalence criteria were met for all comparisons between 20vPnC lots. The 2-sided 95% CIs for the model-based estimate of serotype-specific OPA GMRs 1 month after vaccination for each pair of lot comparisons (Lot 1/Lot 2, Lot 1/Lot 3, and Lot 2/Lot 3) are contained in the prespecified interval (0.5, 2.0) for each of the 20 serotypes (Figure below).

OPA GMFRs, proportion of participants with ≥ 4 -fold rise in OPA Pneumococcal Titres, and proportion of participants with OPA titres ≥ LLOQ were generally simila r across all three lots supporting lot equivalence.. These results are discussed with the results of the main studies under 'ancillary analyses'.

Figure 6: Model-Based OPA GMRs With 95% CIs- Evaluable Immunogenicity Population

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Study B7471002 (Phase 2)

This was a phase 2, multicentre, randomised, active-controlled, double-blind study (2-arm parallel design conducted in the US) to evaluate the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in 444 healthy, pneumococcal vaccine naïve adults 60 through 64 years of age (randomised 1:1 to receive either 20vPnC/saline or 13vPnC/PPSV23 one month apart).

## Study results

For each of the 13vPnC serotypes, the 95% confidence intervals (CIs) for OPA GMTs 1 month after Vaccination 1 overlapped in the vaccine groups, although this was marginal for 19F.

For the seven additional serotypes, the 95% CIs for the OPA GMTs 1 month after Vaccination 1 for the 20vPnC/saline group and 1 month after Vaccination 2 for the 13vPnC/PPSV23 group did not overlap for serotypes 10A, 15B, 22F, and 8. The OPA GMTs 1 month after vaccination with 20vPnC from the 20vPnC/saline group were higher than the OPA GMTs 1 month after vaccination with PPSV23 from the 13vPnC/PPSV23 group for serotypes 10A, 15B, and 22F, but the OPA GMT from the 20vPnC/saline group was lower than the OPA GMT from the 13vPnC/PPSV23 group for serotype 8.

A 6-fold or higher OPA GMFR was observed for all 20 serotypes 1 month after vaccination with 20vPnC. Overall, a similar tendency between treatment groups was seen as for the GMT analysis.

Pneumococcal OPA GMTs for all serotypes increased substantially after vaccination and then declined but remained elevated above baseline levels (before vaccination) at 12 months after Vaccination 1.

Examples of patterns of OPA GMTs across the time points for the 13 serotypes matched to 13vPnC are denoted by serotype 1 and 19F and for the seven additional serotypes are denoted by serotype 8 and 10A.

Figure  7:  Antibody  Response  Curve  12  months  after  vaccination,  OPA  GMTs  -  Evaluable Immunogenicity Population; representative examples

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 34: Summary of Pneumococcal OPA GMTs 1 and 12 Months After Vaccination with 20vPnV/saline or 13vPnC/PPSV23

|     |               |     |                         | Baseline                | after        | Vaccination 1                   | 1 Month   | 1 Month   | 1 Month   | 1 Month                            | after Vaccination 2   | 12      | Months after   | Vaccination 1    | %vacc   |
|-----|---------------|-----|-------------------------|-------------------------|--------------|---------------------------------|-----------|-----------|-----------|------------------------------------|-----------------------|---------|----------------|------------------|---------|
| ST  |               | n   | GMT                     | 95% CI                  | 1 Month n    | 95% CI                          | GMFR      | n         | GMT       | 95% CI                             | GMFR                  | n       | GMT            | 95% CI           |         |
| 1   | 20vPnC/saline | 209 | 14 ( 12.4, 15.8)        |                         | GMT 205 302  | ( 239.6, 381.4)                 | 21.2      | 204 243   |           | ( 189.0, 311.8)                    |                       | 200     | 58             | ( 45.9, 72.7)    | 19      |
|     | 13vPnC/PPSV23 | 208 | 13 (                    | 11.9, 15.2)             | 205 454      | (352.6, 584.5)                  | 33.5      | 203       | 410       | (321.2, 522.5)                     |                       | 199     | 94             | ( 74.0, 118.4)   | 21      |
| 3   | 20vPnC/saline | 210 | 9 ( 7.6, 9.5)           |                         | 208 51       | 43.2, 61.2)                     |           | 51        |           | ( 43.0, 60.1)                      |                       | 198     | 16             | ( 13.9, 18.7)    | 31      |
|     | 13vPnC/PPSV23 | 208 | 9 (                     | 8.0, 10.2)              | 204 64       | ( ( 54.1, 76.7)                 | 6.0 7.1   | 204 203   | 103       | ( 89.4, 118.7)                     |                       | 199     | 22             | ( 18.7, 25.4)    | 34      |
| 4   | 20vPnC/saline | 200 | 22 (                    | 27.3)                   | 202          | ( 676.8, 1134.7)                | 37.8      | 195       | 859       | ( 652.5, 1131.0)                   |                       | 189     | 245            | (178.8, 334.4)   | 28      |
|     | 13vPnC/PPSV23 | 201 | 17.2, 22 ( 17.7,        | 200                     | 876 1153     | 883.3, 1504.1)                  | 51.0      | 200       | 1519      | ( 1188.4, 1941.5)                  |                       | 192     | 334            | (242.6, 459.0)   | 29      |
| 5   | 20vPnC/saline | 210 | 17 ( 16.0,              | 27.8) 18.6) 204         | 144          | ( ( 113.3, 183.2)               | 8.3       | 201       | 152       | ( 118.4, 195.5)                    |                       | 200     | 41             | ( 34.0, 48.8)    | 28      |
|     | 13vPnC/PPSV23 | 208 | 18 ( 16.5,              | 20.5) 202               | 215          | ( 168.7, 274.4)                 | 11.6      | 196       | 231       | ( 184.3, 290.6)                    |                       | 199     | 50             | ( 40.9, 61.3)    | 23      |
| 6A  | 20vPnC/saline | 201 | 32 ( 26.5,              | 205                     | 1907         | ( 1492.7, 2436.2)               | 58.6      | 201       | 1995      | ( 1553.9, 2560.6)                  |                       | 195     | 492            | (379.3, 638.3)   | 26      |
|     | 13vPnC/PPSV23 | 200 | 34 ( 27.7,              | 37.6) 40.8)             | 199 2440     | ( 1848.9, 3219.9)               | 68.6      | 199       | 2913      | ( 2276.1, 3728.0)                  |                       | 193     | 634            | (490.3, 819.7)   | 26      |
| 6B  | 20vPnC/saline | 201 | 64 ( 50.5,              | 80.0) 201               | 2006         | ( 1591.4, 2527.5)               | 29.6      | 198       | 1873      | ( 1465.7, 2392.3)                  |                       | 195     | 652            | (499.9, 850.4)   | 33      |
|     | 13vPnC/PPSV23 | 194 | 53 ( 42.0,              | 202                     | 2218         | ( 1716.9, 2865.1)               | 38.8      | 201       | 2570      | ( 2019.3, 3271.5)                  |                       | 191     | 798            | (612.7,1038.4)   | 36      |
| 7F  | 20vPnC/saline | 198 | ( 104.9,                | 66.9) 147.0)            | 1581         | ( 1361.6, 1836.0)               | 12.2.     | 204       | 1620      | ( 1387.8, 1892.0)                  |                       | 198     | 412            | ( 344.1, 494.3)  | 26      |
|     | 13vPnC/PPSV23 | 197 | 124 120 ( 102.0,        | 207 140.7 204           | 1936         | ( 1651.1, 2269.6)               | 15.8      | 203       | 2285      | ( 1986.7, 2628.7)                  |                       | 198     | 497            | ( 419.0, 589.0)  | 26      |
| 9V  | 20vPnC/saline | 205 | ( 123.2,                | 176.0)                  | 2447         | ( 2013.0, 2975.6)               | 7.7       | 202       | 1148      | 944.3, 1396.6)                     |                       | 195     | 663            | ( 546.5, 805.4)  | 27      |
|     | 13vPnC/PPSV23 | 201 | 147 157                 | (                       | 201 3016     | ( 2469.5, 3684.4)               | 10.1      | 196       | 1842      | ( ( 1510.2, 2246.8)                |                       | 194     | 726            | ( 588.0, 897.1)  | 24      |
| 14  | 20vPnC/saline | 202 | 125 ( 96.5,             | 131.5, 187.5) 161.0)    | 199 206 1114 | ( 905.0, 1371.4)                | 8.5       | 202       | 1119      | ( 898.1, 1393.7)                   |                       | 199     | 527            | ( 423.9, 655.1)  | 47      |
|     | 13vPnC/PPSV23 | 202 | 131 ( 101.2,            | 170.2)                  | 204 1282     | ( 1017.4, 1614.9)               | 9.6       | 201       | 1823      | ( 1465.9, 2267.0)                  |                       | 196     | 682            | ( 544.0, 855.4)  | 53      |
| 18C | 20vPnC/saline | 206 | 47 (                    | 37.0, 59.2) 35.8, 57.0) | 204 1322     | ( 1053.2, 1658.9)               | 26.8      | 201       | 1205      | ( 951.5, 1527.0)                   |                       | 194     | 416            | ( 319.5, 542.7)  | 31      |
|     | 13vPnC/PPSV23 | 200 | 45 (                    | 203                     | 1660         | ( 1335.1, 2064.5)               | 35.2      | 202       | 2101      | ( 1717.5, 2569.5)                  |                       | 192     | 540            | ( 418.8, 696.1)  | 33      |
| 19A | 20vPnC/saline | 207 | 40 (                    | 32.1, 49.2)             | 207 943      | ( 783.5, 1136.1)                | 23.3      | 204       | 904       | ( 741.5, 1101.4)                   |                       | 196     | 257            | ( 210.9, 314.2)  | 27      |
|     | 13vPnC/PPSV23 | 207 | 37 (                    | 29.4, 46.4)             | 203 1137     | ( 936.5, 1379.4)                | 30.9      | 202       | 1457      | ( 1219.5, 1739.9)                  |                       | 198     | 376            | ( 309.2, 456.6)  | 33      |
| 19F | 20vPnC/saline | 207 | 39                      | 33.6, 44.3)             | 204 455      | ( 349.2, 592.2)                 | 11.8      | 198       | 423       | ( 323.4, 552.8)                    |                       | 198     | 128            | ( 101.7, 162.2)  | 28      |
|     | 13vPnC/PPSV23 | 207 | ( 40 ( 34.4, 47.7)      | 205                     | 738          | ( 582.1, 936.5)                 | 18.4      | 198       | 893       | ( 713.1, 1117.8)                   |                       | 197     | 193            | ( 153.7, 242.6)  | 26      |
| 23F | 20vPnC/saline | 209 | 12 (                    | 10.0, 14.4)             | 206 408      | ( 293.0, 568.0)                 | 33.6      | 203       | 427       | ( 309.6, 589.4)                    |                       | 200     | 129            | ( 93.9, 177.6)   | 32      |
|     | 13vPnC/PPSV23 | 206 | 13                      | 10.4, 15.3)             | 205          | ( 377.3, 687.1)                 | 39.8      | 200       | 558       | ( 416.1, 748.9)                    |                       | 194     | 158            | ( 116.6, 213.3)  | 31      |
| 8   | 20vPnC/saline | 206 | ( 20 ( 16.1,            | 207                     | 509 740      | ( 598.0, 915.7)                 | 37.1      | 201       | 536       | ( 425.4, 674.4)                    |                       | 192     | 113            | ( 87.4, 145.8)   | 15      |
|     | 13vPnC/PPSV23 | 204 | 24.2) 21 ( 17.0, 26.5)  | 203                     | 32           | ( 25.0, 42.0)                   |           | 200 1150  | 2020      | ( 944.4, 1401.6) ( 1664.6, 2452.2) | 56.9                  | 194     | 219            | ( 167.5, 286.6)  | 19      |
| 10A | 20vPnC/saline | 198 | 54 57                   | 39.1, 73.4)             | 201 2604     | ( 2096.4, 3234.4)               | 49.3      | 202       |           |                                    |                       | 191     | 960            | (732.2,1257.5)   | 37      |
|     | 13vPnC/PPSV23 | 198 | ( ( 41.2,               | 79.9)                   | 197 77       | ( 53.7, 109.5)                  |           | 197       | 988       | ( 731.2, 1335.5)                   | 17.1                  | 192     | 563            | ( 389.6, 813.2)  | 57      |
| 11A | 20vPnC/saline | 202 | 288 (                   | 219.2, 378.9)           | 197 3210     | ( 2613.2, 3943.8)               | 11.2      | 200       | 3389      | ( 2873.0, 3997.4)                  |                       | 194     | 1752           | (1400.8,2191.4)  | 55      |
|     | 13vPnC/PPSV23 | 183 | 292 ( 216.3,            | 393.2)                  | 186 336      | ( 248.5, 454.1)                 |           | 200       | 3007      | (2443.0, 3700.3)                   | 9.8                   | 189     | 1504           | (1188.7,1902.1)  | 50      |
| 12F | 20vPnC/saline | 193 | ( 42.0,                 | 64.3)                   | 200 6571     | ( 5022.2, 8597.3)               | 113.4     | 191       | 4046      | ( 3236.5, 5057.8)                  |                       | 192     | 748            | ( 566.0, 987.1)  | 11      |
|     | 13vPnC/PPSV23 | 200 | 52 60                   | (47.3, 75.1)            | 190 79       | ( 59.9, 103.7)                  |           | 191       | 4290 1385 | ( 3190.8, 5769.1) (1082.2, 1773.6) | 77.0                  | 189 197 | 621            | ( 442.2, 871.7)  | 14      |
| 15B | 20vPnC/saline | 205 | 32 33                   | (27.0, 38.8)            | 205 1889     | ( 1434.7, 2488.3)               | 57.1      | 199       |           |                                    |                       |         | 316            | ( 236.8, 422.2)  | 17      |
|     | 13vPnC/PPSV23 | 203 | (28.0,                  | 203                     | 47           | ( 37.7, 59.0)                   |           | 200       | 720       | ( 530.8, 975.9)                    | 21.3                  | 195     | 185            | ( 137.5, 248.4)  | 26      |
| 22F | 20vPnC/saline | 192 | 39.8) 110 (80.5, 149.2) | 201                     | 6286         | ( 5025.0, 7863.2)               | 55.4      | 191       | 4093      | ( 3383.7, 4950.3)                  |                       | 188     | 1214           | ( 919.8, 1602.7) | 19      |
|     | 13vPnC/PPSV23 | 196 | 164 (121.6,             | 221.6)                  | 184 182      | ( 129.3, 257.0) 4374.1, 7128.0) | 14.0      | 189       | 3513 (    | 2824.8, 4367.7)                    | 20.3                  | 192     | 976            | ( 724.4, 1314.9) | 28      |
| 33F | 20vPnC/saline | 190 | 379 430                 | (287.9, 500.2)          | 185 5584     | (                               |           | 185       | 2929      | ( 2385.5, 3595.7)                  |                       | 185     | 2288           | (1825.1,2867.3)  | 41      |
|     | 13vPnC/PPSV23 | 194 | (333.1, 555.9           | 189                     | 480          | ( 366.0, 629.8)                 |           | 181       | 3940      | ( 3136.2, 4950.9)                  | 8.9                   | 181     | 2072           | (1589.9,2700.8)  | 53      |

<div style=\"page-break-after: always\"></div>

Subjects with ≥4 -fold change in OPA titres 1 year after vaccination (all 20 serotypes)

Table 35 : Proportion of Subjects Achieving a ≥4 -fold Rise in OPA Titres From Before Vaccination 1 to 12 Months After Vaccination 1- Evaluable Immunogenicity Population

| serotype   | 20vPnC/Saline   | 20vPnC/Saline   | 20vPnC/Saline   | 20vPnC/Saline   | 13vPnC/PPSV23   | 13vPnC/PPSV23   | 13vPnC/PPSV23   | 13vPnC/PPSV23   |
|------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|            | N               | n               | %               | (95 CI)         | N               | n               | %               | (95 CI)         |
| 13vPnC     |                 |                 |                 |                 |                 |                 |                 |                 |
| 1          | 197             | 96              | 48.7            | (41.6, 55.9)    | 195             | 116             | 59.5            | (52.2, 66.4)    |
| 3          | 196             | 49              | 25.0            | (19.1, 31.7)    | 195             | 66              | 33.8            | (27.2, 41.0)    |
| 4          | 178             | 96              | 53.9            | (46.3, 61.4)    | 181             | 105             | 58.0            | (50.5, 65.3)    |
| 5          | 198             | 61              | 30.8            | (24.5, 37.7)    | 195             | 65              | 33.3            | (26.8, 40.4)    |
| 6A         | 186             | 131             | 70.4            | (63.3, 76.9)    | 183             | 131             | 71.6            | (64.5, 78.0)    |
| 6B         | 188             | 120             | 63.8            | (56.5, 70.7)    | 175             | 114             | 65.1            | (57.6, 72.2)    |
| 7F         | 184             | 81              | 44.0            | (36.7, 51.5)    | 183             | 88              | 48.1            | (40.7, 55.6)    |
| 9V         | 189             | 92              | 48.7            | (41.4, 56.0)    | 184             | 89              | 48.4            | (41.0, 55.8)    |
| 14         | 189             | 77              | 40.7            | (33.7, 48.1)    | 186             | 77              | 41.4            | (34.2, 48.8)    |
| 18C        | 188             | 104             | 55.3            | (47.9, 62.6)    | 181             | 118             | 65.2            | (57.8, 72.1)    |
| 19A        | 192             | 105             | 54.7            | (47.4, 61.9)    | 193             | 128             | 66.3            | (59.2, 72.9)    |
| 19F        | 193             | 72              | 37.3            | (30.5, 44.5)    | 192             | 97              | 50.5            | (43.2, 57.8)    |
| 23F        | 197             | 117             | 59.4            | (52.2, 66.3)    | 188             | 114             | 60.6            | (53.3, 67.7)    |
| Additional |                 |                 |                 |                 |                 |                 |                 |                 |
| 8          | 186             | 96              | 51.6            | (44.2, 59.0)    | 186             | 118             | 63.4            | (56.1, 70.4)    |
| 10A        | 181             | 125             | 69.1            | (61.8, 75.7)    | 181             | 109             | 60.2            | (52.7, 67.4)    |
| 11A        | 187             | 100             | 53.5            | (46.1, 60.8)    | 162             | 84              | 51.9            | (43.9, 59.8)    |
| 12F        | 176             | 120             | 68.2            | (60.8, 75.0)    | 177             | 107             | 60.5            | (52.8, 67.7)    |
| 15B        | 190             | 121             | 63.7            | (56.4, 70.5)    | 186             | 88              | 47.3            | (40.0, 54.7)    |
| 22F        | 170             | 110             | 64.7            | (57.0, 71.9)    | 176             | 91              | 51.7            | (44.1, 59.3)    |
| 33F        | 165             | 94              | 57.0            | (49.0, 64.6)    | 168             | 93              | 55.4            | (47.5, 63.0)    |

Abbreviations: OPA = opsonophagocytic activity; LLOQ = lower limit of quantitation. Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. N = number of subjects with valid and determinate assay results for the specified serotype. These values are used as the denominators for the percentage calculations. n = Number of subjects with a ≥4 -fold rise in antibody titre for the specified serotype.

Note: The 9V serotype data at 1 month after Vaccination 1 is retest data.

Exact 2-sided CI based upon the observed proportion of subjects, calculated using the Clopper and Pearson method.

## Study B7471005 (Phase 1b)

Study B7471005 was a phase 1b, randomised, controlled (3-arm parallel design), double-blind trial, conducted at 3 sites in the US, to evaluate the safety and immunogenicity of multivalent pneumococcal conjugate vaccines in approximately 99 healthy pneumococcal vaccine naïve Japanese adults 18-49 yoa. Subjects were randomised equally 1:1:1 to receive a single dose of 20vPnC, c7vPnC (an unauthorised investigational vaccine including the 7 serotypes not included in 13vPnC) or 13vPnC as control group.

## Immunogenicity results

One month after vaccination, increased OPA GMTs were observed for all serotypes in the respective groups. OPA GMFRs for all 20 serotypes with 20vPnC ranged between 6.1-fold (serotypes 3 and 11A) to 150.7-fold (serotype 8).

The majority of participants vaccinated with 20vPnC achieved a ≥4 -fold rise in OPA titres from before to 1 month after vaccination for all 20 serotypes (range: 54.8% (serotype 7F) to 97.0% (serotype 23F)).

<div style=\"page-break-after: always\"></div>

## 2.6.6. Discussion on clinical efficacy

The applied indication for 20vPnC/Apexxnar, a 20-valent protein conjugated pneumococcal vaccine, is 'active immunisation for the prevention of invasive pneumococcal disease (IPD) and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age'. Currently other vaccines are licensed for this indication in adults in the EU: e.g. Prevenar13 (13vPnC) and PNEUMOVAX23 (PPSV23). Another pneumococcal vaccine is licensed but not for the intended adult population (Synflorix). The applicant is also the marketing authorisation holder of 13vPnC and 20vPnC is based on the same manufacturing process as Prevenar 13 (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) with 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F). PPSV23 is an unconjugated polysaccharide vaccine containing 23 serotypes, including the serotypes of 20vPnC, except 6A, which is only included in 20vPnC and 13vPnC. The additional serotypes of PPSV23 are 2, 9N, 17F, 20. Both vaccines are routinely used in European vaccination programmes. Both vaccines are used as comparators for this MAA. The choice of the comparator vaccines is considered acceptable and has been agreed in the scientific advice.

Currently, no correlate of protection has been established in the adult population for pneumococcal vaccines. Consequently, efficacy has to be inferred via immunobridging between 20vPnC and vaccines with proven protective efficacy: 13vPnC (for the 13 shared serotypes) and PPSV23 (for the 7 additional serotypes). This immunobridging approach is in accordance with the respective EMA guidance (EMEA/CHMP/VWP/164653/2005) and scientific advice.

The clinical programme for 20vPnC consists of six randomised controlled trials to study safety and immunogenicity of 20vPnC. Studies B7471007 (pivotal, pneumococcal vaccine naïve subjects) and B7471006 (primed subjects) are considered as main evidence for this application as separate important aspects of the target population are covered (including relevant age groups, risk factors and pneumococcal vaccination history). Supportive data derives from two Phase 1 studies (B7471001 (FIH), B7471005 (Japanese subjects)), a Phase 2 study (B7471002) and a Phase 3 lot consistency study (B7471008).

No dedicated dose-finding studies were conducted for 20vPnC, since prior experience with its predecessor 13vPnC exists. Both 13vPnC and 20vPnC contain 2.2 μg pneumococcal polysaccharide per serotype (4.4 μg for serotype 6B) per single dose of 0.5 mL IM.

No studies with 20vPnC have been performed to evaluate the ability to induce memory, the longevity of protection or boosting. Respective information should be extrapolated from 13vPnC given a robust bridge has been established.

## Design and conduct of main clinical studies

The main evidence for the immunological bridge is generated in the pivotal study B7471007 in different steps represented by the primary and secondary objectives. The primary comparison between 20vPnC and 13vPnC is performed in pneumococcal vaccine naïve adults ≥60 years of age (cohort 1) to establish non-inferiority of 20vPnC to 13vPnC in this age group. Subsequently, non-inferiority of the immune response elicited by 20vPnC should be established in 60-64-year-old subjects (a subset of cohort 1) and the younger cohorts 2 and 3 (50 - 59 and 18 - 49 years of age). No additional comparison between vaccines (20vPnC and 13vPnC or PPSV23) was intended for these cohorts. This approach to bridge to younger cohorts was previously discussed during the scientific advice procedure (EMEA/H/SA/3940/1/2018/III CORRIGENDUM). Since it is in line with the previous development programme of 13vPnC, it was considered appropriate, if it is confirmed that the vaccine is essentially

<div style=\"page-break-after: always\"></div>

the same medicinal product as 13vPnC, plus seven additional serotypes. According to the assessment of the quality part of the provided dossier, no differences are expected. However, the planned noninferiority margin (0.5) was seen critical in this advice as meeting this margin was not considered to ensure that adults 18 through 49 and 50 through 59 years of age will have non-inferior immune responses to 20vPnC compared to 13vPnC. The clinical (ir)relevance of the employed non-inferiority margins is currently not known. Additionally, it is known, also from 13vPnC, that immune response declines with age and it is to be expected that the immune response in younger subjects will be higher than in older subjects. Consequently, non-inferior immune response in the younger compared to the oldest cohort could be expected regardless of whether the immune response is comparable between 20vPnC and 13vPnC or PPSV23 in younger subjects. The immunological bridge is further discussed with the respective results below.

Study B7471006 enrolled subjects with prior vaccination history. This is considered a relevant part of the intended target population, since pneumococcal vaccines are already available for the adult population since several years or even decades in the case of PPSV23. Consequently, it is very likely that especially the older target population will have received at least one prior vaccination with either or both vaccines. Study B7471006 enrolled subjects ≥ 65 years of age into different cohorts based on their previously received different pneumococcal vaccination (13vPnC, PPSV23 or both sequentially (13vPnC/PPSV23), representing all common prior pneumococcal vaccinations. Unfortunately, the study was not designed to generate confirmatory evidence which would have been preferred and has several shortcomings, including the open label design, the descriptive reporting of results and the lack of immunogenicity data from a control arm to further substantiate the immunological bridge required for this MAA.  Nevertheless, the presented data are considered informative for this subset of the target population.

The inclusion and exclusion criteria are generally comparable for both main studies. Differences relate to definition of relevant subject groups mainly based on age (B7471007) and prior pneumococcal vaccination status (B7471006) in line with the study objectives. The majority of subjects who received 20vPnC were 60-69 years old (in total 1661; naïve: 1312; primed: 349). In addition, a total of 470 subjects older than 70 years (naïve: 195; primed: 275) received 20vPnC. Overall, the included population is considered to adequately reflect the population ≥ 60 yoa, most vulnerable to pneumococcal disease. In addition, 334 subjects 50-59 yoa and 335 subjects 18-49 yoa received 20vPnC in study B7471007. Supportive data for the youngest cohort (18-49 year) is also generated in the lot-to-lot consistency study (n=1463). The main evidence for the intended immunobridge was generated in pneumococcal vaccine naïve subjects ≥ 60 yoa. This population is considered an adequate and sensitive population to establish the intended immunobridge since potential interactions with prior pneumococcal vaccinations can be excluded.

The clinical development programme did not specifically aim to recruit subjects at specific risk for pneumococcal disease, e.g. with chronic comorbidities (e.g. diabetes, chronic heart or lung disease), behavioural habits (e.g. smoking) or subjects living in a community/environment with increased risk of disease transmission. Nevertheless, about 1/3 of all subjects enrolled in study B7471007 had risk factors for pneumococcal disease and a respective analysis comparing subjects with and without risk factors has been performed. No studies were performed in immunocompromised patients and the applicant argues that respective efficacy can be extrapolated from 13vPnC based on the characteristics of a conjugate vaccine. This can currently not fully be agreed on (see below).

The submitted studies were mainly conducted in the US and at some study sites in Sweden. Consequently, the experience with 20vPnC in the European population is limited but prior global experience with 13vPnC and PPSV23 do not give rise to concerns regarding potential differences relevant for the European population.

<div style=\"page-break-after: always\"></div>

The applicant used opsonophagocytic activity (OPA) titres for the evaluation of immune response, which is endorsed and was agreed on during the scientific advice procedure. OPA titres are commonly used as surrogate markers for a protective effect as they reflect the in vivo scenario of antibodymediated protection. However, no correlate of protection has been established. Comparisons across serotypes are also not possible due to different capsule compositions, potentially resulting in different titres required for protection for each serotype. The complementary immunogenicity parameter of IgG concentrations was only used in the Phase 1 and 2 studies but not in the main studies. This is considered acceptable since OPA GMTs are considered a more relevant parameter.

In all studies participants received a single dose of either vaccine (20vPnC, 13vPnC or PPSV23), which is in line with the approved regimen for 13vPnC and PPSV23. Immune responses were evaluated before and one month after vaccination. Serotype-specific OPA geometric mean titres (GMTs) at 1 month after the respective vaccination were used as variables for the primary endpoints.

Secondary endpoints to further assess the immune response included differences in geometric mean fold rises (GMFRs) in serotype-specific OPA titres, the proportion of subjects with a ≥4 -fold OPA GMT rise from baseline and the proportion of subjects with titres above LLOQ. Immunogenicity objectives and endpoints are generally supported and are in line with the vaccine guideline (EMA/CHMP/VWP/164653/05 Rev.1).

In order to be able to evaluate the immune response of both comparator vaccines, 13vPnC and PPSV23 were given to the same subjects one month apart and the respective evaluation was performed separately for the respective serotypes one month after the respective vaccination. This dosing regimen is not representative for the commonly recommended sequential vaccination of 13vPnC and PPSV23. No data concerning a sequential vaccination, as commonly recommended in the EU (with an interval between vaccinations of several weeks up to 1 year, depending on the subject's risk factors and age) was submitted neither with 20vPnC nor as comparison thereof. Respective information collected with 13vPnC could be extrapolated given a robust immunobridge.

## Efficacy data and additional analyses

Overall, 20vPnC was immunogenic in all studies and subgroups tested, based on consistently elevated OPA GMTs 1 month after vaccination compared to baseline.

The main evidence for the immunological bridge to the comparator vaccines with proven efficacy was generated in study B7471007, in several steps:

(1) Establishing noninferiority to 13vPnC for the 13 shared serotypes in Cohort 1 (subjects ≥ 60 yoa),

(2) Establishing non-inferiority to PPSV23 for the seven additional serotypes in Cohort 1 and

(3) Establishing non-inferiority in a subset of cohort 1 (60-64 yoa) and younger subjects in Cohorts 2 (50-59 yoa) and 3 (18-49 yoa), respectively.

Non-inferior immune response is assumed if the lower bound of 2-sided 95% CI for the ratio of OPA GMTs between the respective comparator arms is &gt;0.5 [2-fold NI margin].

- (1) 13 shared serotypes : The defined non-inferiority criteria were met for all 13 serotypes included in 20vPnC and 13vPnC. Nevertheless, lower immune response was observed for 11 serotypes. The ratio of OPA GMTs between 20vPnC and 13vPnC was consistently around 0.8 and the GMR 95%-CI did not include 1. In addition, the 95%-CI of the vaccine specific GMTs were non-overlapping between both vaccines for five serotypes and hardly overlapping for another five. Although meeting the non-inferiority criteria, these differences are noteworthy, especially since both vaccines are essentially the same product (with the additional serotypes

<div style=\"page-break-after: always\"></div>

for 20vPnC). The clinical relevance of this difference is unclear, especially since no correlate of protection exists. However, the protective effect for serotype 3 is unclear given the reduced response although the NI criterion was met. Although both vaccines 13vPnC and PPSV23 contain serotype 3, it is still the most prevalent serotype causing IPD in Europe (14.7% of all reported IPD cases; ECDC 'Invasive Pneumococcal Disease, Annual Epidemiological Report for 2018'). Consequently, these findings have been reflected in the PI in order to provide relevant information to the prescriber. Further, the applicant outlined that the clinical relevance of these findings will be further investigated in the post-marketing setting to confirm 20vPnC effectiveness (see section on post-marketing below).

- (2) 7 additional serotypes : The defined non-inferiority criteria were met for six of the seven additional serotypes. The GMRs for these serotypes were clearly above 1, indicating higher immune response with 20vPnC compared to PPSV23. Only serotype 8 missed the noninferiority margin. The clinical relevance of this finding and the impact on vaccine efficacy and protection against serotype 8 is not known. The applicant argued that protection similar to the other serotypes could be assumed, based on only narrowly missing the criteria (GMR 0.55 (0.49, 0.62)) and other immunogenicity endpoints in the range of other serotypes, but this is not endorsed. In Europe, serotype 8 is the most common serotype causing IPD in subjects 1865 yoa (approx. 22-32% of reported IPD cases) and after serotype 3 (14.7%) the second most common IPD causing serotype in adults ≥65 yoa (14.0%) (IPD Annual Epidemiological Report for 2018; ECDC). The additional benefit for six of the seven additional serotypes can be agreed upon. As regards serotype 8, while acknowledging the potential benefits of conjugateinduced immunity by 20vPnC as opposed to PPSV23, the considerably reduced response to this serotype is of concern. The potential reasons for the pronounced difference observed for serotype 8 compared to the other six new serotypes are unknown. The clinical relevance of this finding will be further investigated to infer vaccine effectiveness against serotype 8 in the post-marketing (see section on post-marketing below). Breakthrough disease due to reduced vaccine effectiveness (or potential vaccine failure) as well as serotype replacement will be followed up via routine pharmacovigilance in the post marketing (see section on postmarketing below).
- (3) Bridge to younger cohorts : After establishing the initial immunological bridge to 13vPnC in cohort 1, a bridge to the younger cohorts should be established via demonstrating noninferiority of immune responses of all 20 serotypes elicited by 20vPnC in a subgroup of cohort 1 (60-64 years) and Cohorts 2 and 3, respectively. The comparison of Cohort 2 (50-59 years) to Cohort 1 (60-64 years) showed GMT ratios around 1 for all serotypes, meeting the NI criteria. The comparison of Cohort 3 to Cohort 1 (60-64 years) showed overall ratios clearly above 1, except for serotype 3 (GMT ratio: 1.00), meeting all NI criteria.

Although all endpoints were met, concerns about the intended bridge to younger cohorts remain. While this approach to compare the immune response across age groups has been accepted in the Scientific Advice, it was also specifically mentioned that the chosen margin does not allow any conclusions about whether the immune response between 20vPnC and 13vPnC would be comparable. Further, it is known also from 13vPnC that higher immune responses are elicited in younger subjects, which was also stated by the applicant. Therefore, higher and consequently non-inferior immune response in younger subjects were to be expected. Information about the comparability of immune response between both vaccines can only be provided with comparative data between 20vPnC and 13vPnC in Cohorts 2 and 3. Although data for 13vPnC was collected, no pre-specified comparative analysis was performed by the applicant. The respective data has been compiled by the assessors and shows that immune response elicited by 20vPnC is consistently lower in all cohorts compared to 13vPnC.

<div style=\"page-break-after: always\"></div>

These observations should be reflected in the SmPC. In Cohort 2, including 50-59-year-old subjects, the difference seems even more pronounced compared to Cohort 1, although the conclusions are somewhat hampered by the small number of subjects receiving 13vPnC. The observations of reduced response are further supported by overall reduced proportion of subjects with a ≥4 -fold rise. The results raise doubts whether the approach to compare immune response between age groups instead of against the comparator vaccine directly is appropriate to establish an immunological bridge between a new vaccine and a vaccine with proven efficacy. Similar reductions have also been observed in other studies were respective data is available: the lot consistency study B7471008 and a paediatric study, submitted by the applicant (B7471003), although this population is not part of the current indication.

Despite the concerns raised regarding the consistently lower immune response compared to 13vPnC in each cohort, it has to be acknowledged that almost all GMTs for 20vPnC in Cohorts 2 and 3 were higher than the GMTs observed for 13vPnC in subjects ≥60 yoa (cohort 1), which are assumed to provide protection against IPD and pneumonia. Consequently, a protective effect of 20vPnC for those two cohorts can be assumed. Nevertheless, the clinical relevance of the observed reduced immune response is currently unknown. Especially, it is not apparent whether the reduced GMTs observed in the most vulnerable age group, subjects ≥60 years, are still predictive for a (long -term) protective effect.

Further, several populations exist in which a reduced immune response was already observed during the development of 13vPnC. These include amongst others primed subjects and subjects with risk factors, who have also been part of this development programme. For both populations reduced GMTs compared to pneumococcal vaccine naïve subjects or subjects without risk factors have been observed (see below). It is not apparent whether the further reduced immune response to 20vPnC would elicit protective titres in these populations or at least in parts of these populations depending potentially on age or prior pneumococcal vaccine (see below). The need of another vaccination schedule (e.g. additional dose), especially for risk groups was not discussed by the applicant and so far, also no plans have been outlined how this could be investigated in the post-marketing (see section on postmarketing below).

Even if the observed titres would be representative for protection against IPD and pneumonia, it is not apparent how long this protection would last. It has to be assumed that the duration of the provided protection would also be reduced. Only limited data with 20vPnC for 12 months are available in about 200 pneumococcal vaccine naïve adults 60-64 years of age from the Phase 2 study B7471002. The data can, however, not be compared to 13vPnC due to the applied dosing regimen and does not provide further information for the populations with reduced immune response. The applicant assumes that immune persistence for 20vPnC can be extrapolated from experience with 13vPnC since both are similar conjugate vaccines. Whether this is the case is, however, currently unclear considering the reduced immune response. No further discussion was provided to substantiate the claim of a protective effect similar to 13vPnC i n adults ≥60 yoa, primed subjects and patients with decreased immune response. Therefore, upon request the applicant provided plans for the post-marketing to monitor breakthrough disease and potential other indications for lack of efficacy (see section on post-marketing below).

## Risk factors

Adult subjects with risk factors for IPD regardless of age are an important target population for pneumococcal vaccines. Although such subjects were not explicitly recruited, about 1/3 of the enrolled subjects of the pivotal study had at least one risk factor. While such an analysis is considered important for this MAA, the initially performed analysis has several shortcomings: (1) The data analysis only compares subjects with risk factor to subjects without risk factor, regardless of type and amount

<div style=\"page-break-after: always\"></div>

of risk factors. (2) the presented analysis combined data from all three cohorts, which is not considered appropriate, since the GMTs differ substantially between cohorts. Upon request, the applicant provided respective analyses for each cohort.

In general, the immune response in patients with risk factors was clearly detectable and supported by other parameters, e.g. a substantial proportion of subjects reached ≥4 -fold GMT rise. However, the observed immune responses (OPA GMTs) were lower in subjects with risk factors compared to those without in all cohorts (GMT ratio ~ 0.6-0.8 , ≥ 4 -fold rise ~5-10% difference). The effect of reduced immune response is also known for 13vPnC. In the requested analyses, the applicant also compared the results between 20vPnC and the respective comparator, 13vPnC for all cohorts and PPSV23 in cohort 1. While the reduction observed between subjects with and without risk factors is similar between 20vPnC and 13vPnC, the reduced immune response of 20vPnC compared to 13vPnC seen in the naïve population of the pivotal study is also seen in this population. This further reduction of immune response raises concerns regarding a protective effect in patients with risk factors. The achieved titres in younger patients (cohort 2 and 3) with risk factors are comparable or above the titres achieved with 13vPnC in cohort 1, which are assumed to elicit a protective effect. However, whether the observed reduction in patients with risk factors of at least 60 years of age has clinical relevance, it is currently unknown. Since the initial titres are reduced, it is likely that the reduced titres also affect the long-term protection. The applicant was invited to further substantiate the claim, that these titres provide a protective effect, discuss respective implications on long term protection and present suitable post-marketing plans. Upon request, the applicant outlined how the clinical impact of these findings can be further investigated in the post-marketing in the general target population. However, some aspects of 20vPnC vaccine effectiveness are not especially addressed including (younger) subjects at risk for pneumococcal disease, primed subjects or immunocompromised patients.

Consequently, it is currently still questioned whether data from 13vPnC can be extrapolated for patients at high risk for pneumococcal disease, e.g. immunocompromised subjects, which were not included in the development programme of 20vPnC. In order to provide supportive information to the prescriber, data derived with 13vPnC are included in the SmPC together with a clear statement that no data with 20vPnC are available and that lower titres have been observed. If vaccine effectiveness is shown in the respective post marketing studies, this will also be reassuring concerning those populations.

The currently approved vaccines for the adult population in the EU include Prevenar13 (13vPnC) and Pneumovax23 (PPSV23, polysaccharide). Since the MAH of 13vPnC is also the applicant for 20vPnC, it is a reasonable assumption that 20vPnC is intended to replace 13vPnC in the applicant's portfolio and will be removed from the European market, creating a lack of alternative conjugate vaccines. Consequently, remaining uncertainties about the protective effect especially in at-risk populations have to be further minimised (see section on post marketing below).

## Primed subjects

The applicant performed Study B7471006 in adults ≥65 years of age (yoa) with prior pneumococcal vaccination separated in three different cohorts based on prior pneumococcal vaccinations. Overall, 20vPnC elicited immune responses across all serotypes and cohorts but the immune responses differed considerably between the different cohorts. Overall, the data indicate that 20vPnC achieved higher immune responses after prior vaccination with the conjugate vaccine 13vPnC compared to prior vaccination with the unconjugated vaccine PPSV23, either alone or after prior vaccination with 13vPnC.

It is not known, whether the elicited immune response in any of the cohorts is comparable to 13vPnC or PPSV23. The design of the study does not allow for such a comparison, which is regarded as shortcoming for this MAA. For cohort A and B, a safety control arm exists with subjects receiving either

<div style=\"page-break-after: always\"></div>

13vPnC (cohort A) or PPSV23 (cohort B) but no immunogenicity data exist for these arms. Alternatively, one general control arm with pneumococcal vaccine naïve subjects would have been suitable to establish a bridge to the pivotal data from study B7471007. Since any kind of bridging is missing, it is not apparent whether an extrapolation of efficacy from 13vPnC and PPSV23 in primed subjects is possible. The applicant did not discuss this issue and argues instead that showing elicited immune response in primed subjects in general, is enough to conclude a protective effect. Although comparing results across studies is not optimal, the assessors compiled respective data to compare results derived in all three cohorts to the GMTs observed in cohort 1 from study B7471007 with a similar age group (≥60 yoa, pneumococcal naïve subjects). While similar immune response can be concluded for most serotypes between naïve subjects and subjects who received only 13vPnC, a reduced response has been observed in both cohorts including subjects who received PPSV23, especially as single vaccination. The applicant confirmed upon request that an effect to a similar degree was also observed with 13vPnC. However, the clinical relevance of this observation in unknown. While it is assumed that the apparent reduced immunity with 20vPnC in subjects previously vaccinated with PPSV23 could be induced by a hypo-response phenomenon, this has not been scientifically proven yet. In addition, the applicant clarified that the role of the interval between the last dose of PPSV23 (in Cohort A and C) and 20vPnC cannot be evaluated since respective data was not collected in the study.

No data about a potential booster vaccination have been submitted. The applicant argues that persistence of immune response can be extrapolated from 13vPnC based on the established immunological bridge and nature of the pneumococcal conjugate response. While this might be possible for the 13 shared serotypes, given a robust immunological bridge, an extrapolation for the seven additional serotypes from 13vPnC is not possible. Although the pivotal study intends to establish an immunological bridge to PPSV23 for these serotypes, extrapolation of immune persistence is questionable. The comparator PPSV23 is an unconjugated polysaccharide vaccine with known limited persistence. Supportive long-term data up to one year is generated in the phase 2 study (B7471002) as exploratory endpoint. For this time-point, control data of a sequential vaccination with 13vPnC followed one month later by PPSV23 are available. Data from 12 months after the first vaccination indicate that OPA GMTs declined similarly over time for both vaccination regimen and OPA titres remained above baseline levels. This allows for a comparison of the immune response between 20vPnC and PPSV23 against the seven additional (non-13vPnC) serotypes but only between 12 months data for 20vPnC and 11 months data for PPSV23. Nevertheless, the additional data are considered informative for the assessment of immune persistence of these seven serotypes. Unfortunately, no direct comparison between 20vPnC and 13vPnC is possible to confirm the extrapolated information for the 13 shared serotypes. The applicant does not intend to conduct a post-marketing study to assess the need for booster vaccination in adults and presented data from a study evaluating multiple doses of 13vPnC in HIV infected patients, showing moderately increased titres after 3 doses. Since it is currently not known whether the observed reduction in OPA GMTs for 20vPnC would result in a reduced protection or whether similar results would be obtained with 20vPnC for multiple doses as presented for 13vPnC and whether the gained increase would improve the protective effect, it is agreed that it is currently not necessary to perform respective multiple dose studies with 20vPnC. This, however, might change, if appropriate post-marketing studies would detect a reduced protection with 20vPnC.

Lot-to-lot consistency (Study B7471008): The pre-defined equivalence criteria were met for all serotypes for all three 20vPnC lots. Each of the pairwise 2-sided 95% confidence intervals (CIs) for the geometric mean ratio (GMR) of OPA titres 1 month after vaccination were contained in the interval (0.5, 2.0). Although the clinical relevance of the defined margins is not established, it is acknowledged that all CI included 1. Lot-to-lot consistency studies are not routinely required based on the EMA guideline on clinical evaluation of vaccines.

<div style=\"page-break-after: always\"></div>

No data on concomitant vaccination with other vaccines relevant to the target population (e.g. Influenza vaccines) are currently available. A respective trial evaluating 20vPnC co-administered with seasonal inactivated influenza vaccine is currently ongoing (variation intended for post marketing).

## Post-marketing assessments to monitor vaccine effectiveness:

The applicant provided an outline of their post-marketing plans to assess effectiveness of 20vPnC. These are considered important to address the remaining uncertainties regarding the lower titres induced by 20vPnC vaccination compared to 13vPnC and the considerable low titre against serotype 8 (compared to PPSV23). The applicant's plans are as follows:

1. A vaccine effectiveness study against vaccine-type community-acquired pneumonia (CAP)

As a post-marketing requirement with the US FDA (condition of accelerated approval), the applicant will conduct a vaccine effectiveness (VE) study against vaccine-type (VT) community-acquired pneumonia (CAP) in the USA (B7471015) in adults ≥65 years of age . 20vPnC VE against all 20 serotypes, VE against the 13vPnC matched and 7 additional serotypes (including serotype 8) will be evaluated employing a test-negative design. Study results are expected by 30 November 2027. The study protocol has been provided with the applicant's response. As serotype distribution differs across continents, the applicant is expected to provide a detailed discussion on the applicability of study results to the European situation together with the study results. With test-negative design, the study will also include subjects with risk factors as well as subjects with pneumococcal vaccination history (≥65 years of age) and has the potential to also provide further information on VE (against CAP) in this population. However, no additional data on subjects at higher risk for pneumococcal disease and/or generally lower immune response to pneumococcal vaccination (e.g. with prior PPSV23 vaccination) &lt; 65 years of age will be generated.

As this study is considered relevant to further address remaining uncertainties, it is added as a postauthorisation obligation (see Product information- Annex II D and Risk Management Plan [RMP]).

2. Two Phase 4 Observational, Real-World Studies of 20vPnC Effectiveness. One against VT CAP in Europe and one against VT IPD in Europe

Two additional studies to evaluate the impact of 20vPnC vaccination on vaccine type (VT) CAP and IPD in Europe (are currently undergoing feasibility evaluation. The applicant is expected to further investigate VE in these populations as part of the post-marketing assessment.

Completion of the feasibility assessment is ongoing, with submission of both protocols in likelihood by end Q1 2024 (date added to RMP). Since the data generated in these studies will be important for the future assessment of the remaining uncertainties, the commitment is included as post-authorisation measure in Annex II D. Tentative timeline for CSRs submission has been set.

3. Monitoring of Pneumococcal Serotype Epidemiology and Vaccine Failures in Europe

Ultimately, European national IPD surveillance systems as well as the ECDC European IPD surveillance system will be employed to monitor serotype epidemiology and breakthrough infections. Annual reports will be submitted. This is considered part of the routine pharmacovigilance measures and therefore expected regardless of other post marketing studies.

Taken together, the presented post-marketing plans are expected to provide valuable information on 20vPnC effectiveness, and the remaining uncertainties related to the clinical impact of reduced immune responses elicited by 20vPnC compared to the majority of serotypes shared with 13vPnC and serotype 8 shared with PPSV23. However, some aspects of 20vPnC vaccine effectiveness are not especially addressed including (younger) subjects at risk for pneumococcal disease, primed subjects or immunocompromised patients. Nevertheless, if vaccine effectiveness is shown in the respective

<div style=\"page-break-after: always\"></div>

studies, this will also be reassuring concerning those populations (Post-authorisation measures stated in Annex II D and RMP).

## 2.6.7. Conclusions on the clinical efficacy

Overall, the results indicate that 20vPnC was immunogenic in all subgroups tested. However, several uncertainties were identified concerning numerically lower immune response compared to 13vPnC (for most shared serotypes) and compared to PPSV23 (for serotype 8). The SmPC appropriately reflects these findings. The applicant will further address these findings in the post-marketing setting and evaluate their impact on 20vPnC effectiveness. The RMP and SmPC Annex II were updated accordingly to include the respective post-marketing commitments.

The CHMP considers the following measures necessary to address issues related to efficacy:

- a. In order to further investigate the long-term effectiveness of Apexxnar for active immunisation for the prevention of pneumonia caused by Streptococcus pneumoniae , the MAH should conduct and submit the results of US study B7471015, a Phase 4 study using a test-negative design to evaluate the effectiveness of Apexxnar against Vaccine-Type Community-Acquired Pneumonia in adults ≥ 65 years of age.
- b. In order to further investigate the long-term effectiveness of Apexxnar for active immunisation for the prevention of pneumonia caused by Streptococcus pneumoniae , the MAH should conduct and submit the results of a Phase 4 Observational, real-world study to evaluate the effectiveness of Apexxnar against Vaccine-Type Community-Acquired Pneumonia in Europe according to an agreed protocol.
- c. In order to further investigate the long-term effectiveness of Apexxnar for active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae , the MAH should conduct and submit the results of a Phase 4 Observational, real-world study to evaluate the effectiveness of Apexxnar against Vaccine-Type Invasive Pneumococcal Disease in Europe according to an agreed protocol.

## 2.6.8. Clinical safety

The 20vPnC adult clinical development programme was designed to characterize the safety, tolerability , and immunogenicity of 20vPnC in adults ≥18 years of age. The adult clinical development programme for 20vPnC is generally modelled after the 13vPnC adult programme and takes into consideration the favourable safety profile established for 13vPnC in the adult clinical development programme and the adult post-marketing experience since initial licensure in 2011.

The safety of 20vPnC was assessed in three early stage (two Phase 1 trials and one Phase 2 trial) and three Phase 3 clinical trials. Early phase trials enrolled adults who were naïve to pneumococcal vaccine 18 through 49 years of age (B7471001 and B7471005) and 60 through 64 years of age (B7471002). The Phase 3 safety data are summarised and discussed separately for individuals who were naïve to pneumococcal vaccine at trial enrolment (B7471007 and B7471008) and for individuals ≥65 years of age who had previously been vaccinated with 13vPnC, PPSV23, or both (B7471006). In all three Phase 3 trials, the safety of 20vPnC was mainly evaluated in comparison to 13vPnC.

## Data pooling :

Each Phase 3 trial has distinct study objectives and design, including different subject populations with regard to age and prior pneumococcal vaccination status. The only overlapping subject populations across studies are pneumococcal vaccine naïve subjects 18-49 years of age from B7471007 Cohort 3

<div style=\"page-break-after: always\"></div>

and B7471008. Age and prior pneumococcal vaccination status are important factors when interpreting safety and tolerability results. As these factors differ by study, safety data are presented mainly by study in side-by-side displays, except that data are pooled for subjects 18-49 years of age

## 2.6.8.1. Patient exposure

The 6 studies contributing to the evaluation of safety enrolled 7048 adult subjects. In total, 4552 subjects received 20vPnC and 2496 received control vaccine. The extent of exposure in the different studies is presented in Table 38. 20vPnC is given as a single IM dose.

Table 36: Number (%) of Subjects who Received at Least 1 Study Vaccination in all Adult Clinical Studies

| Study [20vPnC Group vs Control Group]                                                 | 20rPnC n (%)   | Control (%) u   | Total (%)    |
|---------------------------------------------------------------------------------------|----------------|-----------------|--------------|
| Total Exposured                                                                       | 4552 (100.0)   | 2496 (100.0)    | 7048 (100.0) |
| Phase l                                                                               | 68 (1.5)       | 67 (2.7)        | 135 (1.9)    |
| B7471001 [20vPnC vs Tdap]                                                             | 33 (0.7)       | 33 (1.3)        | 66 (0.9)     |
| B7471005 [20vPnC vs 13vPnC]                                                           | 35 (0.8)       | 34 (1.4)        | 69 (1.0)     |
| Phase 2                                                                               | 221 (4.9)      | 222 (8.9)       | 443 (6.3)    |
| B7471002 [20vPnC/saline Vs 13vPnC/PPSV23]                                             | 221 (4.9)      | 222 (8.9)       | 443 (6.3)    |
| Phase 3                                                                               | 4263 (93.7)    | 2207 (88.4)     | 6470 (91.8)  |
| B7471006 [20vPnC vs 13vPnC or PPSV23]                                                 | 624 (13.7)     | 249 (10.0)      | 873 (12.4)   |
| B7471007[Cohort 1: 20vPnC/saline vs 13vPnC/PPSV23; Cohorts 2 and 3: 20vPnC vs 13vPnC] | 2176 (47.8)    | 1713 (68.6)     | 3889 (55.2)  |
| B7471008 [20vPnC Lot 1, 2, and3 combined vs 13vPnC]                                   | 1463 (32.1)    | 245 (9.8)       | 1708 (24.2)  |

Because adults ≥65 years of age are at increased risk of pneumococcal disease, this is the population most often targeted by national recommendations for adult pneumococcal vaccination. For this reason, safety data are summarised separately for this age group, including both pneumococcal vaccine naïve subjects (in B7471007) and subjects with prior pneumococcal vaccination (in B7471006). The Phase 3 studies enrolled 1885 subjects ≥65 years of age; among these, 1138 received 20vPnC and 747 received control vaccine ( Table 37 ).

<div style=\"page-break-after: always\"></div>

Table 37: Number (%) of Subjects who Received at Least 1 Study Vaccination in the Phase 3 Studies Subjects ≥65 Years of Age by Study an d Pneumococcal vaccination status

| Study Prior Vaccination Status [20vPnC Group vs Control Group]   | 20vPnC n (%)   | Control n (%)   | Total n (%)   |
|------------------------------------------------------------------|----------------|-----------------|---------------|
| Total Exposure a                                                 | 1138 (100.0)   | 747 (100.0)     | 1885 (100.0)  |
| B7471006                                                         |                |                 |               |
| Prior PPSV23 (Cohort A) [20vPnC vs 13vPnC]                       | 253 (22.2)     | 122 (16.3)      | 375 (19.9)    |
| Prior 13vPnC (Cohort B) [20vPnC vs PPSV23]                       | 246 (21.6)     | 127 (17.0)      | 373 (19.8)    |
| Prior 13vPnC and PPSV23 (Cohort C) [20vPnC]                      | 125 (11.0)     |                 | 125 (6.6)     |
| B7471007                                                         |                |                 |               |
| Naïve (Cohort 1) [20vPnC/saline vs 13vPnC/PPSV23]                | 514 (45.2)     | 498 (66.7)      | 1012 (53.7)   |

Across the three Phase 3 trials, subjects were predominantly female (52.0% to 65.9% across groups defined by age and prior pneumococcal vaccination status within the 20vPnC and control vaccine groups). With regard to age, 59.8% of subjects were ≥60 years of age, 6.9% were 50 through 59 years of age, and 33.3% were 18 through 49 years of age. The Phase 3 trials were conducted in the United States and Sweden; subjects in Sweden were enrolled in B7471007 (Cohort 1 only) and B7471006 (Cohort A only). Overall, the safety populations in B7471007 and B7471008 reflected a diverse racial and ethnic distribution (80.7% white, 14.2% black, 2.1% Asian; and 10.3% Hispanic).

In B7471006, subjects were predominantly white (92.4%). Entrance criteria for this study required that subjects had previously received pneumococcal vaccination, which may have affected the racial distribution. In addition, approximately 15% of subjects in the study were enrolled at sites in Sweden.

## 2.6.8.2. Adverse events

## Data collection and analysis strategy

The methods for safety data collection and analysis were the same in all three Phase 3 trials.

Immediate reactions within the first 30 minutes after vaccination were assessed and documented as an AE or SAE, as appropriate, in the case report form (CRF).

Postvaccination safety evaluations were reported by the subject in an electronic diary as follows:

- Specific reactions and events and use of antipyretic or pain medications were reported by subjects in response to specific prompts using an electronic diary (e-diary):
- o local reactions (redness, swelling, and pain at the injection site) occurring within 10 days after vaccination
- o systemic events (fever, headache, fatigue, muscle pain, and joint pain) occurring within 7 days after vaccination
- o use of antipyretic or pain medications within 7 days after vaccination
- AEs occurring within 1 month after vaccination
- SAEs occurring within 6 months after vaccination
- NDCMCs occurring within 6 months after vaccination

<div style=\"page-break-after: always\"></div>

## Immediate adverse events

After each vaccination, subjects were observed for at least 30 minutes by site staff, who recorded AEs occurring during that time.

The proportion of subjects who reported immediate AEs after vaccination was low, both among subjects naïve to pneumococcal vaccine (≤0.2% after 20vPnC; ≤0.9% after 13vPnC) and among subjects ≥65 years of age by prior pneumococcal vaccination status (≤0.4% after 20vPnC; ≤0.8% after control vaccines).

Subjects naïve to pneumococcal vaccine (B7471007 and B7471008)

Table 38: Immediate Adverse Events Reported After Vaccination - Pneumococcal Vaccine Naïve Subjects by Study and Age Group - Safety Population

| Study Age Group                                                   | B7471007 ≥60 Years           | B7471007 ≥60 Years            | B7471007 50-59Years   | B7471007 50-59Years   | B7471007andB7471008 18-49 Years   | B7471007andB7471008 18-49 Years   |
|-------------------------------------------------------------------|------------------------------|-------------------------------|-----------------------|-----------------------|-----------------------------------|-----------------------------------|
| Vaccine Group (as Administered) System Organ Class/ PreferredTerm | 20vPnC/Saline (N=1507) n²(%) | 13vPnC/PPSV23 (N=1490) n* (%) | 20vPnC (N=334) n²(%)  | 13vPnC (N=111) n(%)   | 20vPnC (N=1798) n²(%)             | 13vPnC (N=357) n(%)               |
| Any Event                                                         | 3 (0.2)                      | 3 (0.2)                       |                       | 1 (0.9)               | 2 (0.1)                           | 1 (0.3)                           |
| GASTROINTESTINALDISORDERS                                         | 0                            | 0                             | 0                     | 0                     | 2 (0.1)                           | 0                                 |
| Nausea                                                            | 0                            | 0                             | 0                     | 0                     | 2 (0.1)                           | 0                                 |
| Vomiting                                                          | 0                            | 0                             | 0                     | 0                     | 2 (0.1)                           | 0                                 |
|                                                                   | 1(0.1)                       | 2(0.1)                        |                       | 0                     | 0                                 | 0                                 |
| Injection site pain                                               | 1(0.1)                       | 1(0.1)                        |                       | 0                     | 0                                 | 0                                 |
| Injection site swelling                                           | 0                            | 1 (0.1)                       |                       | 0                     | 0                                 | 0                                 |
| MUSCULOSKELETALANDCONNECTIVETISSUEDISORDERS                       | 2 (0.1)                      | 0                             | 0                     | 0                     | 0                                 | 0                                 |
| Joint swelling                                                    | 1(0.1)                       | 0                             | 0                     | 0                     | 0                                 | 0                                 |
| Musculoskeletal stiffness                                         | 1(0.1)                       | 0                             | 0                     | 0                     | 0                                 | 0                                 |
| NERVOUSSYSTEMDISORDERS                                            | 0                            | 1(0.1)                        | 0                     | 1(0.9)                | 0                                 | 1(0.3)                            |
| Dizziness                                                         | 0                            | 0                             |                       | 0                     | 0                                 | 1(0.3)                            |
| Headache                                                          | 0                            | 0                             | 0                     | 1(0.9)                | 0                                 | 0                                 |
| Somnolence                                                        | 0                            | 1(0.1)                        | 0                     | 0                     | 0                                 | 0                                 |

<div style=\"page-break-after: always\"></div>

Subjects ≥65 years of age by prior pneumococcal vaccination status (B7471006 and B7471007)

Table 39: Immediate Adverse Events Reported After Vaccination Subjects ≥65 Years of Age by Study and Prior Pneumococcal Vaccination Status - Safety Population

Notes:

| Study PriorPneumococcalVaccinationStatus                           | B7471007 Naive               | B7471007 Naive               | B7471006 PriorPPSV23   | B7471006 PriorPPSV23   | B7471006 Prior 13vPnC   | B7471006 Prior 13vPnC   | B7471006 Prior 13vPnC and PPSV23 20vPnC   |
|--------------------------------------------------------------------|------------------------------|------------------------------|------------------------|------------------------|-------------------------|-------------------------|-------------------------------------------|
| Vaccine Group (as Administered) System Organ Class/ Preferred Term | 20vPnC/Saline (N'=514) nb(%) | 13vPnC/PPSV23 (N'=498) nb(%) | 20vPnC (N'=253) nb (%) | 13vPnC (N'=122) n²(%)  | 20vPnC (N=246) (%)q     | PPSV23 (N=127) n²(%)    | (N=125) nb(%)                             |
| Any Event                                                          | 0                            | 1 (0.2)                      | 1 (0.4)                | 0                      | 0                       | 1 (0.8)                 | 0                                         |
| GENERALDISORDERSANDADMINISTRATIONSITE SNOICNOO                     | 0                            | 1 (0.2)                      | 0                      | 0                      | 0                       | 0                       | 0                                         |
| Injection site swelling                                            |                              | 1 (0.2)                      | 0                      | 0                      | 0                       | 0                       | 0                                         |
| METABOLISMANDNUTRITIONDISORDERS                                    | 0                            | 0                            | 1 (0.4)                | 0                      | 0                       | 0                       | 0                                         |
| Dehydration                                                        | 0                            | 0                            | 1(0.4)                 | 0                      | 0                       | 0                       | 0                                         |
| NERVOUSSYSTEMDISORDERS                                             | 0                            | 0                            | 1 (0.4)                | 0                      | 0                       | 1 (0.8)                 | 0                                         |
| Dizziness                                                          | 0                            | 0                            | 1(0.4)                 | 0                      | 0                       | 1(0.8)                  | 0                                         |
| Paraesthesia                                                       | 0                            | 0                            | 1(0.4)                 | 0                      | 0                       | 0                       | 0                                         |
| PSYCHIATRICDISORDERS                                               | 0                            | 0                            | 1(0.4)                 | 0                      | 0                       | 0                       | 0                                         |
| Anxiety                                                            | 0                            | 0                            | 1 (0.4)                | 0                      | 0                       | 0                       | 0                                         |
| VASCULARDISORDERS                                                  | 0                            | 0                            | 1(0.4)                 | 0                      | 0                       | 0                       | 0                                         |
| Hypotension                                                        | 0                            | 0                            | 1(0.4)                 | 0                      | 0                       | 0                       | 0                                         |

MedDRA (v22.1) coding dictiouary applied.

[mmediate AE refers to an AE reported in the 30-minute observation period after Vaccination (after Vaccination 1 for B7471007 Naive).

For B7471007 Naive (subset of Cohort 1), only adverse events reported after Vaccination 1 (20vPnC or 13vPnC) are included a. N= nuber of subjects in the specified group. This value is the denominator for the percentage calculations.

D. = Number of subjects reporting at least 1 occurence of the event specified. For \"Any event', n = number of subjects reporting at least 1 occwrence of any immediate adverse event.

## Solicited adverse events

## Subjects naïve to pneumococcal vaccine (B7471007 and B7471008)

Most local reactions were mild or moderate in severity. Across age groups and in both vaccine groups, the most frequently reported local reaction was pain at the injection site (55% to 79% after 20vPnC; 54% to 78% after 13vPnC), with a trend toward decreasing frequency with increasing age. Other local reactions were reported at lower frequencies (redness: 7.3% to 8.2% after 20vPnC, 5.4% to 7.3% after 13vPnC, and swelling: 7.5% to 9.1% after 20vPnC, 8.0% to 10.8% after 13vPnC). Across age groups and after either 20vPnC or 13vPnC, the median onset day for local reactions was generally between Day 1 to Day 2.5 and reactions generally resolved with a median duration between 1 to 2 days.

<div style=\"page-break-after: always\"></div>

Table 40: Local reactions, by Maximum Severity, within 10 Days after Vaccination pneumococcal vaccine naïve Subjects by Study and Age Group - Safety population

| Study Age Group                  | B7471007 ≥60 Years            | B7471007 ≥60 Years             | B7471007 50-59 Years   | B7471007 50-59 Years   | B7471007 andB7471008 18-49 Years   | B7471007 andB7471008 18-49 Years   |
|----------------------------------|-------------------------------|--------------------------------|------------------------|------------------------|------------------------------------|------------------------------------|
| Vaccine Group (as Adininistered) | 20vPnC/Saline (N=1505) (%) qI | 13vPnC/PPSV23 (N=1483) (%) ql1 | 20vPnC (N=331) nb (%)  | 13vPnC (N=111) (%) qu  | 20vPnC (N'=1791) (%) ql1           | 13vPnC (N*=355) (%) q11            |
| Rednesst                         |                               |                                |                        |                        |                                    |                                    |
| Any                              | 110 (7.3)                     | 92 (6.2)                       | 27 (8.2)               | 6 (5.4)                | 132 (7.4)                          | 26 (7.3)                           |
| Mild                             | 56 (3.7)                      | 56 (3.8)                       | 17 (5.1)               | 3 (2.7)                | 67 (3.7)                           | 14 (3.9)                           |
| Moderate                         | 42 (2.8)                      | 33 (2.2)                       | 9 (2.7)                | 3 (2.7)                | 56 (3.1)                           | 12 (3.4)                           |
| Severe                           | 12 (0.8)                      | 3 (0.2)                        | 1 (0.3)                | 0                      | 9 (0.5)                            | 0                                  |
| Swellingc                        |                               |                                |                        |                        |                                    |                                    |
| Any                              | 113 (7.5)                     | 118 (8.0)                      | 29 (8.8)               | 12 (10.8)              | 163 (9.1)                          | 35 (9.9)                           |
| Mild                             | 72 (4.8)                      | 72 (4.9)                       | 19 (5.7)               | 8 (7.2)                | 103 (5.8)                          | 23 (6.5)                           |
| Moderate                         | 36 (2.4)                      | 42 (2.8)                       | 10 (3.0)               | 4 (3.6)                | 57 (3.2)                           | 12 (3.4)                           |
| Severe                           | 5 (0.3)                       | 4 (0.3)                        | 0                      | 0                      | 3 (0.2)                            | 0                                  |
| Pain at injection sited          |                               |                                |                        |                        |                                    |                                    |
| Any                              | 834 (55.4)                    | 803 (54.1)                     | 240 (72.5)             | 77 (69.4)              | 1418 (79.2)                        | 276 (77.7)                         |
| Mild                             | 682 (45.3)                    | 662 (44.6)                     | 177 (53.5)             | 58 (52.3)              | 871 (48.6)                         | 172 (48.5)                         |
| Moderate                         | 149 (9.9)                     | 136 (9.2)                      | 59 (17.8)              | 18 (16.2)              | 529 (29.5)                         | 99 (27.9)                          |
| Severe                           | 3 (0.2)                       | 5 (0.3)                        | 4 (1.2)                | 1 (0.9)                | 18 (1.0)                           | 5 (1.4)                            |
| Any local reaction               | 864 (57.4)                    | 830 (56.0)                     | 241 (72.8)             | 78 (70.3)              | 1425 (79.6)                        | 276 (77.7)                         |

and 3 groups.

- a. N = number of subjects with any e-diary data reported after vaccination (after Vaccination 1 [20vPnC or 13vPnC] for B7471007 ≥60 years [Cohort 11).

This value is the denominator for the percentage calculations.

b. n = Number of subjects with the specified characteristic.

- C. Mild is &gt;2.0 to 5.0 cm; moderate is &gt;5.0 to 10.0 cm; severe is &gt;10.0 cm.
- d. Mild = does not interfere with activity; moderate = interferes with activity;, severe = prevents daily activity.
- e. Any local reaction = any pain at injection site, any swelling &gt;2.0 cm, or any redness &gt;2.0 cm during Day 1 to Day 10 after vaccination.

Most systemic events were mild or moderate in severity. Across age groups and in both vaccine groups, the most frequently reported systemic event was muscle pain (39% to 63% after 20vPnC; 37% to 65% after 13vPnC). Across the age groups, the frequency of most systemic events tended to decrease with increasing age. Fever ≥38°C was reported at low frequency (0.9% to 1.5% after 20vPnC; 0.8% to 1.1% after 13vPnC).

Across age groups and after either 20vPnC or 13vPnC, the median onset day for most systemic events was generally between Day 1 to Day 2, and systemic events generally resolved with a median duration of 1 to 2 days.

<div style=\"page-break-after: always\"></div>

Table 41: Systemic events, by maximum severity, within 7 days after vaccination pneumococcal vaccine naïve subjects by study and age group - safety population

| Study Age Group                       | B7471007 ≥60 Years              | B7471007 ≥60 Years              | B7471007 50-59 Years   | B7471007 50-59 Years    | B7471007andB7471008 18-49 Year's   | B7471007andB7471008 18-49 Year's   |
|---------------------------------------|---------------------------------|---------------------------------|------------------------|-------------------------|------------------------------------|------------------------------------|
| Vaccine Group (as Administered)       | 20vPnC/Saline (N²=1505) (%) q1I | 13vPnC/PPSV23 (N*=1483) (%) q1I | 20vPnC (N\"=331) (%) qI | 13vPnC (N*=111) (%) qlI | 20vPnC (N*=1791) nb (%)            | 13vPnC (N²=355) (%) q1I            |
| Fever                                 |                                 |                                 |                        |                         |                                    |                                    |
| ≥38.0°℃                               | 14 (0.9)                        | 12 (0.8)                        | 5 (1.5)                | 1 (0.9)                 | 22 (1.2)                           | 4 (1.1)                            |
| ≥38.0°C to 38.4°℃                     | 4 (0.3)                         | 6 (0.4)                         | 2 (0.6)                | 1 (0.9)                 | 13 (0.7)                           | 1 (0.3)                            |
| >38.4°C to 38.9°℃                     | 4 (0.3)                         | 3 (0.2)                         | 1 (0.3)                | 0                       | 5 (0.3)                            | 1 (0.3)                            |
| >38.9°C to 40.0°℃                     | 1 (0.0)                         | 0                               | 1 (0.3)                | 0                       | 4 (0.2)                            | 2 (0.6)                            |
| >40.0℃                                | 5 (0.3)                         | 3 (0.2)                         | 1 (0.3)                | 0                       | 0                                  | 0                                  |
| Fatiguec                              |                                 |                                 |                        |                         |                                    |                                    |
| Any                                   | 454 (30.2)                      | 455 (30.7)                      | 130 (39.3)             | 40 (36.0)               | 836 (46.7)                         | 155 (43.7)                         |
| Mild                                  | 243 (16.1)                      | 260 (17.5)                      | 70 (21.1)              | 20 (18.0)               | 422 (23.6)                         | 82 (23.1)                          |
| Moderate                              | 193 (12.8)                      | 177 (11.9)                      | 57 (17.2)              | 17 (15.3)               | 383 (21.4)                         | 65 (18.3)                          |
| Severe                                | 18 (1.2)                        | 18 (1.2)                        | 3 (0.9)                | 3 (2.7)                 | 31 (1.7)                           | 8 (2.3)                            |
| Headachec                             |                                 |                                 |                        |                         |                                    |                                    |
| Any                                   | 324 (21.5)                      | 345 (23.3)                      | 107 (32.3)             | 40 (36.0)               | 657 (36.7)                         | 130 (36.6)                         |
| Mild                                  | 233 (15.5)                      | 252 (17.0)                      | 68 (20.5)              | 24 (21.6)               | 401 (22.4)                         | 84 (23.7)                          |
| Moderate                              | 81 (5.4)                        | 88 (5.9)                        | 36 (10.9)              | 15 (13.5)               | 224 (12.5)                         | 43 (12.1)                          |
| Severe                                | 10 (0.7)                        | 5 (0.3)                         | 3 (0.9)                | 1 (0.9)                 | 32 (1.8)                           | 3 (0.8)                            |
| Muscle painc                          |                                 |                                 |                        |                         |                                    |                                    |
| Any                                   | 588 (39.1)                      | 553 (37.3)                      | 165 (49.8)             | 55 (49.5)               | 1127 (62.9)                        | 230 (64.8)                         |
| Mild                                  | 435 (28.9)                      | 398 (26.8)                      | 112 (33.8)             | 35 (31.5)               | 682 (38.1)                         | 141 (39.7)                         |
| Moderate                              | 147 (9.8)                       | 148 (10.0)                      | 51 (15.4)              | 19 (17.1)               | 425 (23.7)                         | 83 (23.4)                          |
| Severe                                | 6 (0.4)                         | 7 (0.5)                         | 2 (0.6)                | 1 (0.9)                 | 20 (1.1)                           | 6 (1.7)                            |
| Joint painc                           |                                 |                                 |                        |                         |                                    |                                    |
| Any                                   | 190 (12.6)                      | 203 (13.7)                      | 51 (15.4)              | 23 (20.7)               | 290 (16.2)                         | 54 (15.2)                          |
| Mild                                  | 104 (6.9)                       | 106 (7.1)                       | 35 (10.6)              | 14 (12.6)               | 166 (9.3)                          | 29 (8.2)                           |
| Moderate                              | 81 (5.4)                        | 94 (6.3)                        | 16 (4.8)               | 8 (7.2)                 | 118 (6.6)                          | 22 (6.2)                           |
| Severe                                | 5 (0.3)                         | 3 (0.2)                         | 0                      | 1 (0.9)                 | 6 (0.3)                            | 3 (0.8)                            |
| Any systemic eventd                   | 831 (55.2)                      | 822 (55.4)                      | 230 (69.5)             | 75 (67.6)               | 1377 (76.9)                        | 269 (75.8)                         |
| Use of antipyretic or pain medication | 278 (18.5)                      | 303 (20.4)                      | 81 (24.5)              | 31 (27.9)               | 406 (22.7)                         | 70 (19.7)                          |

Note: The 20vPnC group from B7471008 is the pooled 20vPnC group, which includes subjects from the 20vPnC Lot 1, 2, and3groups.

a. N = number of subjects with any e-diary data reported after vaccination (after Vaccination 1 [20vPnC or 13vPnC] for B7471007 ≥60 years [Cohort 1]).

Thisvalue is the denominatorfor thepercentage calculations.

b. n =Number of subjects with the specified characteristic.

C. Mild = does not interfere with activity; moderate = some interference with activity; severe = prevents daily activity.

d. Any systemic event = any fever ≥38.0°C, any fatigue, any headache, any joint pain, or any muscle pain during Day 1 toDay 7 after vaccination.

e. Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect yes responses (ie, number of eventsreported)

<div style=\"page-break-after: always\"></div>

## Subjects ≥65 years of age by prior pneumococcal vaccination status (B7471006 and B7471007)

Most local reactions were mild or moderate in severity. In all groups defined by prior pneumococcal vaccination status and after both 20vPnC and control vaccines, the most frequently reported local reaction was pain at the injection site (44% to 61% after 20vPnC; 43% to 56% after control vaccines). Other local reactions were reported at much lower frequencies (redness: 4.8% to 8.6% after 20vPnC; 2.5% to 13% after control vaccines; swelling: 4.0% to 9.9% after 20vPnC; 6.6% to 14% after control vaccines). In B7471006, after either 20vPnC or control vaccine, and across the cohorts, the median onset day for local reactions was Day 1 or Day 2, and reactions generally resolved with a median duration of 1 to 2 days.

Table 42: Local Reactions, by Maximum Severity, Within 10 Days After Vaccination Subjects ≥65 Years of Age by Study and Prior Pneumococcal Vaccination Status - Safety Population

| Study Prior Pneumococcal Vaccination Status   | B7471007 Naive               | B7471007 Naive               | B7471006 Prior PPSV23   | B7471006 Prior PPSV23         | B7471006 Prior 13rPnC                    | B7471006 Prior 13rPnC        | B7471006 Prior 13vPnC and PPSV23   |
|-----------------------------------------------|------------------------------|------------------------------|-------------------------|-------------------------------|------------------------------------------|------------------------------|------------------------------------|
| Vaccine Group (as Administered)               | 20vPnC/Saline (N=514) nb (%) | 13+PnC/PPSV23 (N=493) nb (%) | 20rPnC nb (%)           | 13rPnC (N=153) (N=121) nb (%) | 20rPnC n(%)                              | PPSV23 (N=245)(N=126) (%) q\" | 20rPnC (N=125) nb (%)              |
| Redness\"                                      |                              |                              |                         |                               |                                          |                              |                                    |
| Any                                           | 40 (7.8)                     | 30 (6.1)                     | 20 (7.9)                | 3 (2.5)                       | 21 (8.6)                                 | 16 (12.7)                    | 6 (4.8)                            |
| Mild                                          | 19 (3.7)                     | 16 (3.2)                     | 9 (3.6)                 | 2 (1.7)                       | 7 (2.9)                                  | 6 (4.8)                      | 2 (1.6)                            |
| Moderate                                      | 14 (2.7)                     | 13 (2.6)                     | 8 (3.2)                 | 1 (0.8)                       | 13 (5.3)                                 | 9 (7.1)                      | 4 (3.2)                            |
| Severe                                        | 7 (1.4)                      | 1 (0.2)                      | 3 (1.2)                 | 0                             | 1 (0.4)                                  | 1 (0.8)                      | 0                                  |
| Swelling\"                                     |                              |                              |                         |                               |                                          |                              |                                    |
| Any                                           | 34 (6.6)                     | 36 (7.3)                     | 25 (9.9)                | 8 (6.6)                       | 23 (9.4)                                 | 18 (14.3)                    | 5 (4.0)                            |
| Mild                                          | 20 (3.9)                     | 24 (4.9)                     | 13 (5.1)                | 8 (6.6)                       | 14 (5.7)                                 | 8 (6.3)                      | 2 (1.6)                            |
| Moderate                                      | 11 (2.1)                     | 10 (2.0)                     | 9 (3.6)                 | 0                             | 9 (3.7)                                  | 9 (7.1)                      | 3 (2.4)                            |
| Severe                                        | 3 (0.6)                      | 2 (0.4)                      | 3 (1.2)                 | 0                             | 0                                        | 1 (0.8)                      | 0                                  |
| Pain at injection sited                       |                              |                              |                         |                               |                                          |                              |                                    |
| Any                                           | 224 (43.6)                   | 217 (44.0)                   |                         |                               | 127 (50.2)52 (43.0)150 (61.2)71 (56.3)   |                              | 66 (52.8)                          |
| Mild                                          | 184 (35.8)                   | 178 (36.1)                   |                         |                               | 116 (45.8) 47 (38.8)134 (54.7) 51 (40.5) |                              | 59 (47.2)                          |
| Moderate                                      | 39 (7.6)                     | 37 (7.5)                     | 11 (4.3)                | 4 (3.3)                       | 15 (6.1)                                 | 18 (14.3)                    | 7 (5.6)                            |
| Severe                                        | 1 (0.2)                      | 2 (0.4)                      | 0                       | 1 (0.8)                       | 1 (0.4)                                  | 2 (1.6)                      | 0                                  |
| Any local reaction                            | 239 (46.5)                   | 226 (45.8)                   |                         |                               | 134 (53.0)53 (43.8)157 (64.1)73 (57.9)   |                              | 68 (54.4)                          |

a. N= number of subjects with any e-diary data reported after vaccination (after Vaccination 1 [20vPnC or l3vPnC] for B7471007 Naive [subset of

Cohort ll). This value is the denominator for the percentage calculations.

b. n = Number of subjects with the specified characteristic.

- C. Mild is &gt;2.0 to 5.0 cm; moderate is &gt;5.0 to 10.0 cm; severe is &gt;10.0 cm.
- d. Mild = does not interfere with activity; mo derate = interferes with activity;, severe = prevents daily activity.
- e. Any loeal reaction = any pain at injection site, any swelling &gt;2.0 cm, or any redness &gt;2.0 em during Day 1 to Day 10 after vaccination.

Most systemic events were mild or moderate in severity. In all groups defined by prior pneumococcal vaccination status and after both 20vPnC and control vaccines, the most frequently reported type of systemic event was muscle pain (32% to 38% after 20vPnC; 31% to 46% after control vaccines). Fever ≥38°C was reported at low frequency (0.0% to 1.2% after 20 vPnC; 0.0% to 1.6% after control vaccines). In B7471006, in the 20vPnC and control vaccine groups, the median onset day for each type of systemic event was between Day 1 and Day 3.5. Systemic events generally resolved with a median duration of 1 to 2 days.

<div style=\"page-break-after: always\"></div>

Table 43: Systemic Events, by Maximum Severity, Within 7 Days After Vaccination Subjects ≥65 Years of Age by Study and Prior Pneumococcal Vaccination Status - Safety Population

| Study Prior Pneumococcal Vaccination Status   | B7471007 Naive   | B7471007 Naive                            | B7471006 Prior PPSV23   | B7471006 Prior PPSV23   | B7471006 Prior 13vPnC                | B7471006 Prior 13vPnC                | B7471006 Prior 13vPnC and PPSV23   |
|-----------------------------------------------|------------------|-------------------------------------------|-------------------------|-------------------------|--------------------------------------|--------------------------------------|------------------------------------|
| Vaccine Group (as Administered)               | (N=514) nb (%)   | 20vPnC/Saline 13vPnC/PPSV23 (N=493) nb(%) | 20vPnC (N=153) nb (%)   | 13rPnC (N=121) nb (%)   | 20vPnC (N=245) nb(%)                 | PPSV23 (N=126) nb(%)                 | 20vPnC (N=125) nb (%)              |
| Fever                                         |                  |                                           |                         |                         |                                      |                                      |                                    |
| ≥38.0°℃                                       | 6 (1.2)          | 8 (1.6)                                   | 2 (0.8)                 | 0                       | 0                                    | 2 (1.6)                              | 0                                  |
| ≥38.0°C to 38.4°℃                             | 1 (0.2)          | 3 (0.6)                                   | 2 (0.8)                 | 0                       | 0                                    | 1 (0.8)                              | 0                                  |
| >38.4°C to 38.9°C                             | 1 (0.2)          | 2 (0.4)                                   | 0                       | 0                       | 0                                    | 1 (0.8)                              | 0                                  |
| >38.9°C to 40.0°C                             | 1 (0.2)          | 0                                         | 0                       | 0                       | 0                                    | 0                                    | 0                                  |
| >40.0°C                                       | 3 (0.6)          | 3 (0.6)                                   | 0                       | 0                       | 0                                    | 0                                    | 0                                  |
| Fatiguec                                      |                  |                                           |                         |                         |                                      |                                      |                                    |
| Any                                           | 130 (25.3)       | 134 (27.2)                                |                         |                         |                                      | 73 (28.9)27 (22.3)76 (31.0)42 (33.3) | 41 (32.8)                          |
| Mild                                          | 64 (12.5)        | 77 (15.6)                                 | 45 (17.8)               | 12 (9.9)                |                                      | 48 (19.6)25 (19.8)                   | 24 (19.2)                          |
| Moderate                                      | 64 (12.5)        | 51 (10.3)                                 | 28 (11.1)               | 12 (9.9)                |                                      | 25 (10.2)17 (13.5)                   | 15 (12.0)                          |
| Severe                                        | 2 (0.4)          | 6 (1.2)                                   | 0                       | 3 (2.5)                 | 3 (1.2)                              | 0                                    | 2 (1.6)                            |
| Headache\"                                     |                  |                                           |                         |                         |                                      |                                      |                                    |
| Any                                           | 81 (15.8)        | 95 (19.3)                                 |                         |                         |                                      | 45 (17.8)22 (18.2)33 (13.5)27 (21.4) | 24 (19.2)                          |
| Mild                                          | 59 (11.5)        | 67 (13.6)                                 |                         | 32 (12.6)15 (12.4)      | 24 (9.8)                             | 26 (20.6)                            | 16 (12.8)                          |
| Moderate                                      | 18 (3.5)         | 26 (5.3)                                  | 12 (4.7)                | 7 (5.8)                 | 9 (3.7)                              | 1 (0.8)                              | 7 (5.6)                            |
| Severe                                        | 4 (0.8)          | 2 (0.4)                                   | 1(0.4)                  | 0                       | 0                                    | 0                                    | 1 (0.8)                            |
| Muscle pain*                                  |                  |                                           |                         |                         |                                      |                                      |                                    |
| Any                                           | 164 (31.9)       | 159 (32.3)                                |                         |                         | 81 (32.0)38 (31.4)83 (33.9)58 (46.0) |                                      | 47 (37.6)                          |
| Mild                                          | 119 (23.2)       | 114 (23.1)                                |                         |                         |                                      | 66 (26.1)29 (24.0)62 (25.3)40 (31.7) | 35 (28.0)                          |
| Moderate                                      | 44 (8.6)         | 41 (8.3)                                  | 14 (5.5)                | 6 (5.0)                 | 21 (8.6)                             | 15 (11.9)                            | 11 (8.8)                           |
| Severe                                        | 1 (0.2)          | 4 (0.8)                                   | 1 (0.4)                 | 3 (2.5)                 | 0                                    | 3 (2.4)                              | 1 (0.8)                            |
| Joint pain                                    |                  |                                           |                         |                         |                                      |                                      |                                    |
| Any                                           | 69 (13.4)        | 59 (12.0)                                 | 17 (6.7)                | 13 (10.7)               |                                      | 29 (11.8)20 (15.9)                   | 21 (16.8)                          |
| Mild                                          | 30 (5.8)         | 32 (6.5)                                  | 12 (4.7)                | 6 (5.0)                 | 19 (7.8)                             | 13 (10.3)                            | 16 (12.8)                          |
| Moderate                                      | 37 (7.2)         | 26 (5.3)                                  | 5 (2.0)                 | 6 (5.0)                 | 10 (4.1)                             | 7 (5.6)                              | 5 (4.0)                            |
| Severe                                        | 2 (0.4)          | 1 (0.2)                                   | 0                       | 1 (0.8)                 | 0                                    | 0                                    | 0                                  |
| Any systemic eventd                           | 245 (47.7)       | 247 (50.1)                                | 131 (51.8)              | 53 (43.8)               | 123 (50.2)                           | 75 (59.5)                            | 66 (52.8)                          |
| Use of antipyretic or pain medication         | 70 (13.6)        | 80 (16.2)                                 |                         |                         |                                      | 40 (15.8)18 (14.9)42 (17.1)25 (19.8) | 22 (17.6)                          |

Supplementary data from phase 1/2 studies B7471001, B7471002 and B7471005

## B7471001

Local reactions were reported by a similar proportion of subjects in the 20vPnC group and Tdap group with the majority being either mild or moderate in severity. One subject who was in the 20vPnC group reported severe pain at the injection site and severe limitation of arm movement. The most commonly reported local reaction in the 20vPnC and Tdap group was pain at the injection site (69.7% and 63.6%, respectively), followed by limitation of arm movement (36.4% and 18.2%, respectively). Redness and swelling were reported by 1 (3.0%) subject each in the 20vPnC group, and by no subjects in the Tdap group.

<div style=\"page-break-after: always\"></div>

Systemic events were reported by a higher proportion of subjects in the 20vPnC group (72.7%) compared to the Tdap group (57.6%). The majority of systemic events were mild or moderate in severity. The most commonly reported systemic event in the 20vPnC and Tdap groups was new muscle pain (45.5% and 42.4%, respectively), followed by fatigue and headache (each reported by 39.4% and 30.3% of subjects in the 20vPnC and Tdap group, respectively). Fever was reported by 1 (3.0%) subject each in the 20vPnC group. One (1) subject who received 20vPnC reported a severe headache on Day 3 after vaccination and 1 subject who received Tdap report severe fatigue on Day 7 after vaccination.

A total of 21.2% of subjects in the 20vPnC group and 18.2% of subjects in the Tdap group reported the use of antipyretic or pain medication. The median day of onset for the use of medication to treat pain/fever was similar between subjects who received 20vPnC (Day 3) and Tdap (Day 4).

## B7471002

The proportions of participants who reported prompted local reactions within 10 days after vaccination with 20vPnC or 13vPnC by maximum severity were similar in the 2 groups (60.9% in the 20vPnC/Saline group and 56.8 in the 13vPnC/PPSV23 group). The most frequent local reaction reported was pain at injection site, and most local reactions were mild or moderate in severity. Redness was observed slightly more often in 20vPnC higher (11.4%) compared to control (6.8%). The proportions and maximum severity of prompted systemic events reported within 7 days after Vaccination 1 were similar for the 2 groups (54.5% in the 20vPnC/Saline group and 55.9% in the 13vPnC/PPSV23 group). The most frequent systemic event reported was muscle pain, and most systemic events were mild or moderate in severity. Muscle pain was slightly higher in 20vPnC (43.2%) compared to control vaccine group (36.5%).

## B7471005

The proportions of participants who reported prompted local reactions within 14 days after vaccination by maximum severity in the 20vPnC and c7vPnC groups were similar to the 13vPnC group. The most frequent local reaction reported was pain at injection site (77.1% in the 20vPnC group; 76.5% in the 20vPnC group; 79.4% in the 13vPnC group). Most local reactions were mild or moderate in severity. Swelling was reported by 2 subjects in each arm (&lt;6%). Redness was reported by 2 subjects in 20vPnC and c7vPnC groups, whereas no events of redness were reported in 13vPnC group. The majority of local reactions had a median day of onset of between 1 to 3 days after vaccination. The majority of local reactions generally resolved with median durations between 1 to 3 days.

The proportions and maximum severity of prompted systemic events reported within 14 days after vaccination in the 20vPnC and c7vPnC groups were mostly similar to the 13vPnC group, except that a higher number of participants reported headache (mostly mild) in the 20vPnC group (13 out of 35 [37.1%] participants) compared to the c7vPnC group (8 out of 34 [23.5%] participants) and 13vPnC group (5 out of 34 [14.7%] participants). The most frequent systemic event reported was muscle pain (57.1% in the 20vPnC group; 35.3% in the c7vPnC group; 52.9% in the 13vPnC group). Most systemic events were mild or moderate in severity. The majority of systemic events had a median day of onset of between 1 to 2.5 days after vaccination, with the exception of headache (5 days in the 20vPnC groups, 7 days in the 13vPnC group) , and generally resolved with median durations between 1 to 4 days.

## Unsolicited adverse events

Subjects naïve to pneumococcal vaccine (B7471007 and B7471008)

Only AEs (MedDRA Preferred Terms) reported for more than 1% of subjects in either vaccine group within each age group are presented here ( Table 44 ).

<div style=\"page-break-after: always\"></div>

The proportions of subjects reporting any AE within 1 month after vaccination were similar across age groups and were similar for subjects who received 20vPnC (8.4% to 10%) and 13vPnC (7.3% to 11%). Overall, the AEs reported were generally diseases and conditions often observed in adults in these age groups. The most frequently reported AEs were in the Infections and Infestations SOC (3.1% to 5.1% after 20vPnC; 3.2% to 5.4% after 13vPnC). Few AEs (MedDRA Preferred Terms) were reported for more than 1% of subjects in either vaccine group within each age group.

Table 44 : Adverse Events Reported in ≥1% Subjects in At Least One Group From Vaccination to 1 Month After Vaccination - Pneumococcal Vaccine Naïve Subjects by Study and Age Group -Safety Population

| Study Age Group                              | B7471007 260 Years     | B7471007 260 Years      | B7471007 50-59 Years   | B7471007 50-59 Years   | B7471007andB7471008 18-49 Years   | B7471007andB7471008 18-49 Years   |
|----------------------------------------------|------------------------|-------------------------|------------------------|------------------------|-----------------------------------|-----------------------------------|
| Vaccine Group (asAdministered)               | 20vPuC/Saline (N=1507) | 13vPnC/PPSV/23 (N=1490) | 20vPuC (N=334)         | 13vPnC (N=111)         | 20vPuC (N=1798)                   | 13vPnC (N=357)                    |
| System Organ Class/ Preferred Term Any Event | n² (%6)                | n*(%)                   | n²(%)                  | n²(96)                 | n²(%)                             | n*(46)                            |
|                                              | 148 (9.8)              | 166 (11.1)              | 34 (10.2)              | 9 (8.1)                | 151 (8.4)                         | 26 (7.3)                          |
| NFECTIONSANDINFESTATIONS                     | 46 (3.1)               | 47 (3.2)                | 17 ( 5.1)              | 6 (5.4)                | 74 (4.1)                          | 14(3.9)                           |
| Upper respiratory tract infection            | 12 (0.8)               | 8 (0.5)                 | 4(1.2)                 | 3 (2.7)                | 16 (0.9)                          | 1(0.3)                            |
| INIURY.POISONINGANDPROCEDURAL COMPLICATIONS  | 12 (0.8)               | 23 (1.5)                | 6 (1.8)                |                        | 13 (0.7)                          | 1(0.3)                            |
| Fall                                         | 5 (0.3)                | 7(0.5)                  | 4(1.2)                 | 0                      | 3(0.2)                            |                                   |

MedDRA (v22.1) coding dictionary applied.

Notes:

For B7471007≥60 years (Cohort 1).only adverse events reported after Vaccination 1 (20vPnCor 13vPnC)are included a. N= mwber of subjects in the specified group. This vahue is the denominator for the percentage calculations.

Ihe 20vPnC group from B7471008 is the pooled 20vPnC group, which includes subjects from the 20vPnC Lot 1, 2, and 3 groups.

b. n = Number of subjects reporting at least 1 occurence of the event specified. For Any event', n = number of subjects reporting at least 1 occuwrence of amy adverse event.

Subjects ≥65 years of age by prior pneumococcal vaccination status (B7471006 and B7471007)

The proportions of subjects reporting any AE within 1 month after vaccination were similar for subjects who received 20vPnC (4.9% to 10%) or control vaccines (9.0% to 12%). Overall, the AEs reported were generally the types of diseases and conditions often observed in adults ≥65 years of age. The most frequently reported AEs were in the Infections and Infestations SOC (1.2% to 3.2% after 20vPnC; 1.6% to 4.9% after control vaccines). Few AEs (MedDRA Preferred Terms) were reported for more than 1% of subjects in any vaccine group.

Table 45: Adverse Events Rep orted in ≥1% Subjects in At Least One Group From Vaccination to 1 Month After Vaccination Subjects ≥65 years of age by study and prior pneumococcal vaccination status-Safety Population

| Study PriorPneumococcalVaccinationStatus   | B7471007 Naive        | B7471007 Naive         | B7471006 PriorPPSV23   | B7471006 PriorPPSV23   | B7471006 Prior13vPnC   | B7471006 Prior13vPnC   | B7471006 Prior13vPnC andPPSV23   |
|--------------------------------------------|-----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|----------------------------------|
| VaccineGroup(asAdministered)               | 20vPnC/Saline (N=514) | 13vPnC/PPSV23 (N²=498) | 20vPnC (N=253)         | 13vPnC (N=122)         | 20vPnC (N=246)         | PPSV23 (N=127)         | 20vPnC (N'=125)                  |
| SystemOrganClass/ PreferredTerm            | (%) qI                | (%) qI                 | (%) q1                 | (%) q1                 | n (%)                  | (%) q                  | (%)                              |
| Any Event                                  | 47 (9.1)              | 58 (11.6)              | 19 (7.5)               | 11 (9.0)               | 12 (4.9)               | 14 (11.0)              | 13 (10.4)                        |
| INFECTIONSANDINFESTATIONS                  | 14 (2.7)              | 15 (3.0)               | 8 (3.2)                | 6 (4.9)                | 3 (1.2)                | 2 (1.6)                | 3 (2.4)                          |
| Nasopharymngitis                           | 1(0.2)                | 4 (0.8)                | 3(1.2)                 | 1 (0.8)                | 0                      | 0                      | 0                                |
| Urinary tract infection                    | 1(0.2)                | 1(0.2)                 | 0                      | 2(1.6)                 | 1(0.4)                 | 0                      | 1 (0.8)                          |
| NERVOUSSYSTEMDISORDERS                     | 3 (0.6)               | 4 (0.8)                | 4 (1.6)                | 0                      | 3 (1.2)                | 2 (1.6)                | 0                                |
| Dizziness                                  | 0                     | 0                      | 2 (0.8)                | 0                      | 1(0.4)                 | 2 (1.6)                | 0                                |

MedDRA (v22.1)codingdictionary applied.

Notes:

ForB7471007Naive (subset of Cohort 1),only adverse events reported after Vaccination 1 (20vPnC or 13vPnC) are included.

a. N= number of subjects in the specified group.This value is the denominator for the percentage calculations.

b. n=Number of subjects reporting at least 1 occurence of the event specified.For \"Any event\", n= number of subjects reporting at least 1 occuurence of any adverse event.

<div style=\"page-break-after: always\"></div>

## Supplementary data from phase 1/2 studies B7471001, B7471002 and B7471005

B7471001: In the 20vPnC and the Tdap vaccine groups, 15 (45.5%) and 11 (33.3%) subjects reported AEs within 1 month after vaccination. The most frequently reported AEs in both the 20vPnC and Tdap groups were in the gastrointestinal disorders SOC (15.2% and 9.1% of subjects, respectively). The most frequently reported AEs in the 20vPnC group (reported by more than 1 subject) were dyspepsia, viral upper respiratory tract infection, headache, insomnia and dysmenorrhea (2 [6.1%] subjects each). All other AEs in both the 20vPnC and Tdap groups were reported in single subjects.

B7471002: At 1 month after Vaccination 1, the proportions of participants reporting any AEs were similar in the 2 groups (12.2% in the 20vPnC/Saline group and 13.1% in the 13vPnC/PPSV23 group). From Vaccination 2 to 1 month after Vaccination 2, the proportions of participants reporting any AEs were higher in the 13vPnC/PPSV23 group than in 20vPnC/saline group, particularly in system organ class (SOC) of general disorders and administration site conditions, which may be expected as one group received saline while the other received PPSV23 (7% in the 20vPnC/Saline group and 18.7 % in the 13vPnC/PPSV23 group). One month after participants received each vaccination, infections and infestations were the most frequently reported types of AEs by SOC in both groups. The most frequently reported AEs by preferred term within 1 month after each vaccination was upper respiratory tract infection in both groups, whereas injection site pain, and injection site swelling were also frequently reported in the 13vPnC/PPSV23 group 1 month after Vaccination 2.

B7471005: At 1 month after vaccination, the proportions of participants reporting any AEs were similar in the vaccine groups i.e. 2/35 (5.7%) in the 20vPnC group versus 3/34 (8.8%), with no more than 3 participants from each vaccine group reporting any AEs. No PT was reported in more than 1 participant. The most frequently reported AEs.

## Related adverse events

## Subjects naïve to pneumococcal vaccine (B7471007 and B7471008)

The proportions of subjects reporting any AE occurring within 1 month after vaccination and considered by the investigator to be related to study vaccine were low and were similar after 20vPnC (≤0.9%) or 13vPnC (≤1.5%) and across age groups ( Table 46 ). The most frequently reported types of AEs considered by the investigator to be related to study vaccine were injection site reactions in the SOC of general disorders and administration site conditions.

Subjects ≥65 years of age by prior pneumococcal vaccination status (B7471006 and B7471007)

AEs considered related to study vaccine were reported for ≤1.6% of subjects after 20vPnC and for ≤2.4% after control vaccines ( Table 47 ).

<div style=\"page-break-after: always\"></div>

Table 46: Related Adverse Events Reported From Vaccination to 1 Month After Vaccination Pneumococcal Vaccine Naïve Subjects by Study and Age Group -Safety Population

| Study Age Group                                              | B7471007 ≥60 Years      | B7471007 ≥60 Years      | B7471007 50-59 Years   | B7471007 50-59 Years   | B7471007andB7471008 18-49 Years   | B7471007andB7471008 18-49 Years   |
|--------------------------------------------------------------|-------------------------|-------------------------|------------------------|------------------------|-----------------------------------|-----------------------------------|
| Vaccine Group (as Administered)                              | 20vPnC/Saline (N*=1507) | 13vPnC/PPSV23 (N*=1490) | 20vPnC (N²=334)        | 13vPnC (N*=111)        | 20vPnC (N*=1798)                  | 13vPnC (N\"=357)                   |
| SystemOrganClass/ PreferredTerm                              | (%) qI                  | nb (%)                  | (%) q1I                | (%) qlI                | (%) q1I                           | (%) qI                            |
| Swelling                                                     | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Vaccination site pruritus                                    | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Vaccination site swelling                                    | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| INFECTIONSANDINFESTATIONS                                    | 0                       | 1(0.1)                  | 0                      | 0                      | 0                                 | 0                                 |
| Upper respiratory tract infection                            | 0                       | 1(0.1)                  | 0                      | 0                      | 0                                 | 0                                 |
| INJURY,POISONINGANDPROCEDURAL COMPLICATIONS                  | 0                       | 1(0.1)                  | 0                      | 0                      | 0                                 | 0                                 |
| Contusion                                                    | 0                       | 1(0.1)                  | 0                      | 0                      | 0                                 | 0                                 |
| MUSCULOSKELETALANDCONNECTIVETISSUE DISORDERS                 | 2 (0.1)                 | 1(0.1)                  | 0                      | 0                      | 2 (0.1)                           | 1 (0.3)                           |
| Muscle oedema                                                | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Musculoskeletal pain                                         | 0                       | 0                       | 0                      | 0                      | 0                                 | 1(0.3)                            |
| Musculoskeletal stiffness                                    | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Myalgia                                                      | 0                       | 1(0.1)                  | 0                      | 0                      | 1(0.1)                            | 0                                 |
| Neck pain                                                    | 0                       | 0                       | 0                      | 0                      | 0                                 | 1(0.3)                            |
| Pain in extremity                                            | 0                       | 0                       | 0                      | 0                      | 1(0.1)                            | 0                                 |
| NEOPLASMSBENIGN,MALIGNANTAND UNSPECIFIED(INCLCYSTSANDPOLYPS) | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Lipoma                                                       | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| NERVOUSSYSTEMDISORDERS                                       | 1(0.1)                  | 4 (0.3)                 | 0                      | 0                      | 2(0.1)                            | 1(0.3)                            |
| Dizziness                                                    | 0                       | 0                       | 0                      | 0                      | 0                                 | 1(0.3)                            |
| Dysgeusia                                                    | 1 (0.1)                 | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Headache                                                     | 0                       | 3 (0.2)                 | 0                      | 0                      | 1(0.1)                            | 0                                 |
| Migraine                                                     | 0                       | 0                       |                        | 0                      | 1(0.1)                            | 0                                 |
| Somnolence                                                   | 0                       | 1(0.1)                  | 0                      | 0                      | 0                                 | 0                                 |
| PSYCHIATRICDISORDERS                                         | 1(0.1)                  | 0                       | 0                      | 0                      | 1(0.1)                            | 0                                 |
| Anxiety RESPIRATORY,THORACICANDMEDIASTINAL                   | 1(0.1) 0                | 0 1(0.1)                | 0                      | 0                      | 1(0.1)                            | 0 0                               |
| DISORDERS                                                    |                         |                         | 0                      | 0                      | 0                                 | 0                                 |
| Bronchialhyperreactivity                                     | 0                       | 1 (0.1)                 | 0                      | 0                      | 0                                 |                                   |
| SKINANDSUBCUTANEOUSTISSUEDISORDERS                           | 3 (0.2)                 | 3 (0.2)                 | 1 (0.3)                | 0                      | 3 (0.2)                           | 0                                 |
| Dermatitis contact Erythema                                  | 0                       | 1 (0.1)                 | 0                      | 0                      | 0                                 | 0                                 |
|                                                              | 0                       | 1 (0.1)                 | 1 (0.3)                | 0                      | 0                                 | 0                                 |
| Hyperhidrosis                                                | 1(0.1)                  | 0                       | 0                      | 0                      | 0                                 | 0                                 |
| Pruritus                                                     | 2 (0.1) 0               | 0                       | 0                      | 0                      | 1(0.1)                            | 0                                 |
| Rash                                                         |                         | 1(0.1)                  | 0                      | 0                      | 2(0.1)                            | 0                                 |
| Urticaria                                                    | 0                       | 1(0.1)                  | 0                      | 0                      | 0                                 | 0                                 |

Notes:

For B7471007≥60years (Cohort 1),only adverse events reported afterVaccination 1 (20vPnC or 13vPnC)are included.

MedDRA (v22.1) coding dictionary applied.

The 20vPnC group from B7471008 is the pooled 20vPnC group,which includes subjects from the 20vPnC Lot 1, 2, and 3 groups.

b. n=Number of subjects reporting at least 1 occurrence of the event specified.For\"Any event\", n= number of subjects reporting at least 1 occurrence of any related adverse event.

a. N =number of subjects in the specified group.This value is the denominator for the percentage calculations.

<div style=\"page-break-after: always\"></div>

Table 47: Related Adverse Events Reported From Vaccination to 1 Month After Vaccination Subjects ≥65 years of age by study and prior pneumococcal vaccination status -Safety Population

| Study PriorPneumococcalVaccinationStatus         | B7471007 Naive        | B7471007 Naive         | B7471006 Prior PPSV23   | B7471006 Prior PPSV23   | B7471006 Prior 13vPnC   | B7471006 Prior 13vPnC   | B7471006 Prior 13vPnC and PPSV23   |
|--------------------------------------------------|-----------------------|------------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------------------------|
| Vaccine Group (as Adininistered)                 | 20vPnC/Saline (N=514) | 13vPnC/PPSV23 (N*=498) | 20vPnC (N=253)          | 13vPnC (N*=122)         | 20vPnC (N=240)          | PPSV23 (N=127)          | 20vPnC (N*=125)                    |
| SystemOrgan Class/ Preferred Term                | nb(%)                 | (%) qI                 | (%) q11                 | nb(%)                   | nb(%)                   | nb (%)                  | (%) qI                             |
| Any Event                                        | 5 (1.0)               | 9 (1.8)                | 1 (0.4)                 | 0                       | 4 (1.6)                 | 3 (2.4)                 | 0                                  |
| GASTROINTESTINALDISORDERS                        | 0                     | 0                      | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| Diamhoea                                         | 0                     | 0                      | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| GENERALDISORDERSAND ADMINISTRATIONSITECONDITIONS | 4 (0.8)               | 8 (1.6)                | 1(0.4)                  | 0                       | 2(0.8)                  | 1(0.8)                  | 0                                  |
| Fatigue                                          | 0                     | 2 (0.4)                | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Feeling abnormal                                 | 1(0.2)                | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Injection site bruising                          | 0                     | 1 (0.2)                | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Injection site erythema                          | 0                     | 0                      | 0                       | 0                       | 1 (0.4)                 | 1 (0.8)                 | 0                                  |
| Injection site pain                              | 1 (0.2)               | 1(0.2)                 | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Injection site pruritus                          | 0                     | 2 (0.4)                | 1(0.4)                  | 0                       | 1(0.4)                  | 0                       | 0                                  |
| Injection site reaction                          | 0                     | 1 (0.2)                | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Injection site swelling                          | 0                     | 1(0.2)                 | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Injection site warmth                            | 0                     | 1(0.2)                 | 1(0.4)                  | 0                       | 0                       | 0                       | 0                                  |
| Pain                                             | 1(0.2)                | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Swelling                                         | 1(0.2)                | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| MUSCULOSKELETALAND CONNECTIVETISSUEDISORDERS     | 1(0.2)                | 0                      | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| Muscle oedema                                    | 1(0.2)                | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Pain in extremity                                | 0                     | 0                      | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| NERVOUSSYSTEMDISORDERS                           | 0                     | 0                      | 0                       | 0                       | 1(0.4)                  | 1(0.8)                  | 0                                  |
| Dizziness                                        | 0                     | 0                      | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| Headache                                         | 0                     | 0                      | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS     | 0                     | 1(0.2)                 | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Bronchial hyperreactivity                        | 0                     | 1(0.2)                 | 0                       | 0                       | 0                       | 0                       | 0                                  |
| SKINANDSUBCUTANEOUSTISSUE DISORDERS              | 3 (0.6)               | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Hyperhidrosis                                    | 1 (0.2)               | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Pruritus                                         | 2(0.4)                | 0                      | 0                       | 0                       | 0                       | 0                       | 0                                  |

Notes:

ForB7471007Naive(subset of Cohort 1),onlyadverseeventsreported afterVaccination1(20vPnCor13vPnC)are included.

MedDRA (v22.1) coding dictionary applied.

a. N=number of subjectsinthe specifiedgroup.Thisvalue is the denominatorforthe percentage calculations.

b. n=Number of subjects reporting at least 1 occurrence oftheevent specified.For\"Any event\",n=number of subjects reporting atleast 1occurrence of any related adverse event.

## Supplementary data from phase 1/2 studies B7471001, B7471002 and B7471005

## B7471001

Within 1 month of vaccination there were 2 (6.1%) subjects each in the 20vPnC and Tdap groups who reported related AEs. Two (2) subjects in the 20vPnC group reported a total of 2 events and 2 subjects in the Tdap group reported a total of 4 events. No subjects reported related AEs after 1 month postvaccination. Onset of related events ranged from the day of vaccination (Day 1) to 9 days after vaccination and the duration ranged from 1 to 31 days. Related AEs were reported by two subjects (decreased appetite [1] and limb discomfort [1]) in the 20vPnC group and by two subjects (limb discomfort [1] and photophobia, nausea, and dizziness [1]) in the Tdap group.

## B7471002

Few participants reported AEs that were considered related to vaccination after receiving Vaccination 1 to 1 month after vaccination and after receiving Vaccination 2 to 1 month after vaccination in the 2

<div style=\"page-break-after: always\"></div>

groups. The most frequent related AEs reported were in the SOC of general disorders and administration site conditions.

## B7471005

Of the few AEs reported in the study, only 2 participants reported AEs that were considered related to vaccination. Following AEs were considered vaccine-related AEs: injection site erythema and swelling in the 20vPnC group; fatigue, vomiting and headache in the c7vPnC group. In the 13vPnC group no AE was considered as vaccine related.

## Severe adverse events

The proportion of subjects who reported severe AEs after vaccination was low, both among subjects naïve to pneumococcal vaccine (≤0.8% after 20vPnC; ≤1.1% after 13vPnC) and among subjects ≥65 years of age by prior pneumococcal vaccination status (≤1.6% after 20vPnC; ≤2.4% after control vaccines).

## Other Significant AEs/ Newly diagnosed medical conditions

The proportions of subjects reporting NDCMCs within 6 months after vaccination was low, both among subjects naïve to pneumococcal vaccine (≤2.3% after both 20vPnC and 13vPnC) and among subjects ≥65 years of age by prior pneumococcal vaccination status (≤4.0% after 20vPnC; ≤2.4% after control vaccines). The most frequently reported NDCMCs were in the SOCs of Musculoskeletal and connective tissue disorders, Metabolism and nutrition disorders (predominantly Type 2 diabetes mellitus), and Vascular disorders (predominantly hypertension). Overall, the NDCMCs reported were generally diseases and conditions often observed in adults in these age groups.

Of note that as of the cut-off date, two cases of autoimmune disorders (Basedow's disease [1] and rheumatoid arthritis [1]) were reported after 20nPvC.

## 2.6.8.3. Serious adverse event/deaths

## Subjects naïve to pneumococcal vaccine (B7471007 and B7471008)

The proportions of subjects reporting one or more SAEs within 6 months after vaccination were low and similar after 20vPnC (≤2.4%) or 13vPnC (≤1.9%). SAEs were reported at a s lightly higher frequency among subjects ≥60 years of age (2.4% after 20vPnC, 1.9% after 13vPnC) than in younger age groups (≤0.9% after either vaccine). None of the SAEs reported were considered by the investigator to be related to study vaccine. The most frequently reported SAEs were in the Infections and infestations SOC. ( Table 48 ).

<div style=\"page-break-after: always\"></div>

Table 48: Serious Adverse Events Reported Within 6 Months After Vaccination Pneumococcal Vaccine Naïve Subjects by Study and Age Group - Safety Population

| Study Age Group                              | B7471007 260 Years          | B7471007 260 Years          | B7471007             | B7471007                         | B7471007 and B7471008 18-49 Years   | B7471007 and B7471008 18-49 Years   |
|----------------------------------------------|-----------------------------|-----------------------------|----------------------|----------------------------------|-------------------------------------|-------------------------------------|
| Vaccine Group (as Administered)              | 20vPnC/Saline (N=1507) (4)q | 13vPnC/PPSV23 (N=1490) *(%) | 20vPnC (N=334) *(%6) | 50-59 Years 13vPnC (N=111) n (%) | 20vPnC (N=1798) n²(%)               | 13vPnC (N=357) *(%6)                |
| System Organ Class/ Preferred Term Any Event | 36 (2.4)                    | 29 (1.9)                    | 1 (0.3)              | 1 (0.9)                          | 12 (0.7)                            | 1 (0.3)                             |
| BLOODANDLYMPHATICSYSTEMDISORDERS             | 0                           | 1(0.1)                      | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Blood loss anaemia                           | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| Splenic cyst                                 | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| CARDIAC DISORDERS                            | 5(0.3)                      | 5(0.3)                      | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Acute myocardial infrction                   | 0                           | 1(0.1)                      | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Atrial fibrillation                          | 1(0.1)                      | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| Cardiac fhilure congestive                   | Q                           | 2(0.1)                      |                      | 0                                | 0                                   | 0                                   |
| Coronary artery disease                      | 3 (0.2)                     | 1(0.1)                      |                      | 0                                |                                     | 0                                   |
| Myocardial infarction                        | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Silent myocardial infarction                 | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| GASTROINTESTINALDISORDERS                    | 0                           | 3(0.2)                      | 0                    | 0                                | 3(0.2)                              | 0                                   |
| Colitis                                      | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| Gastitis                                     | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Gastointestinal haemonhage                   | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| Gastrooesophageal reflux disense             | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Hiatus hemia                                 | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Upper gastrointestinal haemonhage            | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| GENERAL DISORDERSAND ADMINISTRATION          | 2(0.1)                      | 2(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| SITE CONDITIONS                              |                             |                             |                      |                                  |                                     |                                     |
| Chest pain                                   | 0                           | 1(0.1)                      |                      | 0                                | 0                                   |                                     |
| Hemia                                        | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Non-cardiac chest pain                       | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Systemic inflammatory response syndrome      | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| HEPATOBILIARYDISORDERS                       | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Biloma                                       | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| INFECTIONSANDINFESTATIONS                    | 7(0.5)                      | 3(0.2)                      | 0                    | 1(0.9)                           | 2(0.1)                              | 1(0.3)                              |
| Abdominal abscess                            | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Appendicitis                                 | 2(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Arthritis infective                          | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Cellulitis                                   | 2(0.1)                      | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| Clostidium difficile colitis                 | 1(0.1)                      |                             |                      | 0                                | 0                                   |                                     |
| Diverticulitis                               | 0                           | 1(0.1)                      | 0                    | 0                                | 0                                   | 0                                   |
| Erysipelas                                   | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |
| Herpes simplex meningitis                    | 0                           | 0                           | 0                    | 0                                | 0                                   | 1(0.3)                              |
| Kidney infection                             | 0                           | 1( 0.1)                     | 0                    | 0                                | 0                                   | 0                                   |
| Osteomyelitis                                | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Pneumonia mycoplasmal                        | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| Skin bacterial infection                     | 0                           | 0                           | 0                    | 1(0.9)                           | 0                                   | 0                                   |
| Staphylococcal bactenemia                    | 0                           | 0                           | 0                    | 0                                | 1(0.1)                              | 0                                   |
| INIURY,POISONINGANDPROCEDURAL COMPLICATIONS  | 4(0.3)                      | 4(0.3)                      |                      | 0                                | 2 (0.1)                             | 0                                   |
| Femu facture                                 | 1(0.1)                      | 0                           | 0                    | 0                                | 0                                   | 0                                   |

<div style=\"page-break-after: always\"></div>

Table  48  (cont.):  Serious  Adverse  Events  Reported  Within  6  Months  After  Vaccination  Pneumococcal Vaccine Naïve Subjects by Study and Age Group - Safety Population

| Study Age Group                     | B7471007 260 Years           | B7471007 260 Years           | B7471007 50-59 Years   | B7471007 50-59 Years   | B7471007 and B7471008 18-49 Years   | B7471007 and B7471008 18-49 Years   |
|-------------------------------------|------------------------------|------------------------------|------------------------|------------------------|-------------------------------------|-------------------------------------|
| Vaccine Group (as Administered)     | 20vPnC/Saline (N=1507) (46)q | 13vPnC/PPSV23 (N=1490) n²(%) | 20rPnC (N=334) b(46)   | 13rPnC (N=111) n²(%)   | 20PnC (N=1798) n²(%)                | 13vPuC (N=357) b(%)                 |
| Sstem Organ Class/ Preferred Term   | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Gun shot wound Head injuy           | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Heat exhaustion                     | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Humenus fachure                     | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Meniscus injuy                      |                              | 1(0.1)                       | 0                      | 0                      |                                     | 0                                   |
| Muscle npture                       | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Post procedural haemahuria          | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Procedural pneumothorax             | 0                            | 0                            | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Stress fiacture                     | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Subcutaneous haematoma              | 0                            | 0                            | 0                      | 0                      | 1(0.1)                              | 0                                   |
| INVESTIGATIONS                      | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Blood pressiue increased            | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| METABOLISMAND NUTRITIONDISORDERS    | 1(0.1)                       | 3 (0.2)                      | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Dehydration                         | 0                            | 1(0.1)                       | 0                      | 0                      |                                     | 0                                   |
| Diabetic ketoacidosis               | 0                            | 0                            | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Hyperglycaemia                      | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Hypomatraemia                       | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Type 2 diabetes mellinus            | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| MUSCULOSKELETALANDCONNECTIVETISSUE  | 4(0.3)                       | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| DISORDERS                           |                              |                              |                        |                        |                                     |                                     |
| Arthralgia                          | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Neck mass                           | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Osteoarthritis                      | 2(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Rhabdomyolysis                      | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   |                                     |
| NEOPLASMS BENIGN, MALIGNANT AND     | 4(0.3)                       | 4(0.3)                       | 0                      | 0                      | 0                                   | 0                                   |
| UNSPECIFIED (INCL CYSTS AND POLYPS) |                              |                              |                        |                        |                                     |                                     |
| Colon cancer                        | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Glioblastonn multiforme             | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Malignant melanoma                  | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Metastases to peritoneum            | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Pancreatic carcinoma                | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Prostate cancer                     | 2(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Transitional cell carcinoma         | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| NERVOUSSYSTEMDISORDERS              | 5(0.3)                       | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Cerebrovascular accident            | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Hepatic encephalopathy              | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Ischaemic stroke                    | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Syncope                             | 1(0.1)                       | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Transient ischaemic attack          | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| PRODUCTISSUES                       | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| Device malfmction                   | 0                            | 1(0.1)                       | 0                      | 0                      | 0                                   | 0                                   |
| PSYCHIATRICDISORDERS                | 1(0.1)                       | 0                            | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Completed suicide                   | 1(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |
| Suicidal ideation                   | 0                            | 0                            | 0                      | 0                      | 1(0.1)                              | 0                                   |
| RENALANDURINARYDISORDERS            | 4(0.3)                       | 1(0.1)                       | 1(0.3)                 | 0                      | 0                                   | 0                                   |
| Acute kidney injury                 | 2(0.1)                       | 0                            | 0                      | 0                      | 0                                   | 0                                   |

<div style=\"page-break-after: always\"></div>

Table 48 (cont.): Serious Adverse Events Reported Within 6 Months After Vaccination Pneumococcal Vaccine Naïve Subjects by Study and Age Group - Safety Population

| Study Age Group                                            | B7471007 260 Years           | B7471007 260 Years          | B7471007 50-59 Years   | B7471007 50-59 Years   | B7471007 and B7471008 18-49 Years   | B7471007 and B7471008 18-49 Years   |
|------------------------------------------------------------|------------------------------|-----------------------------|------------------------|------------------------|-------------------------------------|-------------------------------------|
| Vaccine Group (as Administered)                            | 20vPnC/Saline (N=1507) (46)q | 13tPnC/PPSV23 (N=1490) m(%) | 20vPnC (N=334) n* (4)  | 13vPnC (N=111) ㎡(%)    | 20vPuC (N=1798) (%)                 | 13vPuC (N=357) (4%)                 |
| System Organ Class/ Preferred Term End stage renal disease | 0                            | 1(0.1)                      | 0                      | 0                      | 0                                   | 0                                   |
| Haematuia                                                  | 1(0.1)                       | 0                           | 0                      | 0                      | 0                                   | 0                                   |
| Nephrolithiasis                                            | 0                            | 0                           | 1(0.3)                 | 0                      | 0                                   | 0                                   |
| Remal failure                                              | 1(0.1)                       | 0                           | 0                      | 0                      | 0                                   | 0                                   |
| Ureteric obstuction                                        | 0                            | 0                           | 1(0.3)                 | 0                      | 0                                   | 0                                   |
| RESPIRATORY.THORACICANDMEDIASTINAL DISORDERS               | 3(0.2)                       | 3(0.2)                      | 0                      | 0                      | 2(0.1)                              | 0                                   |
| Acute respintory failure                                   |                              | 1(0.1)                      | Q                      | 0                      | 0                                   | 0                                   |
| Chronic obstructive pulumonary disease                     | 0                            | 1(0.1)                      | 0                      | 0                      | 0                                   | 0                                   |
| Dyspnoea                                                   | 2(0.1)                       | 0                           | 0                      | 0                      | 0                                   | 0                                   |
| Hypoxia                                                    | 0                            | 1(0.1)                      | 0                      | 0                      | 0                                   | 0                                   |
| Pleual effision                                            | 0                            | 0                           | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Pulmonary embolism                                         | 1(0.1)                       | 0                           | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Pulmonary oedema                                           | 0                            | 1(0.1)                      | Q                      | 0                      | 0                                   | 0                                   |
| Respintory filure                                          | 0                            | 1(0.1)                      | 0                      | 0                      | 0                                   | 0                                   |
| SKINANDSUBCUTANEOUSTISSUEDISORDERS                         | 0                            | 0                           | 0                      | 0                      | 1(0.1)                              | 0                                   |
| Skin necrosis                                              | 0                            | 0                           | 0                      | 0                      | 1(0.1)                              | 0                                   |

MedDRA (v22.1) coding dictionary applied.

Notes:

The 20vPnC goup from B7471008 is the pooled 20vPnC group, which includes subjects fom the 20vPnC Lot 1, 2, and 3 goups.

D. n = Number of subjects reporting at least 1 occurence of the event specified. For \"Any event', n = number of subjects reporting at least 1 occurence of any serious adverse event.

1. N = mumber of subjecis in the specified group. This value is the denominator for the perceninge calculations.

Subjects ≥65 years of age by prior pneumococcal vaccination status (B7471006 and B7471007)

The proportions of subjects reporting one or more SAEs within 6 months after vaccination were low and similar after 20vPnC (≤3.7% in naïve and 2.4% in previously vaccinated) or control vaccine (≤2.8% in naïve or 1.6% in previously vaccinated). None of the SAEs reported were considered related to study vaccine by the investigator ( Table 49 ).

<div style=\"page-break-after: always\"></div>

Table 49: Serious Adverse Events Reported Within 6 Months After Vaccination - Subjects ≥65 years of age by study and prior pneumococcal vaccination status -Safety Population

| Study Prior Pueumococcal Vaccination Status   | B7471007 Naive        | B7471007 Naive        | B7471006 Prior PPSV23   | B7471006 Prior PPSV23   | B7471006 Prior 13vPnC   | B7471006 Prior 13vPnC   | B7471006 Prior 13vPnC and PPSV23   |
|-----------------------------------------------|-----------------------|-----------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------------------------|
| Vaccine Group (as Administered)               | 20vPnC/Saline (N=514) | 13vPnC/PPSV23 (N=498) | 20vPnC (N=253) n(9%)    | 13vPnC (N=122)          | 20rPnC (N=246)          | PPSV23 (N=127)          | 20vPnC (N=125)                     |
| System Organ Class/ Preferred Term            | (46)q                 | ()q                   |                         | n*(%)                   | n² (%)                  | (6)                     | nk (4%)                            |
| Any Event                                     | 19 (3.7)              | 14 (2.8)              | 2 (0.8)                 | 2(1.6)                  | 6(2.4)                  | 2(1.0)                  | 2 (1.0)                            |
| CARDIAC DISORDERS                             | 4(0.8)                | 3 (0.6)               | 1(0.4)                  | 0                       | 1(0.4)                  | 0                       | 0                                  |
| Acute myocardial infrction                    | 0                     | 0                     | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| Atial fbrillation                             | 0                     | 1(02)                 | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Cardiac failhure congestive                   | 0                     | 0                     | 1(0.4)                  | 0                       | 0                       | 0                       | 0                                  |
| Coronary artery disease                       | 3(0.6)                | 1(0.2)                | 0                       | 0                       |                         | 0                       | 0                                  |
| Myocardial infarction                         | 1 (0.2)               | 0                     | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Silent myocardial infarction                  | 0                     | 1(0.2)                | 0                       | 0                       | 0                       | 0                       | 0                                  |
| GASTROINTESTINALDISORDERS                     | 0                     | 0                     | 0                       | 0                       | 1(0.4)                  | 1(0.8)                  | 0                                  |
| Dysphngia                                     | 0                     | 0                     | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| Gastrointestinal haemonhage                   | 0                     | 0                     | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| HEPATOBLIARYDISORDERS                         | 1 (0.2)               | 0                     | 0                       | 1(0.8)                  | 0                       | 0                       | 0                                  |
| Biloma                                        | 1(0.2)                | 0                     | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Cholecystiis                                  |                       | 0                     | 0                       | 1(0.8)                  | 0                       | 0                       |                                    |
| INFECTIONSANDINFESTATIONS                     | 3(0.6)                | 1(0.2)                | 0                       | 0                       | 0                       | 2(1.0)                  | 1(0.8)                             |
| Appendicitis                                  | 1(0.2)                | 0                     | 0                       | 0                       | 0                       | 1 (0.8)                 | 0                                  |
| Cellulitis                                    | 0                     | 1(0.2)                | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Clostidim difficile colitis                   | 1(0.2)                | 0                     | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| Erysipelas                                    | 1(0.2)                | 0                     | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Pneumonia                                     | 0                     | 0                     | 0                       | 0                       | 0                       | 0                       | 1(0.8)                             |

<div style=\"page-break-after: always\"></div>

| Study Prior Pueumococcal Vaccination Status                     | B7471007             | B7471007                    | B7471006 Prior PPSV23   | B7471006 Prior PPSV23   | B7471006 Prior 13vPuC   | B7471006 Prior 13vPuC   | B7471006 Pnior 13vPnC and PPSV23   |
|-----------------------------------------------------------------|----------------------|-----------------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------------------------|
| Vaccine Group (as Administered)                                 | 20vPaCSaline (N=514) | 13vPuC/PPSV23 (N=498) (46)q | 20rPuC (N=253) n*(%)    | 13vPuC (N=122) (6)      | 20rPuC (N=240) (46)     | PPSV23 (N=127) (96)0    | 20vPuC (N=125) (96)q               |
| System Organ Class/ Preferred Term                              | (46)                 |                             | 0                       | 0                       |                         | 0                       | 0                                  |
| INIURY,POISONINGAND PROCEDURAL COMPLICATIONS                    | 1(0.2) 1(0.2)        | 4 (0.8) 0                   | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Femmr fachure Humers facture                                    | 0                    | 1(02)                       | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Meniscus injury                                                 | 0                    | 1(0.2)                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Muscle rupture                                                  | 0                    | 1(0.2)                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Post procedural hematuria                                       | 0                    | 1(02)                       | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Stess fachure                                                   | 0                    | 1(0.2)                      | 0                       | 0                       | 0                       | 0                       | 0                                  |
| INVESTIGATIONS                                                  | 0                    | 0                           | 0                       | 1(0.8)                  | 0                       | 0                       | 0                                  |
| Blood pressuwre decreased                                       | 0                    | 0                           | 0                       | 1(0.8)                  | 0                       | 0                       | 0                                  |
| METABOLISMANDNUTRITION                                          | 1(0.2)               | 1(02)                       | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| DISORDERS Dehydation                                            | 0                    | 0                           | 0                       | 0                       | 0                       | 1(0.8)                  | 0                                  |
| Hyperglycaemia                                                  | 0                    | 1(02)                       | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Hypomataemia                                                    | 1(0.2)               | 0                           | 0                       | 0                       | 0                       | 0                       | 0                                  |
| MUSCULOSKELETALAND                                              | 3 (0.6)              | 1(0.2)                      | 0                       | 0                       | 0                       | 0                       | 1(0.8)                             |
| CONNECTIVETISSUEDISORDERS Arthralgia                            | 1(0.2)               | 0                           | 0                       | 0                       | 0                       | 0                       | 0                                  |
|                                                                 | 0                    | 1(02)                       | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Osteourthritis                                                  | 2(0.4)               | 0                           | 0                       |                         | 0                       | 0                       | 1(0.8)                             |
| NEOPLASMS BENIGN, MALIGNANT ANDUNSPECTFIED(INCLCYSTSAND POLYPS) | 1(0.2)               | 2(0.4)                      | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| Colon cancer                                                    | 0                    | 1(02)                       | 0                       | 0 0                     | 0                       | 0                       | 口                                  |
|                                                                 | 0                    | 1(0.2)                      |                         |                         |                         | 0                       |                                    |
| Maligant melanomn                                               |                      |                             | 0                       | 0                       | 0                       |                         |                                    |
| Prostate cancer                                                 | 1(0.2)               | 0                           | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |
| NERVOUSSYSTEMDISORDERS                                          | 4(0.8)               | 0                           | 1(0.4) 1(0.4)           | 0 0                     | 2(0.8)                  | 0 0                     | 0 0                                |
| Charotid artery stenosis Cerebrowascular accident               | 0 1(0.2)             | 0 0                         | 0                       | 0                       | 0 0                     | 0                       | 0                                  |
|                                                                 | 1(0.2)               |                             |                         |                         |                         |                         |                                    |
| Ischaenic stroke                                                | 1(0.2)               | 0                           | 0                       | 0                       | 0                       | 0                       | 0                                  |
| Syucope                                                         |                      | 0                           | 0                       | 0                       | 2(0.8)                  | 0                       | 0                                  |
| Tansient ischaemic attack                                       | 1(0.2)               | 0                           | 0                       | 0                       | 0                       | 0                       | 0                                  |
|                                                                 |                      |                             |                         | 0                       |                         |                         |                                    |
| Device malimction                                               | 0                    | 1(02) 1(0.2)                | 0                       | 0                       | 0                       | 0                       |                                    |
| RESPIRATORY, THORACIC AND                                       | 2(0.4)               | 2(0.4)                      | 0                       |                         | 0                       |                         | 0                                  |
| MEDIASTINAL DISORDERS Acuterespiratory failure                  | 0                    | 1(0.2)                      |                         | 0 0                     | 0                       |                         |                                    |
|                                                                 | 0                    | 1(02)                       | 0 0                     |                         |                         | 0 0                     | 0                                  |
| Chronic obstuctive pulmonary disease Dyspnoea                   | 2(0.4) 0             | 0 1(0.2)                    | 0                       | 0                       | 0 0                     | 0 0                     | 0 0                                |
| Hypovia Respiatory filure                                       | 0                    | 1(02)                       | 0 0                     | 0 0                     | 0                       |                         | 0                                  |
| SURGICALAND MEDICAL PROCEDURES                                  | 0                    | 0                           | 0                       | 0                       | 0 1(0.4)                | 0 0                     | 0 0                                |
| Chrdiac pacemakerreplacement                                    | 0                    | 0                           | 0                       | 0                       | 1(0.4)                  | 0                       | 0                                  |

MedDRA (v22.1) coding dictionary applied

## Notes:

al.N = number of subjects in the specified group. This vahue is the denominator for the percentage calculations.

- b. n= Number of subjects reporting at least 1 occurence ofthe event specified. For \"Any event', n = mumber of subjects reporting at least 1 occurence of any serious adverse event.

Supplementary data from phase 1/2 studies B7471001, B7471002 and B7471005

B7471001: Two subjects (6.1%) who received 20vPnC reported SAEs from the visit 1 month after vaccination through the 6-month follow-up visit. One subject, who received 20vPnC, reported a SAE of loss of consciousness caused by exposure to carbon monoxide 30 days after vaccination. Another subject, who also received 20vPnC, reported a SAE of back pain 83 days after vaccination. None of the reported SAEs were considered related to vaccine.

B7471002: Few participants reported SAEs at 1 month after each vaccination. The majority of SAEs occurred 1 month after Vaccination 2 (5 events in the 20vPnC/saline group and 4 events in the 13vPnC/PPSV23 group). No SAEs reported were considered related to vaccine.

<div style=\"page-break-after: always\"></div>

B7471005: No participants reported SAEs during the study.

## Deaths

In B7471007 Cohort 1, a 60-year-old male who was naive to pneumococcal vaccine and received 20vPnC/saline, died 48 days after receiving Vaccination 2. The investigator considered the death not related to study vaccine.

In study B7471001, one subject died during the study due to a motor vehicle accident 75 days after vaccination. The cause of death was determined not to be related to the study vaccine by the investigator.

In B7471005, B7471006 and B7471008 no participants died during the studies.

## 2.6.8.4. Laboratory findings

Clinical laboratory evaluations were not performed systematically in any of the Phase 3 trials. Any clinical laboratory values of concern that came to the attention of the investigator were to be reported as AEs.

## Supplementary data from phase 1 study B7471001

Standard laboratory testing for cardiac function, haematology, chemistry, and urinalysis were performed. Serial cardiac enzyme (cardiac troponin I) levels were assessed as a response to nonclinical observations of microscopic inflammation with degeneration/necrosis of cardiac myocytes or myocardial fibrosis in a small number of rabbits in the repeat-dose toxicity study. Nonclinical investigations supported that the rabbit cardiac findings were likely related to toxicity study procedures and handling, not directly related to 20vPnC, and unlikely to have any translational relevance to humans. No elevations in troponin I were observed, and no other cardiovascular concerns were identified in the Phase 1 trial. No cardiovascular signals have been identified in the Phase 2 and 3 trials. No other lab values were clinically significant. There were no clinically significant ECG results and no clinically significant ECG findings in the isolated number of subjects with ECGs conducted after vaccination for events of interest.

## 2.6.8.5. Safety in special populations

## Sex, Race and Age

Within each Phase 3 trial, as appropriate based on population size and composition, the proportions of subjects with local reactions, systemic events, and AEs were summarised by sex (all 3 studies), race (B7471007 and B7471008 only), and age (B7471007 only).

Local Reactions: Within each of the sex, race, and age subgroups, the proportions of subjects reporting local reactions were similar after 20vPnC or control vaccine. There were trends toward a higher frequency of local reactions among females than among males in both vaccine groups, although this varied by study. In B7471007, the frequency of pain at the injection site decreased with increasing age across the age cohorts (see Section 2.7.4.2.1.1) and across age subgroups (60-64 years, 65-69 years, 7079 years, and ≥80 years).

Systemic Events: Within each of the sex, race, and age subgroups, the proportions of subjects reporting systemic events were similar after 20vPnC or control vaccine. There were trends toward a higher frequency of systemic events among females than among males. In B7471007, the frequency of

<div style=\"page-break-after: always\"></div>

systemic events decreased with increasing age across the age cohorts (see Section 2.7.4.2.1.2) and across age subgroups (60-64 years, 65-69 years, 7079 years, and ≥80 years).

Adverse Events: Within each Phase 3 trial, as appropriate, AEs reported by ≥4 subjects in at least 1 vaccine group were summarised by sex, race, and age. In B7471007 and B7471008, within each of the sex, race, and age subgroups, the proportions of subjects reporting at least 1 AE were similar after 20vPnC or control vaccine. AEs were not summarised by sex for B7471006 because no AEs were reported for ≥4 subjects in that study. Overall, there wer e no consistent trends in the frequency of AEs by sex, race, or age.

## Individuals at increased risk for pneumococcal disease

20vPnC had an acceptable safety profile in the B7471007 safety population, approximately 34% of whom were adults ≥18 years of age w ith risk factors that placed them at increased risk for serious pneumococcal disease, including smoking (13%), and medical conditions of chronic cardiovascular disease (5.5%), chronic pulmonary disease including asthma (8.7%), chronic liver disease (0.4%), and diabetes mellitus (14%).

## Pregnancy and lactation

Women who were pregnant or lactating were not eligible for studies of 20vPnC. In total eight women became pregnant during participation in the Phase 3 trials; seven subjects who received 20vPnC and 1 subject who received 13vPnC in B7471007 and B7471008. These pregnancies were not associated with AEs but were communicated to the sponsor on an SAE form and AE case report form per sponsor guidance, and are included in the AE listings within each CSR.

Among the 7 subjects with reported events of pregnancy who had received 20vPnC, 6 events had an outcome of full-term live birth and 1 event had an unknown outcome. The subject who had received 13vPnC (in Study B7471008) reported being in a motor vehicle accident 187 days after vaccination and reported a spontaneous abortion 9 days later. This event occurred outside the safety reporting window and therefore was not included in the AE listing in the CSR. The investigator considered there was not a reasonable possibility that this event was related to study vaccine. The event was more likely triggered by the motor vehicle accident and associated with a foetal genetic anomaly (post-foetal demise test results showed 'likely trisomy 21'). Further details about the events of pregnancy can be found in the CSRs (Module 5.3.5.1 B7471007 Report Body Section 12.5.5; Module 5.3.5.1 B7471008 Report Body Section 12.5.5).

It is not known whether 20vPnC is excreted in human milk. No vaccine-related effects on female fertility or the development of foetuses or offspring were observed in a fertility and developmental toxicity study of 20vPnC in rabbits (Module 4.2.3.5.1 20168231 [18GR287]).

## Vaccination 2 in the Cohort 1 in the Study B7471007 (20vPnC/Saline vs. 13vPnC/PPSV23)

In B7471007, subjects in Cohort 1 received 2 vaccinations. At Vaccination 1, each subject received either 20vPnC or 13vPnC (control vaccine). Subjects in Cohort 1 who received 20vPnC at Vaccination 1, received saline at Vaccination 2. Subjects in Cohort 1 who received 13vPnC at Vaccination 1, received PPSV23 at Vaccination 2. Vaccination 2 took place 28-42 days after Vaccination 1.

Serious AEs as well as n diagnosed chronic medical conditions (NDCMC) reported from vaccination 2 to 1 month after vaccination 2 in Cohort 1 are already included in the tables presenting Serious AEs and NDCMC reported within 6 months from Vaccination 1 and thus not repeated here.

In Cohort 1, immediate AEs reported after vaccination 2 (saline or PPSV23) were low in frequency (&lt;1%) for the 20vPnC/saline and 13vPnC/PPSV23 groups. Fewer immediate AEs were reported in the 20vPnC/saline group (0.1%) than in the 13vPnC/PPSV23 group (0.6%). Observed AEs were local

<div style=\"page-break-after: always\"></div>

reactions, pain in extremity, dizziness and headache. In the 20vPnC arm, no PT was reported in more than 1 participant.

The proportion of participants with AEs related to study was lower in the 20vPnC/saline group (0.4%) than in the 13vPnC/PPSV23 group (6.4%). In the 20vPnC/saline group AEs that were considered to be related to the vaccine were diarrhoea, injection site erythema, pyrexia, bronchitis, headache and rash. No PT was reported in more than 1 participant in the 20vPnC/saline group.

## 2.6.8.6. Immunological events

Immunogenicity represents the PD effect of the vaccine and represents the main evidence for this application. Results are described and assessed in section 3.

Among pneumococcal vaccine naïve subjects, two cases of hypersensitivity considered unrelated to the study vaccine were reported.

## 2.6.8.7. Safety related to drug-drug interactions and other interactions

No drug-drug interactions were investigated, and no data are available regarding concomitant use of 20vPnC with other vaccines in adults. A safety and immunogenicity trial of 20vPnC co-administered with seasonal inactivated influenza vaccine in adults ≥65 years of age is currently ongoing.

## 2.6.8.8. Discontinuation due to adverse events

AEs leading to discontinuation from the study were reported only for subjects in B7471007, Cohort 1 (subjects ≥60 years of age); these included 12 subjects (0.8%) who received 20vPnC and 8 (0.5%) who received 13vPnC. All of these subjects were withdrawn from the study after Vaccination 1 (20vPnC or 13vPnC) and before Vaccination 2 (saline or PPSV23), except for the subject in the 20vPnC/saline group who died (after Vaccination 2). The AEs leading to withdrawal were considered related to study vaccine for 5 of the subjects who received 20vPnC and 4 of the subjects who received 13vPnC; most of these AEs were injection site reactions.

Reasons for discontinuation in the 20vPnC arm considered to be related to the study vaccine were palpitations and anxiety (moderate/moderate); vaccination site pruritus and vaccination site swelling (moderate/moderate); feeling abnormal and pruritus (mild/moderate); swelling (severe); erythema (severe). Reasons for discontinuation which were considered not related to the study vaccine by the investigator were completed suicide, angioedema (due to concomitant medication, mild), presyncope, atopic dermatitis (pre-existing condition), hypersensitivity (seasonal allergens), coronary artery disease (cardiac disease), and arthritis (worsening of pre-existing condition).

Reasons for discontinuation in the 20vPnC arm considered to be related to the study vaccine were injection site pain and myalgia (mild/mild); headache (moderate), injection site reaction (mild), bronchial hyperreactivity (severe). Reasons for discontinuation which were considered not related to the study vaccine by the investigator were cystitis (primary cystitis), lower respiratory tract infection (community exposure); muscle rupture (old injury) and COPD (exacerbation).

A listing of AEs leading to discontinuation is available in Module 5.3.5.1 B7471007 Appendix 16.2.7.9.1.

No withdrawals due to AEs were reported in the other cohorts in B7471007 (18-49 and 50-59 years of age), nor in B7471006 or B7471008.

There were no withdrawals due to AEs in phase 1/2 studies B7471001, B7471002 or B7471005.

<div style=\"page-break-after: always\"></div>

## 2.6.8.9. Post marketing experience

No post-marketing data are available as 20vPnC has not been marketed for adults in any country.

## 2.6.9. Discussion on clinical safety

The safety profile of 20vPnC was evaluated in 6 clinical trials in adults ≥18 years of age. The three Phase 1 and Phase 2 trials evaluated 20vPnC administered to adults 18 through 49 years of age (B7471001 and B7471005) and 60 through 64 years of age (B7471002). The Phase 3 trials included pneumococcal vaccine naïve adults≥18 years of age (B7471007 and B7471008) and adults ≥65 years previously vaccinated with a pneumococcal vaccine (B7471006). Age and prior pneumococcal vaccination status were considered as important factors resulting in a pooled analysis from pneumococcal vaccine naïve subjects 18-49 years of age from B7471007 Cohort 3 and B7471008. Safety data from other subjects were displayed side-by-side.

Methods to assess the reactogenicity and safety of 20vPnC are in principle considered appropriate. Local solicited reactions including redness, swelling, and pain at the injection site were followed for 7 days and systemic solicited events including fever, headache, fatigue, muscle pain, and joint pain were followed for 10 days. Although known to occur following vaccination with Prevenar 13, late onset local reactions were not observed following vaccination with 20vPnC in the early stage of development (Phase 1 and 2 studies). The choice of time for solicited local and systemic reactions in the phase 3 trials is therefore deemed acceptable. Subjects were followed for 6 months, which is considered a sufficient period of time to collect relevant adverse events. AEs were collected through 30 days postvaccination, SAEs and NDCMCs were collected through 6-month post-vaccination.

Phase 1 and Phase 2 trials demonstrated that 20vPnC was well tolerated in this population, with a safety profile similar to that of 13vPnC, and supported the initiation of Phase 3 studies of 20vPnC in adults.

In all three Phase 3 trials, the safety of 20vPnC was mainly evaluated in comparison to 13vPnC. 20vPnC contains 13 serotypes already included in the licensed vaccine Prevenar 13 plus 7 additional serotypes that are included in the currently marketed unconjugated polysaccharide vaccine, Pneumovax 23 (PPSV23). PPSV23 was used as an additional comparator vaccine, although the direct comparison between 20vPnC and PPSV23 is based on a too small number of subjects (Study B7471006, Cohort B: 246 participants received 20vPnC and 127 participants received PPSV23) to draw definite conclusions.

Study B7471006 was conducted open label while studies B7471007 and B7471008 were double blinded. However, in the study B7471007 at Vaccination 2 (Cohort 1 only), saline and PPSV23 were prepared and administered by a third-party unblinded site staff member. The applicant clarified that in the Study B7471007 blinding of the site staff as well as the study participant was maintained.

## Exposure

Overall, 4552 subjects received 20vPnC, while 2496 received control vaccine across all studies (majority of subjects received 13vPnC, while only a small number received PPSV23). The size of the safety database is considered sufficient for the assessment of the safety profile of 20vPnC, also taking into consideration that 20vPnC shares 13 serotypes with the licensed Prevenar 13, for which extensive safety data are available. Nonetheless, the size of the safety database limits the detection of more rare adverse events.

<div style=\"page-break-after: always\"></div>

## Immediate Adverse Events

The proportion of subjects who reported immediate AEs after vaccination was low, both among subjects naïve to pneumococcal vaccine (≤0.2% after 20vPnC; ≤0.9% after 13vPnC) and among subjects ≥65 years of age by prior pneumococcal vaccination status (20vPnC: ≤0.4; control vaccines: ≤0.8%).

## Solicited Adverse Events

Across all age groups and independent of the previous pneumococcal status, observations about solicited AEs were consistent, with majority of participants experiencing 1 or more solicited AEs, and injection-site pain being the most frequently reported solicited AE, followed by myalgia and fatigue. In addition, most AEs were mild to moderate in intensity. Overall, the safety profile of 20vPnC was generally comparable to control vaccines 13vPnC/PPSV23.

The safety results from phase 1/2 studies B7471001, B7471002 and B7471005 resemble the adverse event profile evaluated in the phase 3 trials. Adverse events and use of antipyretic or pain medication were in general comparable between treatment groups. Limitation of arm movement was not explicitly solicited for in the phase 3 trials, however it was solicited for and observed with 20vPnC in the study B7471001 (36.4% in the 20vPnC group). The applicant complied with the request to add 'limitation of arm movement' to the section 4.8 of the SmPC.

In subjects naïve to pneumococcal vaccine, local and systemic reactions were reported with a similar frequency after 20vPnC and Prevenar13 across all age groups. Majority of both local and systemic solicited AEs were mild or moderate in severity and resolved within 1-3 days in both intervention groups. The most frequently reported local reaction across all age groups was pain at the injection site (55% to 79% after 20vPnC; 54% to 78% after 13vPnC), with a trend toward decreasing frequency with increasing age. Other local reactions were reported at much lower frequencies (redness: 7.3% to 8.2% after 20vPnC; 5.4% to 7.3% after 13vPnC and swelling: 7.5% to 9.1% after 20vPnC; 8.0% to 10.8% after 13vPnC). The most frequently reported systemic event across all age groups was myalgia (39% to 63% after 20vPnC; 37% to 65% after 13vPnC) followed by fatigue (20vPnC: 30% to 47%; 13vPnC: 30% to 44%), headache (21.5% to 36.7% following 20vPnC; 23.3% to 36.6% following 13vPnC) and arthralgia (12.6% to 16.2% following 20vPnC; 13.7% to 20.7% following 13vPnC).

In subjects ≥65 years of age with prior pneumococcal vaccination local and systemic reactions were reported with a similar frequency after 20vPnC or control vaccine (13vPnC or PPSV23). Solicited local as well as systemic reactions were primarily mild or moderate in intensity and resolved within 1-3 days. Most frequently reported local reaction was pain at the injection site (44% to 61% after 20vPnC; 43% to 56% after control vaccines), followed by redness (4.8% to 8.6% after 20vPnC; 2.5% to 13% after control vaccines) and swelling (4.0% to 9.9% after 20vPnC; 6.6% to 14% after control vaccines. The most frequently reported type of systemic event was muscle pain (32% to 38% after 20vPnC; 31% to 46% after control vaccines), followed by fatigue (28.9% to 32.8% after 20vPnC; 22.3% to 33.3% after control vaccines), headache (13.5% to 19.2% after 20vPnC; 18.2% to 21.4% after control vaccines) and joint pain (6.7% to 16.8% after 20vPnC; 10.7% to 15.9% after control vaccines).

In the 13vPnC arm in Cohort A (previously vaccinated with PPSV23) the frequency of solicited local and systemic events was in general slightly lower than in the PPSV23 arm in Cohort B (previously vaccinated with 13vPnC). Therefore, frequencies of AE were slightly higher in the 20vPnC arm compared to 13vPnC and slightly lower in 20vPnC when compared to PPSV23.

In subjects ≥65 years of age solicited local reaction were slightly more frequent in pr eviously vaccinated (53 to 64,1% in 20vPnC vs 43.8 to 57.9% in control) compared to naïve subjects (46.5 % vs 45.8%) over 65 years, mostly due to higher numbers of swelling and pain at injection site. Solicited systemic events were comparable.

<div style=\"page-break-after: always\"></div>

## Unsolicited Adverse Events

In both groups (pneumococcal vaccine naïve and with prior pneumococcal vaccine) the proportions of subjects reporting any AE were comparable across age groups and were similar for subjects who received 20vPnC or control vaccine. The most frequently reported AEs were in the SOC Infections and Infestations (≤5.1% after 20vPnC; ≤5.4% after 13vPnC).

Among subjects naïve to pneumococcal vaccine, the proportions of those reporting any AE within 1 month after vaccination were 8.4% to 10% following vaccination with 20vPnC and 7.3% to 11% following vaccination with 13vPnC.

In subjects ≥65 years of age unsolicited local reaction were slightly less frequent in previously vaccinated (4.9% to 7.5% in 20vPnC vs 9% to 11% in control) compared to naïve subjects (9.1% in 20vPnC vs 11.6% in control) over 65 years.

In the Phase 1 trial (B7471001), serial cardiac enzyme (cardiac troponin I) levels were assessed as a response to nonclinical observations of microscopic inflammation with degeneration/necrosis of cardiac myocytes or myocardial fibrosis in a small number of rabbits in the repeat-dose toxicity study. No elevations in troponin I were observed in the Phase 1 trial and no other cardiovascular concerns were identified by the applicant in Phase 1 or subsequent phases of vaccine development. However, as several cardiac events were reported in phase 2 and 3 studies, the applicant was asked to provide reassurance that these were indeed not related to the vaccine. A comprehensive analysis of cardiac events was submitted and no apparent evidence of an increased risk of cardiac AEs with the use of 20vPnC could be observed.

## Related Adverse Events

AEs considered related to study vaccine were reported with a similar frequency in subjects naïve to pneumococcal vaccine after 20vPnC (≤0.9%) and after 13vPnC (≤1.5%) vaccination. The most frequently reported types of AEs considered to be related to study vaccine were injection site reactions. AEs considered related to study vaccine were reported with a similar frequency in subjects ≥65 years of age with prior pneumococcal vaccination status after 20vPnC (≤1.6% of subjects) and after control vaccines (≤2.4% of subjects). None of the provided tables for related AEs included solicited adverse events, therefore tabular listings of all vaccine-related AEs including solicited injection-site and systemic AEs were requested for all studies and for the pooled analysis of studies B7471007 (Cohort 3) and B7471008 and respective data have been provided.

## Newly diagnosed chronic medical conditions (NDCMCs)

The proportions of subjects reporting NDCMCs was low, both among subjects naïve to pneumococcal vaccine (≤2.3% after both 20vPnC and 13vPnC) and among subjects ≥65 years of age by prior pneumococcal vaccination stat us (≤4.0% after 20vPnC; ≤2.4% after control vaccines). Overall, the NDCMCs reported were generally diseases and conditions often observed in adults in these age groups.

As of the cut-off date, two cases of autoimmune disorders (Basedow's disease [1] and rheumatoid arthritis [1]) were reported after 20nPvC. Regarding the theoretical increased risk of autoimmune disorders after immunisation, the applicant was asked to provide additional information about these case-reports. Based on the reported information, it was agreed that there is no need to act for the time being.

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events and Death

Overall, the proportion of patients with SAEs occurring 6 months after vaccination was low and comparable between study vaccine in both vaccine naïve (≤2.4%) as well as previously vaccinated subjects (20vPnC (≤2.4%) and control vaccine (≤1.6%). In pneumococcal naïve group SAEs were reported at a slightly higher frequency among subjects ≥60 years of age (2.4% after 20vPnC, 1.9% after 13vPnC) than in younger age groups (≤0.9% after either vaccine). In subjects ≥65 years of age serious AE were slightly less frequent in previously vaccinated (0.8% to 2.4% in 20vPnC vs 1.6% in control) compared to naïve subjects (3.7% in 20vPnC vs 2.8% in control) over 65 years. Since no subject narratives of serious adverse events were submitted, no assessment of SAEs can be made to confirm applicant's claims of unrelatedness. Upon request respective subject narratives for all serious adverse events reported in Phase 3 studies were provided. Majority of serious adverse events occurred in older participants with significant co-morbidities and investigator's conclusion that they are most likely attributable to underlying medical conditions and confounding factors, which was also concurred by the applicant, is agreed. Considering close temporal relationship with the vaccine administration and absence of pertinent medical history, the applicant was asked to provide a detailed discussion how the unrelatedness to 20vPnC was inferred for the events of pulmonary embolism and transient ischemic attack. Based in the provided information, the applicant's conclusion that there was no causal relationship between the 20vPnC and the events of pulmonary embolism and transient ischemic attack is agreed.

Over the course of the 6 studies, 2 participants died. One participant in B7471007 Cohort 1 who received 20vPnC and one participant in study B7471001 died 75 days after 20vPnC vaccination, both due to traumatic injuries. None were related to study interventions.

## Safety in special populations

## Age, sex, race

As expected, increasing age led to a decrease in reactogenicity. For the solicited AEs this decrease was seen for injection-site pain in study B7471007. Besides the lower frequency, the overall profile of AE remained similar.

Trends of higher frequency of both local and systemic reactions in females compared to males were seen, but do not impact the use of the vaccine.

Sex, race and age did not have a major impact on the overall safety profile of 20vPnC.

## Prior pneumococcal vaccination

Prior pneumococcal vaccination has no major impact on the safety profile of 20vPnC, as the overall safety profile in participants with prior exposure to 13vPnC/PPSV23 was similar to the safety profile in the pneumococcal vaccine naïve population and no new safety signals are observed. In subjects ≥65 years of age solicited local reaction were slightly more frequent in previously vaccinated (53 to 64,1% in 20vPnC vs 43.8% to 57.9% in control) compared to naïve subjects (46.5 % vs 45.8%) over 65 years, mostly due to higher numbers of swelling and pain at injection site. In subjects ≥65 years of age unsolicited local reaction were slightly less frequent in previously vaccinated (4.9% to 7.5% in 20vPnC vs 9% to 11% in control) compared to naïve subjects (9.1% in 20vPnC vs 11.6% in control) over 65 years. Beside these slight differences in solicited local reactions and unsolicited reactions, the AEs were reported in similar proportions in both intervention groups and no concerns are raised.

## Use in pregnancy/lactation

Currently there are no clinical data on the use of this vaccine in women who are pregnant/lactating and respective adaptions in the SmPC were requested. No vaccine-related effects on female fertility or the

<div style=\"page-break-after: always\"></div>

development of foetus or offspring were observed in a fertility and developmental toxicity study of 20vPnC in rabbits. Eight reports of pregnancy had been received from clinical trials [B7471007 (2), B7471008 (6)]; none reported associated clinical adverse events (AEs). There were no cases reporting 20vPnC administration during breastfeeding.

However, as currently available data on 20vPnC vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy, 20vPnC should only be considered when the potential benefits outweigh any potential risks for the mother and foetus. Respective sections in the SmPC were adapted.

## Individuals at increased risk for pneumococcal disease

In the B7471007 safety population, approximately 34% of participants had risk factors for serious pneumococcal disease at enrolment including smoking (13%), chronic cardiovascular disease (5.5%), chronic pulmonary disease including asthma (8.7%), chronic liver disease (0.4%), and diabetes mellitus (14%). The safety and immunogenicity of 7vPnC and 13vPnC in the high-risk populations generally reflected the same profile observed for 13vPnC in the general population, although responses were lower in immunocompromised individuals, as would be expected given the altered ability to respond to vaccines. Reduced immune response was observed with 20vPnC in comparison to 13vPnC (see OC in the efficacy part) which raises doubts about the protective effect of 20vPnC in patients with risk factors for IPD. Nonetheless, this is not expected to have negative effects on the safety in this group of patients.

Studies in human immunodeficiency virus (HIV) and bone marrow transplant participants have not been conducted with 20vPnC, which could be acceptable. Respective sections were included in the SmPC, also referring to data from Prevenar 13.

In general, the safety profile in the different subgroups was similar to the safety profile in the overall population and no new safety signals are observed.

No concerns arise from the review of reported AEs following Vaccination 2 in the 20vPnC/saline group in Cohort 1.

## Immunological events

Among pneumococcal vaccine naïve subjects, two cases of hypersensitivity judged unrelated to the study vaccine were reported. Hypersensitivity is listed as an adverse reaction in the PI.

## Concomitant administration

No data are available regarding concomitant use of 20vPnC with other vaccines in adults. However, a safety and immunogenicity trial of 20vPnC co-administered with seasonal inactivated influenza vaccine in adults ≥65 years of age is currently ongoing. No other studies have been conducted to examine the concomitant administration of 20vPnC with other vaccines licensed for use in adults 18 years of age and older.

Data from post-marketing clinical study evaluating the impact of prophylactic use of antipyretics (ibuprofen and paracetamol) on the immune response to 13vPnC suggest that administration of paracetamol concomitantly or within the same day of vaccination may reduce the immune response to 13vPnC after the infant series (infants and children aged 6 weeks to 5 years). The applicant was asked to discuss whether the same could also be extrapolated to adults receiving concomitantly 20vPnC and the same antipyretics. The applicant provided a reassuring discussion and confirmed that the effect observed in infants is not likely to replicate in adults.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to AE

Only participants in the Cohort 1 of study B7471007 received a second vaccine (20vPnC/saline or 13vPnC/PPSV23) and could be discontinued from the study intervention. All subjects in this cohort were ≥60 years of age. The proportion of participants who discontinued the study were generally comparable across groups (12 subjects (0.8%) who received 20vPnC and 8 (0.5%) who received 13vPnC).

Out of AEs which led to discontinuation, 5/12 (20vPnC arm) and 4/8 (13vPnC arm) were vaccine related. These AEs were mostly injection site reactions. In both arms, the intensity (severity) of AEs ranged from mild to severe, with severe AEs being swelling and erythema (following 20vPnC) and bronchial hyperreactivity (following Prevenar 13).

All adverse reactions reported in clinical trials that were considered related to the IP have been included in the Summary of Product Characteristics.

## 2.6.10. Conclusions on the clinical safety

The safety profile of 20vPnC appears to be comparable to the safety profile of 13vPnC. Furthermore, no major safety differences between 20vPnC and PPSV23 were observed, although the number of subjects who received PPSV23 was too small to draw definite conclusions. A majority of participants reported 1 or more AEs, mostly mild or moderate in intensity and of short duration. The most frequently reported AEs by PT were solicited AEs including injection-site pain, myalgia, fatigue, headache, joint pain, swelling and redness. As expected, reactogenicity decreased with age, especially for solicited local and systemic reactions. The safety profile was also overall comparable between pneumococcal vaccin e naïve adults ≥18 years of age and adults ≥65 years of age who have previously been vaccinated with 13vPnC/PPSV23. No deaths occurred that were considered possibly related.

All outstanding issues have been resolved. In conclusion, 20vPnC is well tolerated in adults ≥18 years and no major safety concerns were identified.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

## Summary of the safety concerns

| Important identified risks   | None.                                                                                                 |
|------------------------------|-------------------------------------------------------------------------------------------------------|
| Important potential risks    | None.                                                                                                 |
| Missing information          | Concomitant use of 20vPnC with quadrivalent inactivated influenza vaccine or COVID-19 mRNA vaccine. a |

## 2.7.2. Pharmacovigilance plan

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study/ Status                                                                                                              | Summary of Objectives                                                                                                      | Safety Concerns Addressed                                                                                                  | Milestones                                                                                                                 | Due dates                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation |
| None.                                                                                                                      |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |

<div style=\"page-break-after: always\"></div>

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study/ Status                                                                                                                                                                                                                                           | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                              | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None.                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance                                                                                                                                                                                                      | Category 3 - Required additional pharmacovigilance                                                                                                                                                                         | activities                                                                                                                                                                                                                 |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| B7471004 A phase 3, randomised, double-blind trial to evaluate the safety and immunogenicity of a 20- valent pneumococcal conjugate vaccine (20vPnC) when coadministered with seasonal inactivated influenza vaccine (SIIV) in adults ≥65 years of age. | Evaluate the safety and immunogenicity of 20vPnC when coadministered with quadrivalent inactivated influenza vaccine in adults ≥65 years of age.                                                                           | Concomitant use of 20vPnC with other vaccine(s)                                                                                                                                                                            | Submission of final study results by                                                                                                                                                                                       | 30/04/2022                                                                                                                                                                                                                 |
| B7471026 A phase 3, randomised, double blind trial to describe the safety and immunogenicity of 20- valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older. Ongoing              | Evaluate the safety and immunogenicity of 20vPnC when coadministered with a booster dose of COVID- 19 mRNA vaccine in adults ≥65 years of age.                                                                             | Concomitant use of 20vPnC with other vaccine(s)                                                                                                                                                                            | Submission of final study results by                                                                                                                                                                                       | 30/06/2022                                                                                                                                                                                                                 |

## 2.7.3. Risk minimisation measures

## Summary Table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety Concern                                                                                     | Risk Minimisation Measures                                                                                                                                                                                                                                                                                          | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information                                                                                | Missing Information                                                                                                                                                                                                                                                                                                 | Missing Information                                                                                                                                                                                                                                                                                                                             |
| Concomitant use of 20vPnC with quadrivalent inactivated influenza vaccine or COVID-19 mRNA vaccine | Routine risk minimisation measures: EU SmPC Section 4.5 Interaction with other medicinal products and other forms of interaction . PL Section 2 ( Other medicines/vaccines and Apexxnar ) Medicine's legal status : Medicinal product subject to medical prescription. Additional risk minimisation measures: None. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: • Study B7471004 (quadrivalent inactivated influenza vaccine coadministration study) CSR due on 30/04/2022; • Study B7471026 (COVID-19 mRNA vaccine coadministration study) CSR due on 30/06/2022. |

<div style=\"page-break-after: always\"></div>

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 1.0 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 08.06.2021. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Labelling exemptions

None requested.

## 2.9.3. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Apexxnar (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) is included in the additional monitoring list as it is a biological product and additionally contains five new serotypes, 8, 10A, 11A, 12F and 15B conjugated to CRM197 carrier protein which can be qualified as new active substances.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Pneumococcal disease mainly presents as non-invasive disease, such as non-bacteraemic pneumonia, sinusitis or acute otitis media (the latter most commonly in young children). The less frequent albeit generally more severe invasive pneumococcal disease (IPD) occurs when S. pneumoniae gains access to more distal, normally sterile anatomical sites. IPD presents as meningitis, bacteraemic pneumonia, bacteraemia without focus and septic arthritis. In general, pneumococcal pneumonia is associated with complications and long-term sequelae in all age groups (e.g. respiratory failure requiring hospitalisation, exacerbations of chronic medical conditions, decline in quality of life, increased risk of death within 30 days (acute) and 1 year (long-term) after the event.)

Pneumococcal disease burden is highest in young children ≤5 yoa and older adults ≥65 yoa. Irrespective of age, certain comorbid conditions (e.g. chronic lung disease, chronic liver disease, chronic heart disease, diabetes mellitus, asthma) and immunodeficiency (e.g. HIV, HSCT patients) and lifestyle factors (e.g. smoking) predispose to pneumococcal disease.

## 3.1.2. Available therapies and unmet medical need

## Disease Treatment

S. pneumoniae infections are treated based on clinical presentation and susceptibility data to antimicrobials. Broad-spectrum antibiotics are the most commonly used antimicrobials against S. pneumoniae . Although S.pneumoniae is not considered as a 'classical' multi-resistant pathogen, increasing resistance rates have been reported which may lead to treatment failures.

## Disease Prevention

Recommendations for pneumococcal vaccination in adults are typically based on age or risk for pneumococcal disease. However national recommendations differ world-wide and also within the EU.

In the EU, prevention of pneumococcal disease in adults currently includes vaccination with two authorised vaccines - Prevenar 13 (13vPnC, protein-conjugated) and PNEUMOVAX23 (PPSV23, polysaccharide, unconjugated) - and the prophylactic use of antibiotics in special populations. Serotypes currently covered by vaccines are 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Prevenar 13) and 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F (PNEUMOVAX23).

20vPnC targets the same 13 serotypes as Prevenar 13 plus seven additional serotypes which are also targeted by PNEUMOVAX23 (8, 10A, 11A, 12F, 15B, 22F, and 33F). The applicant is also the marketing authorisation holder of Prevenar 13.

During this procedure, Vaxneuvance received a positive CHMP opinion (14 10 2021), with a Commission Decision (authorisation) adopted on 13.12.2021. This pertains a 15-valent pneumococcal vaccine containing the 13 serotypes included in Prevenar 13 and additionally serotypes 22F and 33F. All 15 serotypes are also contained in 20vPnC.

<div style=\"page-break-after: always\"></div>

## Unmet medical need

While current vaccination campaigns against S. pneumoniae have led to a substantial reduction in pneumococcal disease burden, mortality rates particularly for IPD in older adults and adults with certain comorbidities have remained high. According to the Global Burden of Disease Study 2016 (GBD 2016 Lower Respiratory Infections Collaborators, The Lancet), S. pneumoniae was 'the leading cause of lower respiratory infection morbidity and mortality globally, contributing to more deaths than all other aetiologies combined in 2016 (1 189 937 deaths, 95% UI 690 445-1 770 660)'.

Serotype replacement (i.e. more frequent isolation of disease-causing serotypes not covered by current vaccines) is a commonly observed phenomenon. Vaccines with broader serotype coverage, (ideally serotype-independent) and higher effectiveness against certain serotypes targeted by authorised vaccines are highly warranted.

## 3.1.3. Main clinical studies

The clinical programme to develop 20vPnC consists of six randomised controlled trials (three Phase 3, one Phase 2, two Phase 1 studies) to study immunogenicity and safety. No efficacy studies have been conducted. Since currently no correlate of protection has been established in the target population, the clinical development aims at demonstrating comparative immunogenicity between 20vPnC and vaccines with proven protective efficacy: 13vPnC (for the 13 shared serotypes) and PPSV23 (for the 7 additional serotypes). This immuno-bridging approach is in accordance with the respective EMA guidance (EMEA/CHMP/VWP/164653/2005) and has been agreed on in a Scientific Advice (EMEA/H/SA/3940/1/2018/III CORRIGENDUM).

Immunogenicity data obtained from the Phase 3 studies B7471007 (pivotal) and B7471006 are considered main evidence for this MAA.

B7471007 was the pivotal noninferiority trial in pneumococcal vaccine naïve adults ≥18 years of age, that was intended to establish the immunological bridge to the comparator vaccines. Participants were enrolled into 3 cohorts based on age. The applicant plans to establish the required immunological bridge to vaccines with known efficacy by establishing non-inferior immune response in cohort 1 first (subjects ≥ 60 yoa) and extend the bridge to other age groups by s howing non-inferior immune response of all 20 serotypes in a subset of cohort 1 and the younger cohorts 2 (50-59 yoa) and 3 (1849 yoa).

Study B7471006 evaluated the safety and immunogenicity of 20vPnC in adults ≥65 yoa with prior pneumococcal vaccination. Participants were enrolled into 3 cohorts based on their pneumococcal vaccination history (PPSV23, 13vPnC or 13vPnC/PPSV23).

In all submitted studies, 20vPnC was administered as a single dose, which is in line with both comparator vaccines. Immunogenicity data was collected immediately before and one month after vaccination in all studies.

## 3.2. Favourable effects

Opsonophagocytic activity (OPA) titres were used as surrogate marker for immune response in all studies. 20vPnC induced immune response against all 20 serotypes in all studies and subgroups. Immune responses were generally higher in younger subjects and decreased with age but was still present in subjects ≥70 years of age. Subjects without risk factors for pneumococcal disease showed higher immune response compared to subjects with risk factors. Further, pneumococcal vaccine naïve

<div style=\"page-break-after: always\"></div>

subjects showed higher titres compared to subjects with pneumococcal vaccination history, especially when previously vaccinated with PPSV23.

Non-inferiority against 13vPnC. The defined non-inferiority criteria - the lower bound of the 2-sided 95% CI for the OPA GMT ratio of 20vPnC/13vPnC &gt; 0.5 - were met for all 13 shared serotypes in adults ≥ 60 yoa (cohort 1, B7471007).

Non-inferiority against PPSV23. The defined non-inferiority criteria - the lower bound of the 2sided 95% CI for the OPA GMT ratio of 20vPnC/PPSV23 &gt; 0.5 - were met for six of the seven additional serotypes in adults ≥ 60 yoa (cohort 1, B7471007). Serotype 8 missed the lower margin with a GMT ratio of 0.55 (0.49, 0.62). OPA GMT ratios for the six other serotypes were clearly above 1.

Non-inferiority of younger subjects (cohort 2: 50-59yoa, cohort 3: 18-49 yoa) to older subjects (60-64 yoa). The defined non-inferiority criteria - the lower bound of the 2-sided 95% CI for the respective OPA GMT ratio of younger cohort/(60-64yoa) &gt; 0.5 - were met for all serotypes for both younger cohorts. While the immune responses induced by 20vPnC vaccination in the youngest cohorts (adults 1849) were higher than in adults ≥ 60 yoa, the immune response in cohort including adults 50-59 yoa was overall similar or higher compared to the oldest cohort.

Additional endpoints further showed similar trends to these results (serotype-specific GMFRs, proportions of participants with a ≥4 -fold in OPA titres, serotypespecific OPA titres ≥LLOQ).

Long term data for 20vPnC is available for approx. 200 subjects from phase 2 study (B7471002). Data from 12 months after the first vaccination indicate that OPA GMTs declined over time to approx. 30% (range 11-55%) compared to one month after vaccination but remained above baseline levels.

## 3.3. Uncertainties and limitations about favourable effects

No efficacy or effectiveness data is available for 20vPnC. The application is based on an immunological bridge comparing humoral immune responses induced by 20vPnC and authorised vaccines (13vPnC and PPSV23) that are known to protect against pneumococcal disease.

No correlate of protection against pneumococcal disease exists in adults. Opsonophagocytic activity (OPA) titres are commonly used as surrogate markers for a protective effect as they reflect the in vivo scenario of antibody-mediated protection, yet no threshold for a protective effect has been established. Comparisons across serotypes are also not possible due to different capsule compositions, potentially resulting in different titres required for protection for each serotype. The comparative approach to vaccines with known efficacy is therefore essential for the interpretation of a potential protective effect of 20vPnC.

The clinical relevance of the applied non-inferiority margin of 0.5 has not been justified and it is not known whether meeting the defined criteria will result in a clinically relevant protection. The applicant has been advised accordingly in a scientific advice procedure (EMEA/H/SA/3940/1/2018/III CORRIGENDUM).

Reduced response compared to 13vPnC : Despite meeting non-inferiority for all 13 shared serotypes between 20vPnC and 13vPnC, a consistent trend of numerically lower GMTs with ratios of about 0.8 [20vPnC/13vPnC] became apparent. Further, the upper bound of the 2-sided 95% CI of the GMT ratio did not contain 1.00 for most serotypes. The ~20% reduction has been consistently observed in all studies for which respective data for 13vPnC was available. The lower titres are especially of concern for serotype 3, which is still the second most common serotype causing invasive pneumococcal disease in the EU in younger adults and the most common serotype in subjects &gt;65 yoa (~14% across age groups in 2018; ECDC AER) despite being included in currently approved vaccines.

<div style=\"page-break-after: always\"></div>

Serotype 8: The immune response against serotype 8 induced by 20vPnC compared to PPSV23 missed the pre-defined non-inferiority criterion (GMR: 0.55 (0.49; 0.62, 2-sided 95% CI)). Although not meeting the predefined non-inferiority margin of 0.5, might be explained technically by multiplicity aspects, the response differs drastically to all other 6 additional serotypes, which showed much higher titres compared to PPSV23. Concerning the lower titres and the potentially reduced protective effect, the applicant argued that immune response elicited with PPSV23 and 20vPnC are difficult to compare due to the different vaccine types (polysaccharide vs conjugate vaccine), which is in general acknowledged, but this does not mitigate the concerns.

Bridging to younger subjects: A comparison performed by the assessors (based on data in the report annex) shows reduced immune response of 20vPnC compared to 13vPnC also in the younger cohorts. In subjects 50-59 yoa the non-inferiority criteria might have even been missed for some serotypes. Despite being lower compared to 13vPnC in the respective age group, the observed titres are higher than the titres obtained with 13vPnC in cohort 1 (≥60yoa), consequently a protective effect for the induced immune response in both younger cohorts can be assumed for 20vPnC.

Persistence. Throughout the clinical development programme, humoral immune responses were compared one month after vaccination. The phase 2 study (B7471002) is the only study included in the application that provides (exploratory) long-term data one year after vaccination. Unfortunately, this study does not allow for a direct comparison between 20vPnC and 13vPnC at this later time point, as sequential regimes 20vPnC/saline and 13vPnC/PPSV23 were compared. Therefore, it is unknown whether OPA GMTs induced by 20vPnC vs 13vPnC differ over time.

Whether a protective effect can be claimed or how long such an effect could be claimed for subjects with already reduced immune response is currently unclear, including subjects with risk factors and subjects with prior pneumococcal vaccination with PPSV23.

No dedicated studies in adults at high risk for pneumococcal disease (e.g. asplenia, HIV, haematopoietic stem cell transplants or other immunocompromising conditions) were conducted. The applicant argues that prior (albeit limited) experience with 7vPnC and 13vPnC in these populations is also applicable to 20vPnC. This strategy had been considered acceptable in a previous scientific advice provided that comparable immunogenicity and safety in immunocompetent subjects can be shown between 20vPnC and 13vPnC. Given the observed reduced immune response, it is currently not clear whether data from 13vPnC can be extrapolated in this population.

Concomitant vaccination. No data on concomitant vaccination with other vaccines relevant to the target population were provided.

## 3.4. Unfavourable effects

The safety profile of 20vPnC was overall comparable to the safety profile of the control vaccines (13vPnC/ PPSV23).

Across all age groups and independent of the previous pneumococcal vaccination status, observations about solicited AEs were consistent, with the majority of participants experiencing 1 or more solicited AEs, and injection-site pain being the most frequently reported solicited AE, followed by myalgia and fatigue. In addition, most AEs were mild to moderate in intensity and resolved within 1-3 days.

In subjects naïve to pneumococcal vaccines, local and systemic solicited AEs were reported with a similar frequency after 20vPnC and Prevenar 13:

- -Pain at the injection site: 55% to 79% after 20vPnC, 54% to 78% after 13vPnC;
- -Redness: 7.3% to 8.2% after 20vPnC; 5.4% to 7.3% after 13vPnC;

- Swelling: 7.5% to 9.1% after 20vPnC; 8.0% to 10.8% after 13vPnC;

- Myalgia: 39% to 63% after 20vPnC; 37% to 65% after 13vPnC;

- Fatigue: 30% to 47% after 20vPnC; 30% to 44% after 13vPnC;

- Headache: 21.5% to 36.7% after 20vPnC; 23.3% to 36.6% after 13vPnC;

- Arthralgia: 12.6% to 16.2% after 20vPnC; 13.7% to 20.7% after 13vPnC.

<div style=\"page-break-after: always\"></div>

In subjects ≥65 years of age with prior pneumococcal vaccination local and systemic reactions were overall reported with a similar frequency. Frequencies of AE were slightly higher in the 20vPnC arm compared to 13vPnC and similar or slightly lower in 20vPnC when compared to PPSV23:

- -Pain at the injection site: 44% to 61% after 20vPnC; 43% to 56% after control vaccines;
- -Redness: 4.8% to 8.6% after 20vPnC; 2.5% to 13% after control vaccines;
- -Swelling: 4.0% to 9.9% after 20vPnC; 6.6% to 14% after control vaccines
- -Myalgia: 32% to 38% after 20vPnC; 31% to 46% after control vaccines;
- -Fatigue: 28.9% to 32.8% after 20vPnC; 22.3% to 33.3% after control vaccines;
- -Headache: 13.5% to 19.2% after 20vPnC; 18.2% to 21.4% after control vaccines;
- -Arthralgia: 6.7% to 16.8% after 20vPnC; 10.7% to 15.9% after control vaccines.

In both groups (pneumococcal vaccine naïve and with prior pneumococcal vaccination) the proportions of subjects reporting any AE were comparable across age groups and were similar for subjects who received 20vPnC or control vaccine. The most frequently reported AEs were in the SOC Infections and Infestations. In subjects ≥65 years of age unsolicited local reaction were slightly less frequent in previously vaccinated compared to naïve subjects over 65 years.

AEs considered related to study vaccine were reported with a similar frequency after 20vPnC and after control vaccines for both subjects naïve to pneumococcal vaccine and subjects ≥65 years of age with prior pneumococcal vaccination status.

Overall, the proportion of patients with SAEs occurring 6 months after vaccination was low and comparable between study and control vaccine in both vaccine naïve (≤2.4%) and previously vaccinated subjects (20vPnC (≤2.4%) and control vaccine (≤1.6%). In pneumococcal naïve treatment group SAEs were reported at a slightly higher frequency among subjects ≥60 years of age (2.4% after 20vPnC, 1.9% after 13vPnC) than in younger age groups (≤0.9% after either vaccine). In subjects ≥65 years of age serious AE were slightly less frequent in previously vaccinated (0.8% to 2.4% in 20vPnC vs 1.6% in control) compared to naïve subjects (3.7% in 20vPnC vs 2.8.6% in control) over 65 years.

As expected, increasing age led to a decrease in reactogenicity, most noticeably for injection-site pain. Beside the lower frequency, the overall profile of AE remained similar.

Prior pneumococcal vaccination does not seem to have a major impact on the safety profile of 20vPnC, as the overall safety profile in participants with prior exposure to 13vPnC/PPSV23 was similar to the safety profile in the pneumococcal vaccine naïve population and no new safety signals are observed.

Deaths: In total, two participants died during the studies due to traumatic injuries, The deaths were considered not related to study vaccine.

In total 20 participants had AEs leading to study discontinuation. Out of AEs which led to discontinuation, 5/12 (20vPnC arm) and 4/8 (13vPnC arm) were vaccine related. Related AEs were mostly injection site reactions and the intensity (severity) of AEs ranged from mild to severe in both arms, with severe AEs being swelling and erythema (following 20vPnC) and bronchial hyperreactivity (following Prevenar 13).

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Comparison to PPSV23: In all three Phase 3 trials, the safety of 20vPnC was mainly evaluated in comparison to 13vPnC. PPSV23 was used as an additional comparator vaccine in most studies. A direct comparison between 20vPnC and PPSV23 included only a limited number of subjects, hampering conclusions (Study B7471006, Cohort B: 246 participants treated with 20vPnC and 127 participants treated with PPSV23).

Serious AEs: No assessment of SAEs and their relatedness to the study vaccine could be made based on the initially provided data. In order to confirm the applicant's claims of unrelatedness, subject narratives for all serious adverse events reported in the Phase 3 studies were requested. Following additional information provided by the applicant, investigator's conclusions on the relationship to the medicine (or lack thereof) seemed justified and were accepted.

Limited information is available on 20nPvC use in:

- Patients with relevant comorbidities. Only in the B7471007 safety population, approximately 34% of participants had risk factors for serious pneumococcal disease at enrolment including smoking (13%), chronic cardiovascular disease (5.5%), chronic pulmonary disease including asthma (8.7%), chronic liver disease (0.4%), and diabetes mellitus (14%);
- Individuals with impaired responsiveness, whether due to use of immunosuppressive therapy or other causes (HIV infection, HSCT, genetic defect);
- Pregnant and lactating women. Information regarding use in pregnant women will be collected through routine pharmacovigilance

No data on sequential vaccination with other pneumococcal vaccines or a booster dose are available for Apexxnar.

## 3.6. Effects Table

Table 50: Effects Table for Apexxnar (20vPnC) indicated for the active immunisation for the prevention of invasive pneumococcal disease (IPD) and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age.

| Effect             | Short Description                                               | Unit               | Treatment Control                                   | Uncertainties/ Strength of evidence                                                    | Reference s        |
|--------------------|-----------------------------------------------------------------|--------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects                                              | Favourable Effects | Favourable Effects                                  | Favourable Effects                                                                     | Favourable Effects |
| Immune response    | NI of 13 shared serotypes to 13vPnC                             | OPA GMT ratio      | Non-inferiority met for all 13 serotypes (13vPnC)   | For most serotypes GMT ratio around 0.8 and 95%-CI below 1 Only in subjects ≥60yoa     | CSR B7471007       |
| Immune response    | NI of the 7 additional serotypes to PPSV23                      | OPA GMT ratio      | Non-inferiority met for 6/7 serotypes (PPSV23)      | Reduced titre for serotype 8                                                           | CSR B7471007       |
| Immune response    | NI of younger cohorts (Cohort 2: 50-59yoa; Cohort 3: 18-49 yoa) | OPA GMT ratio      | Non-inferiority met for all serotypes (20vPnC)      | No comparison to comparator vaccines; NI expected as immune response declines with age | CSR B7471007       |
| Immune response    | In subjects with risk factors                                   | OPA GMT            | Lower immune response in subjects with risk factors | Pooled analysis despite large titre differences between age groups                     | CSR B7471007       |

<div style=\"page-break-after: always\"></div>

| Effect               | Short Description    | Unit                 | Treatment                                                                                                                 | Control              | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                     | Reference s                              |
|----------------------|----------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Immune response      | In primed subjects   | OPA GMT              | Lower response observed subjects with PPSV23 vaccination (alone or 13vPnC/PPSV23) compared to subjects primed with 13vPnC | immune for prior     | No comparison to comparator vaccines or pneumococcal vaccine naïve subjects                                                                                                                                                                                                                                                                                                             | CSR B7471006                             |
| Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                      | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                                                                                                                                    | Unfavourable Effects                     |
| Injection- site AE   | Injection-site pain  | %                    | 55-79 (44-61)                                                                                                             | 54-78 (43-56)        | These were the most commonly reported AEs in subjects ≥ 18 years of age or older naïve to pneumococcal vaccine (Studies B7471007 and B7471008). Numbers in parentheses represent incidence of AEs in subjects ≥65 years of age previously vaccinated with 13vPnC, PPSV23, or both (Studies B7471006 and B7471007). Ranges refer to incidences of AEs observed in different age cohorts. | CSR B7471006, CSR B7471007, CSR B7471008 |
| Systemic AE          | myalgia              | %                    | 39-63 (32-38)                                                                                                             | 37-65 (31-46)        | These were the most commonly reported AEs in subjects ≥ 18 years of age or older naïve to pneumococcal vaccine (Studies B7471007 and B7471008). Numbers in parentheses represent incidence of AEs in subjects ≥65 years of age previously vaccinated with 13vPnC, PPSV23, or both (Studies B7471006 and B7471007). Ranges refer to incidences of AEs observed in different age cohorts. | CSR B7471006, CSR B7471007, CSR B7471008 |
|                      | Fatigue              | %                    | 30-47 (29-33)                                                                                                             | 30-44 (22-33)        | These were the most commonly reported AEs in subjects ≥ 18 years of age or older naïve to pneumococcal vaccine (Studies B7471007 and B7471008). Numbers in parentheses represent incidence of AEs in subjects ≥65 years of age previously vaccinated with 13vPnC, PPSV23, or both (Studies B7471006 and B7471007). Ranges refer to incidences of AEs observed in different age cohorts. | CSR B7471006, CSR B7471007, CSR B7471008 |

Abbreviations:  13vPnC  =  Prevenar  13,   PPSV23  =  Pneumovax23,  CSR  =  clinical  study  report,  AE  = adverse event

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

This application relies on establishing an immunological bridge to authorised vaccines with known protective efficacy against pneumococcal disease (13vPnC and PPSV23). No efficacy or effectiveness data has been submitted. This approach is in general acceptable and in line with respective EMA guidance and previous scientific advice.

In the pivotal study, in subjects ≥ 60 yoa, the defined non -inferior criteria were met for all 13 serotypes shared with 13vPnC and for 6 of the 7 additional serotypes also targeted by PPSV23 (except serotype 8, which showed a pronounced difference compared to the other new serotypes). Nevertheless, consistently numerically lower titres have been observed for most shared serotypes (GMT ratios of about 0.8 [20vPnC/13vPnC] and the upper limit of the 95% CI below 1). This approx. 20% reduction was consistently observed in all other studies in which 13vPnC comparator data were generated. The clinical relevance of this reduction is currently unclear, especially since 20vPnC is essentially the same vaccine as 13vPnC. These findings have been reflected in the SmPC to provide relevant information to the prescriber. The applicant also outlined how the clinical relevance of the numerically reduced immune response of most shared serotypes and serotype 8 will be further investigated and how inferring effectiveness of 20vPnC will be further confirmed by appropriate postmarketing studies. Taken together, the presented post-marketing studies are expected to provide

<div style=\"page-break-after: always\"></div>

valuable information on 20vPnC effectiveness, and the remaining uncertainties related to the clinical impact of numerically reduced immune responses elicited by 20vPnC compared to the majority of serotypes shared with 13vPnC and serotype 8.

The planned post-marketing studies are included as post-authorisation measures in SmPC Annex II.

Notably, in Europe serotype 8 is the most common serotype causing IPD in subjects 18-65 yoa (approx. 22-32% of reported IPD cases) and after serotype 3 (14.7%) the second most common IPD causing serotype i n adults ≥65 yoa (14.0%). Both serotypes are increasing in prevalence in the last years (2018; ECDC AER). At the same time, however, it is acknowledged, that 20vPnC offers the potential benefits of a conjugate vaccine to target serotype 8, which is so far only included in the polysaccharide vaccine PPSV23.

Regarding the bridge to younger subjects, all non-inferiority criteria were met when comparing 20vPnC vaccination in adults 60-64 yoa to adults 50-59 yoa or 18-49 yoa. This was expected as immune responses generally decline with age. No formal comparison between 13vPnC and 20vPnC in younger subjects was performed by the applicant. However, a comparison by the assessors shows similar reduced immune response of 20vPnC compared to 13vPnC also in the younger cohorts. The titres induced by 20vPnC are, however, higher than the titres induced by 13vPnC in 60-64-year-old subjects, which is assumed to provide a protective effect. Therefore, although this aspect of the bridging approach is not considered ideal, it can be concluded that 20vPnC has a similar effect regardless of age and that initially protective titres are reached in subjects younger than 60 years.

Even if the titres induced by primary vaccination with 20vPnC can be assumed to provide a protective effect, the consistently lower immune response affects the ability to extrapolate other aspects like persistence and expected magnitude of a potential booster response from 13vPnC. Numerically lower initial titres might lead to an earlier loss of protection compared to 13vPnC. However, OPA GMTs induced by 20vPnC and 13vPnC followed one month later by PPSV23 decline to a similar extent one year after vaccination, which is preliminarily reassuring. Still, it has to be assumed that, given the numerically lower induced titres and a similar decline, the protective effect of 20vPnC will wane off earlier than the protective effect induced by 13vPnC. The need of another vaccination schedule (e.g. additional dose), especially for risk groups has not been discussed.

In addition, it is unclear how these findings manifest regarding initial and long-term protection in subjects with numerically lower immune response compared to healthy subjects, including subjects with risk factors regardless of age or subjects with prior PPSV23 vaccination, for whom no comparative data to 13vPnC is available. Furthermore, it is not clear whether data from 13vPnC can be extrapolated for subjects at high risk of pneumococcal infection (e.g. with immunocompromising conditions), who have not been included in the development programme. Respective wording for the SmPC has been implemented.

Although post-marketing plans have been outlined, some aspects of 20vPnC vaccine effectiveness are not specifically addressed including (younger) subjects at risk for pneumococcal disease, primed subjects or immunocompromised patients. Nevertheless, if vaccine effectiveness is shown in the planned studies, this will provide reassurance concerning those populations.

The documented safety exposure is considered sufficient for the assessment of the safety profile of 20vPnC.

The safety profile of 20vPnC was overall comparable to the safety profile of 13vPnC/PPSV23. In the six studies submitted in the dossier, no new safety signals were observed for 20vPnC compared to 13vPnC/PPSV23. In subjects ≥65 years of age with prior pneumococcal vaccination 20vPnC was slightly more reactogenic compared to 13vPnC, leading to a higher percentage of participants experiencing 1 or more AEs; and similar or less reactogenic compared to PPSV23. For all three

<div style=\"page-break-after: always\"></div>

interventions, most participants experienced 1 or more AEs in all studies and the most commonly reported AEs were solicited AEs. 20vPnC is well-tolerated since most of the AEs are mild in intensity, of short duration (≤ 3 days) and th e discontinuations due to adverse events are low.

## 3.7.2. Balance of benefits and risks

20vPnC was immunogenic across all subgroups tested. Several uncertainties have been identified that preclude final conclusions on the potential clinical benefit. Although additional coverage of seven serotypes with 20vPnC compared to 13vPnC is considered beneficial, the observed reduced immune response of 11 of the 13 serotypes shared with 13vPnC and of serotype 8 are of concern. While the advantage of targeting 6 additional serotypes is acknowledged - together they currently account for about 21% of confirmed cases of invasive pneumococcal disease (2018; ECDC AER) - the clinical relevance of the observed lower GMTs for serotype 8 and serotypes shared with 13vPnC is unknown. Since invasive pneumococcal disease/pneumonia can be life-threatening or severely debilitating, especially for at-risk populations, the observed reduction in GMTs, especially for both most common serotypes causing invasive disease, is still of concern. The applicant confirmed that 20vPnC real -world effectiveness as regards impact on IPD as well as VT- CAP will be addressed further in the postmarketing. Information on breakthrough disease will be collected through European national and ECDC surveillance systems to be submitted annually. This is considered important to address the remaining uncertainties regarding the lower titres induced by 20vPnC vaccination compared to 13vPnC and to serotype 8.

The currently outlined post-marketing strategy does not foresee to specifically study 20vPnC effectiveness in at-risk subjects. However, it is expected that 20vPnC effectiveness data generated post-approval in the general population will also provide further information to this more vulnerable group.  In addition, these findings have been reflected in the SmPC to provide relevant information to the prescriber.

The safety profile of 20vPnC is characterised by injection-site pain, muscle pain, fatigue, headache, joint pain, swelling and redness.

Overall, the benefit risk balance is deemed positive.

## 3.8. Conclusions

The overall benefit/risk balance of Apexxnar is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus decision that the benefit-risk balance of Apexxnar is favourable in the following indication:

Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.

Apexxnar should be used in accordance with official recommendations

<div style=\"page-break-after: always\"></div>

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Official batch release

In accordance with Article 114 Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.

## Other conditions and requirements of the marketing authorisation

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Due date           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Post-authorisation efficacy studies (PAES): 1. In order to further investigate the long-term effectiveness of Apexxnar for active immunisation for the prevention of pneumonia caused by Streptococcus pneumoniae , the MAH should conduct and submit the results of US study B7471015, a Phase 4 study using a test-negative design to evaluate the effectiveness of Apexxnar against vaccine-type radiologically-confirmed community-acquired pneumonia in adults ≥ 65 years of age. | CSR due 31/12/2027 |
| 2. In order to further investigate the long-term effectiveness of Apexxnar for active immunisation for the prevention of pneumonia caused by Streptococcus pneumoniae ,                                                                                                                                                                                                                                                                                                                | CSR due            |

<div style=\"page-break-after: always\"></div>

| Description                                                                                                                                                                                                                                                                                                                                                                                                       | Due date           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| the MAH should conduct and submit the results of a Phase 4 observational, real-world study to evaluate the effectiveness of Apexxnar against vaccine-type community- acquired pneumonia in Europe according to an agreed protocol.                                                                                                                                                                                | 31/12/2030         |
| 3. In order to further investigate the long-term effectiveness of Apexxnar for active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae , the MAH should conduct and submit the results of a Phase 4 observational, real-world study to evaluate the effectiveness of Apexxnar against vaccine-type invasive pneumococcal disease in Europe according to an agreed protocol. | CSR due 31/12/2030 |

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) contains five new serotypes, 8, 10A, 11A, 12F and 15B conjugated to CRM197 carrier protein which can be qualified as new active substances.